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V 
ABSTRACT 
Bacterial resistances are on the rise which necessitates the development of novel 
anti-infectives to stay forearmed against bacterial infections. In this work, two 
different strategies were pursued to accomplish this goal.  
 
The “switch region” of bacterial RNA polymerase (RNAP) was chosen as a novel 
binding site, which was recently found to be targeted by the natural -pyrone 
antibiotic myxopyronin. It is of particular interest as the -pyrone antibiotics show no 
cross-resistance to the clinically used rifampicin. Based on a hit compound obtained 
during a pharmacophore-based virtual screening, a series of small molecule 
inhibitors was synthesized and their in vitro potency was evaluated. The resulting 
compounds display good antibacterial activity against Gram positive bacteria and 
Gram negative Escherichia Coli TolC, coming along with a reduced resistance 
frequency compared to rifampicin. 
Furthermore, mutasynthesis was investigated as an approach to generate 
myxopyronin derivatives. Thereby, the substrate specificity of the involved 
biosynthetic enzymes was determined and the production of several myxopyronin 
analogs was analytically proven. 
 
A second attempt aimed for a reduction of P. aeruginosa virulence by jamming its 
quorum sensing enzyme PqsD. The application of molecular docking complemented 
by biophysical methods enabled the rational design of potent PqsD inhibitors. 
Moreover the structural features of two distinct inhibitor classes could be successfully 
combined. 
VI 
ZUSAMMENFASSUNG 
Bakterielle Resistenzen sind auf dem Vormarsch. Um weiterhin gegen bakterielle 
Infektionen gewappnet zu sein, ist die Entwicklung neuer Antiinfektiva erforderlich. In 
dieser Arbeit wurden zwei Strategien verfolgt um dieses Ziel zu erreichen. 
 
Die „Switch Region“ der bakteriellen RNA Polymerase (RNAP), kürzlich als 
Angriffspunkt des natürlichen -Pyron Antibiotikums Myxopyronin entdeckt, wurde 
als neue Bindestelle ausgewählt. Da die -Pyron Antibiotika keine Kreuzresistenz mit 
Rifampicin aufweisen ist sie von besonderem Interesse. Basierend auf einer Hit-
Verbindung aus einem Pharmakophor basierten virtuellen Screening, wurde eine 
Reihe von Inhibitoren synthetisiert und auf ihre in vitro Potenz untersucht. Die 
resultierenden Verbindungen weisen gute antibakterielle Effekte und eine verringerte 
Resistenz-Frequenz im Vergleich zu Rifampicin auf. 
Daneben wurde die Mutasynthese als alternative Herstellungsmethode neuer 
Myxopyronin-Derivate untersucht. Hierbei konnte die Substratspezifität der 
beteiligten Biosynthese-Enzyme bestimmt und die Produktion verschiedener 
Myxopyronin Analoga analytisch nachgewiesen werden. 
 
Ein zweiter Versuch hatte eine Reduktion der Virulenz von P. aeruginosa durch 
Hemmung seines quorum sensing Enzyms PqsD zum Ziel. Der Einsatz von Docking, 
ergänzt durch biophysikalische Methoden ermöglichte das rationale Design potenter 
PqsD Inhibitoren. Außerdem konnten die strukturellen Eigenschaften zweier 
unterschiedlicher Inhibitor-Klassen erfolgreich kombiniert werden. 
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1 
1 Introduction 
For thousands of years, bacterial infections were a main cause of death threatening 
mankind. The discovery of microorganisms as the trigger of these infections 
established the basis for a targeted treatment and prevention measures. Besides 
improvements in sanitation and hygiene as well as the introduction of vaccinations, 
the discovery of antibiotics in the late 19th century was a milestone in fighting 
infectious diseases [Davies and Davies 2010]. After the approval of sulfonamides 
and penicillins in the 1930s and 1940s, the rate of mortality dropped dramatically and 
the suffering of patients was alleviated [von Nussbaum et al. 2006]. Furthermore, 
antimicrobials enabled the prophylaxis and the treatment of surgery-related infections 
leading to advances in surgical techniques [Chopra. 2007]. This story of success 
continued for about 25 years. During that period more and more new classes of 
antibiotics like the aminoglycosides, macrolides and fluoroquinolones were 
developed and approved (Fig. 1). William Stewart, the US Surgeon General, was 
quoted in 1967 saying “the time has come to close the book on infectious diseases”, 
illustrating the growing optimism [Upshur 2008 WHO]. The premature celebration of 
the victory in the combat against bacterial pathogens resulted in declining interest 
and research efforts in the field of antibiotics. Blinded by the sudden and unexpected 
supremacy, no new classes of antibiotics were introduced in the years from 1962 to 
2000 [Walsh and Wencewicz 2013].  
 
 
Figure 1. Approval of antibiotics in the time from 1935−2013 [Walsh and Wencewicz 2013]. 
 
Nowadays infectious diseases are gaining ground again and are high in number 
among the leading causes of death, especially in low income countries [WHO, World 
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Health Statistics 2014]. Stewart’s statement was clearly falsified in the meantime by 
the development of bacterial resistances, which cause the emergence of microbes 
that are insensitive towards a particular antibiotic treatment. Resistances rise at an 
alarming rate and are about to turn back the clock to the pre-antibiotic era [von 
Nussbaum et al. 2006]. Especially hospitals, where antibiotics are heavily used, are a 
rich source for the development of new resistances [Leeb 2004]. The responsible 
genes are often located on plasmids, small circular DNAs, which can be 
independently replicated and swapped within the bacterial population [Walsh 2000]. 
Mechanisms of bacterial resistances are diverse. They comprise efflux pumps, target 
modifications, inactivating enzymes or bypasses of the affected pathways. Multidrug 
resistant (MDR) germs synergistically use these mechanisms and are therefore 
completely, or almost completely resistant to currently used antibiotics, drastically 
hampering the therapy options. Mycobacterium tuberculosis represents a prominent 
example as about 1.5 million patients die each year from tuberculosis (TB) infections 
[WHO 2014]. The emergence of MDR M. tuberculosis strains (MDR-TB), which are at 
least resistant to the first line TB drugs rifampicin and isoniazid or even extensively 
drug resistant strains (XDR-TB) that are additionally resistant towards at least one of 
the second line TB drugs, rises and is a major health threat [Dalton et al. 2012, 
Zignol et al. 2012, Haebich and von Nussbaum 2009]. Other examples are MDR 
resistant Staphylococcus aureus and Pseudomonas aeruginosa that are leading 
causes of nosocomial infections that are decreasingly under control and very difficult 
to treat [Baquero 1997, Aloush et al. 2006, Grundmann et al. 2006].  
In the past, mainly two strategies were pursued to overcome existing resistances. 
One is the combined administration of several antibiotics, to lower the likelihood of 
resistance development. Another method aims for the resistance mechanisms 
themselves exemplified for the -lactams, which can be applied together with the -
lactamase inhibitor clavulanic acid. Both strategies are ineligible to treat MDR 
pathogens, stressing the urgent need for antibacterials with novel target-sites or 
mechanisms of action.  
 
1.1 Rational Drug Design 
Prior to the 1960s, drug discovery was exclusively a trial and error process. 
Thousands of compounds with natural or synthetical origin were screened for a 
desired effect. Upon finding of a promising lead compound, medicinal chemists 
1  INTRODUCTION  3 
generated libraries comprising hundreds of derivatives. Thereby, development of a 
safe and effective drug mainly depended on serendipity [Kaul 1998, Rester 2008]. A 
major drawback of screening is that it does not reveal the mode of action of the 
obtained hits and thus does not give any hints how to optimize the molecules [Reddy 
and Parrill 1999]. Rising costs and a focus on resource saving methods rendered the 
screening approach less attractive and triggered the development of rational drug 
discovery. Advancements in this field were mainly enabled by tremendous progress 
in computational techniques, statistics, structural biology and biophysical methods 
[Mavromoustakos et al. 2011].  
 
1.1.1 Early statistical approaches 
Studies from Hansch and Topliss in 1960-1980 [Hansch et al. 1962, Hansch 1969; 
Topliss 1972, 1977] decisively changed the drug optimization process [Reddy and 
Parrill 1999]. Hansch developed a statistical method (Hansch analysis) that 
established the basis for quantitative structure activity relationships (QSAR). For the 
first time, biological activities were correlated with structural properties like the 
Hammet substituent and partition coefficients [Hansch et al. 1962]. Topliss applied 
the Hansch approach in drug design and developed systematic schemes, which 
should maximize the chances to obtain the most potent analogues of a compound 
series as early as possible [Topliss 1972, 1977]. 
 
1.1.2 Ligand-based approaches  
The next steps were taken through the introduction of ligand-based approaches, 
starting in the late 1970s [Marshall et al. 1979]. They can especially be utilized if no 
3D target-structure is available [Yang 2010]. These methods make use of structural 
information about molecules that cause the same biological response [Reddy and 
Parrill 1999] and can be mainly separated into pharmacophore modeling and 3D-
QSAR. 
Pharmacophore modeling is a computational technique that generally encompasses 
two steps. Firstly a set of compounds binding to the same target (training set) is 
subjected to a flexible alignment. Herein the molecules are superimposed in a three 
dimensional space according to their structural features. In a second step, the 
common functionalities, necessary to ensure optimal biological activity, can be 
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determined. The ensemble of these features represents the so called 
pharmacophore model (Fig. 2) that can subsequently be used to guide de novo 
synthesis, or a targeted pharmacophore-based virtual screening of 3D databases, to 
develop new drugs with effects on the investigated target [Wermuth et al. 1998, Yang 
2010, Vuorinen et al. 2014]. 
Comparative molecular field analysis (CoMFA) [Cramer et al. 1988] is an alternative 
ligand-based technique and has become a prototype of 3D QSAR [Podlogar and 
Ferguson 2000]. It considers the extent of molecular fields that surround ligands 
rather than their direct structural features. Like in the above mentioned process of 
pharmacophore determination, the ligands are first aligned in a 3D space and 
subsequently placed into a virtual 3D grid box. Afterwards, different chemical probes 
are used to determine the strength of interactions (hydrophobic, polar, hydrogen 
bonds etc.) at each grid point. The results of these measurements deliver a structure 
of interactions on the molecular surface. Thus, using CoMFA, the quantitative 
influence of specific molecular features on the biological activity can be identified 
[Verma et al. 2010]. 
 
 
Figure 2. Pharmacophore model based on the flexible alignment of penicillin derivatives.  
 
1.1.3 Structure-based approaches 
Major breakthroughs in x-ray crystallography and nuclear magnetic resonance (NMR) 
investigations on proteins, caused the latest revolution in rational drug design. For 
the first time, 3D structural information of the protein could be utilized to search for, or 
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to synthesize molecules, exhibiting an appropriate conformation while carrying 
suitable functional groups to form favorable interactions with the target protein. 
A pharmacophore, representing the prerequisite features for potent molecules, can 
also be determined as a negative fingerprint of a putative binding site. In contrast to 
the ligand based approach, such a pharmacophore can also include features that are 
not covered by known ligands and can also be used for virtual screening of chemical 
libraries or synthesis of matching compounds [Yang 2010]. 
The gold standard of modern structure based design is given by co-crystal structures 
that visualize how a ligand binds to its contact site. Important interactions as well as 
the appropriate conformation can be derived from such data. Thus, making use of 
complex-structures enables a targeted optimization of the ligands for example by 
rigidification or introduction of additional functional groups to generate new 
interactions. In some cases co-crystal structures of promising ligands cannot be 
obtained due to various reasons. Molecular docking, a computational technique, can 
be a solution of such problems. Based on complex algorithms it is able to predict the 
probability of different conformations and interactions of a ligand with a particular 
binding site. These results have to be treated with caution and need to be frequently 
evaluated by experimental results.  
In conclusion, rational drug design provides several tools that allow a targeted 
optimization of hit and lead compounds enabling a straightforward drug development. 
 
1.1.4 Biophysical methods in rational drug design 
Modern biophysical techniques are currently involved in drug design in two ways: (1) 
qualitative detection of small molecules binding to a particular target and (2) 
quantitative determination of physical parameters associated to binding [Renaud and 
Delsuc 2009]. The latter enables detailed investigations of receptor ligand 
interactions contributing to a rational drug design strategy. Some of the available 
biophysical methods, utilized in this thesis, should be briefly introduced in the 
following. 
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1.1.4.1 Isothermal titration calorimetry (ITC) 
ITC is a technique to rapidly characterize the thermodynamics of interactions like for 
example binding of a ligand to a receptor. Thereby it enables the determination of 
enthalpic (H [kcal mol−1]) as well as entropic changes (S [kcal mol−1]) of the 
reaction that result in the free binding energy (G [kcal mol−1]) according to 
equation 1 (T = temperature [K]; R = gas constant: 8.314 J (mol K)−1; KA = 
association constant [mol L−1]; KD = dissociation constant [mol L
−1]). 
Equation 1: G = H − TS = RTlnKA = −RTlnKD 
G reports on the binding affinity in total. Whereas H is associated with forming 
and breaking of non-covalent bonds upon formation of the receptor-ligand complex, 
the change in entropy (S) is due to the overall changes in the degrees of freedom of 
a system [Ladbury 2010]. These shifts can for example be caused by liberation of 
highly ordered water molecules in the binding site, or losses of ligand flexibility. 
Being equipped with detailed knowledge on the thermodynamics of a molecular 
interaction, this information can help to better understand the biological system, and 
to optimize molecules in a rational design process. 
Furthermore, ITC provides the opportunity of assessing the stoichiometry of a ligand-
receptor interaction and thus enables to distinguish real hits and artifacts resulting 
from a screening. 
1.1.4.2 Surface plasmon resonance (SPR) 
Application of SPR in drug discovery can be used to analyze the interaction between 
ligands and a particular receptor. In a typical SPR experiment, the receptor is 
immobilized on the surface of a biosensorchip while the ligand is injected in solution 
(Fig. 3). Binding of ligand molecules leads to an alteration of the refractive index near 
the medium of the surface. This change can be monitored in real time to measure 
accurately the amount of bound ligand, its affinity for the receptor and the association 
and dissociation kinetics of the interaction [Cooper 2002].  
Availability of ligands with known binding sites allows for SPR competition 
experiments. In such experiments it can be investigated to which extent the binding 
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affinity of a compound of interest, is influenced by the presence of a known ligand. 
The results can be used to determine or narrow down the binding site of the 
investigated compounds.  
 
Figure 3. Schematic illustration of the set-up of a typical SPR experiment, adapted from [Cooper 
2002]. A ligand solution is pipelined over a biosensorchip, loaded with immobilized receptor 
molecules. Binding of ligand molecules causes a change of the refractive index which can be 
determined by the optical detection unit. 
1.1.4.3 Nuclear magnetic resonance (NMR) 
Ligand-based NMR experiments like saturation transfer difference (STD) NMR and 
interligand NOE for pharmacophore mapping (INPHARMA) that involve both, 
receptor and ligand, are valuable techniques to deeply study receptor-ligand 
interactions.  
STD-NMR [Mayer and Meyer 1999] can be used to provide information on binding 
epitopes distinguishing the functional groups of a ligand that are involved in 
interactions to the receptor and such that are not. These results can facilitate the 
decision at which position a molecule should be modified in order to improve its 
binding affinity. 
INPHARMA NMR is a powerful technique enabling determination of the relative 
orientation of two competitive ligands A and B. Therefore the receptor is incubated 
with a mixture of A and B, and a NOESY spectrum is recorded. In simplified terms, A 
binds to the receptor and one of its protons (HA) transfers its magnetization to proton 
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HR of the receptor. After dissociation of A, B can bind and the afore mentioned 
magnetization can now be transferred to proton HB of ligand B, causing a NOE signal 
meaning that HA and HB are in close proximity to HR in the respective ligand-receptor 
complexes (Fig. 4). Observation of a number of such interligand NOE signals 
visualizes the relative orientation of the two ligands [Sanchez-Pedregal 2005]. In 
such cases where a crystal structure of the receptor with ligand A is available, this 
method enables a rational structure-based optimization of ligand B.  
 
Figure 4. Schematic illustration of the proceedings during the INPHARMA NMR measurement, 
adapted from [Sánchez-Pedregal et al. 2005]. From left to right: When ligand A binds, proton HA 
transfers its magnetization to the receptor proton HR. After dissociation of the receptor-ligand A 
complex, B binds and the magnetization is then transferred to its proton HB, resulting in an 
interligand NOE signal.  
1.2 Bacterial RNA polymerase as a target for antibiotics
The bacterial RNA polymerase (RNAP) is a validated target for antibacterial 
substances which follows from three facts [Darst 2004, Chopra 2007, Mukhopadhyay 
et al. 2008]. It is a key enzyme in protein biosynthesis catalyzing the pivotal 
transcription process and therefore guarantees the efficacy of RNAP inhibitors. The 
enzyme is highly conserved among a wide range of bacteria, enabling the 
development of broad spectrum antibiotics. Finally, the protein sequences of 
bacterial and eukaryotic RNAP bear significant differences permitting therapeutic 
selectivity. The macromolecule is composed of a catalytic core comprising the 
subunits α, β, β’, ω, and a dissociable σ-factor (Fig. 5). The latter is important for 
promoter recognition and therefore fine-tunes gene expression [Tupin et al. 2009]. 
Around the turn of the millennium, several x-ray structures of the bacterial RNAP 
have been elucidated revealing a “crab-claw” shaped structure [Zhang et al. 1999, 
Ebright 2000]. The pincers are formed by the two biggest subunits  and ’ that 
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encase a 27 Å wide channel ending in a Mg2+ containing active center cleft. Opening 
of the claw allows a double-stranded DNA template to enter the enzyme and bind to 
the catalytic center. Subsequent clamp closure around the bound DNA enables 
transcription initiation [Brueckner and Cramer 2008, Haebich and von Nussbaum 
2009]. 
 
Figure 5. Schematic illustration of the bacterial RNA polymerase revealing the shape of a crab 
claw.  
 
Although being a validated drug target, the rifamycins and the lately approved 
fidaxomicin are the only RNAP inhibitors in clinical use. Rifamycins are the most 
prominent RNAP inhibitors being used since the 1960s. Based on their outstanding 
antimycobacterial effects, rifamycins are first line drugs in the treatment of 
tuberculosis infections. They bind close to the active site of the RNAP, inhibiting the 
extension of small RNA transcripts and thus the transcription [Campbell et al. 2001, 
Chopra 2007]. Rifamycins are prone to resistance development as their contact site 
on the -subunit is located in a relatively dispensable region [Campbell et al. 2001, 
Artsimovitch et al. 2005, 2012]. Thus, point mutations in this area drastically 
decrease their antibacterial activity. Moreover, the fitness costs associated with these 
mutations can be compensated by additional mutations in RNAP genes, supporting 
the evolution and competitiveness of resistant strains [Comas et al. 2011]. 
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The second clinically used RNAP inhibitor fidaxomicin was approved by the US Food 
and Drug Administration (FDA) in 2011, as a narrow spectrum antibiotic for the 
treatment of Clostridium difficile infections [Artsimovitch et al. 2012]. Molecular 
biological experiments showed that fidaxomicin inhibits the separation of DNA 
strands which is necessary for transcription. Thus it only blocks the RNA synthesis if 
added before formation of the open promoter complex. In further experiments, 
spontaneous mutants were generated and sequenced. The results suggest, that 
fidaxomicin targets the “switch region” and thus binds distant from the rifamycins. Not 
surprisingly rifamycin-resistant bacteria possess no cross-resistance to fidaxomicin, 
which renders the “switch region” an interesting target site for the development of 
new RNAP inhibitors in order to overcome rifamycin resistances [Kurabachew et al. 
2008, Venugopol and Johnson 2012]. 
 
1.3 The “switch region” of bacterial RNAP; target site for 
-pyrone antibiotics
The “switch region” of bacterial RNAP is located at the conjunction of  and ’ subunit 
at the lower end of the “crab claw”. It is often described as a hinge that mediates 
opening and closing of the active center cleft [Mukhopadhyay et al. 2008, Haebich 
and von Nussbaum 2009]. As it is conserved among various bacterial strains, the 
“switch region” bears the potential to be a target for broad spectrum antibacterials 
[Mukhopadhyay et al. 2008]. In 2008, the “switch region” was found to be the binding 
site for the closely related -pyrone antibiotics myxopyronin (myx) and corallopyronin 
(cor). Myx and cor were isolated for the first time in the mid 1980s by Irschik and co-
workers [Irschik et al. 1983, 1985, Kohl et al. 1983] from the soil bacterium 
Myxococcus fulvus Mx f50. Both are composed of an -pyrone core decorated with a 
carbamate containing side-chain (eastern chain), and a hydrophobic side-chain 
(western chain) at the opposite site of the core (Chart 1). Besides low toxicity, myx 
and cor feature good in vitro inhibitory potency of bacterial RNAP coming along with 
strong antibacterial effects against Gram-positive strains. As already described for 
fidaxomicin, “switch region” inhibitors possess no cross-resistance to rifamycins 
which makes their further development worthwhile. In the meantime, the biosynthetic 
pathways of myx and cor have been elucidated [Erol et al. 2010, Sucipto et al. 
2013]. In both cases the two chains are produced independently by multimodular 
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enzymatic machineries and combined in a final enzymatic step to give rise to the 
characteristic -pyrone ring (Fig. 6).  
The crystal structure of Thermus thermophilus RNAP in complex with myx (PDB-ID 
3DXJ) [Mukhopadhyay et al. 2008] reveals its binding contacts. The eastern 
sidechain reaches into a narrow channel. Its polar carbamate function forms several 
water mediated hydrogen bonds with the protein and is therefore decisive for binding. 
The carbonyl oxygen of the ester function in the -pyrone core interacts with a 
Ser1084 at the entrance of the “switch region”. The western chain of myx is 
lipophilic bearing two conjugated double bonds and consequently occupies a mainly 
hydrophobic area of the “switch region”.  
 
 
Chart 1. Natural -pyrone antibiotics myx A/B and cor A/B. 
 
Despite structural similarity myx and cor display interesting differences in their 
inhibitory mechanisms. Whereas myx is not able to completely block the RNA 
synthesis even at very high concentrations, cor entirely prevents RNA formation, 
which has to be associated with the additional alkyl chain of cor [Irschik et al. 1985]. 
Nevertheless, myx shows better minimal inhibitory concentration (MIC) values 
against several pathogens including M. tuberculosis, S. aureus and Enterococcus 
faecalis [Srivastava et al. 2011]. The discovery of the RNAP “switch region” as a 
binding site for antibiotics triggered the development of synthetic inhibitors following 
medicinal chemistry approaches. Although the compounds displayed good activity in 
cell-free enzyme assays, significant antibacterial effects could not be achieved 
[McPhillie et al. 2011, Buurmann et al. 2012]. 
In conclusion, natural or synthetical RNAP inhibitors, binding to the “switch region”, 
are attractive for further development due to their activity against rifamycin resistant 
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strains. Furthermore, a wide conservation of the RNAP “switch region” enables the 
design of broad spectrum antibiotics. 
 
Figure 6. Biosynthetic pathway of myx [Sucipto et al. 2013]. The western chain (red) is produced 
by the PKS system MxnK. The eastern chain (blue) is derived from the combined PKS/NRPS 
system MxnI/MxnJ. The two chains are condensed by the ketosynthase MxnB via intermolecular 
Claisen condensation. 
 
1.4 Mutasynthesis
Approximately 75 percent of the FDA approved drugs for the treatment of infectious 
diseases have a natural origin [Newman et al. 2003]. Especially bacteria themselves 
are a rich source for secondary metabolites with antibacterial properties. This is not 
surprising taking into account their competitive struggle with other bacterial species, 
forcing them to develop measures for self-defense [von Nussbaum et al. 2006]. The 
natural compounds are often highly potent and selective but suffer from poor 
physicochemical properties which have to be improved by medicinal chemistry 
approaches in order to turn them into clinically applicable drugs [Kennedy 2008; 
Haebich and von Nussbaum 2009]. Many chiral centers as well as the presence of 
various functional groups frequently hamper their total synthesis and thus the 
generation of improved derivatives. These features consequently lead to synthesis 
routes comprising many steps and often low yields [Prusov 2013]. Furthermore, total 
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synthesis often involves the application of hazardous and/or expensive chemicals 
making an industrial scale up difficult [Kennedy 2008, Anderson 2012].  
Over the past decades, several alternatives have been developed to generate natural 
product derivatives, which can compensate for the drawbacks of total synthesis 
approaches. Two examples are the precursor directed biosynthesis (PDS) and the 
closely related mutasynthesis that is briefly explained in the following. During 
biosynthesis, a natural product is usually built in a step by step process involving 
multimodular enzyme complexes, as illustrated in Fig. 7a. In PDS, synthetic 
molecules mimicking the naturally used intermediates are fed to a bacterial culture. In 
case of success, the artificial substrates are incorporated resulting in new derivatives 
of the respective natural product (Fig. 7b). As the synthetic precursors compete with 
the natural substrates, incorporation is often insufficient. To circumvent this problem, 
mutasynthesis has been developed. Herein, the biosynthetic pathway is interrupted 
by a targeted mutation to prevent formation of the respective native intermediate. A 
now applied synthetic precursor, structurally adjusted to the subsequent enzymatic 
steps, will then be rather accepted and incorporated, to yield novel natural product 
derivatives (Fig. 7c) [Kirschning et al. 2007]. 
 
Figure 7. Schematic illustration of the multi-step assembly of natural products and their 
derivatives in a) biosynthesis; b) precursor-directed biosynthesis and c) mutasynthesis. Natural 
precursors and intermediates are labeled in black, artificial ones in red. Roman numerals 
designate the respective biosynthetic steps. Adapted from [Kirschning et al. 2007]. 
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Due to the structural requirements for acceptance by the biosynthetic enzymes, PDS 
and mutasynthesis can certainly not reach the flexibility of total synthesis. 
Nevertheless several successful examples show that these methods can significantly 
broaden the chemical space of natural products and yield compounds that are 
difficult to access via chemical synthesis [Zlatopolskiy et al. 2006, Grond et al. 2000, 
Gregory et al. 2005, Dutton et al. 1991].  
 
1.5 Pseudomonas aeruginosa
P. aeruginosa is a Gram negative rod-shaped bacterium initially discovered in 1900 
by the German botanist Walter Migula. It is an opportunistic pathogen which can 
adapt to many natural environments, growing on plants and animal tissues as well as 
soil, marshes and coastal marine habitants [Khan et al. 2010, Stover et al. 2000]. 
P. aeruginosa can cause a number of severe diseases, like for instance urinary tract 
infections in catheterized persons or hospital acquired pneumonia in artificially 
respirated patients [Bodey et al. 1983]. Moreover it is a leading cause of death in 
cystic fibrosis patients [Dubern and Diggle 2008]. During the last years P. aeruginosa 
has become a major cause of nosocomial infections [de Bentzmann and Plésiat 
2011, Stover et al. 2000] and therefore gained center stage in drug discovery 
programs. P. aeruginosa infections have historically been one of the most hard to 
treat [O’Shea and Moser 2008]. Being a Gram negative bacterium, the pathogen is 
naturally equipped with an orthogonal double membrane system that makes it hardly 
permeable for antibacterial substances. A polysaccharide beset outer membrane 
hampers the entrance of lipophilic compounds whereas the hydrophobic inner 
membrane closes the gate for too hydrophilic molecules. In a comprehensive study 
on the physicochemical requirements of antibiotics, O’Shea mentions a clogD7.4 
below 0 and a molecular weight cutoff of approximately 600 Da as prerequisite for 
molecules to enter P. aeruginosa [O’Shea and Moser 2008]. In addition, P. 
aeruginosa possesses diverse efflux pump systems (e.g. MexAB-OprM, Mex-CD-
OprJ, MexXY-OprM) with a broad substrate specificity, discharging numerous 
molecules that successfully entered the cell interior [Masuda et al. 2000]. 
Moreover P. aeruginosa is able to form biofilms which is associated with persistent 
infections that further complicate antibacterial treatment and hamper the human 
immune response [Bjarnsholt et al. 2010]. Such biofilms are extracellular polymeric 
matrices consisting of polysaccharides, extracellular DNA, proteins, lipids and 
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biosurfactants embedding the bacteria. The formation of biofilms occurs in distinct 
steps comprising surface attachment and multiplication, microcolony formation, 
followed by differentiation into a mature, structured biofilm (Fig. 8) [Costerton et al. 
1999, Whiteley et al. 2001]. Lowered metabolic activity and prolonged doubling times 
of cells growing in biofilms decrease the antibacterial effectiveness of many 
antibiotics [Hoiby et al. 2010]. Furthermore, studies on the gene expression in 
biofilms show significant differences to free-living cells, causing antibiotic resistances 
especially to tobramycin, a front-line drug used to treat P.aeruginosa infections 
[Whiteley et al. 2001]. 
 
 
Figure 8. Schematic illustration of distinct steps during biofilm formation, adapted from [Costerton 
et al. 1999]. 
 
Besides the described intrinsic insusceptibility, the pathogen can rapidly acquire 
further antibiotic resistances via mutation or horizontal gene transfer rendering the 
common therapy options ineffective. These mechanisms are even more pronounced 
among biofilm-growing cells [Driffield et al. 2008, Molin and Tolker-Nielsen 2003]. 
Taken together new antibiotics are urgently needed to stay forearmed against 
infections caused by P. aeruginosa. In the meantime, the whole genome sequence of 
P. aeruginosa has been elucidated and many virulence mechanisms have been 
discovered [Stover et al. 2000, de Bentzmann and Plésiat 2011]. This provides new 
opportunities to develop antibiotics with novel targets to fight P. aeruginosa 
infections. Inhibition of the bacterial quorum sensing system is a promising example 
which will be described in detail in paragraph 1.6 and 1.7. 
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1.6 Quorum Sensing in P. aeruginosa
For a long time, bacteria were regarded as individual and autonomous organisms. 
The discovery of bacterial cell-to-cell communication systems changed this 
perspective. Nowadays it is widely accepted that bacteria employ a variety of 
techniques, termed quorum sensing (QS), enabling a social behavior. In order to 
communicate, bacteria produce and secrete signal molecules, comparable with 
human hormones, being detected by the surrounding cells. As the signal strength 
rises as a function of cell count, the bacterial community can utilize it to assess its 
cell density [Swift et al. 2001]. Awareness of the population size equips the bacteria 
with the ability to effectively coordinate group behavior and thus, perform concerted 
actions. These include for example the production of virulence factors and the 
formation of biofilms, both decisively contributing to pathogenicity [Whiteley et al. 
1999]. Whereas Gram positive bacteria predominantly use small hydrophobic oligo-
peptides, Gram negative cells apply a number of small, structurally diverse molecules 
[Miller and Bassler 2001, Federle and Bassler 2003]. Upon binding to their respective 
receptors, the resulting complex autoinduces the genes that are involved in the 
production of signal molecules. This positive feedback guarantees a rapidly rising 
signal when a certain cell-density threshold has been reached [Williams et al. 1992]. 
QS in P. aeruginosa is a tripartite system consisting of two N-acylhomoserine-lactone 
(AHL) dependent circuits (las and rhl) and a 2-alkyl-4-quinolone (AQ) system (Fig. 9). 
In the las system, LasI conducts the synthesis of N-(3-oxo-dodecanoyl)-L-
homoserine lactone (3-oxo-C12-HSL). 3-Oxo-C12-HSL interacts with the LasR 
receptor, a transcriptional regulator, which activates target promoters [Gambello and 
Iglewsky 1991, Passador et al. 1993, Dubern and Diggle 2008]. Furthermore LasR 
activation is associated with the production of the virulence factors elastase and 
alkaline protease [Gambello and Iglewski 1991, Dubern and Diggle 2008]. The 
processes in the closely related rhl system are similar. Herein RhlI directs the 
synthesis of N-(butanoyl)-L-homoserine lactone (C4-HSL) which activates the 
transcriptional regulator RhlR, followed by activation of target promoters [Ochsner et 
al. 1994, Ochsner and Reiser 1995, Dubern and Diggle 2008]. Moreover, production 
of the virulence factors pyocyanin, LecA, elastase, rhamnolipids, hydrogen cyanide 
and alkaline protease increases upon activation of RhlR [Dubern and Diggle 2008]. 
Besides the described AHL-systems that are widespread among Gram negative 
bacteria, P. aeruginosa is additionally equipped with an AQ system, termed pqs, that 
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exclusively exists in certain Pseudomonas and Burkholderia strains [Pesci et al. 
1999, Diggle et al. 2006]. It regulates several virulence phenotypes for e.g. biofilm 
formation, elastase production and membrane vesicle formation [Pesci et al. 1999, 
Heeb et al. 2011, O’Connell et al. 2013]. 
2-Heptyl-3-hydroxy-4-quinolone (Pseudomonas quinolone signal, short form PQS) 
and its precursor 2-heptyl-4-quinolone (HHQ) are the two main signal molecules in 
the pqs system. The enzymatic machinery responsible for their biosynthesis 
underlies the expression of the pqsABCDE operon. The characteristic feedback loop 
described above for las and rhl, exists also here [Xiao et al. 2006]. Upon binding of 
HHQ or PQS to the transcriptional regulator PqsR (formerly termed MvfR for multiple 
virulence factor regulator), the activated PqsR triggers expression of the pqsABCDE 
operon resulting in rising HHQ and PQS levels. Compared to HHQ, PQS binds with a 
100 fold higher affinity to PqsR [Xiao et al. 2006]. Furthermore it is able to chelate 
Fe(III), a pivotal nutrient for P. aeruginosa, potentially facilitating its uptake into the 
cell [Diggle et al. 2007]. Moreover it has been shown that PQS is able to down-
regulate the host innate immune response [Kim et al. 2010]. 
 
Figure 9. Schematic illustration of the quorum sensing system in P. aeruginosa [Dubern and 
Diggle 2008].  
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The function of PqsE is not entirely clarified. It is encoded by the pqsABCDE operon 
without taking part in the AQ biosynthesis. Nevertheless it controls the production of 
important virulence factors like elastase and pyocyanin [Yu et al. 2009, Rampioni et 
al. 2010]. 
The three QS systems of P. aeruginosa are closely linked and thus influence each 
other. The las system is considered superordinate, controlling both, the rhl as well as 
the pqs circuit. Whereas activated PqsR triggers expression of rhlR, its product RhlR 
down-regulates expression of the pqsABCDE operon. The connection among the 
systems is further confirmed by a study with several Pseudomonas aeruginosa 
strains, mutated in their distinct QS-pathways including lasR−, rhlR−, pqsR−, pqsC− 
and pqsD− knock-out mutants. All of them were defective in the production of the 
virulence factor pyocyanin [Gallagher et al. 2002] Taking this into consideration, 
inhibition of one of the respective QS circuits might also affect the others resulting in 
extensive effects. 
 
1.7 Inhibition of P. aeruginosa QS as an anti-virulence 
strategy
As the name suggests, antibiotics kill bacteria by inhibiting their important cell 
functions. These mainly include DNA/RNA synthesis, cell wall synthesis, protein 
biosynthesis, folate synthesis or cell membrane integrity (Fig. 10) [Wright 2010]. 
Affecting the viability of bacteria creates selection pressure and therefore inevitably 
leads to resistances against these antibacterial agents, limiting their efficacy and life-
span [von Nussbaum et al. 2006]. Hence, there is a continuous need for novel 
antibiotics. 
Recent strategies to break out of this vicious cycle include the development of anti-
infectives that attenuate the virulence of bacteria by inhibiting the bacterial cell-to-cell 
communication systems [O’Connell et al. 2013, Kalia and Purohit 2011]. The basic 
idea underlying this approach is, that turning infective bacteria into harmless 
microbes might not cause a selection pressure and consequently does not favor the 
development of resistant bacteria [Defoirdt et al. 2010, Hentzer et al. 2003, Njoroge 
and Sperandio. 2009]. As the fitness implications associated with the blockage of QS 
are not entirely clear, this idea is controversially discussed [Maeda et al. 2012]. 
Nevertheless, interference with QS might be an attractive attacking point in this 
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context. Production and secretion of numerous virulence factors in P. aeruginosa 
depend on cell-to-cell communication [Bera et al. 2009]. Therefore, jamming these 
systems should significantly reduce pathogenicity. 
 
 
Figure 10. Targets of antibiotics, adapted from [Wright  2010]. 
 
This theory could already be proven for several QS inhibitors, (Chart 2) of which 
some should be briefly introduced. The first compounds that delivered the proof of 
concept regarding QS inhibition as an antimicrobial target, were published by 
Hentzer et al in 2002, including the halogenated furanone C-30 (A). It downregulates 
the expression of numerous genes associated with QS and consequently reduces 
virulence factor production. Furthermore P. aeruginosa biofilms, grown in the 
presence of C-30, are much more susceptible to treatment with tobramycin [Hentzer 
et al. 2002, 2003, Hoiby et al. 2013]. The LasR inhibitor PD12 (B) can be regarded 
as a mimic of the natural ligand 3-oxo-C12-HSL. Its strong antagonistic potency (IC50: 
30 nM determined in a reporter gene assay) is reflected in the ability to decrease 
pyocyanin and elastase production [Müh et al. 2006]. Our group focusses on 
inhibition of the pqs-QS system in P. aeruginosa. In 2012 we described the first PqsR 
inhibitors, discovered in a ligand-based approach, originating from HHQ. Applied in 
low micromolar concentrations, C was able to reduce the pyocyanin production in 
P. aeruginosa PA14 by about 60-70% without affecting bacterial growth [Lu et al. 
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2012]. Advancements in this structural class yielded D, a potent PqsR antagonist, 
displaying remarkable abilities in reducing the mortality of P. aeruginosa PA14 
infected Caenorhabditis elegans and Galleria mellonella [Lu et al. 2014]. In a related 
work, our group reported on further PqsR antagonists with more drug like properties 
(E,F) applying fragment-based drug design procedures [Klein et al. 2012, Zender et 
al. 2013]. Although displaying lower antagonistic activity, these compounds were also 
able to reduce the pyocyanin and HHQ production in a P. aeruginosa culture, while 
being more suitable for further development due to low molecular weight and 
favorable physico-chemical properties. In 2012, 2-nitrophenyl methanol derivatives 
(G) were identified in our department as potent PqsD inhibitors. They were capable 
of reducing the biofilm formation in planktonic P. aeruginosa cultures, validating 
PqsD as a promising drug target [Storz et al. 2012]. 
 
 
Chart 2. Quorum sensing inhibitors targeting the AHL- (A,B) or AQ- (C-G) mediated QS-systems 
in P. aeruginosa. 
 
1.8 AQ Biosynthesis in P. aeruginosa
In contrast to the relatively simple las and rhl related biosynthesis pathways, AQ 
synthesis is more complex involving several enzymes and intermediates (Scheme 1). 
The biosynthetic enzymes catalyzing AQ synthesis depend on the expression of the 
pqsABCDE operon. Mutagenesis experiments proved that pqsA−, pqsB−, pqsC− and 
pqsD− mutants do not produce AQs in measurable amounts [Dulcey et al. 2013] In 
contrast, pqsE does not essentially contribute to AQ biosynthesis [Diggle et al. 2003, 
Déziel et al. 2004, Farrow et al. 2008]. 
Anthranilic acid (AA) is the starting precursor of AQ biosynthesis. It originates either 
from the kynurenine pathway or from the alkylquinolone specific anthranilate 
synthase. The latter is encoded by phnAB [Bera et al. 2009]. After activation to its 
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corresponding coenzyme A (CoA) thioester by PqsA [Coleman et al. 2008] 
anthraniloyl-CoA (ACoA) is covalently transferred to the Cys112 residue of PqsD. 
Malonyl-CoA acts as the second substrate of PqsD and is linked to anthranilate 
under the loss of CO2, to yield 2-aminobenzoylacetate (2-ABA) in a two-step reaction 
via its CoA thioester. Once purified, 2-ABA is unstable and rapidly decomposes into 
2-amino acetophenone (2-AA) and 2,4-dihydroxyquinoline (DHQ) upon storage at 
room temperature [Dulcey et al. 2013]. It is propagated that this reaction also 
happens spontaneously in vivo [Zhang et al. 2008]. 
The aliphatic tail in AQs was identified to originate from octanoic acid. Bound to 
PqsC, it is transferred to 2-ABA, under loss of CO2. The resulting intermediate 
undergoes spontaneous ring closure yielding HHQ. Oxidation of HHQ by PqsH, a 
NADH dependent monooxygenase, results in the main pqs-QS signaling molecule 
PQS [Schertzer et al. 2010]. 
The role of PqsB in the presented pathway still remains to be determined. It seems to 
be tightly associated to PqsC, hypothetically being involved in its correct folding, but 
certainly required for PqsC to be active. Only if the two enzymes are present 
simultaneously, production of HHQ can be accomplished [Dulcey et al. 2013]. 
 
Scheme 1. Biosynthesis of alkyl-quinolones in P. aeruginosa, adapted from [Dulcey et al. 2013]. 
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Until recently it was believed, that HHQ is directly produced by PqsD from ACoA and 
-ketodecanoic acid which has indeed been shown to happen in vitro [Pistorius et al. 
2011]. This reaction was successfully used in several studies to assess the potency 
of PqsD inhibitors. Despite, Dulcey et al. could recently show by applying 13C-labeling 
experiments that -ketodecanoic acid is not a direct precursor of HHQ in vivo.  
The production of 4-Hydroxy-2-heptylquinoline-N-oxide (HQNO), the N-oxide of HHQ, 
depends on the monooxygenase PqsL [Lépine et al. 2004]. The substrate of PqsL is 
not known but it was hypothesized to be 2-ABA [Dulcey et al. 2013].  
The important functions of PQS and HHQ in cell-to-cell communication as well as 
their influence on the host have already been described in paragraph 1.6. In addition, 
also the other agents mediate crucial effects. 2-AA itself is a volatile substance, 
known to promote phenotypes of P. aeruginosa that cause chronic infections while 
reducing acute virulence [Kesarwani et al. 2011]. It modulates the host immune 
response in a manner that facilitates persistence while supporting host tolerance 
[Bandyopadhaya et al. 2012]. Zhang et al. reported that DHQ exhibits growth 
inhibitory effects on mouse lung epithelial cells, indicating a contribution of DHQ to 
the pathogenicity of P. aeruginosa [Zhang et al. 2008]. HQNO was described to bear 
antibacterial activity and thus equips P. aeruginosa with a powerful tool to prevail 
against competitive bacteria [Déziel et al. 2004, Machan et al. 1992]. 
In conclusion, the biosynthesis of AQs in P. aeruginosa follows a complex scheme. 
The production of AQs, 2-AA and DHQ elementarily depends on PqsA and PqsD that 
synthesize the key intermediate 2-ABA. Hence, an inhibition of these enzymes 
should have a major impact on cell-to-cell communication.  
 
1.9 PqsD as a drug target
PqsD is a key player in the AQ biosynthesis in P. aeruginosa, catalyzing the 
synthesis of the important intermediate 2-ABA (Scheme 1), among others, origin for 
DHQ, HHQ and PQS biosynthesis [Dulcey et al. 2013]. Recent studies from our 
group show, that biofilm formation and the production of signal molecules can be 
decreased by inhibiting PqsD, confirming its suitability as a target for anti-virulence 
drugs [Storz et al. 2012]. 
The enzyme consists of 337 amino acids and has a molecular weight (MW) of 36.4 
kDa. In solution it primarily exists as a dimer (Fig. 11a) [Bera et al. 2009]. Sequence 
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alignments suggest that PqsD belongs to the family of -ketoacyl-ACP synthase (III) 
type enzymes, like FabH, an enzyme in bacterial fatty acid biosynthesis [Bera et al. 
2009, Davies et al. 2000]. This assumption is strongly corroborated by crystal 
structures of PqsD that reveal a closely related fold to FabH enzymes from several 
species [Bera et al. 2009]. Furthermore astonishing parallels with chalcone and 
stilbene synthases can be observed especially in terms of the conserved active site 
residues. Chalcone and stilbene synthases are plant polyketide synthases that use 
similar enzymatic mechanisms as bacterial fatty acid synthases [Austin and Noel 
2003, Bera et al. 2009]. 
PqsD is equipped with an about 15 Å deep and rather narrow binding channel with 
an approximate volume of 650 Å3. The channel can be divided into three parts. A 
positively charged entrance and a mainly hydrophobic middle segment, followed by a 
polar bottom part, which is delimited by the catalytic residues Cys112, His257 and 
Asp287 (Fig. 11b).  
 
 
Figure 11. a) Secondary structure of PqsD showing a dimer. b) Binding channel of PqsD with 
covalently bound anthranilate (PDB-ID: 3H77) . The channel is illustrated as green mesh. Protein 
residues and anthranilate are labeled white and turquoise respectively.  
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2 Aim of the Thesis 
Bacterial resistances are on the rise and might turn back the clock to the pre-
antibiotic era. Their development is just a matter of time which limits the efficacy and 
life-span of antibacterial agents. This creates a continuous need for new antibiotics to 
stay forearmed against bacterial infections. Developing substances against already 
known and exploited targets involves the risk of cross-resistances. It is more 
promising to find chemical entities that address new targets-(sites) or bearing novel 
mechanisms of action. This thesis aims at the generation of such antibacterial agents 
and can be separated into two main parts. 
The first task is the development of transcription inhibitors that bind to the RNAP 
“switch region”, a recently discovered binding site. Two separate approaches are 
followed. One focusses on the structure-based optimization of a low molecular hit 
compound, which was discovered in a pharmacophore based virtual screening. 
Optimization of this compound should follow a rational design process that enables 
the determination of clear structure-activity relationships (SAR). Besides good target 
activity, the resulting inhibitors should ideally feature broad-spectrum antibacterial 
effects, while overcoming existing resistances.  
Another approach involves natural -pyrone antibiotics from the myx and cor family. 
They are already known to inhibit the bacterial RNAP via binding to the “switch 
region”. The total synthesis of these natural products has been achieved but it is 
laborious and time-consuming. In this work an alternative route for the generation of 
-pyrone antibiotics should be investigated. Thereby mutasynthesis, a combined 
procedure comprising enzymatic and organic synthesis is used. Initial investigations 
focus on determination of the substrate specificity of the involved enzymes. The 
subsequent design of the synthetical precursors should consider the complex crystal-
structure of RNAP with myx, to enable a targeted introduction of new substituents to 
generate further interactions while improving the physicochemical properties of 
potential novel -pyrone-derivatives. 
The second part of this thesis is dedicated to the development of PqsD inhibitors, a 
key enzyme in the quorum sensing system of Pseudomonas aeruginosa. A blockade 
of quorum sensing has been shown to reduce the virulence of pathogens without 
affecting their viability. Therefore it is considered a promising novel mechanism of 
2  AIM OF THE THESIS  25 
action for antibacterial agents that are less prone to resistance development. Starting 
from an experimental hit, the target affinity should be optimized and the binding mode 
should be elucidated. 
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Publication A 
 
Abstract: Rising resistance against current antibiotics necessitates the development 
of antibacterial agents with alternative targets. The “switch region” of RNA 
polymerase (RNAP), addressed by the myxopyronins, could be such a novel target 
site. Based on a hit candidate discovered by virtual screening, a small library of 5-
phenyl-3-ureidothiophene-2-carboxylic-acids was synthesized resulting in 
compounds with increased RNAP inhibition. Hansch analysis revealed π (lipophilicity 
constant) and σ (Hammet substituent constant) of the substituents at the 5-phenyl 
moiety to be crucial for activity. The binding mode was proven by the targeted 
introduction of a moiety mimicking the enecarbamate side chain of myxopyronin into 
the hit compound, accompanied by enhanced RNAP inhibitory potency. The new 
compounds displayed good antibacterial activities against Gram positive bacteria and 
Gram negative E. coli TolC, accompanied by a reduced resistance frequency 
compared to the established antibiotic rifampicin.  
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Introduction 
The bacterial RNA polymerase (RNAP) catalyzes the pivotal transcription process 
and therefore is an attractive drug target for antibacterial agents [1−3]. Due to its high 
conservation among a wide range of bacteria, inhibitors of the RNAP are applicable 
against a broad spectrum of bacterial pathogens [4]. The architecture of the bacterial 
enzyme significantly differs from eukaryotic RNAP, facilitating a selective blockade of 
the essential bacterial cell function [5,6]. This is exemplified by a wide range of 
compounds which selectively effect the prokaryotic RNAP [2]. Several classes of 
inhibitors targeting bacterial RNAP are known [1,3]. but at the current state the 
clinically used compounds are limited to lately approved fidaxomicin and members of 
the rifamycin family [2,7]. For example rifampicin is used in combination with other 
antibacterials, in the first line therapy of tuberculosis [3,8]. In the meantime some 
resistant strains, including multi-resistant Mycobacterium tuberculosis, emerged 
[4,9,10]. This creates an urgent need for the development of new classes of 
antibacterial agents [2,5,11]. 
A promising strategy to face resistance is the exploration of novel target sites [6,12]. 
Recently, the “switch region” has been discovered as an interesting new binding 
domain of bacterial RNAP [2,4]. Myxopyronin B (1), a natural α-pyrone antibiotic 
isolated from the myxobacterium Myxococcus fulvus [13], and its synthetic derivative 
desmethyl myxopyronin B (2) [14], have been demonstrated to target this region 
[4,15]. Due to the different binding mode compared to the rifamycin antibiotics, 
compounds binding to the “switch region” are expected to overcome existent 
resistance [4]. Studies concerning the activity of myxopyronins towards rifamycin 
resistant strains of S. aureus have confirmed, that the “switch region” inhibitors do 
not exhibit cross-resistance to the rifamycins [16,17]. Although the natural compound 
myxopyronin B (1) is highly active in vitro (IC50 = 0.35 µM; minimal inhibitory 
concentration = 0.8 µg/mL for E. coli TolC), its use as a drug is hampered by 
insufficient physicochemical properties [18,19]. Therefore small molecule inhibitors 
possessing a higher in vivo efficacy should be developed. 
Another project of our group is focused on the optimization of novel RNAP inhibitors 
of the benzamidobenzoic acid type, identified by a virtual screening, based on the 
flexible alignment of known inhibitors. Besides good in vitro activity these compounds 
also possess antibacterial effects [20]. In a previous study Fishwick et al. developed 
inhibitors of bacterial RNAP, using a structure-based de novo design approach. 
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These compounds, predicted to bind to the “switch region”, possessed inhibitory 
activity against E. coli RNAP, but displayed no antibacterial properties [21]. Very 
recently Buurmann et al. reported on the first synthetic RNAP inhibitors which have 
been shown to target the “switch region”. Although these compounds were highly 
active (IC50 as low as 4.4 µM), they showed only weak antibacterial effects [22]. In a 
further work compounds supposed to interact with the “switch region” were identified 
by virtual screening, but the putative hits were not experimentally validated [23]. 
 
 
Chart 1. Myxopyronins 1 and 2, hit compound 3, its ester 4 and S. aureus RNAP inhibitors 5, 6 and 7. 
 
Recently, we identified novel RNAP inhibitors also following a virtual screening 
approach. A homology model of E. coli RNAP was used to set up a 3D-
pharmacophore model, which included ligand features from 1 and 2, but also protein-
derived characteristics, matching the “switch region”. Finally, a pharmacophore-
based virtual screening of the Chemiotheque Nationale library (~42.000 compounds) 
was performed resulting in a selection of 70 virtual hits. In vitro activity determination 
using a E. coli RNAP inhibition assay led to the identification of hit compound 3 
showing a moderate inhibitory activity with an IC50 value of 75 µM and MIC value of 
11 µg/mL (E. coli TolC) [24]. Interestingly, the related ureido cyclooctathiophenes 
reported by Arhin et al. for example the acid 5 and especially the esters 6 and 7 have 
been described to inhibit S. aureus RNAP, but their binding site was not further 
investigated. They showed antibacterial effects against several S. aureus strains but 
not against other Gram positive or Gram negative bacteria [25]. As we expect our 
compounds to bind to the “switch region” of RNAP, which is highly conserved among 
various bacterial strains [4], we considered compound 3 to be a good starting point 
for the development of novel antibacterials with broad spectrum activity. 
 
3  RESULTS  29 
 
Figure 1. Binding mode of desmethyl-myxopyronin 2 (yellow) and compound 3 (green) as front- (a) 
and top-view (b). 
 
Molecular Modeling and Optimization Strategy 
To find out whether the SAR of the ureido cyclooctathiophenes is reasonable to be 
considered in our study, compounds 5, 6 and 7 were subjected to the virtual 
screening using our 3D-pharmacophore model. None of them was recognized. This 
is in accordance with the observation of Buurmann et al. that these ureido 
cyclooctathiophenes failed to dock to the “switch region” of the RNAP [22]. In both 
crystal structures of T. thermophilus RNAP with 1 (PDB ID: 3DXJ) [4] and 2 (PDB ID: 
3EQL) [15] the myxopyronins adopt a U-shaped conformation filling the “switch 
region” binding pocket. According to the docking pose (Figure 1) hit compound 3 is 
predicted to bind in a tilted conformation. The thiophene core is placed on the top of 
the entrance to the switch-2 binding cavity, anchored by atomic interactions (H-bond 
or ion-pair) of its carboxylic acid moiety with Lys334. Such an interaction is not 
possible with the corresponding ester 4. The 4-chlorophenyl ring occupies the lower 
part of the enecarbamate-binding pocket of myxopyronins. Thereby, the chloro atom 
is fitted into a small negatively-charged site delimited by Leu343, Gly344 and Lys345 
(β’ subunit) at one side, and Phe1270, Gly1271, Val1275 and Leu1291 (β subunit) on 
the other side (red area of the electrostatic potential surface in the orange circle in 
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Figure 1a) The ureido moiety, stabilized by an intramolecular hydrogen-bond (Chart 
2) with the carboxylic acid group, overlaps with the dienone side chain of 
myxopyronins, pointing the lipophilic substituents ethyl and benzyl into the 
hydrophobic pocket delimited by Leu1326 and Ile1337 (β subunit) and Phe1319, 
Ile1320, Ala1323, Thr1328, Ile1352 (β’ subunit). Based on this binding mode, 3 was 
divided into the carboxy-thiophene-core and two variable fragments for structure-
activity exploration and optimization: the substituted phenyl ring (A), and the ureido 
group (B) as depicted in chart 2. 
 
Chart 2. Optimization strategy of 5-aryl-3-ureidothiophene-2-carboxylic acids. 
 
Chemistry 
The synthesis of the 5-aryl-3-ureidothiophene-2-carboxylic acids (Scheme 1) started 
from readily available acetophenones (I) which were converted to the 5-aryl 
thiophene anthranilic acid methylesters (II) via an Arnold-Vilsmaier-Haack reaction 
followed by a cyclization using methylmercaptoacetate [26]. The esters (II) were then 
hydrolysed under basic conditions to afford the thiophene anthranilic acids (III) which 
were converted into the thiaisatoic anhydrides (IV) [27,28]. The anhydrides (IV) were 
reacted with various primary and secondary amines giving rise to the 5-aryl-3-
ureidothiophene-2-carboxylic acids (V) [29]. Compounds 5, 6 and 7 were synthesized 
as previously described [25]. Compound 4 was obtained by methylation of compound 
3. 
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Scheme 1. Synthesis of 5-aryl-3-ureidothiophene-2-carboxylic acids (V). Reagents and conditions: (a) 
POCl3, DMF, 50 °C to rt, then NH2OH∙HCl, up to 150 °C, 75–90%. (b) Methylthioglycolate, NaOMe, 
MeOH, reflux, 65–85%. (c) KOH, MeOH, THF, H2O, reflux, 40–80%. (d) COCl2, THF, 50–70%. (e) 
Amine, H2O, 100 °C then at 0 °C conc. HCl, 40–80%. 
 
Results and Discussion 
As expected, the ester of 3, compound 4 did not show E. coli RNAP inhibition. 
Interestingly, not only the esters 6 and 7, but also the free acid 5 were inactive (Table 
S2 in Supporting Information). During the hit optimization process of the discovered 
5-phenyl-3-ureidothiophene-2-carboxylic-acids, two aims were pursued: Firstly, the 
putative binding mode of hit compound 3 was investigated by chemical modifications 
of the substituents on ring A. Thereby the Topliss’ logical was followed to optimize 
the hydrophobic and electronic effects [30]. Secondly, the hydrophobic pocket of the 
“switch region”, occupied by the dienone side chain of myxopyronins, was explored 
by varying the substitution pattern of the ureido moiety B.  
The removal of the chlorine (ring A) decreased activity as well as its exchange by a 
methoxy or methyl group. The introduction of the strongly electron-withdrawing and 
lipophilic trifluoromethyl group was accompanied by a slight increase in activity. 
Whereas a more hydrophilic, electron-withdrawing nitro group (12) was tolerated, but 
did not enhance the activity, a cyano group at the same position (13) led to a 
decreased inhibitory effect. An additional chloro substituent improved activity 
independent of the position of both substituents. This correlates well with the 
distribution of favorable interaction contour plots for chloro atoms within the 
subpocket of the “switch region” as computed with Molecular Operating Environment 
(MOE) [31] (Figure 2) localized close to positions 2, 3 and 4. The most active 
compounds in this series were the 3,4 di-chloro compound 18 and 22 with a 
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trifluoromethyl and a chloro substituent present in positions 3 and 4. Regarding 
quantitative structure-activity relationship (QSAR) an excellent correlation was 
observed when π and σ were used in a multiparameter regression analysis. The 
obtained Hansch equation (Equation 1: pIC50 = 3.71 + 0.34 × π + 0.60 × σ (n = 16, R
2 
= 0.95, RMSE = 0.071)) clearly indicates that highly lipophilic and strongly electron-
withdrawing groups result in the most potent compounds (Figure 3). 
 
Figure 2. Small subpocket of the “switch region” with contour graphics (yellow grid) indicating regions 
where chlorine has interaction energies within isovalues of −4 kcal/mol. 
In order to elucidate the influence of the substitution pattern of ring A on the inhibitory 
potency, ab initio geometry optimizations for compounds 3, 9, 13 and 18 were carried 
out and molecular electrostatic potentials (MEP) were visualized (Figure 4). As shown 
by a larger blue area on ring A the electrostatic potential was less negative for the 
potent compound 18, followed by 13, 3 and the inactive compound 9. As seen in the 
docking poses of compound 3 and 18 ring A is sandwiched between Leu343, 
Val1351, Ile1352 and the alkyl chain of Lys345, almost perpendicular to the α-pyrone 
ring of myxopyronin (Figure 1 and 5). CH-π and van der Waals interactions are 
formed between ring A and these residues. The introduction of inductive electron-
withdrawing substituents on ring A leads to a less polarized/negative potential as 
shown in the MEP maps (progressively less negative potential – Figure 4). The 
increase in potency seen for electron-withdrawing groups might depend on stronger 
London dispersion forces resulting from more balanced electron redistribution at both 
sides of the ring. The fact that lipophilic (e.g. Cl, CF3) substituents outreach 
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hydrophilic ones (e.g. CN) fits well with the presence of several apolar residues in the 
surrounding, i.e. Phe1270, Val1275, Leu1291, Val1351, Ile1352, Val1353 (Figure 2). 
 
Figure 3. Comparison of experimentally determined and calculated activities (based on Equation 1) of 
compounds 3 and 8–22. 
Within the small negatively charged subpocket (Figure 1 (orange circle) and Figure 2) 
the chloro derivatives 3 and especially 18 are favored due to a complementary 
electrostatic surface (blue at chloro atom). The more negative potential (green at 
nitrogen or oxygen) on the methoxy in 9 and cyano group in 13 probably causes 
electrostatic repulsions and is consequently associated with a drop in activity. 
Subsuming, the substitution pattern of ring A finetunes charge density distribution of 
the phenyl system and the thiophene core, enabling enhanced interactions with the 
target protein. 
To proof the binding mode proposed in Figure 1, compound 23 was synthesized [40]. 
It was deduced from the docking pose, that position 3 at the phenyl ring A should be 
appropriate for an elongation into the pocket occupied by the enecarbamate chain of 
myxopyronins (red circle in Figure 1). As a linker a C4 unit has been considered to be 
suitable for the positioning of a carbamate group. For synthetic reasons we 
introduced a saturated chain as the corresponding myxopyronin analogue has been 
described to show a similar biological activity as 1 [14]. The resulting compound 23 
that contains a mimic of the myxopyronin enecarbamate chain indeed possessed 
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increased activity compared to the parent compound 3 (Table 2). Nevertheless the 
putative new interactions (Figure S2 in Supporting Information) would suggest an 
even higher gain in activity. We suppose that the entropic penalty for the binding of 
the highly flexible chain has a negative effect on affinity. Furthermore, it can be 
rationalized that the positive inductive effect of the introduced alkylcarbamate chain 
negatively affects the electronic properties of ring A according to equation 1. The fact 
that 23 is more active than 3, despite these two negative effects, corroborates the 
validity of the docking pose. 
 
Figure 4. Ab initio molecular electrostatic potential (MEP) of compounds 3, 9, 13 and 18. 
Turning our interest to the ureido motif B, we retained the 3,4 di-chloro ring A. The 
unsubstituted ureido compound 24 (R2=R3=H) displayed low affinity compared to 18 
containing two lipophilic alkyl chains. This was concordant with the proposed binding 
mode since B is located in a highly lipophilic cavity where hydrophobic contacts, Van 
der Waals and CH-π interactions, prevail. As depicted in Figure 5 the urea moiety 
does not form hydrogen-bonds with surrounding residues, but acts as a planar linker 
for the obligatory hydrophobic groups. Within the compound series derived from 
primary alkyl amines an increased activity was observed for chain elongation. For 
example the n-hexyl derivative 28 displayed the highest potency compared to smaller 
substituents. Besides long aliphatic chains, aromatic residues (phenyl, benzyl or 
phenethyl) were also suitable. The introduction of a second chain at the nitrogen was 
in general accompanied by an increasing activity. 
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Figure 5. Docking simulation of compounds 18 (a) and 40 (c) and two dimensional illustration of the 
interaction between 18 (b) and 40 (d) and RNAP. The main interacting amino acids and the key 
interactions are highlighted. Numbers of amino acid residues from β and β’ subunit are labeled in 
black and blue. Polar amino acids are illustrated in purple and hydrophobic amino acids in green 
circles. 
The increase in potency of compounds 35−40 compared to the mono-substituted 
derivatives 29−31 appears to rely on additional hydrophobic contacts within the 
lipophilic pocket. In fact these compounds present a second sterically demanding, 
hydrophobic substituent at the ureido motif (B). These moieties better fill the dienone-
binding cavity reaching into the pocket delimited by Leu1326 and Ile1330 (β subunit), 
and Lys332, Ser1324, Thr1328, and Leu1332 (β’ subunit). For instance, the higher 
affinity of 37 can be explained by additional CH-π interactions between the second 
aromatic ring and Lys334 (β’ subunit) as well as by non-bonded interactions with 
Leu1322 and Thr1328, whereas compound 18 only interacts with Ile1320 and 
Leu1326 in the dienone pocket (Figure 5). Subsuming, the increase of activity by 
extension of the lipophilic side chains in part B can be attributed to a better fit into the 
binding cavity and therefore extension of the hydrophobic contact area and 
displacement of water molecules. 
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Table 1. Inhibitory activities against E. coli RNA polymerase in vitro and antibacterial activities.  
  
Cpd R
1
 
Inhibition 
of E. coli 
RNAP
a 
MIC 
(µg/mL)
b,c Cpd R
2
 R
3
 
Inhibition 
of E. coli 
RNAP
a 
MIC 
(µg/mL)
b,c 
3 4-Cl 75 µM 11 24 H H 26% >25 
8 H 292 µM 17 25 H i-Propyl 26% 15 
9 4-OCH3 240 µM 15 26 H n-Butyl 91 µM 13 
10 4-CH3 137 µM 21 27 H n-Pentyl 35 µM 10 
11 4-CF3 51 µM 21 28 H n-Hexyl 19 µM >25 
12 4-NO2 73 µM 23 29 H Phenyl 25 µM 12 
13 4-CN 133 µM 25 30 H Benzyl 45 µM 10 
14 4-OCF3 45 µM 21 31 H Phenethyl 26 µM 8 
15 3-Cl 72 µM 9 32 Methyl Phenyl 45 µM 9 
16 3-CF3 53 µM 38 33 Methyl Benzyl 12% 5 
17 3-NO2 80 µM 22 34 Ethyl Phenyl 36 µM 16 
18 3,4-di-Cl 22 µM 10 18 Ethyl Benzyl 22 µM 10 
19 2,4-di-Cl 32 µM 8 35 n-
Propyl 
Benzyl 14 µM >25 
20 2,5-di-Cl 35 µM 9 36 n-
Propyl 
Phenethyl 12 µM >25 
21 3,5-di-Cl 25 µM n.d. 37 n-Butyl Phenyl 14 µM >25 
22 3-CF3-,4-Cl 21 µM 12 38 n-Butyl Benzyl 9 µM >50 
1 myx B 0.35 µM 0.8 39 n-Butyl Phenethyl 7 µM >25 
 rifampicin 0.03 µM 5 40 Benzyl Benzyl 6 µM >25 
 
a 
IC50 values [µM] or inhibition at 100 µM [%] of E. coli RNA polymerase; 
b 
Minimal inhibitory concentration in E. coli 
TolC; 
c
 >: MIC-determination was limited due to insufficient solubility of the tested compounds. n.d. = not determined 
 
In addition to the RNAP in vitro inhibition, the effect of 18 on RNA synthesis was 
investigated in a whole-cell assay with E. coli TolC using radiolabeled 3H-uridine. At a 
concentration of 100 µM the RNA level was reduced by 60% after 40 minutes. 
(Figure S2).  
Further biological evaluation was carried out by determination of minimal inhibitory 
concentrations (MIC) in E. coli TolC (Table 1), which is defective in the multidrug 
AcrAB-TolC efflux system. Most of the compounds active against the bacterial 
enzyme displayed growth inhibitory effects in the range of 5−25 µg/mL. Their 
antibacterial activity is comparable to that of the reference drug rifampicin (5 µg/mL 
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E. coli TolC). The effect on the bacterial growth reflects that the ureidothiophene-
carboxylic acids can diffuse across the asymmetric bilayer to gain access to the cell 
interior, as described for lipohilic antibacterials including macrolides and rifamycins 
[32]. However, the most potent RNAP inhibitors 35−40 - the compounds with the 
highest lipophilicity in that class - showed lower antibacterial potency against E. coli 
TolC. These results can be explained by the fact that the outer membrane of Gram 
negative bacteria is well known to be a potent barrier, hindering too lipophilic 
compounds from entering the cell [33,34]. 
Table 2. Structure and biological data of 23. 
 
 
IC50 E. coli RNAP: 
20 µM 
MIC E. coli TolC: 
25 µg/mL 
 
To explore the spectrum of bacteria possessing susceptibility to selected compounds, 
MIC values in two Gram positive and two Gram negative strains were determined 
(Table 3). While the Gram positive strains (B. subtilis, S. aureus) were in general 
sensitive, wild type Gram negative bacteria (E. coli K12, P. aeruginosa) were not 
affected. For B. subtilis and S. aureus similar inhibitory effects compared to E. coli 
TolC were observed. Considering that the RNAP “switch region” is highly conserved 
among various bacterial strains, we assume that the unequal antibacterial potencies 
are due to differences in cell wall permeability between Gram negative and Gram 
positive bacteria. 
The fact that most compounds were potent against the TolC mutant of E. coli and 
almost ineffective against E. coli K12 suggests that drug-efflux, deactivated in E. coli 
TolC, is responsible for the lack of antibacterial potency in Gram negative bacteria. 
An essential requirement for an effective antibacterial agent is that its potency is not 
reduced by the occurrence of resistant strains. Spontaneous resistance towards 
myxopyronin B in S. aureus occurs at a frequency of 8 x 10−8, similar to that of 
rifampicin [17]. The determination of the in vitro resistance frequencies in E. coli TolC 
at 2 x MIC revealed a significant (>500-fold) lower value for 15 (<4.2 x 10−11) 
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compared to rifampicin (8.3 x 10−8) and myxopyronin B (7.1 x 10−8). This 
phenomenon can be explained by the fact that 15 occupies only a part of the “switch 
region” whereas myxopyronin fills a larger area, including the narrow enecarbamate 
binding pocket. Especially mutations in this part, which lead to resistance against 
myxopyronin [4,35], should not affect the antibacterial activity of our compounds. 
Another mechanism that can contribute to the low resistance frequency can be the 
effect on an additional target. This will be investigated in further experiments. Our 
finding indicates, that the probability of occurring resistant strains, is reduced with our 
compounds compared to existing drugs. This makes these compounds promising 
candidates for further optimization as novel antibacterials. 
Table 3. Antibacterial activities of selected 5-aryl-3-ureidothiophene-2-carboxylic acids. 
Cpd 
MIC
a
 
E. coli TolC 
(µg/mL) 
MIC
a
      
E. coli K12 
(µg/mL) 
MIC
a
 
P. aeruginosa 
(µg/mL) 
MIC
a
          
B. subtilis    
(µg/mL) 
MIC
a
 
S. aureus 
(µg/mL) 
14 21 >100 >100 20 9 
15 9 >100 >100 12 21 
18 10 >25 >25 11 8 
19 8 >50 > 50 10 12 
22 12 >50 >50 20 5 
27 10 >25 >25 8 >25 
29 12 >50 >50 12 6 
31 8 >25 >25 7 6 
38 >50 >50 >50 >50 >50 
40 >25 >25 >25 >25 3 
1 0.8 >25 >25 0.9 0.5 
rifampicin 10 7 13 4.8 0.02 
myxopyronin B 0.8 >25 >25 0.9 0.5 
a 
>: MIC-determination was limited due to insufficient solubility of the tested compounds 
 
Conclusions 
With the aim to develop antibacterial substances with broad-spectrum activity, we 
have chosen the “switch region” of bacterial RNAP as a target site, as it is conserved 
among various bacterial strains [4]. In a previous work we had discovered hit 
compound 3 via virtual screening using a 3D-pharmacophore model [24], based on 
the cocrystal structures of myxopyronins 1 and 2 in the “switch region” [4,15]. In this 
paper the SAR of compound 3 was explored and the inhibitory potency was 
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optimized following a rational approach (Hansch, Topliss) supported by computational 
methods (docking studies, MEPs). Furthermore, the binding mode was 
experimentally validated by mimicking the natural ligand myxopyronin via introduction 
of a carbamate sidechain into compound 3. The new inhibitors show activity against 
Gram positive (B. subtilis, S. aureus) and Gram negative (E. coli TolC) bacterial 
strains accompanied by outstanding low resistance frequencies. In contrast, other 
synthetic RNAP inhibitors possess weak bacterial growth inhibitory activity [21,22] or 
have only narrow spectrum activity among the S. aureus genus [25]. The lack of 
activity towards Gram negative wild type strains, is most likely due to poor 
penetration and/or drug efflux. Therefore further optimization is required. Improving 
the physicochemical properties by introduction of hydrophilic or ionisable groups 
could enhance cellular availability in Gram negative bacteria. Ring A seems to be 
inappropriate since equation 1 shows the importance of lipophilic substituents in this 
part. In our opinion, the ureido-motif B is so far underexploited and should be utilized. 
As it is known, that the introduction of polar groups can have negative impact on the 
activity unless they contribute to favourable enthalpic interactions [36,37], this issue 
has to be taken into consideration. In the binding area of B the polar amino acids 
(Ser1324, Thr 1329) and some backbone regions could be addressed for such 
interactions. Thus, clinically applicable, broad spectrum antibacterial agents, that are 
urgently needed to combat infectious diseases, could finally be obtained. The present 
work lays the foundation for future structure-based design and expansion of the 
chemical space in this class. 
Experimental Procedures 
Chemistry 
Materials and methods. Starting materials were purchased from commercial 
suppliers and used without further purification. Column flash chromatography was 
performed on silica gel (40–63 µM), and reaction progress was monitored by TLC on 
TLC Silica Gel 60 F254 (Merck). All moisture-sensitive reactions were performed 
under nitrogen atmosphere using oven-dried glassware and anhydrous solvents. 1H 
and 13C NMR spectra were recorded on a Bruker Fourier spectrometer (300 or 75 
MHz) at ambient temperature with the chemical shifts recorded as δ values in ppm 
units by reference to the hydrogenated residues of deuteriated solvent as internal 
standard. Coupling constants (J) are given in Hz and signal patterns are indicated as 
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follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet, br., broad 
signal. The melting points (m.p.) were determined using a Stuart Scientific SMP3. 
The purity of the final compounds was ≥95% as measured by HPLC. The Surveyor 
LC system consisted of a pump, an autosampler, and a PDA detector. Mass 
spectrometry was performed on a MSQ electrospray mass spectrometer 
(ThermoFisher, Dreieich, Germany). The system was operated by the standard 
software Xcalibur. A RP C18 NUCLEODUR 100-5 (125 mm x 3 mm) column 
(Macherey-Nagel GmbH, Dühren, Germany) was used as the stationary phase. All 
solvents were HPLC grade. In a gradient run the percentage of acetonitrile 
(containing 0.1% trifluoroacetic acid) was increased from an initial concentration of 
0% at 0 min to 100% at 15 min and kept at 100% for 5 min. The injection volume was 
10 µL, and flow rate was set to 800 µL/min. MS analysis was carried out at a spray 
voltage of 3800 V and a capillary temperature of 350 °C and a source CID of 10 V. 
Spectra were acquired in positive mode from 100 to 1000 m/z at 254 nm for the UV 
trace. 
General Procedure for the synthesis of ureidothiophene-2-carboxylic acids. 
General procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic acid 
methylester (II). POCl3 (26.1 g, 0.17 mol) was added dropwise to DMF (24.9 g, 0.34 
mol) maintaining the temperature beyond 25 °C (cooling in ice bath) and stirred for 
additional 15 min. The acteophenone I (85.0 mmol) was added slowly and the 
temperature was kept between 40 and 60 °C. After complete addition, the mixture 
was stirred for 30 minutes at room temperature. Hydroxylamine hydrochloride (23.6 
g, 0.34 mol) was carefully added portionwise (exothermic reaction!) and the reaction 
was stirred for additional 30 min without heating. After cooling to room temperature, 
the mixture was poured into ice water (300 mL). The precipitated β-chloro-
cinnamonitrile was collected by filtration, washed with H2O (2 x 50 mL) and dried 
under reduced pressure over CaCl2. In the next step sodium (1.93 g, 84.0 mmol.) 
was dissolved in MeOH (85 mL) and methylthioglycolate (6.97 g, 65.6 mmol) was 
added to the stirred solution. The β-chloro-cinnamonitrile (61.1 mmol) was added and 
the mixture was heated to reflux for 30 min. After cooling to room temperature, the 
mixture was poured into ice water (300 mL). The precipitated solid was collected by 
filtration, washed with H2O (2 x 50 mL) and dried under reduced pressure over CaCl2. 
If necessary, recrystallisation from EtOH was performed. 
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General procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic acid (III). 
The 5-Aryl-3-amino-2-carboxylic acid methyl ester (16.6 mmol) was added to a 
solution of KOH (60 mL, 0.6M in H2O) and MeOH (60 mL). The mixture was heated 
to reflux for 3 h, concentrated, and washed with EtOAc (2 x 50 mL). The aqueous 
layer was cooled with ice and acidified by addition of a saturated aqueous solution of 
KHSO4. The precipitated solid was collected by filtration, washed with H2O (2 x 30 
mL) and dried under reduced pressure over CaCl2. 
General procedure for the synthesis of 5-Aryl-2-thiaisatoic-anhydrid (IV). To a 
solution of the 5-Aryl-3-amino-2-carboxylic acid (III) (5.28 mmol) in THF (50 mL) a 
solution of phosgene (6.10 mL, 20 wt% in toluene, 11.6 mmol) was added dropwise 
over a period of 30 min. The reaction mixture was stirred for 2 h at room temperature, 
followed by the addition of saturated aqueous solution of NaHCO3 (30 mL) and H2O 
(50 mL). The resulting mixture was extracted with EtOAc/THF (1:1, 3 x 100 mL). The 
organic layer was washed with saturated aqueous NaCl (100 mL), dried (MgSO4) and 
concentrated. The crude material was suspended in a mixture of n-hexane/EtOAc 
(2:1, 50 mL) heated to 50 °C and after cooling to room temperature separated via 
filtration. 
General procedure for the synthesis of of 5-Aryl-3-ureidothiophene-2-
carboxylic acid (V). The 5-Aryl-2-thiaisatoic-anhydrid (IV) (0.46 mmol) was 
suspended in water (7.5 mL) and the appropriate amine (4.60 mmol) was added. The 
reaction mixture was stirred, heated to 100 °C and then cooled to room temperature. 
The reaction mixture was poured into a mixture of concentrated HCl and ice (1:1) and 
extracted with EtOAc/THF (1:1, 60 mL). The organic layer was washed with aqueous 
HCl (2M), followed by saturated aqueous NaCl (2 x 50 mL), dried (MgSO4) and 
concentrated. The crude material was suspended in a mixture of n-hexane/EtOAc 
(2:1, 20 mL) heated to 50 °C and after cooling to room temperature separated via 
filtration. 
Spectroscopic data of final compounds. Spectroscopic data of final compounds 
can be found in the Supporting Information. Compound 3 is presented as example. 
 
5-(4’-Chlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-carboxylic 
acid (3). Yellow powder, m.p. 173–174 °C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, 
J = 7.1 Hz, 3 H), 3.39 (q, J = 7.1 Hz, 2 H), 4.58 (s, 2 H), 7.24–7.38 (m, 5 H), 7.50 (d, 
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J = 8.5 Hz, 2 H), 7.71 (d, J = 8.5 Hz, 2 H), 8.29 (s, 1 H), 10.06 (s, 1 H), 13.40 (br. s, 1 
H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 107.2, 117.8, 
127.1, 127.1, 127.4, 128.5, 129.3, 131.5, 133.8, 138.1, 146.1, 146.7, 153.0, 165.6 
ppm. 
Biology 
Transcription assay. E. coli RNA polymerase holo enzyme was purchased from 
Epicentre Biotechnologies (Madison, WI). Final concentrations in a total volume of 30 
µL were one unit of RNA polymerase (0.5 µg) which were used along with 60 nCi of 
[5,6-3H]-UTP, 400 µM of ATP, CTP and GTP as well as 100 µM of UTP, 20 units of 
RNAse inhibitor (RiboLock, Fermentas), 10 mM DTT, 40 mM Tris-HCl (pH 7.5), 150 
mM KCl, 10 mM MgCl2 and 0.1% CHAPS. As a DNA template 3500 ng of religated 
pcDNA3.1/V5-His-TOPO were used per reaction [38]. Prior to starting the 
experiment, the compounds were dissolved in DMSO (final concentration during 
experiments: 2%). Dilution series of compounds were prepared using a liquid 
handling system (Janus, Perkin Elmer, Waltham, MA). The components described 
above (including the inhibitors) were preincubated in absence of NTPs and DNA for 
10 min at 25 °C. Transcription reactions were started by the addition of a mixture 
containing DNA template and NTPs and incubated for 10 min at 37 °C. The reaction 
was stopped by the addition of 10% TCA, followed by a transfer of this mixture to a 
96 well Multiscreen GFB plate (Millipore, Billerica, MA) and incubation for 45 min at 4 
°C. The plate underwent several centrifugation and washing steps with 10% TCA and 
95% ethanol to remove residual unincorporated 3H-UTP. After that the plate was 
dried (30 min, 50 °C) and 30 µL of scintillation fluid (Optiphase Supermix, Perkin 
Elmer) was added to each well. After 10 min the wells were assayed for presence of 
3H-RNA by counting using a Wallac MicroBeta TriLux system (Perkin Elmer). To 
obtain inhibition values for each sample, their counts were related to DMSO controls. 
RNA synthesis assay. E. coli TolC was cultured in lysogeny broth (LB) medium. 3H-
uridine (1 µCi/mL) was added during the logarithmic growth phase and 3 min before 
the addition of compound 18 at 100 µM (0.5% DMSO). 300 µL of the cultured 
bacteria were harvested 40 min after addition of the inhibitors and supplemented with 
2 volumes of 10% TCA. After 45 min at 4 °C the precipitates were collected and 
washed using a 96 well glass fiber filter plate (Multiscreen GFB) (Millipore, Billerica, 
MA). After adding Optiphase Supermix (Perkin Elmer, Waltham, MA) the 
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quantification of radioactivity was performed using a Wallac MicroBeta TriLux system 
(Perkin Elmer).  
Determination of IC50 values. For the determination of IC50 values three different 
concentrations of a compound were chosen (two samples for each concentration) 
including data points above and below the IC50 value. The calculation of the IC50 
value was performed by plotting the percent inhibition vs. the concentration of 
inhibitor on a semi-log plot. From this the molar concentration causing 50% inhibition 
was calculated. At least three independent determinations were performed for each 
compound. 
Minimal inhibitory concentration (MIC) determinations. MIC values in E. coli TolC 
were performed with all compounds. Selected compounds were additionally tested in 
E. coli K12, Bacillus subtilis subsp. subtilis, Pseudomonas aeruginosa PAO1 and 
Staphylococcus aureus subsp. aureus (Newman strain). As a bacteria start OD600 
0.03 was used in a total volume of 200 µL in lysogeny broth (LB) containing the 
compounds predissolved in DMSO (maximal DMSO concentration in the experiment: 
1%). Final compound concentrations prepared from serial dilutions ranged from 0.02 
to 100 µg/mL (double values for each concentration) depending on their antibacterial 
activity and the observation of compound precipitation in the growth medium. The 
ODs were determined after addition of the compounds and again after incubation for 
18 h at 37 °C and 50 rpm (200 rpm for PAO1) in 96 well plates (Sarstedt, Nümbrecht, 
Germany) using a FLUOStar Omega (BMG labtech, Ortenberg, Germany). Given 
MIC values are means of two independent determinations (three if MIC <10 µg/mL) 
and are defined as concentrations at which bacterial growth was no more detectable. 
Determination of resistance frequency. The amount of E. coli TolC cells per mL 
was determined by plating bacteria dilutions on LB agar plates following colony 
counting. Different amounts of cells were incubated in LB in presence of the 2 x MIC 
of rifampicin, myxopyronin B and compound 18 in parallel (16 h, 37 °C, 50 rpm) 
following LB exchange, re-cultivation and growth control. A threshold was determined 
at which bacterial growth and hence resistance development occurred following 
calculation of the resistance frequency.   
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Computational Chemistry 
Docking Calculations. Selected compounds were docked into the “switch region” of 
the E. coli RNAP homology model using Goldv5.0 [24].  
Molecular Electrostatic Potential. For compounds 3, 9, 13, and 18 ab initio 
geometry optimizations were performed choosing as basis set HF/6-31+ G (d,p) by 
means of the Gaussian 03 software, and the molecular electrostatics potential map 
(MEP) was plotted using GaussView, version 3.0, the 3D molecular graphics package 
of Gaussian [39]. Electrostatic potential surfaces were generated mapping the 
electrostatic potentials onto molecular electron densities at an isovalue of 0.0004 
e/A°. The MEP maps are color-coded, ranging from −85 (red) to −44 (blue) kcal/mol). 
QSAR model. The QSAR model (Equation 1) was obtained using the software 
Molecular Operating Environment (MOE) v. 2010.10. 
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Abstract: The bacterial RNA polymerase (RNAP) represents a validated target for 
the development of broad-spectrum antibiotics. However, the medical value of RNAP 
inhibitors in clinical use is limited by the prevalence of resistant strains. To overcome 
this problem, we focused on the exploration of alternative target sites within the 
RNAP. Previously, we described the discovery of a novel RNAP inhibitor class 
containing an ureidothiophene-2-carboxylic acid core structure. Herein, we 
demonstrate that these compounds are potent against a set of methicillin-resistant 
Staphylococcus aureus (MRSA) strains (MIC: 2–16 μg ml-1) and rifampicin-resistant 
Escherichia coli TolC strains (MIC: 12.5–50 μg ml-1). Additionally, an abortive 
transcription assay revealed that these compounds inhibit the bacterial transcription 
process during the initiation phase. Furthermore, the binding mode of the 
ureidothiophene-2-carboxylic acids was characterized by mutagenesis studies and 
ligand-based NMR spectroscopy. Competition saturation transfer difference (STD) 
NMR experiments with the described RNAP inhibitor myxopyronin A (Myx) suggest 
that the ureidothiophene-2-carboxylic acids compete with Myx for the same binding 
site in the RNAP “switch region”. INPHARMA (interligand NOE for pharmacophore 
mapping) experiments and molecular docking simulations provided a binding model 
in which the ureidothiophene-2-carboxylic acids occupy the region of the Myx 
western chain binding site and slightly occlude that of the eastern chain. These 
results demonstrate that the ureidothiophene-2-carboxylic acids are a highly 
attractive new class of RNAP inhibitors that can avoid the problem of resistance.  
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Introduction 
Antimicrobial resistance has become a global health concern due to the widening 
gap between the rapid spread of resistant pathogens (1) and the shortage of effective 
treatment options (2, 3). Thus, the development of novel and potent anti-infectives is 
urgently needed. A validated but hitherto underexploited target for the development 
of broad-spectrum antibiotics is the bacterial RNA polymerase (RNAP). Up to date, 
rifamycins and fidaxomicin are the only RNAP inhibitors used in clinical practice (4–
8). Rifampicin (Rif) (Figure 1), a member of the rifamycin family, plays a fundamental 
role in tuberculosis treatment as a first-line agent in combination with isoniazid (9). 
However, its use is limited due to the prevalence of Rif-resistant Mycobacterium 
tuberculosis (MTB) strains (10, 11). Resistance to the class of rifamycins arises from 
point mutations in the rpoB gene encoding for the RNAP β subunit (12). 
A strategy to overcome the problem of resistance is to explore alternative target 
sites, which are distant from the Rif binding pocket. Therefore, we applied a virtual 
screening approach addressing the RNAP “switch region” (18). This target site 
resides at the base of the RNAP clamp, a domain of the β' subunit and coordinates 
the opening and closing of the RNAP active centre cleft. The “switch region” is not 
overlapping with the Rif binding site and is highly conserved among Gram-positive 
and Gram-negative bacteria grading it as an attractive target for the identification of 
novel broad-spectrum antibiotics (13–15). Using a homology model of E. coli RNAP a 
3D-pharmacophore model was established, which incorporates protein-derived 
properties of the “switch region” as well as ligand features from Myx, a well-known 
“switch region” binder (16–18) (Figure 1). The virtual screening based on this model 
identified a hit compound containing an ureidothiophene-2-carboxylic acid core, 
which served as starting point for activity-guided optimization (18). This class of 
compounds (Figure 1) showed promising in vitro RNAP transcription inhibition and 
antibacterial activity against Gram-positive bacteria (S. aureus, B. subtilis) and E. coli 
TolC. Moreover, they possessed a significantly lower resistance frequency compared 
to Rif or Myx (18). Present work described here revealed that the ureidothiophene-2-
carboxylic acids are also active against several clinical MRSA isolates and Rif-
resistant spontaneous E. coli TolC mutants. Thus, the ureidothiophenes are 
considered promising candidates for further development.               
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Here, we established the mode of binding of the ureidothiophenes by using a 
combination of site-directed mutagenesis and ligand-based NMR methods including 
STD NMR and INPHARMA. As common methods like SPR or protein based NMR 
approaches are not feasible to detect binding of small molecules to RNAP due to its 
large size (core enzyme: ~ 380 kDa), the two ligand-based NMR spectroscopic 
methods applied herein represent excellent alternatives as they do not impose 
restrictions on the size of the target protein (19, 20). Besides, to gain deeper insight 
into the mode of action of the ureidothiophene-2-carboxylic acids an abortive 
transcription assay was performed. 
 
Figure 1. (a) RNAP inhibiting natural products, (b) ureidothiophene-2-carboxylic acid derivates 
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Results and discussion 
Antibacterial Activity. First of all, the activity of the ureidothiophene-2-carboxylic 
acid derivatives against resistant strains, including Rif-resistant E. coli TolC and 
multidrug-resistant S. aureus, was assessed by broth microdilution methods (Table 
1a and 1b).  
Table 1. (a) MIC value determination in clinical Staphylococcus aureus (MRSA) 
isolates; (b) MIC value determination in Rif-resistant E. coli TolC mutants 
(a) 
MRSA MIC [μg ml
-1
] 
Isolate Type
a
 2 9 Myx Rif 
USA300 Lac CA-MRSA 8 2 1 0.0156 
COL HA-MRSA 16 2 1 0.0078–0.0156 
5191 LA-MRSA 16 2 0.5–1 0.0078–0.0156 
R44 LA-MRSA 8 2 1 0.0156 
 
(b) 
Strain 
MIC [μg ml
-1
] 
1 3 4 5 6 7 Myx Rif 
Ec TolC 12.5–25 12.5–25 25 12.5 25 25 1.25 8 
Ec TolC β 
Q513L
b
 
12.5 12.5–25 25 12.5 25–50 25 1.25 >100 
Ec TolC β 
H526Y
b
 
12.5 12.5–25 25 12.5 50 25 1.25 >100 
a
 CA-MRSA, community acquired MRSA; HA-MRSA, hospital acquired MRSA; LA-MRSA, livestock-
associated MRSA 
b
 Rif-resistant E. coli TolC strains with mutations in the rpoB gene encoding for the RNAP β subunit. 
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Spontaneous Rif-resistant E. coli TolC mutants with single point mutations in the 
rpoB gene causing high level resistance to Rif, were still susceptible towards the 
ureidothiophene-2-carboxylic acids. These results indicate that the ureidothiophenes 
show no cross-resistance with Rif as intended by our approach to address the RNAP 
“switch region”. Moreover, the compounds display potent activity against a set of 
methicillin-resistant Staphylococcus aureus (MRSA) isolates with differing 
antimicrobial resistance patterns (Table S1), such as the community acquired MRSA 
strain USA300 Lac (21), the early hospital acquired MRSA strain COL (22) and the 
livestock-associated MRSA CC398 isolates 5191 (23) and R44 (24). Compound 9 
(Figure 1) was found to be the most potent. It exhibited a MIC value of 2 μg ml-1 in all 
screened MRSA strains, which is similar to that of the reference compound Myx 
(Table 1a).  
Abortive Transcription Assay. It has been shown that Myx inhibits the transcription 
initiation (14). Since the ureidothiophene-2-carboxylic acids were designed to bind to 
the same binding site than Myx, it can be assumed that these compounds may also 
inhibit the initiation of the transcription cycle. To confirm this hypothesis, an HPLC-
based abortive transcription assay (25) was performed. Inhibition of transcription 
initiation was measured by quantification of abortive transcripts that are usually 
formed during the initiation phase (26, 27). As illustrated in Figure 2, compounds 1 
and 6 (Figure 1) induced a drastic reduction of abortive transcript formation. As 
expected, this data demonstrate that the ureidothiophenes interfere with the 
transcription process during the initiation phase.  
 
Figure 2. Abortive Transcription Assay. Dose-dependent inhibition of 1 and 6 on abortive product 
formation (ApUp³H-C) using ApU and ³H-CTP as substrates. Standard deviations from two 
independent experiments are indicated by error bars. 
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Mutagenesis studies. The ureidothiophene-2-carboxylic acids were designed as 
RNAP inhibitors that bind into the “switch region”. Recent docking studies suggest 
that these compounds bind in a tilted conformation overlapping with the Myx western 
chain but do not extend in the binding region of the eastern chain (18). To corroborate 
these findings, several amino acid substitutions in the “switch region” were introduced 
(Figure S1). Subsequently, the effects of these mutations on both the RNAP 
transcription inhibition and the antibacterial activity were examined. As expected, 
mutations in the binding pocket of the Myx eastern chain including RNAP β V1275M 
and β E1279K, did not impair the antibacterial activity of the ureidothiophene-2-
carboxylic acid series against E. coli TolC (Table S2). Surprisingly, substitution of 
amino acids located in the proposed binding site such as RNAP β S1322, β L1291, β' 
K345, β' K334 and β' Δ334–5 neither had a significant effect on the antibacterial 
activity against E. coli TolC nor on the in vitro activity (Table S2, S3).  
Characterization of the Binding Mode by STD NMR, INPHARMA and Molecular 
Docking. All together, the above mentioned results raise the question whether the 
RNAP “switch region” is indeed the binding site of the ureidothiophene compound 
series as obtained from our molecular docking experiments. Thus, we performed 
competition STD NMR (28) experiments where the representative compound 6 
(Figure 1) was titrated into a 100:1 complex of Myx/RNAP. Difference spectra were 
monitored for a change in intensity of signals belonging to either 6 or Myx during the 
titration. As shown in Figure 3, stepwise addition of 6 to the complex Myx/RNAP 
diminished the signal intensities of Myx concomitant with steady increases in signal 
intensities belonging to 6. In fact, addition of three equivalents of 6 resulted in a 
∼70% uniform decrease in intensity for signals belonging to Myx (see Figure 3C). By 
addition of five equivalents of 6 the signals of Myx were almost unnoticeable. 
Consequently, 6 and Myx bind the “switch region” of RNAP in a competitive manner.   
Additionally, competition STD NMR experiments were performed between 6 and two 
other described “switch region” binders, corallopyronin A (Cor) and ripostatin A (Rip) 
(29, 30) (Figure 1). Cor is a structural analog of Myx whereas Rip is a cyclic 
macrolide. So far no crystal structures for these natural products have been reported. 
Nevertheless, isolation and sequencing of Cor- and Rip-resistant mutants show that 
the binding pocket of Rip and Cor overlap with that of Myx (14). As illustrated in 
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Figure S2, an overall reduction of the Cor and Rip STD signals is observed upon the 
addition of 6, further indicating that 6 binds into the RNAP “switch region”.  
 
Figure 3. STD NMR competition experiments of 6 and Myx binding to core RNAP. (A) Expanded 
1
H STD NMR spectrum of Myx (250 μM) in the presence of core RNAP (2.5 μM). (B-D) STD 
NMR spectra of the same sample upon  addition of (B) 1, (C) 3 and (D) 5 equivalents of 6. 
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The INPHARMA method was used to exclude allosteric effects on the displacement 
of Myx by 6 (31). This method is based on the observation of protein-mediated NOE 
transfer between two ligands binding competitively to the same protein binding 
pocket. Additionally, we qualitatively analyzed the INPHARMA correlations (32, 33) to 
determine the binding orientation of 6 in the “switch region” of RNAP relative to that 
of Myx. To this respect, 2D-NOESY experiments were performed for a mixture of 
RNAP/Myx/6 in a concentration ratio of 1:150:150 at mixing times ranging from 20 to 
600 ms. Interligand NOE signals were not detected between 6 and Myx in absence 
of RNAP at mixing times as high as 200 ms, thus excluding a direct interaction 
between 6 and Myx. Due to the size of the receptor (~380 kDa) and to avoid “long” 
spin-diffusion pathways contributing to the interligand signals, 2D NOESY 
experiments acquired with a mixing time of 70 ms were chosen to analyze spin-
diffusion-mediated interligand NOE interactions (34). In particular, INPHARMA 
correlations of different intensities were observed between protons of the aromatic 
rings of 6 and protons Me-24, H-23, H-22, Me-21, Me-17, and H-10 of Myx (Figure 4 
and Table 2).  
Interestingly, besides the weak INPHARMA correlations from H-10 no other signals 
were observed from protons belonging to the eastern chain of Myx. These results 
corroborate that 6 and Myx bind competitively to the “switch region” of RNAP, and 
furthermore indicate that 6 occupies the region of the Myx western chain binding site 
and slightly occludes that of the eastern chain. Additionally, the strongest 
INPHARMA correlations were observed from Me-24Myx to the protons of both, phenyl 
and benzyl rings of 6 (Figure 4), suggesting that these two rings and Me-24Myx 
occupy the same area in the binding site. This can only be accomplished if 6 binds to 
the RNAP “switch region” in two different poses. In one pose, the phenyl ring is 
residing at a similar site to that of Me-24Myx while in the second pose the benzyl 
moiety is placed at the Me-24Myx position. Unfortunately, overlapping of proton 
signals for Me-5’’ of 6 and Me-8Myx prevents us from using diagnostic INPHARMA 
correlations from the latter to further corroborate this hypothesis. To circumvent this 
problem, an ureidothiophene analogue (13) without the ethyl group at the position of 
R2 (Figure 1) was synthesized. Additionally, a methoxy group was introduced to the 
benzyl ring of 13 to avoid the signal overlap of H-18Myx with H-8''/H-12'' of 6. 
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Figure 4. NOESY spectra (a) of a mixture of RNAP (2.5 μM), Myx (375 μM) and 6 (375 μM) and 
(b) of a mixture of RNAP (2.5 μM), Myx (375 μM) and 13 (375 μM). Signals are assigned in the 
1D spectra. The numbering of the atoms of Myx and 6 corresponds to that shown in Figure 3, 
numbering of 13 is shown in the SI (Figure S4). Black peaks represent the interligand transferred 
NOEs (INPHARMA NOEs) mediated by the hydrogen atoms of RNAP. Overlapping signals are 
colored in green and intramolecular transferred NOEs from 13 are colored in blue. 
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Table 2. Observed INPHARMA signals between the hydrogen atoms of Myx and 6 and 13, 
respectively 
a
 indicates overlapping signals 
As a matter of fact, a 2D NOESY spectrum of the mixture RNAP/13/Myx clearly 
showed strong interligand NOE interactions from Me-8Myx to the protons of the phenyl 
ring and benzyl moiety indicating that all these three residues are located near the 
same protein protons (Figure 4b and Table 2). Also, Me-24Myx showed strong 
INPHARMA correlations to protons of both aromatic rings of 13. Taken together, 
these results suggest that both, 6 and 13, can bind to the “switch region” of RNAP in 
two different poses with inverted orientations (vide supra). Moreover, the INPHARMA 
data indicate that 6 and 13 partially occlude the Myx binding site in a region that 
ranges from Me-24Myx to Me-8Myx. 
Myx Compound 6 Compound 13 
Me-24 H-2', H-4', H-5', H-4/6'
a
, H-4'', 
H-9''–11'' 
H-2', H-4', H-5', H-4/6'
a
,  
H-6''/10'', H-7''/9'', MeO-8'' 
H-23 H-4', H-4/6'
a
, H-9''–11'' H-2', H-4', H-4/6'
a
, H-6''/10'',  
H-7''/9'', 8''MeO-8'' 
H-22 H-2', H-4/6'
a
, H-9''–11'' H-2', H-4', H-4/6'
a
, H-6''/10'',  
H-7''/9'', MeO-8'' 
Me-21 H-2', H-4', H-5', H-4/6'
a
,  
H-9''–11'' 
H-2', H-4', H-4/6'
a
, H-6''/10'', 
H-7''/9'', MeO-8'' 
Me-17 H-4/6'
a
, H-9''–11'' H-2', H-4', H-4/6'
a
, H-6''/10'',  
H-7''/9'', MeO-8'' 
H-10 H-2', H-4/6'
a
, H-8''–12'' H-4/6'
a
, H-6''/10'', H-7''/9'',  
MeO-8'' 
Me-8  – H-2', H-4', H-4/6'
a
, H-6''/10'',  
H-7''/9'', MeO-8'' 
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To further evaluate the binding mode of 6 and 13 in the “switch region” of RNAP, we 
performed molecular docking studies using MOE (Molecular Operating Environment) 
(31) based on the INPHARMA results. The obtained docking poses with inverted 
orientations for 6 and 13 that correlated best with the STD and INPHARMA results 
are illustrated in Figure 5.  
In poses A and C the NO2-substituted phenyl ring is positioned in the upper 
hydrophobic region of the Myx western chain pocket whereas the benzyl ring 
occupies the lower part of the eastern chain pocket of Myx. In docking poses B and 
D the same area of the “switch region” is occupied by 6 and 13, but the benzyl and 
the phenyl ring bind in inverted orientations compared to poses A and C.  
 
Figure 5. Proposed binding modes of 6 (A, B) and 13 (C, D) in the RNAP “switch region”. Since 
there is no high-resolution crystal structure of the E. coli RNAP “switch region” available, an E. 
coli homology model (18) was used. The binding mode of Myx (green) is shown to illustrate its 
relative orientation to 6 and 13 (blue). Hydrophobic and hydrophilic areas of the pocket are 
colored turquois and red, respectively. 
Recently we could demonstrate that the ureidothiophene-2-carboxylic acids are 
capable of inhibiting the σ:core assembly which would indicate that these compounds 
could also bind to the σ:core interface (36). Existence of a second binding site is also 
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supported by the fact that titrating Myx into a 6/RNAP complex did not result in the 
displacement of the STD signals of 6 (data not shown).  Further evidence of a 
second binding site for the ureidothiophenes was achieved by monitoring the dose-
dependent effect of 6 to quench the intrinsic fluorescence of RNAP core enzyme. 
Graphical representation of the results displayed a monophasic curve progression for 
Myx (14) and Rif  whereas 6 showed a biphasic character of the curve indicating that 
6 can bind to more than one binding site. Besides that these compounds can bind in 
two orientations, a second binding site within RNAP could also contribute to the fact, 
that amino acid substitutions in the “switch region” do not impair the inhibitory activity 
of the ureidothiophene-2-carboxylic acids.  
Conclusion 
In summary, we have shown that the ureidothiophene-2-carboxylic acids possess 
good antibacterial activity against different clinically relevant MRSA isolates and Rif-
resistant E. coli TolC strains indicating the absence of cross-resistance with existing 
antibiotics. On the basis of the STD NMR and INPHARMA data, these compounds 
bind competitively to Myx in the RNAP “switch region”. The structural information 
provided by the transfer NOE experiments along with molecular docking studies 
allowed us to propose a plausible binding mode for the ureidothiophene-2-carboxylic 
acids, which occupy the same area of the “switch region” as the Myx western chain 
and the 2-pyrone core. Moreover, our results confirm that our pharmacophore-based 
virtual screening approach has been successful in identifying easily accessible small 
molecule RNAP inhibitors that bind to the intended target site, the RNAP “switch 
region”, thus providing the potential to avoid the problem of resistance. In closing, 
these results provide useful insights into the structural requirements for optimized 
interactions with the target site and may thus facilitate structure-based optimization of 
this inhibitor class. 
Methods 
Plasmids. For purification of E. coli wild type core RNAP the plasmid pVS10 was 
used which encodes the E. coli rpoA-rpoB -rpoC [His6] and rpoZ ORFs under control 
of a T7 promoter (37). Amino acid substitutions in the E. coli RNAP subunits were 
constructed by site-directed mutagenesis on the basis of pVS10, pRL663 and pIA458 
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containing a fragment from β SdaI to β’ BsmI  (17) and were verified by sequencing. 
Detailed information about the plasmids are provided in the SI. 
Selection of Rif- and Myx-resistant E. coli TolC spontaneous mutants. The 
procedure was performed as described earlier (38). 
Protein Purification. Wild type and altered RNAP core enzymes were purified as 
described previously (37) without the DNA-affinity chromatography step. 
MIC determination. 3–4 isolated colonies of E. coli TolC transformed with a pRL663 
or pRL706 derivative or colonies of spontaneous myxopyronin-resistant E. coli TolC 
mutants were transferred into 5 ml MHB  containing 200 μg ml-1 ampicillin and 
incubated over night  at 37 ºC with shaking. The turbidity of the bacterial suspension 
was adjusted to that of a McFarland standard 0.5 (OD 600 ~ = 0,1 for 108 cfu ml-1) 
and was then diluted by a factor of 1:100 with sterile MHB (106 cfu ml-1). Aliquots of 
100 μl bacterial suspension were subcultured in 100 μl MHB containing the 
compounds dissolved in DMSO in different concentrations in a 96-well plate in 
triplicates and incubated at 37 °C for 18 h with shaking (50 rpm). Final DMSO 
concentration in the experiment was 1 %.  For testing E. coli TolC transformed with a 
pRL663 and pRL706 derivative, the MHB was supplemented with IPTG (1 mM). 
Given MIC values are means of at least two independent determinations (three if 
MIC<10 mg mL-1) and are defined as the lowest concentration of the compounds that 
inhibit visible growth of the tested isolates. 
MICs for MRSA isolates were determined by broth microdilution as recommended by 
the Clinical and Laboratory Standards Institute (39). Antibiotic resistance profiles of 
the MRSA isolates were determined using the Vitek 2 automated antimicrobial 
susceptibility testing system (bioMérieux, Marcy l'Étoile, France).  
Transcription assay. The assay was performed as described previously (18, 40, 41) 
with minor modifications. Final concentrations in a total volume of 30 μL were 56 nM 
wild type or mutant core RNAP, respectively. An equimolar amount of σ70  was used 
along with 60 nCi of [5,6-3H]-UTP, 400 μMol ATP, CTP and GTP as well as 100 μM 
of UTP, 20 units of RNAse inhibitor (RiboLock, Fermentas), 10 mM DTT, 40 mM tris–
HCl (pH 7.5), 150 mM KCl, 10 mM MgCl2 and 0.1% CHAPS.  As a DNA template 
3500 ng of religated pcDNA3.1/V5-His-TOPO was used per reaction. Prior to starting 
the experiment, core enzyme was preincubated with σ70 for 10 min at 25 °C to allow 
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formation of the holo enzyme. Subsequent steps are performed as described 
previously (18). 
HPLC-based Abortive Transcription Assay. The assay was performed as 
described previously (42). 
NMR Spectroscopy. STD NMR data were recorded at 290 K on a Bruker Avance 
500 NMR instrument equipped with a cryogenically cooled 5 mm inverse triple 
resonance gradient probe. Experiments were recorded with the carrier set at −2 ppm 
for on-resonance irradiation and 40 ppm for off-resonance irradiation. Control spectra 
were recorded under identical conditions. Selective protein saturation (2 s) was 
accomplished using a train of 50 ms Gauss-shaped pulses, each separated by a 1 
ms delay, at an experimentally determined optimal power (50 dB on our probe); a 
T1ρ filter (15 ms) was incorporated to suppress protein resonances. Experiments 
were recorded using a minimum of 256 scans and 32 K points. On- and off-
resonance spectra were processed independently and subtracted to provide a 
difference spectrum. 2D NOESY (INPHARMA) experiments were recorded at 290 K 
on a Bruker Ascend 700 NMR instrument equipped with a cryogenically cooled 5 mm 
inverse triple resonance gradient probe. Samples containing 150:150:1 Myx/6/core 
RNAP and Myx/13/core RNAP were prepared in deuterated buffer (20 mM NaPO4 
and 50 mM NaCl, pH 6.8). 2D NOESY experiments were acquired using standard 
pulse sequences with water suppression (WATERGATE), 96 scans as 2048x400 
data points at mixing times ranging from 20–800 ms.   
Computational Chemistry. The virtual binding modes of compounds 6 and 13 were 
created using MOE (Molecular Operating Environment). The model of E. coli RNAP 
in complex with myxopyronin A, which was used as receptor in the following docking 
experiments, was created by superposition of 3DXJ (T. thermophilus RNAP in 
complex with myxopyronin A) (14) and an E. coli RNAP homology model (18). After 
removal of the T. thermophilus protein the remaining receptor-ligand complex was 
energy minimized using the LigX module of MOE (standard settings) tethering 
receptor and ligand (strength: 10). Employing the docking module of MOE, 
compounds 6 and 13 were docked into the myxopyronin binding site. “Triangle 
Matcher” was chosen as placement method and “London dG” was selected as 
scoring function. “Rotate bonds” and “Remove duplicates” functions were switched 
on and 30 hits were retained. Implying the results of the NMR experiments a 
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pharmacophore containing two aromatic features (radius F1: 2 Å, F2: 1.5 Å) was 
used to guide the docking. Furthermore the same docking was performed with an 
additional forcefield refinement. The docking results were searched for the poses 
which correlated best with the NMR results. These were further refined using the 
LigX module (standard settings) tethering the receptor (strength: 5000) to afford the 
final binding modes. 
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Abstract: Myxopyronin is a natural -pyrone antibiotic isolated from the soil 
bacterium Myxococcus fulvus Mx f50. Myxopyronin is able to inhibit the bacterial 
RNA polymerase (RNAP) by binding to a part of the enzyme not targeted by the 
clinically used rifamycins. This mode of action makes myxopyronins promising 
molecules for the development of novel broad-spectrum antibacterials. Herein we 
describe the derivatization of myxopyronins using an advanced mutasynthesis 
approach as a first step towards this goal. Site-directed mutagenesis of the 
biosynthetic machinery was used to block myxopyronin biosynthesis at different 
stages. The resulting mutants were fed with distinct precursors mimicking 
biosynthetic intermediates to restore production. Mutasynthon incorporation and 
production of novel myxopyronin derivatives was analyzed by HPLC-MS/MS. This 
work sets the stage for accessing numerous myxopyronin derivatives thus 
significantly expanding the chemical space of the class of -pyrone antibiotics.  
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Introduction 
The current development of bacterial resistances against clinically used antibiotics is 
alarming. Resistant Mycobacterium tuberculosis (MTB) strains for example represent 
a major health threat and approximately 1.5 million patients die from tuberculosis 
infections each year.[1] Over the last decades multi-drug resistant tuberculosis strains 
(MDR-TB) evolved, which are resistant to the first line TB drugs rifampicin and 
isoniazid.[2] These strains gave rise to the increasingly prevalent extensively drug 
resistant tuberculosis strains (XDR-TB). These strains are additionally resistant 
towards at least one of the second line TB drugs.[3,4] Rifampicin is the most prominent 
anti TB drug. It binds at the active site of the bacterial RNA polymerase (RNAP), 
inhibiting the initiation of RNA synthesis and thus the transcription process.[5,6] 
Consequently, widespread occurrence of rifampicin resistance dramatically hampers 
tuberculosis therapy.[7] This situation stresses the importance of the development of 
new antibiotics that can overcome existing resistances. However, developing 
substances addressing already known and exploited targets involves the risk of 
cross-resistances. It is more promising to identify inhibitors of novel targets and 
binding sites to avoid such effects.[8−10] Recently the switch region of the bacterial 
RNAP was discovered as a new binding site. It is targeted by the natural -pyrone 
antibiotic myxopyronin (Chart 1),[11] which was isolated from the terrestrial 
myxobacterium Myxococcus fulvus Mx f50.[12,13] It was shown that rifampicin resistant 
mutants exhibit no cross-resistance to myxopyronin which makes myxopyronins a 
promising starting point for drug development.[14] Corallopyronins, which are 
structurally closely related to myxopyronins (Chart 1), represent further members of 
the -pyrone class of antibiotics.. 
 
Despite the close structural similarity between myxopyronins and corallopyronins, 
there are remarkable differences in their pharmacodynamic profiles. Whereas 
corallopyronin completely blocks RNA synthesis in vitro, myxopyronin only achieves 
inhibition to a certain extent even at high concentrations.[15] Nevertheless, 
myxopyronin shows a lower minimal inhibitory concentration (MIC) against several 
pathogens including M. tuberculosis H37Rv than corallopyronin (myxopyronin: 1.6 
µg/mL; corallopyronin: 3.1 µg/mL).[16] 
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The total synthesis of myxopyronin, corallopyronin and several derivatives has been 
reported.[17−19] Due to the complexity of the compounds the described procedures are 
laborious, comprise many steps with relatively low final yields and are not 
economically viable.  
 
 
 
Chart 1. Natural -pyrone antibiotics myxopyronin A/B and corallopyronin A/B. 
 
Mutasynthesis represents an attractive approach for the generation of derivatives of 
complex natural products, without the necessity of multi-step organic synthesis.[20−23] 
In this method, small and chemically relatively simple precursors (mutasynthons), 
mimicking biosynthetic intermediates, are added to the culture of a mutagenized 
microbe, in which natural product biosynthesis was blocked at a certain stage. The 
mutasynthons enter the cells and are incorporated into the modified biosynthetic 
pathway resulting structurally diverse compounds. Currently, most successful 
examples in the literature target precursor biosynthesis such as the 3-amino-5-
hydroxybenzoic acid (AHBA) moiety of ansamitocins.[24,25] The technology has rarely 
been used to incorporate more advanced biosynthetic intermediates or even complex 
parts of the final molecule. 
 
Recently, the biosynthetic pathways of myxopyronin (Figure 1a) and corallopyronin 
were elucidated, establishing the basis for mutasynthesis approaches.[26,27] The 
natural products are composed of a central pyrone core decorated with two 
sidechains (“western” (green) and “eastern” (blue), Figure 1a). The western and 
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eastern moieties originate from two enzymatic machineries that independently 
catalyze the assembly of each chain (here described for myxopyronins). The western 
chain is generated by the polyketide synthase (PKS) MxnK and the carbamate 
containing eastern chain is produced by the hybrid PKS / non-ribosomal peptide 
synthetase (NRPS) system MxnI/MxnJ. Such multimodular megasynthetases 
catalyze the stepwise assembly of simple precursors into complex molecules by 
using a distinct set of catalytic domains ordered in modules. Each module 
incorporates one specific unit into the growing biosynthetic intermediate. After chain 
assembly, both halfs are connected by the ketosynthase MxnB via intermolecular 
Claisen-condensation resulting in the characteristic -pyrone core structure. 
 
 
Figure 1. a) Biosynthetic pathway of myxopyronin.
[26]
 The western chain (green) is produced by 
the PKS system MxnK. The eastern chain (blue) is derived from the combined PKS/NRPS 
system MxnI/MxnJ. The two chains are connected by the ketosynthase MxnB. b) Mutasynthesis 
approach. Synthetic western chains (red) are fed to a M. fulvus mxnK culture, incapable of 
producing the native western chain. During fermentation, the synthetic precursors are combined 
with the native eastern chain to yield novel myxopyronin derivatives. 
 
The physicochemical properties of myxopyronin are more complex than those of 
common clinically used antibiotics.[7,28] Its high lipophilicity causes decreasing MIC 
values in the presence of serum albumin. The compound also features a conjugated 
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double bond system which makes it unstable and sensitive to UV light.[7,29] Moreover, 
myxopyronin is highly flexible causing a significant entropic penalty when binding to 
its target site which probably reduces its potency. The present work focuses on 
setting the stage for the advanced mutasynthesis-based development of new 
myxopyronin derivatives (Figure 1b), which could potentially overcome these 
problems and ideally display higher inhibitory potency. So far the corallopyronin 
producer was not amenable to the genetic modifications required for mutasynthesis 
and we therefore focused our work on myxopyronin. The major aim of this study was 
to elucidate the structural requirements for the mutasynthons to be taken up by the 
producing strain and to be accepted by the myxopyronin biosynthetic machinery. Due 
to the high structural similarity between myxopyronin and corallopyronin it is 
expected that our results will be transferable to the corallopyronin system. 
 
Results and discussion 
Myxopyronin adopts a U-shaped conformation inside the switch region of the 
bacterial RNAP (Figure 2). The eastern chain extends into a narrow channel 
delimited by V1037, W1038, E1041 of the RNAP -subunit and K1097, V1099, 
D1100, H805, K1463, V1466, I1467 of the ’-subunit. Its polar carbamate function 
forms several crucial water mediated hydrogen bonds with D1100, K1463 (’) and 
W1038 (). Initial structure activity relationship (SAR) studies show that slight 
variations in the eastern part of the molecule result in a dramatic loss of inhibitory 
activity, with one exception. The derivative lacking the (R)-methyl group, right next to 
the -pyrone core (desmethyl-myxopyronin), possesses the thus far highest activity, 
approximately three times that of the natural product.[19] 
 
The western chain of myxopyronins provides wider scope for structural variations. It 
is only composed of hydrophobic functionalities that do not significantly contribute to 
interactions with the RNAP switch region. Nevertheless, interactions with several 
polar amino acids and protein backbones are addressable in this region. 
Establishment of a single specific hydrogen bond could therefore result in improved 
RNAP inhibitors. Moreover, the larger RNAP binding pocket in this area provides the 
option to introduce bulkier groups, which would resemble corallopyronins that are 
significantly larger in the western chain part. Thus, we focused on the production of 
myxopyronin derivatives with modified western chains. N-acetyl cysteamine (NAC) 
3  RESULTS  71 
thioesters were chosen as substrates for feeding experiments as they mimic carrier 
protein (CP) bound biosynthetic intermediates of the assembly line. In general, the 
application of NAC thioesters for mutasynthesis approaches with PKS/NRPS 
assembly lines is well established. They are known to enter cells and to be accepted 
as substrates by biosynthetic enzymes.[20] 
 
Figure 2. Crystal structure of myxopyronin inside the switch region of Thermus thermophilus 
RNAP (PDB-ID; 3DXJ).
[11]
 
In a first attempt we aimed to synthesize mimics of the fully matured western chain 
intermediate, which should directly enter the chain condensation reaction catalyzed 
by MxnB. Synthesis of the required -keto NAC-thioesters from the corresponding -
ketoacids is intractable due to the instability of the free acids or undesired side 
products under coupling conditions.30 Therefore, we developed a synthetic route 
which involves dioxinones as protected -ketoacid equivalents. The majority of the 
desired -keto NAC thioesters was obtained according to the synthesis route shown 
in Scheme 1. The first step involves an acylation of Meldrum’s acid (I)[31] followed by 
a rearrangement, yielding dioxinone II.[32] After conversion to the dioxinone 
phosphonate III,[33] the resulting compound was coupled with the appropriate 
aldehyde in a Horner-Wadsworth-Emmons reaction to yield the unsaturated 
dioxinone IV.[34] Final conversion with NAC-H gave rise to the desired -keto-NAC-
thioester V.[30]  
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Scheme1. Synthesis of the -keto intermediates. 
The generated mutasynthons 1-12 (detailed descriptions of the synthesis can be 
found in the supporting information (SI)) represent mimics of fully matured western 
chain intermediates bound to the terminal CP domain of MxnK. To block native 
western chain biosynthesis in order to avoid competition with the mutasynthons, 
MxnK was inactivated by deletion of a 5.6 kb internal fragment from the 18 kb mxnK 
gene. This chromosomal modification was performed according to a previously 
established procedure for markerless site-directed mutagenesis in the myxopyronin 
producer M. fulvus Mx f50.[26] LC-MS analysis revealed that, as expected, 
myxopyronin production was completely abolished in the obtained mutant strain Mx 
f50 pHSU-mxn18 (mxnK). Subsequently, mutasynthesis experiments were carried 
out by feeding the precursors to small-scale mxnK cultures. Analysis of the culture 
extracts by HPLC-MS/MS revealed the successful incorporation of most of the 
mutasynthons as discussed below. Production of the expected myxopyronin 
derivatives was verified by high-resolution mass spectrometry and fragmentation 
pattern analysis (see Table 2 and Figures S3−S18 in SI). 
As a proof of concept the -keto NAC thioester that represents the exact mimic of the 
native biosynthetic intermediate (1) was investigated. Myxopyronin production was 
restored when 1 was fed to the mxnK mutant. The successful incorporation and 
restoration of myxopyronin production demonstrates that the constructed 
mutasynthesis system is fully functional. Functional groups of the “natural” precursor 
were then systematically removed to analyze whether they are mandatory for the 
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chain condensation reaction catalyzed by MxnB. While removal of the methyl group 
in the -position (2) was tolerated and resulted in the production of the novel 
derivative W2, additional elimination of the methyl in the -position (3) did not yield 
the expected product. Compound 4 lacking the -methyl and the γ-double bond was 
accepted again whereas the completely saturated precursor 5 was not incorporated. 
From these results we concluded, that the -methyl group as well as the -double 
bond are essential for substrate acceptance and pyrone ring formation by MxnB. 
Hence, these structural features were included in all further synthesized 
mutasynthons to maximize the probability of incorporation.  
Next we evaluated if mutasynthons with terminal phenyl substituents are 
incorporated. Such aromatic systems allow an easy introduction of a variety of 
functional groups. When attached at the appropriate positions of the ring, these 
groups can be used to engineer new and specific interactions with bacterial RNAP. A 
closer look at the complex-crystal structure of bacterial RNAP with myxopyronin 
(PDB-ID: 3DXJ) revealed that the pocket accepting the western part should be wide 
enough to adapt to this dramatic structural change. Compound 6 was initially tested 
as a prototype for this purpose and resulted in production of the desired derivative 
W6 (compare Figure 3). Replacement of the -methyl group by an ethyl function (7) 
or omitting of the -double bond (8) allowed for incorporation as well. 
 
Molecular modelling studies with the myxopyronin derivative W6 suggested that a 
hydroxyl function in the meta position of the phenyl ring might lead to a water 
mediated H-bond with W1434 (’-subunit). Moreover, the additional hydrophilic 
function could lead to improved physicochemical properties. For this purpose, 
compound 9 was synthesized and successful incorporation yielding derivative W9 
was achieved. Encouraged by these promising results a precursor with a bromo-
substituent instead the hydroxyl function (10) was synthesized and fed, which 
enabled the production of the expected myxopyronin analog (W10). Such a 
brominated derivative provides extended possibilities for further derivatization, e.g. 
under Suzuki35 or Buchwald Hartwig[36] conditions, to access a broader chemical 
space. 
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Table 1. Synthetic western side chain mimics. If accepted, the red part of the structure is included in 
the final myxopyronin derivative.  
 
Entry Formula  Myx derivative 
1 
 
W1 
2 
 
W2 
3 
 
n.p. 
4 
 
W4 
5 
 
n.p. 
6 
 
W6 
7 
 
W7 
8 
 
W8 
9 
 
W9 
10 
 
W10 
11 
 
W11 
12 
 
W12 
n.p. no product 
 
We next intended to introduce a terminal alkyne functionality to create the possibility 
for subsequent synthetic modifications of the expected mutasynthesis product. The 
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resulting myxopyronin analog could for example react with different azides under mild 
conditions (click-chemistry)[37] to generate triazole containing myxopyronin derivatives 
with various substitution patterns. A corresponding mutasynthon (11) was 
synthesized and successfully incorporated resulting in the production of myxopyronin 
derivative W11. Inspired by corallopyronin, we finally synthesized a mutasynthon 
bearing a terminal hydroxyl group (12) at the same position as in the corallopyronin 
western chain. So far there is no x-ray structure of a corallopyronin – RNAP complex. 
Due to the close similarity to myxopyronin and several mutagenesis studies,[38] its 
binding mode can be assumed to be analogous to myxopyronin’s. The additional 
alkyl chain of corallopyronin likely extends into an adjacent lipophilic pocket 
interacting with -L1326 (Figure 4).[11,16] The hydroxyl function presumably 
contributes to its activity by forming a hydrogen-bond with the protein. A 
corresponding myxopyronin derivative (W12) might therefore benefit from an 
additional interaction similar to corallopyronin and was obtained after feeding of 12 to 
a mxnK culture. 
 
 
Figure 3. W6 detected in an extract from a culture of Mx f50 mxnK after feeding 6. Top: MS 
spectrum; bottom: fragment spectrum of the parent ion m/z 438.19 [M+H]
+
 (Table 2).  
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Table 2. Characterization of novel myxopyronin analogs with representative fragmentation patterns 
observed 
 
 
Chemical 
formula 
Calculated 
mass 
m/z [M+H]
+
 
Observed 
mass 
m/z [M+H]
+
 
Fragmentation due to losses of 
H2O 
(m/z = 18) 
CH3OH 
(m/z = 32) 
H2N-CO2CH3 
(m/z = 75) 
H2N-CO2CH3, 
CO2 (m/z = 119) 
Myx 
A 
C23H32NO
6 
418.22241 418.22217 400.211
29 
386.195
76 
343.18988 299.20017 
W1 C23H32NO
6 
418.22241 418.22227 400.211
12 
386.195
67 
343.18981 299.20007 
W2 C22H30NO
6 
404.20676 404.20666 386.195
88 
372.180
20 
329.17446 285.18464 
W4 C22H32NO
6 
406.22241 406.22250 38 .210
78 
374.195
59 
331.18951 287.19987 
W6 C25H28NO
6 
438.19111 438.19103 420.179
30 
406.163
92 
363.15828 319.16866 
W7 C26H30NO
6 
452.20676 452.20686 434.195
44 
420.181
46 
377.17400 333.18430 
W8 C25H30NO
6 
440.20676 440.20659 422.195
29 
408.179
54 
365.17410 321.18438 
W9 C25H28NO
7 
454.18602 454.18643 436.174
68 
n.o.
[a] 
379.15314 335.16345 
W10 C25H26NO
6Br 
516.10163 516.10175 498.090
73 
484.075
30 
441.06942 397.07952 
W11 C21H26NO
6 
388.17546 388.17557 n.o.
[a] 
n.o.
[a]
 313.14233 269.15311 
W12 C22H30NO
7 
420.20167 420.20148 402.190
59 
n.o.
[a] 
345.16920 301.17982 
W13 C23H32NO
6 
418.22241 418.22232 400.211
63 
386.195
90 
343.18984 299.19999 
W14 C26H30NO
6 
452.20676 452.20670 434.197
36 
420.180
27 
377.17516 333.18508 
W16 C23H32NO
6 
418.22241 418.22235 400.211
37 
386.195
98 
343.18972 299.20000 
W17 C22H30NO
6 
404.20676 404.20675 386.196
35 
372.182
04 
329.17496 285.18512 
W18 C25H28NO
6 
438.19111 438.19118 420.180
41 
406.164
91 
363.15886 319.16910 
[a] 
n.o. not observed 
 
First attempts to isolate sufficient quantities of the new myxopyronin derivatives 
generated via mutasynthesis experiments failed due to the relatively low production 
yields. In general, possible bottlenecks might be caused by limited uptake of the -
keto NAC thioesters, their fast degradation after feeding to the culture or inefficient 
incorporation into the biosynthetic process. Closer analysis of culture extracts after 
fermentation revealed that only trace amounts of the mutasynthons are left, indicating 
that precursor degradation/instability might be a limiting factor. Therefore we decided 
to increase the chemical stability of the mutasynthons and to re-design the 
myxopyronin mutasynthesis approach. In the experiments described above, western 
chain biosynthesis was completely blocked and complementation was achieved by 
feeding mimics of fully matured western chain intermediates. Thus, -keto thioesters 
were required as mutasynthons to enable the final pyrone ring formation via Claisen-
condensation. In order to circumvent the usage of rather unstable -keto thioesters, 
which do also not allow for long-term storage, we aimed to block and complement 
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western chain biosynthesis at earlier stages. This would enable feeding experiments 
with simplified and more stable mutasynthons (see Figures S2a and S2b in SI). 
Therefore, two additional mutants were generated by site-directed mutagenesis to 
inactivate the carrier protein domains from modules 1 and 4 (CP-1W or CP-4W). In 
both cases, the CP active site serine required for posttranslational modification[39] 
was mutated to alanine resulting in the mutant strains CP-1W or CP-4W, 
respectively. Interestingly, western chain biosynthesis was not completely abolished 
as trace amounts of myxopyronin A could still be detected in culture extracts of both 
mutants. We reasoned that in case of CP-1W butyryl-CoA might act as starter unit, 
which is directly elongated and incorporated into the assembly process at module 3. 
However, the production of myxopyronin A by CP-4W is difficult to explain with 
standard PKS biochemistry. One possible scenario might involve an additional 
(iterative) elongation round without keto reduction by module 1W and subsequent 
modification of the -keto moiety possibly on CP-2W (or CP-1W) to introduce the 
methyl branch. 
 
Figure 4. Schematic illustration of myxopyronin (black) and corallopyronin (black + blue) inside 
the RNAP switch region. Adapted from Mukhopadhyay et al.
[11]
 
Although myxopyronin biosynthesis was not completely inhibited, feeding 
experiments with simplified and more stable mutasynthons were performed. Cultures 
of the CP-1W mutant were supplemented with precursors 13−15 and myxopyronin 
production was analyzed by HPLC-MS/MS. As expected, myxopyronin A was 
produced after feeding of compound 13 in larger quantities than in the control without 
feeding. Precursor 14 was also accepted resulting in detection of myxopyronin 
78  3.3  PUBLICATION C 
derivative W14. Interestingly 15, carrying a hydroxyl group in the meta position, did 
not result in the production of a hydroxylated myxopyronin-derivative as observed 
previously when the -keto thioester (9) was used for feeding. It is possible that 
selectivity issues of downstream catalytic domains in the PKS are the cause, which 
are circumvented in feeding experiments with fully matured western chain mimics like 
precursor 9. 
Table 3. Synthetic western side chain mimics. 
Entry Formula  Myx derivative 
13 
 
W13 (= W1) 
14 
 
W14 
15 
 
n.p. 
16 
 
W16 (= W1) 
17 
 
W17 
18 
 
W18 
n.p. no product 
 
Mutant strain CP-4W was analyzed by using extended NAC-thioesters 16−18 to 
mimic module 4W intermediates. All substrates are accepted and the respective 
myxopyronin derivatives could be detected via HPLC-MS/MS analysis (increased 
levels of myxopyronin A in the CP-4W culture fed with 16 compared to the control). 
Although the NAC-thioesters without a -keto function were more stable, the yield of 
final products was still too low for product isolation (1-10 µg/L) to allow for bioactivity 
testing. Detection of large amounts of substrates in the culture supernatants 
suggested that insufficient uptake into the cells is a limiting factor. To address this 
bottleneck modified feeding procedures, including the addition of detergents like 
polyethylenglycol (PEG), Tween or DMSO to increase cell permeability as well as 
increasing the number of feeding points were evaluated. However, improved 
myxopyronin production yields could not be observed. Additional experiments to 
3  RESULTS  79 
improve the final yield will be carried out to fully exploit the established mutasynthesis 
systems and to access compound material from the culture extracts after 
biotechnological process optimization. With regard to this bottleneck, engineering the 
efflux pumps of the producer strain might hold promise to improve precursor uptake. 
Furthermore, we focus on establishing a heterologous production system, potentially 
giving rise to higher yields. 
 
Conclusion 
Mutasynthesis represents a powerful approach to produce libraries of natural product 
derivatives, which are difficult to access by purely synthetic routes. Here we 
established the basis of such an approach for the bacterial RNAP inhibitor 
myxopyronin. Mutants of the native myxopyronin producer M. fulvus Mx f50 were 
generated to completely block or at least significantly reduce native western chain 
assembly. Intriguingly most of the synthesized mutasynthons can be successfully 
incorporated via the established mutasynthesis systems. This  indicates that the 
participating enzymes display relatively high tolerance for variations in the substrate 
structure. The substrate specificity of MxnB, which is responsible for the last step of 
myxopyronin biosynthesis, could be evaluated. The mutant with an entirely 
dysfunctional MxnK required the feeding of -keto NAC thioesters (1−12) to generate 
the final products. On the one hand, these substrates allow the highest degree of 
flexibility concerning structural variations of the resulting myxopyronin derivatives, 
due to the late stage of incorporation. On the other hand their synthesis is more 
laborious and the compounds are relatively unstable. Mutants expressing a partially 
functional western-chain assembly line enabled feeding experiments with shorter 
precursors without a -keto function. These mutasynthons are more stable and 
easier to synthesize in large quantities. However, the variability in terms of tolerated 
structural variations is more restricted compared to the -keto mutasynthons. 
Although productivity is currently too low to allow for full characterization of the 
products and thus clearly has to be improved, the established mutasynthesis 
systems provide a comprehensive basis for upcoming studies to generate various 
new myxopyronin derivatives. This will allow us to further exploit this promising class 
of -pyrone antibiotics. The broad western-chain substrate-tolerance in the final 
condensation reaction even allows the exploration of the corallopyronin chemical 
space via the ‘myxopyronin mutasynthesis system’. The resulting compounds could 
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be streamlined to improve their physicochemical properties and potentially overcome 
the problems of existing antibiotic resistances. 
 
Experimental Section 
Bacterial Strains and Culturing Conditions. Bacterial strains and plasmids used 
during this study are listed in Table S1. Myxococcus fulvus Mx f50 wild type and 
mutants were grown in Casitone Yeast (CY) medium (0.3% casitone, 0.1% yeast 
extract, 0.1% CaCl2 x 2 H2O) supplemented with 5 x 10
−4 g L−1 vitamin B12 after 
autoclaving. For liquid cultures, the strains were grown at 30 C and 105 rpm on an 
orbital shaker and harvested after 3 days. E. coli strains were cultured in lysogeny 
broth (LB) medium (1 % tryptone, 0.5% yeast extract, 0.5% NaCl) at 37 C. 
Appropriate antibiotic selection at a final concentration of 100 g mL−1 ampicillin or 
50 g mL−1 kanamycin was added whenever necessary. 
DNA preparations and PCR. M. fulvus Mx f50 genomic DNA was prepared either 
via the Phenol Chloroform Isoamyl alcohol extraction method[40] or by using the 
Gentra Puregene Genomic DNA Purification Kit (Qiagen) according to the 
manufacturer’s protocol. Plasmid DNA was either purified by standard alkaline 
lysis[40] or by using the GeneJet Plasmid Miniprep Kit (Thermo Fisher Scientific). The 
PCR reactions were carried out in a peqSTAR 96 Universal Gradient thermocycler 
(Peqlab): initial denaturation (3 min, 95 C); 30 cycles of denaturation (30 s, 95 C), 
annealing (30 s, 53 or 57 C) and elongation (varied based on PCR product length 1 
kb min−1, 72 C); and final extension (10 min, 72 C). DNA fragments were separated 
by agarose gel electrophoresis and isolated using the peqGold Gel Extraction 
(Peqlab). The PCR products were cloned into the pJET1.2 blunt (Thermo Fisher 
Scientific) vector and sequenced using the primers pJET1.2For/pJET1.2Rev, 
respectively. Primer sequences are listed in Table S2. 
General procedure for site directed mutagenesis of mxnK by in frame deletion 
and by point mutation. In general, construction of in-frame deletion mutants was 
carried out by amplifying 1000−1250 bp homology regions on each side of the 
desired deletion area by PCR. Each fragment was subcloned to the pJET1.2 blunt 
vector and sequenced using the primers pJET1.2For and pJET1.2Rev. After 
sequence verification the homology regions were cloned into the pSWU41 vector,[41] 
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which contains a neomycin phosphotransferase (nptII) and levansucrose (sacB) gene 
cassette, by using restriction sites indicated in Table S2. The resulting constructs 
were subsequently electroporated into M. fulvus Mx f50. M. fulvus Mx f50 was grown 
in baffled flask with CY medium until an OD600 between 0.6-0.9 was reached. Cells 
were then harvested from 2−4 mL culture (1−2 x 109 cells mL−1) by centrifugation at 
12500 rpm for 1 min at room temperature. After two washing steps with 1 mL H2O at 
room temperature, cells were resuspended in 65 l H2O. Plasmid DNA (1−2 g) was 
mixed with the cell suspension, and electroporation was carried out under the 
following conditions: 25 F, 400 Ω, 650 V using 0.1 cm electroporation cuvettes and 
a GenePulser XCell device (Bio-Rad). 1 mL CY medium was directly added to the 
cell suspension immediately after electroporation and the cells were transferred into 
a 2 mL centrifuge tube. After 6−8 h cultivation at 30 C and 800 rpm on a 
thermomixer, the cells were mixed with 2 mL CY soft agar (CY medium containing 
0.7 % agar) and plated on CY agar plates (CY medium containing 1.7% agar) 
supplemented with 50 µg mL−1 kanamycin or 6.25 µg mL−1 oxytetracycline. The 
plates were incubated at 30 C for 7-10 days until colonies became visible.  
For the construction of markerless double crossover mutants the following strategy 
was applied: After verification of the single crossover mutants (kanamycin-resistant 
mutants) by PCR (integration via two different homology regions was possible), a 
selected single crossover mutant was grown in CY medium in the absence of 
antibiotics. After 3−4 days 1 mL of the well-grown culture was transferred into 50 mL 
fresh medium to start another cultivation cycle at 30 °C for 3−4 days. This procedure 
was repeated for three times to increase the possibility for a second crossover event, 
which would result in the loss of the inactivation plasmid. Depending on the 
homology region used for the second crossover this can yield either the wild type 
genotype (‘revertant’) or the expected double crossover mutant strain, in which the 
targeted region is deleted. To select for clones in which a second crossover took 
place, a counter selection system based on the sacB gene was used.[41] For this, 
different dilutions of the cell population were plated on CY agar supplemented with 
6% sucrose for counter selection. After 7−10 days, first colonies appeared, which 
were then grown in liquid culture (CY medium) to isolate genomic DNA for genotypic 
verification and to extract the cultures for phenotypic analysis as described below. 
Inactivation of mxnK by in-frame deletion. To disrupt mxnK by in-frame deletion, a 
gene inactivation plasmid harbouring two fragments, which are 1001 bp and 1262 bp 
82  3.3  PUBLICATION C 
in size and homologous to the upstream and downstream area of the chromosomal 
target region, was constructed. These fragments were amplified from M. fulvus Mx 
f50 genomic DNA by PCR using the primers mxn54/mxn55 and mxn56/mxn57. After 
hydrolysis of the upstream fragment (mxn54/mxn55 product) with BamHI and NotI, 
and the downstream fragment (mxn56/57 product) with NotI and SacI, the fragments 
were ligated into pSWU41 hydrolyzed with BamHI and SacI to generate pHSU-
mxn18. All subcloning steps were performed using E. coli HS996. For genotypic 
analysis of the single crossover, a set of different PCRs using the primer 
combinations mxn68/mxn69, mxn70/mxn72 and mxn73/mxn71 was carried out to 
verify the correct integration of the inactivation plasmid. For genotypic analysis of the 
putative double crossover mutants PCRs using the primers mxn68/mxn71 were 
carried out. Further confirmation of the deletion mutant was obtained by Southern 
Blot analysis (Figure S1). 
Inactivation of mxnK by point mutation at CP-1W. To disrupt mxnK by point 
mutation, a gene inactivation plasmid harbouring 2445 bp fragment was constructed. 
The fragment was amplified from M. fulvus Mx f50 genomic DNA by overlap PCR 
using the primers mxn169/mxn170 and mxn171/mxn172. After hydrolysis of the 
fragment with PvuI and NotI, it was ligated into pSWU41 hydrolyzed with PvuI and 
NotI to generate pHSU-mxn48. For genotypic analysis of the single crossover, a set 
of different PCRs using the primer combinations mxn185/mxn70 and pSWU41-
F/mxn187 was carried out to verify the correct integration of the inactivation plasmid.  
For genotypic analysis of the double crossover, PCR using primer combination 
mxn189/mxn205 was performed and the amplified product was sequenced. 
Inactivation of mxnK by point mutation at CP-4W. To disrupt mxnK by point 
mutation, a gene inactivation plasmid harbouring 2486 bp fragment was constructed. 
The fragment was amplified from M. fulvus Mx f50 genomic DNA by overlap PCR 
using the primers mxn174/mxn175 and mxn176/mxn177. After hydrolysis of the 
fragment with PvuI and NotI, it was ligated into pSWU41 hydrolyzed with PvuI and 
NotI to generate pHSU-mxn49. For genotypic analysis of the single crossover, a set 
of different PCRs using the primer combinations mxn191/mxn70, pSWU41-F/mxn193 
and mxn195/mxn70 was carried out to verify the correct integration of the inactivation 
plasmid. For genotypic analysis of the double crossover, PCR using primer 
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combination mxn195/mxn206 was performed and the amplified product was 
sequenced. 
Feeding for mutasynthesis experiments. A pre-culture of M. fulvus Mx f50ΔmxnK 
or M. fulvus Mx f50ΔCP-1W or M. fulvus Mx f50ΔCP-4W was grown in CY medium at 
30 C until an OD600 between 0.3−0.6. The pre-culture was used to inoculate 20 mL 
CY medium (7.2 x 106 cells mL−1). Cultivation was carried out for further 12−24 hours 
before feeding the substrate mimics. N-acetyl-cysteamine (SNAC)-esters mimicking 
western chain 1-12 were fed to M. fulvus Mx f50ΔmxnK cultures to a final 
concentration of 20-100 μm. While 13-15 were fed to M. fulvus Mx f50ΔCP-1W, 16-18 
were fed to M. fulvus Mx f50ΔCP-4W. They were grown for another 48 hours before 
the cells were harvested. The supernatant was extracted twice with an equal volume 
of ethyl acetate. After evaporation of the organic phase, the residue was dissolved in 
100 µl methanol. Analysis of the crude extract from the cultures using LC-MS showed 
the formation of novel myxopyronin analogs. Further measurements by high-
resolution mass spectrometry confirmed the incorporation of the precursors, showing 
the same type of fragmentation pattern. 
HPLC-MS/MS analysis. All measurements were performed on a Dionex Ultimate 
3000 RSLC system using a Waters BEH C18, 50 x 2.1 mm, 1.7 µm dp column by 
injection of five µl methanolic sample. Separation was achieved by a linear gradient 
with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl min−1 and 45 
°C. The gradient was initiated by a 0.33 min isocratic step at 5 % B, followed by an 
increase to 95 % B in 9 min to end up with a 1 min flush step at 95 % B before 
reequilibration with initial conditions. UV and MS detection were performed 
simultaneously. Coupling the HPLC to the MS was supported by an Advion Triversa 
Nanomate nano-ESI system attached to a Thermo Fisher Orbitrap. Mass spectra 
were acquired in centroid mode ranging from 200−2000 m/z at a resolution of R = 
30000. 
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Abstract: The present work deals with the optimization of an inhibitor of PqsD, an 
enzyme essential for Pseudomonas aeruginosa quorum sensing apparatus. 
Molecular docking studies, supported by biophysical methods (surface plasmon 
resonance, isothermal titration calorimetry, saturation transfer difference NMR), were 
used to illuminate the binding mode of the 5-aryl-ureidothiophene-2-carboxylic acids. 
Enabled to make profound predictions, structure-based optimization led to increased 
inhibitory potency. Finally a covalent inhibitor was obtained. Binding to the active site 
was confirmed by LC-ESI-MS and MALDI-TOF-MS experiments. Following this 
rational approach, potent PqsD inhibitors were efficiently developed within a short 
period of time. This example shows that a combination and careful application of in 
silico and biophysical methods represents a powerful complement to co-
crystallography. 
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Introduction 
Structure-based drug design is a rational strategy to develop bioactive molecules 
without the necessity of performing many rounds of modifications to derive structure 
activity relationships (SAR). Frequently data from X-ray co-crystallography are used 
to accelerate the lead optimization process. Although this method is undeniably 
efficient, there are some drawbacks: a co-crystal structure does not necessarily 
represent the biological state, as it results in a single “frozen” conformation that is 
affected by the crystallization conditions.1,2 Furthermore, especially the ligand may 
not be well defined even at high resolution.3 In some cases, attempts of co-
crystallizing ligands and their targets were not successful forcing the research groups 
to make use of alternative strategies. The described problems can be overcome by 
the use of biophysical methods such as surface plasmon resonance (SPR), nuclear 
magnetic resonance (NMR) and isothermal titration calorimetry (ITC). An advantage 
of SPR, NMR and ITC is that they can be performed in aqueous solution, which can 
be considered almost “physiological” conditions.  
In the forefront of this work, compound 1 (Figure 1a) was identified as an inhibitor of 
PqsD. The target protein PqsD, is a key player in the quorum sensing system of P. 
aeruginosa. It mediates the formation of heptyl-4-hydroxy-quinoline (HHQ) which is 
the precursor of Pseudomonas quinolone signal (PQS) (Scheme 1). Both molecules 
are potent virulence factors and function as signal molecules of P. aeruginosa, 
coordinating group behavior like the formation of biofilms.4,5 The substrate channel of 
PqsD is about 15 Å long and rather narrow.6 The channel can be divided into three 
parts. A positively charged entrance followed by a mainly hydrophobic middle 
segment, ending in a polar bottom part. The latter is delimited by the catalytic 
residues Cys112, His257 and Asp287. Suppression of PqsD activity has been shown 
recently by our group to inhibit biofilm formation.7 This makes PqsD an attractive 
target for the therapy of chronic P. aeruginosa infections, especially in 
immunosuppressed individuals.8–10 
Herein, we report on the optimization of 1 supported by biophysical methods and 
molecular docking. The approach described in the following, represents a hit to lead 
optimization process that does not involve co-crystallographic structure 
determination. 
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Scheme 1. Biosynthesis of signaling molecules HHQ and PQS in Pseudomonas 
aeruginosa.
 
Anthranilate is transferred to PqsD via thio-esterification of ACoA with Cys112. The 
next step is a condensation with acetyl carrier protein (ACP) bound -ketodecanoic acid to form 
HHQ, which is finally transformed to PQS by PqsH. 
Results and discussion 
The IC50 value of compound 1 (Figure 1a) against PqsD was determined in a 
functional enzyme assay11 to be 6 µM. The same compound has recently been 
reported as a weak inhibitor of bacterial RNA polymerase (IC50: 241 µM)
12, a 
classical target for antibacterial therapy. While targeting quorum sensing an 
antibacterial effect is not desired to avoid selection pressure inevitably leading to the 
development of resistant strains.13 Thus, other potential hit candidates from the 5-
aryl-ureidothiophene-2-carboxylic acid class, displaying poor selectivity, were not 
considered for further optimization (see Table S1 in Supporting Information). 
 
Figure 1. a) Compound 1. Biophysical characterization of 1: b) Thermogram (red) and titration 
curve (black) obtained from ITC of PqsD with 1; c) SPR experiment: ACoA binds to PqsD (black). 
ACoA binding is inhibited by preincubation with 1 (red). The reference signal is shown in grey. 
Attempts to obtain a co-crystal-structure of 1 and PqsD, using soaking techniques, 
were not successful. Therefore, a combination of biophysical methods and molecular 
docking was used to elucidate the binding mode of 1. To exclude a non-specific 
binding behavior (e.g. via aggregation), 1 was examined in an isothermal titration 
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calorimetry (ITC) experiment to ensure stoichiometric binding. Thereby an equimolar 
binding ratio (0.82 ± 0.05) with a KD of 6.3 ± 2.6 µM was determined (Figure 1b), 
confirming that the discovered class of compounds represents a promising starting 
point for further optimization. 
In order to clarify the binding site on PqsD, SPR experiments were conducted. It was 
shown, that the natural substrate ACoA can no longer bind to the enzyme when 
PqsD was preincubated with 1 (Figure 1c). This result indicates that 1 binds inside 
the ACoA-channel, thus blocking the first step of the catalytic reaction.  
From docking simulations with 1, two putative binding modes with similar scoring 
values but reverse orientations were obtained. In the first pose (Figure 2; orange), 
the ureido N-ethyl-benzyl moiety points to the bottom of the pocket (delimited by 
Cys112, His257 and Asn287), whereas in the second pose (Figure 2; green), the 
methoxy-group is placed in this position.  
 
Figure 2. Docking poses of 1 within the ACoA channel of PqsD: (orange; Vina-Score: 8.3 kcal 
mol−1) (green; Vina-Score: 8.2 kcal mol−1). 
To get a reliable starting point for a structure-based optimization, discrimination 
between the two poses was necessary. Therefore, we designed an SPR competition 
experiment with model compounds 1−3 from the 5-aryl-ureidothiophene-2-carboxylic 
acid class, differently substituted in the ureido and aryloxy parts (Figure 3b). As 
competitor compounds the 2-nitrophenyl-methanols A and B were used (Figure 3a). 
They were recently reported as PqsD inhibitors7 and were shown to interact with the 
catalytic residues, especially Cys112, at the bottom of the ACoA-channel.14 
As illustrated in Figure 3a, the presence of A and B should influence the binding of 
the ureidothiophene model compounds depending on their substitution pattern. 
Compared with 2, 1 bears a large substituent at the ureido part, whereas 3 is 
elongated in the aryloxy part, at the opposite site. If the ureido part points to the 
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bottom of the pocket, one would expect that 1 is more sterically hindered than 2 and 
3, when the competitors are present. In contrast, the longer aryloxy part of 3 should 
lead to a reduced binding if the ureidothiophenes bind in the reversed orientation. In 
the absence of a competitor compound, 1−3 displayed comparable responses 
(Figure 3c). When the sterically less demanding 2-nitrophenyl-methanol derivative A 
was present, a reduction of affinity was observed exclusively for 3 bearing a bulky 
phenyl substituent in the aryloxy part. In contrast, the ethyl-benzyl moiety at the 
ureido motif of 1 did not prevent a binding. These results fit to the docking prediction 
with the aryloxy part pointing into the pocket (Figure 2, green). In competition with B, 
the binding affinity of all three compounds was reduced as expected from the docking 
results. (see Figure S1 and S2) Thus a deeper insight into the position of the new 
inhibitors in the binding channel was provided. 
 
Figure 3. a) Schematic illustration of the SPR competition experiments: PqsD was preincubated 
with competitor compounds A and B binding to the ACoA-channel, delimited by Cys112. The 
model compounds 1−3 were subsequently added and the influence of A or B on their binding 
behaviors was investigated. The results shed light on the binding mode of the aryl-
ureidothiophene-2-carboxylic acids. b) Structures of the model compounds 1−3 c) Results from 
SPR-competition experiments suggest the aryloxy-moiety to point into the pocket. 
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Figure 4. a) Docking pose of 2, the starting point for structure-based optimization. b) Docking 
pose of glycine derivative 4. c) Docking pose of optimized compound 7. d) Illustration of the 
limited space in the narrow cleft formed by Arg223 and Phe226. e) Close-up of the benzyl moiety 
of 7, perfectly fitting into the narrow cleft. 
As the starting point for structure activity exploration compound 2 was chosen, a 
truncated derivative of the initial hit 1. It displays comparable ligand efficiency (LE, 
Table 1) whilst being more suitable for further modification at the ureido motif. The 
docking pose of 2 (Figure 4a) suggests an anchoring of the ureido moiety by 
interaction of the carbonyl oxygen with Arg223. To validate this assumption, binding 
of 2 to the R223A mutant, that should display weaker affinity, was investigated by 
SPR. The response of compound 2 was reduced to 6 response units (RU) in 
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comparison to 25 RU for the wild type enzyme (see Figure S4), confirming this 
hypothesis. Arg262, placed in the upper part of the binding pocket, should be a 
potential interaction partner for a negatively charged moiety. The introduction of a 
carboxylate resulting in compounds 4 and 5 (Table 1) indeed led to an increased 
activity, confirming this prediction. In the docking pose, the introduced carboxylic acid 
moiety of 4 is located closely to Arg262 enabling the formation of a new interaction 
(Figure 4b). Based on the finding that 4 is more active than 5, we concluded that a 
methylene linker is more appropriate than a longer spacer unit. This allowed making 
use of α amino acids for simple variations in the next steps, taking advantage of their 
hydrophilicity to increase the polarity of the inhibitors, as low lipophilicity is an 
important requirement for drugs targeting Gram negative bacteria. A study of O’Shea 
et al. shows that almost all antibiotics, effective against P. aeruginosa, possess a 
clogD7.4 value below 0.
15 While our hit compound 1 (logD7.4: 2.58) did not meet this 
criterion, amino acid derivative 4 (logD7.4: −1.62) did 
As illustrated in Figure 4b, docking simulations predict that the glycine derivative 4 is 
anchored by an interaction of the carboxylate group with Arg262. The narrow cleft, 
subjacent to the α-position of 4 and delimited by Arg223 and Phe226, is supposed to 
be addressable by expansion of 4. A targeted approach should replace the pro-S 
hydrogen since the space adjacent to the pro-R hydrogen is blocked by Arg223, 
which could lead to a sterical clash (Figure 4d). Following this strategy, the 
introduction of S-amino acid residues improved the activity resulting in up to 
submicromolar IC50 values in case of the S-alanine and S-phenylalanine derivative 6 
and 7 (Figure 4b−e). Compound 8, the counterpart of 7 that lacks the COOH group 
next to the ureido moiety displays a significantly weaker inhibition. This again 
highlights the importance of the carboxylic acid group, which is in accordance with 
our binding hypothesis. 
In order to complete the picture, the R-enantiomers 9 and 10 were investigated. In 
both cases the activity decreased dramatically. These data corroborate the highly 
selective three-dimensional interaction formed by the S-enantiomeric moieties with 
the target enzyme. To evaluate whether the decreased activity of the R-enantiomer 9 
is due to a sterical clash, as expected, or associated with the absence of the S-
methyl group of 6, the dimethyl compound 11 was investigated. The fact that 11 was 
less active than 4 and 6 confirms the prediction of a sterical collision. 
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To test for selectivity towards bacterial RNA polymerase, the most potent derivatives 
6 and 7 were tested for inhibition of this enzyme. Both displayed only slight inhibitory 
potency (~10−20%) at a concentration of 200 µM. 
Table 1. Inhibition of PqsD in vitro, ligand efficiencies and clogD7.4 values of 
compounds 1−11 
 
Cpd R IC50 
PqsD 
LE
[a] 
clogD7.4
[b] 
1 
 
 
6 µM 0.25 2.58 
2  170 µM 0.26 0.15 
4 
 
7 µM 0.30 −1.62 
5 
 
37 µM 0.25 −1.47 
6 
 
2 µM 0.32 −1.27 
7 
 
0.5 µM 0.28 0.59 
8 
 
58 µM 0.21 2.61 
9 
 
54 µM 0.24 −1.27 
10 
 
26 µM 0.19 0.59 
11 
 
56 µM 0.23 −0.93 
[a] 
Ligand efficiency calculated as LE = 1.4 x (pIC50/HAC) 
[b]
 clogD7.4 calculated with ACDLabs Percepta 2012 
 
Saturation transfer difference (STD) NMR16 was used to identify the binding epitopes 
of 7 (Figure S5). Strong STD enhancements were observed for all protons of 7 with 
the methylene linker protons exhibiting the strongest enhancements. This is 
94  3.4  PUBLICATION D 
 
consistent with the docking simulations, which predict these methylene protons to be 
positioned at the entrance of the narrow subpocket delimited by Arg223 and Phe226. 
Moreover, the fact that the other protons of 7 also displayed strong STD 
enhancements suggests that 7 is nearly completely surrounded by PqsD.  
 
 
Figure 5. Competition of 7 and B binding to PqsD by STD NMR. Expanded 
1
H STD NMR 
spectrum of 7 (1 mM) in the presence of PqsD (10 µM) (black curve). STD NMR spectra recorded 
on the same sample after addition of 0.5 (purple), 1.0 (green), 2.0 (red) and 3.0 (blue) equivalents 
of compound B. Signals of 7 are labeled in black, from B in blue. 
To confirm that the optimized inhibitors bind in a similar way as the model 
compounds 1−3, the SPR-competition experiment with A and B was conducted for 
compound 7. As expected, the binding response was only significantly reduced in the 
presence of B (Figure S3). In addition, we performed an STD-NMR competition 
experiment to validate the SPR results. Increasing amounts of compound B were 
added to a 100:1 complex of 7/PqsD (Figure 5). Difference spectra were monitored 
for a change in intensity of signals belonging to either 7 or B during titration. As seen 
in the spectral expansions showing the aromatic region, stepwise addition of up to 
3.0 equivalents of B with respect to 7 resulted in a uniform decrease in intensity for 
signals corresponding to 7 while signals ascribable to B appeared and steadily 
increased. This confirms that 7 binds deep inside the ACoA-channel of PqsD. 
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Finally, we focused on the substituted 5-aryl ring that is predicted to be located near 
the active site within the ACoA channel (Figure 4). As already shown with phenoxy 
compound 3 (IC50 = 20 µM), larger substituents are tolerated in this part of the 
binding pocket. As Cys112 is pivotal for the catalytic activity of PqsD, a covalent 
trapping of this amino acid should lead to an effective blockade of the enzymatic 
machinery. For that purpose a β-chloroacetyl moiety was introduced, as an 
“electrophilic warhead”,17 at the appropriate position, linked to the 5-aryl ring via an 
amide function (Figure 6a). 
 
Figure 6. a) Schematic illustration of the proposed trapping of Cys112 by the introduced 
electrophilic warhead of 12. MALDI-TOF-MS after tryptic digestion. The mass of the fragment 
containing Cys112 is highlighted in red b) PqsD c) PqsD after incubation with 12. Signals below 
3% intensity were removed for the sake of clarity (raw data is shown in Figure S6 and S7). 
The resulting compound 12 (clogD7.4: −0.59) displays an IC50 value of 2 µM. The 
covalent binding of 12 to PqsD was demonstrated by LC-ESI-MS. The PqsD peak 
(m/z = 36687.5 [M+H]+) shifted after preincubation with 12 to the calculated adduct 
mass (m/z = 37153.1 [M+H]+) (Figure S8). To evaluate whether indeed Cys112 is 
targeted by 12, the tryptically digested protein was analyzed by MALDI-TOF-MS. The 
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signal of the fragment containing Cys112, with a calculated m/z = 1510.8 [M+H]+, 
was found in the reference sample without inhibitor. In the sample treated with 12, 
this signal was absent while two new peaks at m/z = 1975.9 and 1931.9 [M+H]+ 
appeared (Figure 6b,c). The former fits to the Cys112 fragment with covalently bound 
12. The latter refers to its fragmentation product missing a carboxylic acid moiety. 
Taking into account that a long residence time at the active site is considered 
important for in vivo potency of the inhibitor,18 covalently binding compound 12 
carries the potential of strong biological effects. 
Conclusions 
In conclusion, we optimized the PqsD inhibitor 1, following a novel approach. First, 
an equimolar binding behavior to the target protein PqsD was determined by ITC. 
The binding mode was elucidated by examination of three model compounds (1−3) in 
SPR competition experiments. To the best of our knowledge, this is the first example 
of such an approach. These findings allowed profound docking calculations guiding 
our subsequent structure-based optimization process. This approach culminated in 
an irreversible inhibitor, which covalently binds to the active site of PqsD as 
predicted. The optimization of activity was accompanied by reduced lipophilicity 
(Table 1), caused by the introduction of amino acids at the ureido motif. According to 
the literature, this should facilitate permeation into Gram negative cells.15  
For several drug targets, inhibitors with known binding sites and the protein crystal 
structures are available. In such cases, the presented approach of determining the 
binding mode can be helpful to guide a structure-based design of new inhibitors, 
especially if co-crystallization fails. 
While we mainly focused on the inhibitory potency at this early point of development, 
structural variations leading to more drug-like properties (e.g. bio-isosteric exchange 
of the carboxylic groups) remains a challenging task and will be an element of future 
work. Additional efforts will also include studies on intracellular activity and inhibition 
of biofilm formation in P. aeruginosa. In the present study, shortcomings of in silico 
docking simulations (prediction of multiple binding modes) were compensated by the 
use of biophysical methods. This rational approach represents a powerful 
complement to X-ray co-crystallography and should be applicable to many drug 
targets with known ligands. 
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Experimental section 
Materials and Methods. Starting materials were purchased from commercial 
suppliers and used without further purification. Column flash chromatography was 
performed on silica gel (40–63 µM), and reaction progress was monitored by TLC on 
TLC Silica Gel 60 F254 (Merck). All moisture-sensitive reactions were performed 
under nitrogen atmosphere using oven-dried glassware and anhydrous solvents. 1H 
and 13C NMR spectra were recorded on Bruker Fourier spectrometers (500/300 or 
176/126/75 MHz) at ambient temperature with the chemical shifts recorded as δ 
values in ppm units by reference to the hydrogenated residues of deuteriated solvent 
as internal standard. Coupling constants (J) are given in Hz and signal patterns are 
indicated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; m, 
multiplet, br., broad signal. The purity of the final compounds was >95% except for 12 
(90%) measured by HPLC. The Surveyor LC system consisted of a pump, an 
autosampler, and a PDA detector. Mass spectrometry was performed on a MSQ 
electrospray mass spectrometer (ThermoFisher, Dreieich, Germany). The system 
was operated by the standard software Xcalibur. A RP C18 NUCLEODUR 100-5 
(125 mm x 3 mm) column (Macherey-Nagel GmbH, Dühren, Germany) was used as 
the stationary phase. All solvents were HPLC grade. In a gradient run the percentage 
of acetonitrile (containing 0.1% trifluoroacetic acid) was increased from an initial 
concentration of 0% at 0 min to 100% at 15 min and kept at 100% for 5 min. The 
injection volume was 10 µL, and flow rate was set to 800 µL/min. MS analysis was 
carried out at a spray voltage of 3800 V and a capillary temperature of 350 °C and a 
source CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z at 
254 nm for the UV trace.  
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Chemistry 
General synthesis procedures. Experimental details on synthesis of 12 can be 
found in the Supporting Information. 
 
Scheme S1: Synthesis of 5-aryl-3-ureidothiophene-2-carboxylic acids. 
Method A, general procedure for the synthesis of 5-aryl-3-amino-2-carboxylic acid 
methylester (II):19  
POCl3 (26.1 g, 0.17 mol) was added dropwise to DMF (24.9 g, 0.34 mol) maintaining 
the temperature below 25 °C (cooling in ice bath) and stirred for additional 15 min. 
The acteophenone I (85.0 mmol) was added slowly and the temperature was kept 
between 40 and 60 °C. After complete addition, the mixture was stirred for 30 
minutes at room temperature. Hydroxylamine hydrochloride (23.6 g, 0.34 mol) was 
carefully added portionwise (exothermic reaction!) and the reaction was stirred for 
additional 30 min without heating. After cooling to room temperature, the mixture was 
poured into ice water (300 mL). The precipitated β-chloro-cinnamonitrile was 
collected by filtration, washed with H2O (2 x 50 mL) and dried under reduced 
pressure over CaCl2. In the next step sodium (1.93 g, 84.0 mmol.) was dissolved in 
MeOH (85 mL) and methylthioglycolate (6.97 g, 65.6 mmol) was added to the stirred 
solution. The β-chloro-cinnamonitrile (61.1 mmol) was added and the mixture was 
heated to reflux for 30 min. After cooling to room temperature, the mixture was 
poured in ice water (300 mL). The precipitated solid was collected by filtration, 
washed with H2O (2 x 50 mL) and dried under reduced pressure over CaCl2. If 
necessary, recrystallisation was performed from EtOH.   
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Method B, general procedure for the synthesis of 5-aryl-3-amino-2-carboxylic acid 
(III):  
The 5-aryl-3-amino-2-carboxylic acid methyl ester II (16.6 mmol) was added to a 
solution of KOH (60 mL, 0.6M in H2O) and MeOH (60 mL). The mixture was heated 
to reflux for 3 h, concentrated, and washed with EtOAc (2 x 50 mL). The aqueous 
layer was cooled with ice and acidified with a saturated aqueous solution of KHSO4. 
The precipitated solid was collected by filtration, washed with H2O (2 x 30 mL) and 
dried under reduced pressure over CaCl2. 
Method C, general procedure for the synthesis of 5-aryl-2-thiaisatoic-anhydrid 
(IV):20,21 
To a solution of the 5-aryl-3-amino-2-carboxylic acid (III) (5.28 mmol) in THF (50 mL) 
a solution of phosgene (6.10 mL, 20 wt% in toluene, 11.6 mmol) was added dropwise 
over a period of 30 min. The reaction mixture was stirred for 2 h at room temperature, 
followed by the addition of saturated aqueous solution of NaHCO3 (30 mL) and H2O 
(50 mL). The resulting mixture was extracted with EtOAc/THF (1:1, 3 x 100 mL). The 
organic layer was washed with saturated aqueous NaCl (100 mL), dried (MgSO4) and 
concentrated. The crude material was suspended in a mixture of n-hexane/EtOAc 
(2:1, 50 mL) heated to 50 °C and after cooling to room temperature separated via 
filtration. 
Method D, general procedure for the synthesis of of 5-aryl-3-ureidothiophene-2-
carboxylic acid (V):22 
The 5-aryl-2-thiaisatoic-anhydrid (IV) (0.46 mmol) was suspended in water (7.5 mL) 
and the appropriate amine (4.60 mmol) was added. The reaction mixture was stirred, 
heated to 100 °C and then cooled to room temperature. The reaction mixture was 
poured into a mixture of concentrated HCl and ice (1:1) and extracted with 
EtOAc/THF (1:1, 60 mL). The organic layer was washed with aqueous HCl (2M), 
followed by saturated aqueous NaCl (2 x 50 mL), dried (MgSO4) and concentrated. 
The crude material was suspended in a mixture of n-hexane/EtOAc (2:1, 20 mL) 
heated to 50 °C and after cooling to room temperature separated via filtration. 
Spectroscopic data of final compounds and intermediates can be found in the 
Supporting Information. Compound 7 is presented as example. 
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(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-
carboxylic acid (7). 
1H NMR (DMSO-d6, 300 MHz): δ = 12.84 (br. s., 2 H, COOH), 9.42 (s, 1 H), 8.15 (d, J 
= 7.9 Hz, 1 H), 8.09 (s, 1 H), 7.69−7.51 (m, J = 8.8 Hz, 2 H), 7.37−7.25 (m, 4 H), 
7.25−7.17 (m, 1 H), 7.03−6.97 (m, J = 8.8 Hz, 2 H), 4.56−4.28 (m, 1 H), 3.79 (s, 3 H, 
OCH3), 3.11 (dd, J = 13.9, 4.6 Hz, 1 H), 2.88 (dd, J = 13.9, 9.8 Hz, 1 H) ppm. 
13C 
NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.6, 160.1, 153.7, 147.1, 145.9, 137.7, 
129.0, 128.2, 127.1, 126.4, 125.4, 116.7, 114.7, 105.8, 55.3, 54.4, 36.9 ppm. 
Biology and Biophysics 
General procedure for expression and purification of recombinant PqsD WT 
and R223A mutant in E. coli. His6-tagged PqsD (H6-PqsD) and mutants were 
expressed in E. coli and purified using a single affinity chromatography step. Briefly, 
E. coli BL21 (λDE3) cells containing the pET28b(+)/pqsD (kindly provided by Prof. 
Rolf Müller) were grown in LB medium containing 50 µg/mL kanamycin at 37 °C to an 
OD600 of approximately 0.8 units and induced with 0.2 mM IPTG for 16 h at 16 °C. 
The cells were harvested by centrifugation (5,000 rpm, 10 min, 4 °C) and the cell 
pellet was resuspended in 100 mL binding buffer (10 mM Na2HPO4, 2 mM KH2PO4 
pH 7.4, 3 mM KCl, 137 mM NaCl, 20 mM imidazole, 10% glycerol (v/v)) and lysed by 
sonication for a total process time of 2.5 min. Cell debris were removed by 
centrifugation (18500 rpm, 40 min, 4 °C) and the supernatant was filtered through a 
syringe filter (0.20 μm). The clarified lysate was immediately applied to a Ni-NTA 
column, washed with binding buffer and eluted with 500 mM imidazole. The protein 
containing fractions were buffer-exchanged into 125 mM Na2HPO4, 50 mM KH2PO4 
pH 7.6, 50 mM NaCl, 10% glycerol (v/v), using a PD10 column and judged pure by 
SDS-PAGE analysis. Then protein was stored in aliquots at –80 °C. 
Screening assay procedure for in vitro PqsD inhibition.11 The assay was 
performed monitoring enzyme activity by measuring HHQ formed by condensation of 
anthraniloyl-CoA and β-ketodecanoic acid. The reaction mixture contained MOPS 
buffer (0.05 M, pH 7.0) with 0.005% (w/v) Triton X-100, 0.1 µM of the purified enzyme 
and inhibitor. The test compounds were dissolved in DMSO and diluted with buffer. 
The final DMSO concentration was 0.5%. After 10 min preincubation at 37 °C, the 
reaction was started by the addition anthraniloyl-CoA to a final concentration of 5 µM 
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and -ketodecanoic acid to a final concentration of 70 µM. Reactions were stopped 
by addition of MeOH containing 1 µM amitriptyline as internal standard for LC/MS-MS 
analysis. HHQ was quantified using a HPLC-MS/MS mass spectrometer 
(ThermoFisher, Dreieich, Germany) in ESI mode. Ionization of HHQ and the internal 
standard amitriptyline was optimized in each case. The solvent system consisted of 
10 mM ammonium acetate (A) and acetonitrile (B), both containing 0.1% 
trifluoroacetic acid. The initial concentration of B in A was 45%, increasing the 
percentage of B to 100% in 2.8 min and keeping it at 98% for 0.7 min with a flow of 
500 µL/min. The column used was a NUCLEODUR-C18, 100-3/125-3 (Macherey & 
Nagel, Duehren, Germany). Control reactions without the inhibitor, but including 
identical amounts of DMSO, were performed in parallel and the amount of HHQ 
produced was set to 100%. All reactions were performed in triplicates. 
RNAP-transcription assay. E. coli RNA polymerase holo enzyme was purchased 
from Epicentre Biotechnologies (Madison, WI). Final concentrations in a total volume 
of 30 µL were one unit of RNA polymerase (0.5 µg) which were used along with 60 
nCi of [5,6-3H]-UTP, 400 µM of ATP, CTP and GTP as well as 100 µM of UTP, 20 
units of RNAse inhibitor (RiboLock, Fermentas), 10 mM DTT, 40 mM Tris-HCl (pH 
7.5), 150 mM KCl, 10 mM MgCl2 and 0.1% CHAPS. As a DNA template 3500 ng of 
religated pcDNA3.1/V5-His-TOPO were used per reaction.23 Prior to starting the 
experiment, the compounds were dissolved in DMSO (final concentration during 
experiments: 2%). Dilution series of compounds were prepared using a liquid 
handling system (Janus, Perkin Elmer, Waltham, MA). The components described 
above (including the inhibitors) were preincubated in absence of NTPs and DNA for 
10 min at 25 °C. Transcription reactions were started by the addition of a mixture 
containing DNA template and NTPs and incubated for 10 min at 37 °C. The reaction 
was stopped by the addition of 10% TCA, followed by a transfer of this mixture to a 
96 well Multiscreen GFB plate (Millipore, Billerica, MA) and incubation for 45 min at 4 
°C. The plate underwent several centrifugation and washing steps with 10% TCA and 
95% ethanol to remove residual unincorporated 3H-UTP. After that the plate was 
dried (30 min, 50 °C) and 30 µL of scintillation fluid (Optiphase Supermix, Perkin 
Elmer) was added to each well. After 10 min the wells were assayed for presence of 
3H-RNA by counting using a Wallac MicroBeta TriLux system (Perkin Elmer). To 
obtain inhibition values for each sample, their counts were related to DMSO controls. 
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Surface plasmon resonance. SPR binding studies were performed using a Reichert 
SR7500DC instrument optical biosensor (Reichert Technologies, Depew, NY, USA) 
and CMD500M (carboxymethyl dextrane-coated) sensor chips obtained from XanTec 
(XanTec Bioanalytics, Düsseldorf, Germany). 
Immobilization of wild type PqsD and R223A mutant. PqsD was immobilized on a 
CMD500M  sensor chip at 12 °C using standard amine coupling analogous to the 
manufacturers’ instructions. PqsD was diluted into sodium acetate buffer (10 mM, pH 
4.5) to a final concentration of 100 µg/mL. PqsD was immobilized at densities 
between 5000-6000 RU for binding studies and for mutagenesis studies. The PqsD 
mutant was immobilized analogously to the wild type. 
Competition studies. The competition studies were performed at a constant flow 
rate of 50 µL/min in instrument running buffer (50 mM MOPS, pH 8.0, 150 mM NaCl, 
5% DMSO (v/v), 0.1% Triton X 100 (v/v)). 10 mM stock solutions of compounds 1, 2 
and 3 in DMSO were directly diluted to a concentration of 500 µM (50 mM MOPS, pH 
8.0, 150 mM NaCl, 0.1% Triton X-100 (v/v)) and then diluted to a final concentration 
of 100 µM in running buffer (50 mM MOPS, pH 8.0, 150 mM NaCl, 5% DMSO (v/v), 
0.1% Triton X 100 (v/v)). Final concentration of DMSO was retained at 5% (v/v). 
Before the compounds were injected, 6 warm-up blank injections were performed. 
Buffer blank injections and DMSO calibration were included for double referencing. 
ACoA competition. PqsD was preincubated with compound 1, therefore 1 was 
added to the running buffer (100 µM). The sensor chip surface was flushed for 
several hours at a constant flow rate of 50 µL/min until the baseline was stable. 
Afterwards the flow rate was decreased to 10 µL/min and ACoA was injected (100 
µM) twice for 120 s association and 15 min dissociation times. 
Competitor competition. PqsD was preincubated with compounds A or B, therefore 
the competitor compound was added to the running buffer (100 µM). The sensor chip 
surface was flushed for several hours at a constant flow rate of 50 µL/min until the 
baseline was stable. Afterwards the flow rate was decreased to 10 µL/min and 
compound 1, 2 or 3 were injected (100 µM) twice for 120 s association and 300 s 
dissociation times. Due to a slow koff rate of the competitor compounds, kD values 
referring to the concentrations do not play a decisive role during the competition 
experiment. 
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Studies with R223A mutant. The experiments were performed at a constant flow 
rate of 50 µL/min in instrument running buffer (50 mM MOPS, pH 8.0, 150 mM NaCl, 
5% DMSO (v/v), 0.1% Triton X 100 (v/v)) at 12 °C. 10 mM stock solutions of 
compounds 1 or 2 in DMSO were diluted to a concentration of 100 µM analogous to 
the binding studies. Before the compound was injected, twelve warm-up blank 
injections were performed. The obtained data were referenced against blank 
injections and DMSO calibration. The compounds were injected twice for 120 s 
association and 300 s dissociation time. Scrubber software was used for processing 
and analysing data. 
Isothermal titration calorimetry. ITC experiments were carried out using an ITC200 
instrument (Microcal Inc., GE Healthcare). Concentration of the ligand in DMSO stock 
solutions was 20 mM. Final ligand concentrations were achieved by diluting 1:20 (v/v) 
in the experimental buffer resulting in a final DMSO concentration of 5% (v/v). Protein 
concentration was determined by measuring the absorbance at 280 nm using a 
theoretical molarity extinction coefficient of 17,780 M−1 cm−1. DMSO concentration in 
the protein solution was adjusted to 5% (v/v). ITC measurements were routinely 
performed at 25 °C in PBS-buffer, pH 7.4, 10% glycerol (v/v), 5% DMSO (v/v). The 
titrations were performed on 100 μM PqsD-His6 in the 200 µL sample cell using 2 µL 
injections of 1.0 mM ligand solution every 180 s. Raw data were collected and the 
area under each peak was integrated. To correct for heats of dilution and mixing the 
final baseline consisting of small peaks of the same size at the end of the experiment 
was subtracted. The experimental data were fitted to a theoretical titration curve (one 
site binding model) using MicroCal Origin 7 software, with ΔH (enthalpy change in 
kcal mol−1), KA (association constant in M
−1), and N (number of binding sites) as 
adjustable parameters. Thermodynamic parameters were calculated from equation: 
ΔG = ΔH−TΔS = RT ln KA = −RT ln KD 
where ΔG, ΔH, and ΔS are the changes in free energy, enthalpy, and entropy of 
binding, respectively, T is the absolute temperature, and R = 1.98 cal mol−1 K−1. For 
compound 1 four independent experiments were performed. 
Saturation transfer difference NMR. All NMR data were recorded at 298 K on a 
Bruker Avance 500 NMR instrument equipped with a cryogenically cooled z-shielded 
gradient probe. Experiments were recorded with the carrier set at -2 ppm for on-
104  3.4  PUBLICATION D 
 
resonance irradiation and 40 ppm for off-resonance irradiation. Control spectra were 
recorded under identical conditions on samples containing free compound 7 to test 
for artifacts. Selective protein saturation (3 s) was accomplished using a train of 50 
ms Gauss-shaped pulses, each separated by a 1 ms delay, at an experimental 
determined optimal power (50 dB on our probe); a T1ρ filter (15 ms) was 
incorporated to suppress protein resonances. Experiments were recorded using a 
minimum of 512 scans and 32K points. On- and off-resonance spectra were 
processed independently, and subtracted to provide a difference spectrum. Samples 
containing 7 and PqsD at final concentrations of 1 mM and 10 µM, respectively, were 
prepared in 20 mM sodium phosphate, 50 mM NaCl, and 5 mM MgCl2, pH 7.0. 
LC-ESI-MS. PqsD (25 µM) was preincubated with compound 12 (25 µM) for 30 min 
at 37°C in Tris-HCl buffer (0.05 M, pH 8.0) with 0.5% DMSO. Dithiothreitol was 
added and the samples were analyzed by HPLC-ESI. All ESI-MS-measurements 
were performed on a Dionex Ultimate 3000 RSLC system using an Aeris Widepore 
XB-C8, 150 x 2.1 mm, 3.6 µm dp column (Phenomenex, USA). Separation of 2 µl 
sample was achieved by a linear gradient from (A) H2O + 0.05% TFA to (B) ACN + 
0.05% TFA at a flow rate of 250 µl/min and 45 °C. The gradient was initiated by a 
1.0 min isocratic step at 15% B, followed by an increase to 80% B in 4.5 min to end 
up with a 6 min step at 80% B before re-equilibration with initial conditions. UV 
spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was 
split to 75 µl/min before entering the maXis 4G hr-ToF mass spectrometer (Bruker 
Daltonics, Bremen, Germany) using the standard Bruker ESI source. In the source 
region, the temperature was set to 180°C, the capillary voltage was 4000 V, the dry-
gas flow was 6.0 l/min and the nebulizer was set to 1.1 bar. Mass spectra were 
acquired in positive ionization mode ranging from 600 – 1800 m/z at 2.5 Hz scan 
rate. Protein masses were deconvoluted by using the Maximum Entropy algorithm 
(Copyright 1991-2004 Spectrum Square Associates, Inc.). 
MALDI-TOF-MS. PqsD (10 µM) was preincubated with compound 12 (10 µM) for 60 
min at 37°C using identical buffer composition as in the screening assay procedure 
(0.05 M MOPS, pH 7.0 with 0.005 % (w/v) Triton X-100 and 0.5 % DMSO). The 
buffer was exchanged by an NH4HCO3 buffer (0.05 M, pH 8.1) in three diafiltration 
steps. Diafiltration was performed at 1200 g for 6 min at 4°C in Nanosep® Centrifugal 
Devices (MWCO = 10K) of Pall Corporation (Port Washington, NY, USA). The protein 
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was digested with trypsin overnight and dithiothreitol was added. α-Cyano-4-
hydroxycinnamic acid was used as matrix component. Analyzes of the peptides were 
performed on a 4800 TOF/TOF Analyzer mass spectrometer (Applied Biosystems, 
Darmstadt, Germany) in positive reflector mode using a pulsed 200 Hz solid state 
Nd:YAG laser with a wavelength of 355 nm. Laser energy was set to 2000–2300 
units for standards and to 2700–3200 units for real samples. Source 1 voltage was 
set to 20 kV with a grid voltage of 16 kV. Reflector detector voltage was 2.19 kV. 
Spectra of standard peptides used for wide range calibration ranging from 0.8 to 4 
kDa (des-arg1-bradykinin, angiotensin I, glu1-fibrinopeptide B, ACTH 1–17 clip, 
ACTH 18–39 clip and ACTH 7–38 clip) were measured with a delay time of 600 ns. 
One single mass spectrum was formed from 20 subspectra per spot using 25 
accepted laser impulses each. From the standard peptides exclusively monoisotopic 
ions were used with a minimum signal-to-noise (S/N) ratio of 20 and a resolution 
>10000. Mass tolerance was set to 0.3 Da with maximum outlier of 5 ppm. Accepted 
calibration settings were used to measure real sample spectra in the range of 1 to 3.5 
kDa with a minimum S/N range of 10 and a resolution >8000. An internal algorithm 
defined the isotope cluster area subsequently named intensity (I), based on the 
peptides’ molecular weight and their general elemental composition. MALDI-TOF-MS 
resulted in pmfs consisting of mass-intensity spectra (m/z–Iabs, ai). 
Molecular Modeling 
Docking. Inhibitors were built in Molecular Operating Environment (MOE).24 The 
receptor was derived from the co-crystal structure of anthraniloyl coenzyme A with 
PqsD (PDB Code: 3H77)6 ACoA, the covalently bound anthranilate and H2O were 
removed and Cys112 was restored considering its conformation in 3H76.6 
AutoDockTools V.1.5.6 was used to add polar hydrogens and to save the protein in 
the appropriate file formate for docking with Vina. For docking AutoDockVina was 
used.25 The docking parameters were kept at their default values. The docking grid 
was sized 18 Å x 24 Å x 24 Å, covering the entire ACoA channel. 
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Abstract: P. aeruginosa employs a quorum sensing (QS) communication system 
that makes use of small diffusible molecules. Among other effects, the QS system 
coordinates the formation of biofilm which decisively contributes to difficulties in the 
therapy of Pseudomonas infections. The present work deals with the structure-
activity exploration of ureidothiophene-2-carboxylic acids as inhibitors of PqsD, a key 
enzyme in the biosynthetic pathway of signal molecules in the Pseudomonas QS 
system. We describe an improvement of the inhibitory activity by successfully 
combining features from two different PqsD inhibitor classes. Furthermore the 
functional groups, which are responsible for the inhibitory potency, were identified. 
Moreover, the inability of the new inhibitors, to prevent signal molecule formation in 
whole cell assays, is discussed.  
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Introduction 
Antibiotic therapy is characterized by the everlasting competition between the 
generation of novel antibacterial substances and the development of the respective 
bacterial resistances.[1,2] One outstanding example is the opportunistic pathogen 
P. aeruginosa which is responsible for severe infections and is a leading cause of 
death in cystic fibrosis patients.[3] Its ability to rapidly form resistances against the 
currently used antibiotics necessitates new approaches for antibacterial 
treatment.[4,5] Typically, antibiotics affect bacterial viability and thus cause a 
selection pressure that inevitably leads to the development of resistances.[6] In 
recent years several research groups have been trying to break out of this vicious 
cycle by reducing the virulence of the pathogens instead of affecting their viability. 
One approach is the inhibition of the bacterial cell-to-cell communication systems like 
QS.[7] In QS, bacterial cells release a variety of small diffusible molecules which can 
be detected by other bacteria. This kind of molecular signaling allows the bacterial 
population to assess its cell density and coordinate group behavior. The 
Pseudomonas QS system consists of two N-acylhomoserine lactone (AHL) 
regulatory circuits (las and rhl) linked to an 2-alkyl-4-quinolone (AQ) system.[3] 
Whereas the AHL systems are widespread among Gram negative bacteria,[8] our 
group focuses on the so called Pseudomonas quinolone signal quorum sensing 
(PQS-QS) system, an AQ system that exclusively exists in P. aeruginosa and some 
Burkholderia strains.[9] It is involved in the production of a number of virulence 
factors that contribute to their pathogenicity.[10] Moreover, it takes part in regulating 
the formation of biofilms, a main cause for bacterial resistance against conventional 
antibiotics in clinical use.[11] The pqsABCDE operon, whose expression is controlled 
by the transcriptional regulator PqsR (MvfR), directs the AQ biosynthesis in P. 
aeruginosa. Molecules, produced upon activity of this operon are among others, 2-
heptyl-3-hydroxy-4-quinolone (Pseudomonas quinolone signal, PQS) and its 
biosynthetic precursor 2-heptyl-4-quinolone (HHQ).[12] HHQ and PQS themselves 
activate PqsR leading to an auto-induction of the pqsABCDE operon.[13,14] Besides, 
they can modulate the innate immune response of mammalian cells, affecting the 
first defense barrier of the host.[15,16,17] Compounds, interfering with the PQS-QS 
system have proven to be promising candidates for drug development. Treatment 
with antagonists of the PqsR receptor enabled the survival of P. aeruginosa infected 
Galleria mellonella larvae.[18] Furthermore we could show that inhibitors of the 
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enzyme PqsD, a key player in the AQ biosynthesis (Scheme 1), are able to reduce 
biofilm in P. aeruginosa cultures.[19] It was recently reported by Dulcey et al., that 
PqsD produces 2-aminobenzoylacetate-coenzyme A (2-ABA-CoA), a highly active 
intermediate in the HHQ biosynthesis, by converting anthraniloyl-coenzyme A (ACoA) 
with malonyl CoA. Firstly, ACoA is covalently transferred to C112 of PqsD, followed 
by the reaction with malonyl-CoA. Further conversion of the intermediate 2-ABA-CoA 
in several enzymatic steps finally results in HHQ and PQS (Scheme 1).[17] 
Interestingly, PqsD is also capable of directly producing HHQ by converting ACoA 
with -ketodecanoic acid.[20] In the recent past we frequently used this enzymatic 
reaction to assess the activity of PqsD inhibitors.[19,21−25] For compounds 
interfering with the first enzymatic step, the formation of the PqsD-CoA complex, this 
is still a valid method.[23,24] 
 
Scheme 1. Biosynthetic pathway of the signal molecules HHQ and PQS according to Dulcey et 
al. [15]. 
In a recent work, we reported on the class of ureidothiophene-2-carboxylic acids as 
potent inhibitors of PqsD. Biophysical methods were used to confirm a binding 
hypothesis derived from molecular docking studies. This approach enabled the 
structure-based optimization of a screening hit compound resulting in a series of 
highly active molecules (e.g. A and B in Chart 1).[21] According to our docking pose 
and the results from SPR competition experiments, the most active derivative B 
occupies an area, spanning from the entrance of the binding channel to the active 
site, leaving a gap of about 6 Å to the bottom of the pocket where the catalytic 
residues are located. Its carboxylic acid groups are supposed to interact with Asn154 
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and Arg262 respectively anchoring the inhibitor in the binding channel of PqsD The 
phenylalanine residue perfectly fits into a narrow pocket at the channel’s entrance 
delimited by Arg 223 and Phe226 and (Figure 1).  
 
Chart 1. Structures of the PqsD inhibitors A and B. 
In this work we describe further exploration of the chemical space, the structure 
activity relationships (SAR) and the intracellular effects of this class of inhibitors. 
 
Figure 1. Docking pose of B inside the binding channel of PqsD. 
 
Results and discussion 
According to our binding hypothesis, the carboxylate group of the amino acid part in 
A and B interacts with Arg262 at the entrance of the PqsD binding channel 
(Figure 1). The natural substrate anthraniloyl CoA (ACoA) builds several ion bridges 
between its phosphoric acid groups and the arginins on the surface of the protein. 
Such interactions are considered very potent in literature.[26,27] Inspired by ACoA 
we replaced the carboxylic acid moiety by a phosphoric acid group (1). In comparison 
to the glycine derivative A the activity did not increase. Based on these findings, the 
phosphoric acid was not considered for further optimization due to synthetic reasons.  
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Figure 2. Illustration of the proposed clash between the additional methoxy group and the protein 
residue Arg223. 
The so far most active inhibitor B carries a phenylalanine substituent at the ureido 
motif. In order to fine-tune the electronic properties of the aromatic system we 
investigated electron donating and electron withdrawing substituents in para-position. 
In case of an electron donating hydroxyl function (2), the activity dropped to 29 µM 
similar to an additional methoxy group (3; IC50: 31 µM). In case of the latter this is 
probably due to steric reasons, which is in good agreement with our binding 
hypothesis (Figure 2). 
Introduction of an electron withdrawing and lipophilic chlorine substituent (4) also 
resulted in decreased inhibitory potency (14 µM). As both kinds of substituents with 
inverse electronic properties were detrimental to the activity, we considered the 
unsubstituted ring as most favorable. In the next step we shortened (5) and 
prolonged (6) the linker between the -position and the phenyl ring. In the crystal 
structure, the entrance to the sub-pocket, delimited by Arg223 and Phe226 and 
Glu227 is narrow and therefore requires a special conformation. This conformation is 
obviously only provided by the compound with the methylene linker as both, 5 and 6 
displayed significantly weaker inhibitory potency. As a last trial to explore the SAR at 
this part of the molecule, readily available (S)-amino acids were introduced. None of 
the resulting compounds (7-11) outperformed the potency of B. 
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Table 1. Inhibitory activities of 1−11 against P. aeruginosa PqsD in vitro. 
 
Entry R Inhibition of PqsD
a
 
1 
 
7.0 ± 0.7 µM 
2 
 
29.0 ± 0.01 µM 
3 
 
31.3 ± 3.7 µM 
4 
 
13.8 ± 1.1 µM 
5 
 
~50% @ 50 µM 
6 
 
33.7 ± 1.5 µM 
7 
 
31.9 ± 3.0 µM 
8 
 
19.0 ± 2.6 µM 
9 
 
13.2 ± 0.9 µM 
10 
 
5.0 ± 0.9 µM 
11 
 
30.3 ± 0.3 µM 
a 
IC50 values of PqsD 
 
We proceeded, retaining the phenylalanine residue at the ureido-motif, as the most 
promising moiety and subsequently focused on the opposite side of the molecule. 
Firstly parts of the methoxy equipped ring of B were removed to determine the 
essential functional groups. Demethylation, resulting in hydroxyl compound 12 
decreased the activity. Further omitting this OH-group (13) however partially restored 
it. This leads to the assumption that the oxygen of the methoxy group contributes to 
the activity to a certain extent, presumably as a hydrogen bond acceptor. In absence 
of an appropriate interaction partner the hydrogen bond donor of 13 is surrounded by 
highly ordered water molecules, leading to an entropic loss and, therefore, a lowered 
activity. Removal of the entire methoxyphenyl ring (14) results in a total loss of 
inhibitory potency. To reveal the bioactive conformation and the orientation of the 
methoxyphenyl ring towards the thiophene, 15 and 16 were investigated. The methyl 
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group of 15 increased the IC50 to 8 µM suggesting an ortho-effect and thus an 
unfavorable perpendicular orientation of the two rings or a steric clash of the 
additional substituent. Rigidification by an ethylene linker (16), which directly 
connects the two aromatic systems causing a planar structure (Figure 3), did not 
improve the activity as well. The tight shape of the PqsD binding channel that 
demands certain flexibility from entering inhibitors can once more be an explanation 
for these findings. 
 
Figure 3. Energy minimized conformations showing the orientation between the phenyl ring and 
the thiophene core of B, 15 and 16. 
Table 2. Inhibitory activities of 12−17 against P. aeruginosa PqsD in vitro. 
Entry Structure Inhibition of PqsD
a
 
12 
 
21.6 ± 3.9 µM 
13 
 
3.8 ± 1.4 µM 
14 
 
no inhibition @ 50 µM 
15 
 
7.5 ± 1.8 µM 
16 
 
23.7 ± 0.02 µM 
17 
 
11.5 ± 2.0 µM 
a 
IC50 values of PqsD 
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The proposed interaction between the carboxylic acid at the thiophene core with 
Asn154 was corroborated by compound 17. Removal of the carboxylic group 
decreased the activity by about twentyfold. 
By the application of SPR competition experiments in the above mentioned earlier 
work,[21] we were able to narrow down the position of the ureidothiophene-2-
carboxylic acids within the binding channel compared to known PqsD inhibitors from 
the 2-(nitrophenyl)-methanol class (C and D in Chart 2). Whereas the shorter 
compound C (Figure 4a turquoise) did not affect the binding affinity of B, the longer 
derivative D (Figure 4b yellow) prevented binding of B (data not shown), fitting to our 
binding hypothesis.  
 
Figure 4. a) Docking pose of B (green) and C turquoise). b) Docking pose of B (green) and D 
(yellow). 
According to the docking pose, a linkage of the two inhibitor classes in order to 
combine their interactions with PqsD should be possible. We decided to enlarge the 
unsubstituted compound 13 step by step to achieve a full combination with D. Due to 
the absence of strong interactions with the protein, docking studies never delivered 
an unambiguous orientation of the aryl ring at the thiophene core within the pocket. 
Even though an attachment in 3-position (18,19) should be favorable according to the 
dockings with compound B (compare Figure 4), expansion in 4-position (20−22) lead 
to better results. We hypothesized that this is once again due to the tight shape of the 
binding channel which hampers the entrance of the stronger tilted compounds 18 and 
19. 
Whereas the introduction of the first phenyl ring (20) did not result in better inhibition, 
elongation with a hydroxy-methyl function (21), which is supposed to mimic the one 
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of C and D increased the activity by twentyfold compared to 13 (factor three 
compared to B).  
Table 3. Inhibitory activities of 18−22 against P. aeruginosa PqsD in vitro. 
 
Entry 3-Position 4-Position Inhibition of PqsD
a
 
18 
 
H 14.1 ± 0.03 µM 
19 
 
H 19.4 ± 0.02 µM 
20 H 
 
2.7 ± 0.5 µM 
21 H 
 
0.14 ± 0.03 µM 
22 H 
 
0.36 ± 0.06 µM 
a 
IC50 values of PqsD 
Attachment of the second, nitro-substituted ring (22) forfeits parts of the activity gain. 
A possible explanation could be that the final compound is large and inflexible and, is 
therefore, incapable of adapting to conformational changes which would be 
necessary to retain the sum of interactions of the respective single compounds B and 
D. 
To confirm, that the nitro-substituted ring of 22 reaches deep into the binding 
channel, SPR experiments were performed. Firstly, the binding responses of B, 21 
and 22 towards PqsD were recorded in the absence of ACoA. In a second 
experiment, the PqsD loaded sensor chip was treated with ACoA. According to the 
catalytic mechanism of PqsD this results in the anthranilate-PqsD complex, in which 
the anthranilic acid is covalently bound to Cys112. Subsequently the binding 
responses of B, 21 and 22 to this complex were determined. Only the signals of 22 
showed significant differences between treated and untreated PqsD (Figure S1 in 
supporting information). Since this behavior is typical for the 2-nitrophenylmethanol 
derivatives,[22] occupation of the same binding site can be assumed. 
Although the inhibitors displayed high potency in the cell free enzyme assay, none of 
them was able to reduce the HHQ levels in a whole cell P. aeruginosa assay. These 
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findings can be attributed to different reasons like permeation- or efflux problems. 
Several steps were taken to achieve an intracellular activity. 
 
Figure 5. Docking pose of B (green) extended with the NAC moiety (blue) present in 24, 
illustrating how the additional residue is directed outside the binding channel of PqsD. 
Fluoroquinolone and-lactam antibiotics are mostly zwitterionic. According to several 
reports in literature, this feature significantly contributes to their transport into the cell, 
which was shown especially for the -lactams.[28,29] Inspired by that we introduced 
S-histidine instead of S-phenylalanine, using the imidazole ring as a bioisostere of 
the phenyl ring while gaining a basic function and therefore a potentially positive 
charge at the same time. The resulting compound 23 displayed weak activity against 
PqsD (40% inhibition at 50 µM) but showed for the first time significant but very 
moderate reduction of HHQ levels in the whole cell assay (Reduction of HHQ at 250 
µM: 16±5 %). In a second attempt, we made use of an N-acetyl thioester (NAC-ester) 
which is frequently used in mutasynthesis programs. The NAC adducts thereby serve 
as mimics of coenzyme A esters which improve their acceptance as precursors in 
biosynthesis and might also facilitate the entrance into bacterial cells in comparison 
to the free acids.[30] The carboxylic acid moiety of the phenylalanine was considered 
more suitable for the attachment of an NAC unit than the one at the thiophene core. It 
is presumably positioned at the entrance of the pocket (Figure 5) directing the 
additional substituent outside the binding channel of PqsD, and therefore avoiding 
steric hindrance. Thus an intracellular cleavage of the thioester to set the active form 
free might not be mandatory. The resulting compound 24 (Chart 3) still displayed 
reasonable activity (IC50: 32 µM) but turned out to be inactive in the whole-cell assay. 
We further examined the introduction of a cell penetrating peptide (25) at the same 
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position. Again, the inhibitory activity on the cell free level could be retained, but no 
inhibitory effect in the whole cell assay was observed at the test concentration. 
 
 
Chart 3. Structures of compound 23−25, carrying moieties (highlighted in red) which should 
facilitate the entrance into Gram-negative cells. 
 
Conclusions 
In conclusion, we further explored the chemical space of the ureidothiophene-2-
carboxylic acids as inhibitors of PqsD. The pharmacophore of the inhibitor class was 
determined and the essentiality of several functional groups was clarified. Moreover, 
two inhibitor classes could be successfully merged without having access to 
structural information of protein-ligand x-ray structures. The resulting compounds 
display higher inhibitory activity by profiting from the combined interactions with the 
protein. Following this approach, the most potent PqsD inhibitors described so far 
were obtained. Although the potency in cell free assay was high, an intracellular 
activity could not be achieved even by attachment of a cell penetrating peptide. We 
assume that the class of inhibitors is subject to efflux causing natural resistance of P. 
aeruginosa towards the newly developed antibacterial agents. Therefore, we 
consider the ureidothiophene-2-carboxylic acids to be not eligible for further 
development in the field of Pseudomonas quorum sensing inhibitors. The problem 
could eventually be solved by a combined application with efflux pump inhibitors, or 
by using pharmaceutical technological methods, but this is beyond the frame of this 
work. Nevertheless, important interactions of functional groups with the protein were 
revealed that can be used to improve the inhibitory activity of other PqsD inhibitors 
with better intracellular effects. 
Experimental procedures 
Chemistry 
Materials and methods. Starting materials were purchased from commercial 
suppliers and used without further purification. Column flash chromatography was 
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performed on silica gel (40–63 µM), and reaction progress was monitored by TLC on 
TLC Silica Gel 60 F254 (Merck). All moisture-sensitive reactions were performed 
under nitrogen atmosphere using oven-dried glassware and anhydrous solvents. 
Preparative RP-HPLC was carried out on a Waters Corporation setup containing a 
2767 sample manager, a 2545 binary gradient module, a 2998 PDA detector and a 
3100 electron spray mass spectrometer. Purification was performed using a Waters 
XBridge column (C18, 150 x 19 mm, 5 µm), a binary solvent system A and B (A = 
water with 0.1% formic acid; B = MeCN with 0.1% formic acid) as eluent, a flow rate 
of 20 mL/min and a gradient of 60% to 95% B in 8 min were applied. 1H and 13C 
NMR spectra were recorded on a Bruker Fourier spectrometer (500/300 or 125/75 
MHz) at ambient temperature with the chemical shifts recorded as δ values in ppm 
units by reference to the hydrogenated residues of deuterated solvent as internal 
standard. Coupling constants (J) are given in Hz and signal patterns are indicated as 
follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet, br., broad 
signal. Purity of the final compounds was determined by HPLC. The Surveyor LC 
system consisted of a pump, an autosampler, and a PDA detector. Mass 
spectrometry was performed on a MSQ electrospray mass spectrometer 
(ThermoFisher, Dreieich, Germany). The system was operated by the standard 
software Xcalibur. A RP C18 NUCLEODUR 100-5 (125 mm x 3 mm) column 
(Macherey-Nagel GmbH, Dühren, Germany) was used as the stationary phase. All 
solvents were HPLC grade. In a gradient run the percentage of acetonitrile 
(containing 0.1% trifluoroacetic acid) was increased from an initial concentration of 
0% at 0 min to 100% at 15 min and kept at 100% for 5 min. The injection volume was 
10 µL, and flow rate was set to 800 µL/min. MS analysis was carried out at a spray 
voltage of 3800 V and a capillary temperature of 350 °C and a source CID of 10 V. 
Spectra were acquired in positive mode from 100 to 1000 m/z at 254 nm for the UV 
trace. 
Synthesis and spectroscopic details.  
The synthesis of most of the 5-aryl-3-ureidothiophene-2-carboxylic acids (Scheme 2) 
started from readily available acetophenones (I) which were converted to the 5-aryl 
thiophene anthranilic acid methylesters (II) via an Arnold-Vilsmaier-Haack reaction 
followed by a cyclization using methylmercaptoacetate [31]. The esters (II) were then 
hydrolysed under basic conditions to afford the thiophene anthranilic acids (III) which 
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were converted into the thiaisatoic anhydrides (IV) [32,33]. The anhydrides (IV) were 
reacted with various amines giving rise to the 5-aryl-3-ureidothiophene-2-carboxylic 
acids (V) [34]. Further substituents at the 5-aryl ring were introduced using boronic 
acids or esters respectively via Suzuki coupling yielding VI [35].   
 
Scheme 2. Synthesis of 5-aryl-3-ureidothiophene-2-carboxylic acids V or VI respectively. 
Reagents and conditions: (a) POCl3, DMF, 50 °C to rt, then NH2OH∙HCl, up to 150 °C. (b) 
Methylthioglycolate, NaOMe, MeOH, reflux. (c) KOH, MeOH, THF, H2O, reflux. (d) COCl2, THF. 
(e) Amine, H2O, 100 °C then at 0 °C conc. HCl. (f) Na2CO3, Pd(PPh3)4, boronic acid or ester, 
THF, H2O, toluene, 80 °C. 
Further details on the synthesis and spectroscopic data of final compounds and 
intermediates can be found in the supporting information.  
Biology 
General procedure for expression and purification of recombinant PqsD WT 
and R223A mutant in E. coli. His6-tagged PqsD (H6-PqsD) and mutants were 
expressed in E. coli and purified using a single affinity chromatography step. Briefly, 
E. coli BL21 (λDE3) cells containing the pET28b(+)/pqsD (kindly provided by Prof. 
Rolf Müller, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), 
Saarbrücken, Germany) were grown in LB medium containing 50 µg/mL kanamycin 
at 37 °C to an OD600 of approximately 0.8 units and induced with 0.2 mM IPTG for 16 
h at 16 °C. The cells were harvested by centrifugation (5,000 rpm, 10 min, 4 °C) and 
the cell pellet was resuspended in 100 mL binding buffer (10 mM Na2HPO4, 2 mM 
KH2PO4 pH 7.4, 3 mM KCl, 137 mM NaCl, 20 mM imidazole, 10% glycerol (v/v)) and 
lysed by sonication for a total process time of 2.5 min. Cell debris were removed by 
centrifugation (18500 rpm, 40 min, 4 °C) and the supernatant was filtered through a 
syringe filter (0.20 μm). The clarified lysate was immediately applied to a Ni-NTA 
column, washed with binding buffer and eluted with 500 mM imidazole. The protein 
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containing fractions were buffer-exchanged into 125 mM Na2HPO4, 50 mM KH2PO4 
pH 7.6, 50 mM NaCl, 10% glycerol (v/v), using a PD10 column and judged pure by 
SDS-PAGE analysis. Then protein was stored in aliquots at –80 °C. 
Screening assay procedure for in vitro PqsD inhibition [20]. The assay was 
performed monitoring enzyme activity by measuring HHQ formed by condensation of 
anthraniloyl-CoA and β-ketodecanoic acid. The reaction mixture contained MOPS 
buffer (0.05 M, pH 7.0) with 0.005% (w/v) Triton X-100, 0.1 µM of the purified enzyme 
and inhibitor. The test compounds were dissolved in DMSO and diluted with buffer. 
The final DMSO concentration was 0.5%. After 10 min preincubation at 37 °C, the 
reaction was started by the addition anthraniloyl-CoA to a final concentration of 5 µM 
and -ketodecanoic acid to a final concentration of 70 µM. Reactions were stopped 
by addition of MeOH containing 1 µM amitriptyline as internal standard for LC/MS-MS 
analysis. HHQ was quantified using a HPLC-MS/MS mass spectrometer 
(ThermoFisher, Dreieich, Germany) in ESI mode. Ionization of HHQ and the internal 
standard amitriptyline was optimized in each case. The solvent system consisted of 
10 mM ammonium acetate (A) and acetonitrile (B), both containing 0.1% 
trifluoroacetic acid. The initial concentration of B in A was 45%, increasing the 
percentage of B to 100% in 2.8 min and keeping it at 98% for 0.7 min with a flow of 
500 µL/min. The column used was a NUCLEODUR-C18, 100-3/125-3 (Macherey 
Nagel, Dühren, Germany). Control reactions without the inhibitor, but including 
identical amounts of DMSO, were performed in parallel and the amount of HHQ 
produced was set to 100%. 
Determination of extracellular HHQ and PQS levels. For determination of 
extracellular levels of HHQ produced by PA14, cultivation was performed in the 
following way: cultures (initial OD600 = 0.02) were incubated with or without inhibitor 
(final DMSO concentration 1%, v/v) at 37 °C, 200 rpm and a humidity of 75% for 16 h 
in 24-well Greiner BioOne (Frickenhausen, Germany) Cellstar plates containing 1.5 
mL of LB medium per well. For HHQ analysis, according to the method of Lepine et 
al.,[36] 500 μL of the cultures supplemented with 50 μL of a 10 μM methanolic 
solution of the internal standard (IS) 5,6,7,8-tetradeutero-2-heptyl-4(1H)-quinolone 
(HHQ-d4) were extracted with 1 mL of ethyl acetate. After centrifugation (18,620 g, 
12 min), 400 μL of the organic phase were evaporated to dryness and redissolved in 
methanol. UHPLC-MS/MS analysis was carried out as described in detail by Storz et 
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al.[19] The monitored ions were (mother ion [m/z], product ion [m/z], scan time [s], 
scan width [m/z], collision energy [V], tube lens offset [V]): HHQ: 244, 159, 0.5, 0.01, 
30, 106; HHQ-d4(IS): 248, 163, 0.1, 0.01, 32, 113. For each sample, cultivation and 
sample work-up were performed in triplicates. Inhibition values of HHQ formation 
were normalized to OD600. 
Surface Plasmon Resonance 
General. SPR binding studies were performed using a Reichert SR7500DC 
instrument optical biosensor (Reichert Technologies, Depew, NY, USA) and 
CMD500M sensor chips obtained from XanTec (XanTec Bioanalytics, Düsseldorf, 
Germany). Scrubber 2 software (Version 2.0c, 2008, BioLogic Software) was used for 
proceeding and analyzing the data. Changes in refractive index due to DMSO 
dependent solvent effects were corrected by use of a calibration curve (seven 
solutions, 4.25%−5.75% DMSO in buffer). 
Immobilization of His6-PqsD. PqsD (38 kDA, >90% pure based on SDS-PAGE) 
was immobilized at an level of 5919 RU on a CMD500M (carboxymethyldextran-
coated) sensor chip at 18 °C analogous to the method described by Henn et al. [37].  
Binding studies. The ACoA preincubation studies were performed as previously 
described using a constant flow rate of 25 µL/min and HEPES buffer as instrument 
running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5% DMSO (v/v), 0.05% 
Polysorbat 20 (v/v)) [20]. ACoA (100 µM) was injected for approximately 40 minutes 
with a constant flow of 5 µL/min to reach saturation of the ACoA binding site. 
Afterwards, the flow rate was increased to 50 µL/min for 30 min in order to flush all 
CoA away. Once the baseline is stable again the compounds were consecutively 
injected and the responses at equilibrium were compared to those obtained with the 
untreated surface. Experiments were performed in duplicate. For B a concentration 
series of 250, 125 and 62.5 µM were used. Since stronger binding signal was 
observed for 21, the concentration series was decreased to 100, 50 and 25 µM, 
whereas a series of 25, 12.5, and 6.25 µM was measured for 22. The compounds 
were injected for 120 s association times and 300 s dissociation times.  
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Computational Chemistry 
Docking. Inhibitors were built in MOE. The receptor was derived from crystal 
structure of PqsD in complex with ACoA (PDB Code: 3H77)[10] The residuals of CoA, 
the covalently bound anthranilate and H2O were removed and Cys112 was restored 
considering its conformation in 3H76.[10] AutoDockTools V.1.5.6 was used to add 
polar hydrogens and to save the protein in the appropriate file formate for docking 
with Vina. AutoDockVina was used for docking calculations.[38] The docking 
parameters were kept at their default values. The docking grid was sized 18 Å x 24 Å 
x 24 Å, covering the entire ACoA channel. 
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4 Final Discussion 
As stated in chapter two, the prior goal of this thesis was the generation of anti-
infectives with novel target sites and/or new mechanisms of action to overcome 
existing bacterial resistances. Measures of rational drug design should thereby guide 
the development process to systematically obtain potent chemical entities. 
For the sake of clarity, the numbering of compounds was annotated with the letter of 
the respective manuscript from which it originates. For example: Compound “3” from 
manuscript A is termed “A/3” in the following paragraphs.  
 
4.1 Structure activity relationships (SAR) 
Deriving SAR from the biological data of a set of derivatives is the most important 
instrument in medicinal chemistry. It reveals the relationship between structural 
features and pharmacological activity for a series of derivatives [Wermuth et al. 1998] 
and thus, directs a rational drug optimization process. 
4.1.1 Small molecule RNAP inhibitors 
Publication A deals with the development of small molecule inhibitors from the class 
of 5-aryl-3-ureidothiophene-2-carboxylic acids targeting the “switch region” of 
bacterial RNAP. The hit compound A/3 (IC50 = 75 µM) was found in a 
pharmacophore based virtual screening. The performed structural modifications can 
be divided into two parts (Fig. 12). First, the substitution pattern of the 5-aryl moiety 
was modified following the Topliss’ logical. Whereas the introduction of hydrophilic or 
electron donating groups (EDG) lead to reduced inhibitory potencies, lipophilic or 
electron withdrawing groups (EWG) caused constant to enhanced activities. The best 
results were obtained by the introduction of two lipophilic EWGs. To gain a deeper 
insight into the underlying principle of the substituent effects on the biological activity, 
a multi-parameter Hansch regression analysis was performed. The results 
impressively highlighted the relation between the two factors and underlined the 
importance of π (lipophilicity constant) and σ (Hammet parameter) for the biological 
activity. The obtained Hansch analysis represents a valuable support for further 
rational derivatization and should be considered in following optimization programs. 
The second part of publication A focused on the modification of the substituents at 
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the ureido motif at the opposite site of the molecule. Thereby space demanding 
lipophilic moieties were found to be favored in this position, which is in good 
agreement with the propagated docking pose that predicts this part of the molecule to 
reach into a rather large and hydrophobic part of the “switch region”.  
 
 
Figure 12. Summary of the observed SARs of small molecule RNAP inhibitors from the class of 
ureidothiophene-2-carboxylic acids. 
4.1.2 Myxopyronin derivatives via mutasynthesis 
Publication C addresses the generation of novel myx derivatives using 
mutasynthesis as an alternative method to total synthesis. In this case, two kinds of 
structural requirements have to be taken into account. Besides the introduction of 
new substituents that can form further interactions with the RNAP “switch region”, the 
substrate specificity of the participating biosynthetic enzymes needs to be 
considered. Therefore, the design process of mutasynthons followed a two-step 
process, firstly evaluating the flexibility of the biosynthesis and secondly the targeted 
introduction of putative interaction partners.  
In the beginning, the substrate specificity of MxnB, the ketosynthase which catalyzes 
the last step in the myx biosynthesis, was investigated. Starting with the natural 
precursor, functional groups were systematically removed to determine the key 
functions, decisive for substrate acceptance. The results revealed that MxnB is 
sensitive to modifications close to the molecular position at which the intermolecular 
Claisen condensation takes place. The -methyl group and the -double bond turned 
out to be essential for incorporation (Fig. 13). These findings were considered in the 
design process of all further precursors to maximize the probability of incorporation. 
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Figure 13. Basic structure of the applied -keto thioester mutasynthons highlighting the functional 
groups, essential for incorporation by MxnB. 
Afterwards functional groups were introduced into the precursors that should enable 
additional interactions of putative myx analogs with the RNAP “switch region”. 
Thereby the mentioned complex-crystal structure (PDB-ID: 3DXJ) was used to guide 
the design process. Initial investigations included the incorporation of a phenyl ring 
(C/6−C/8) at the end of the chain. Such an aromatic ring could serve as a platform for 
the introduction of various substituents that, if connected to the appropriate position, 
could form additional contacts with the protein and thus, increase the binding affinity. 
After successful incorporation of the phenyl containing substrates C/6−C/8 by MxnB, 
this idea was successfully exemplified for a hydroxyl function (C/9) and a bromo-
substituent (C/10), which were accepted as well. Moreover the short derivative C/11 
carrying an endstanding alkyne moiety, as well as a cor inspired hydroxylated 
precursor C/12 were successfully incorporated. Further studies involved accession of 
the biosynthetical pathway at an earlier stage, using M. fulvus mutants whose 
western chain assembly line was interrupted by targeted point mutation. The design 
of the appropriate precursors (C/13−C/18) was guided by the established -keto-
substrates. Except for C/15, all substrates were successfully incorporated indicating 
that the other involved enzymes can also adapt to structural modifications of the 
biosynthetic intermediates.  
In conclusion, high substrate flexibility is an essential requirement to enable the 
generation of comprehensive libraries by mutasynthesis. This is fulfilled by the 
investigated myx biosynthesis pathway. Whereas the substrate specificity of the 
biosynthetic enzymes could be elucidated, the SAR of the produced myx analogs 
remains theory until their successful isolation and biological evaluation.  
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4.1.3 Ureidothiophene-2-carboxylic acids as PqsD inhibitors 
Publication D and E cover the development of potent PqsD inhibitors. D/1 (= A/9) 
served as a starting point of this work, originating from the RNAP project presented in 
publication A. In accordance with the Hansch equation in A, D/1 hardly inhibits 
RNAP. As a bactericidal effect is undesired while targeting the quorum sensing 
system, selectivity toward RNAP is a crucial prerequisite. Therefore the methoxy 
function was retained in favor of selectivity, even though other derivatives with for 
e.g. chloro substituents displayed better inhibitory potency against PqsD (compare 
Table S1 in the Supporting information of Publication D (section 6.4.2)). Molecular 
docking, complemented by competition SPR experiments delivered a reliable binding 
mode (compare section 4.2) that could be used to perform a structure-based 
optimization.  
After validation of the binding mode, D/2, a truncated version of D/1 was chosen as 
the starting point. Despite lower activity it bears comparable ligand efficiency to D/1 
while being more suitable for further modifications. According to the predicted binding 
mode, the ureido motif serves as an anchor, interacting with R223. This was verified 
by SPR studies with the R223A mutant. Subsequently -amino acids were 
introduced to target R262 with an additional carboxylic function and to extent the 
structure into a narrow sub-pocket at the entrance of the PqsD substrate channel. 
(S)-Phenylalanine (D/6) turned out to have the highest potential in this position. 
Molecular docking studies suggested a perfect fit of the benzyl moiety to the sub-
pocket. Neither introduction of substituents at the phenyl ring (E/2−E/4), nor a 
variation of the linker-length (E/5,E/6) as well as its replacement by other residues 
(E/7−E/11) improved the inhibitory potency. The crucial role of the carboxylic group 
introduced with the amino acid is highlighted by D/8, lacking this group and 
consequently possessing 100 fold lower activity compared to D/6. Interestingly the 
(R)-configurated derivatives (D/9,D/10) displayed approximately 50 fold weaker 
activity in favor of a selective interaction of the (S)-configurated analogs.  
The validated docking pose even enabled the rational design of a covalent inhibitor 
(D/12). As predicted, the targeted introduction of a -chloroacetyl moiety allowed a 
nucleophilic attack by the key residue C112 (Fig. 14). A proposed interaction 
between the carboxylic acid function at the thiophene core and N254 was confirmed 
by the decarboxylated counterpart of D/6, E/17, displaying a 20 fold impaired IC50 
value.  
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Figure 14. Illustration of the proposed binding mode of D/12 based on the docking pose of D/6, 
highlighting the proposed attack of C112 at the -chloroacetyl moiety. 
Freezing the bioactive conformation is a widely used strategy in medicinal chemistry 
to increase the activity of drugs [Fang et al. 2014]. The underlying idea is to reduce 
the loss of entropy upon binding of the ligand. Therefore the rigidified analogs of D/6, 
E/15 and E/16 were investigated. Whereas the methylated compound E/15 favors a 
perpendicular orientation of the 5’-ring to the thiophene core, the ethylene linker of 
E/16 holds the two rings in one plain. The fact that both compounds display low 
activity permits two explanations. Either the appropriate conformation cannot be 
adopted by both, or the additional substituents cause sterical clashes with the 
protein. To draw a final conclusion, further rigidified derivatives need to be examined. 
 
Further studies focused on the 5’-aryl-ring. Whereas removal of the methoxy group 
(E/12,E/13) was tolerated, omitting of the entire 5’-ring (E/14) lead to a complete loss 
of activity.  
In order to gain further interactions, the structures of two inhibitor classes, namely the 
2-nitrophenyl methanols [Storz et al. 2012, 2013, 2014] and the ureidothiophene-2-
carboxylic acids [Sahner et al. 2013] were combined. SPR competition experiments 
allowed a determination of the overlapping contact sites of both classes. Following 
from these results, structural features of the 2-nitrophenyl methanol derivative (E/D) 
were stepwise attached to the 5’aryl ring of E/13. Introduction in para position 
(E/20−E/22) turned out to be superior compared to an attachment at the meta 
position (E/18, E/19). This can be explained by the shape of the narrow substrate 
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channel that necessitates a relatively straight or flexible ligand structure. Thus, the 
meta-substituted compounds are probably too strongly tilted to enter the binding site. 
Taken together, investigations on the SAR in Publication D and E revealed, that 
nearly all structural features of D/6 contribute to its biological activity. However, it is 
not clear yet whether they are the most favorable functional groups or if they can be 
bioisosterically replaced. Nevertheless, D/6 establishes a solid basis for further 
modifications. E/21 and E/22 give a hint how additional interactions can be achieved 
to improve the affinity to the target protein.  
 
4.2 Binding mode validation
Publications A, B and D describe distinct methods to validate the binding mode of the 
respective synthesized inhibitors. In case of the RNAP “switch region” inhibitors 
(Publication A), we decided to perform a chemically driven verification. The binding 
pose, predicted by molecular docking suggested a structure extension into the 
narrow channel representing the contact site of myxopyronin’s eastern chain. 
Therefore a moiety mimicking this part of myx was introduced at the appropriate 
position of the synthetic small molecule inhibitor. The fact that this dramatic structural 
change was tolerated and the resulting compound (A/23) displays increased activity 
compared to the parent compound A/3, is a strong hint, that the predicted binding 
mode is correct. Nevertheless, it cannot be excluded, that the additional substituent 
can form interactions at another part of the protein. Thus, such a chemically driven 
confirmation of the binding mode should ideally be complemented by generation and 
sequencing of spontaneous mutants or mutagenesis studies. Due to low solubility of 
A/23 this was not possible in that particular case. In Publication B, competition STD 
NMR experiments unambiguously proved that myx and the ureidothiophene-2-
carboxylic acids compete for the same binding site. Furthermore the results revealed 
that the ureidothiophenes are able to bind to the “switch region” in two reverse 
orientations and besides have a second target site on RNAP. 
The binding mode of the PqsD inhibitors (Publication D) was verified using SPR. 
SPR is mainly used to assess the binding affinity of ligands to their respective 
targets. However, competition experiments involving ligands with known binding sites 
render it a powerful tool to determine the binding position of new molecules. Hence, 
2-nitrophenyl methanol derivatives, known to bind deep inside the binding channel 
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interacting with the active site residues were used as competitors. Thereby the 
ureidothiophenes could be identified as channel blockers binding about 6 Å distant 
from the bottom of the binding pocket. The availability of model compounds, carrying 
different substitution pattern on both sites of the molecule, even enabled the 
determination of the ligand orientation inside the binding channel. These results 
served as cross-validation of several binding poses predicted by molecular docking 
studies.  
In conclusion, combinations of biophysical experiments (NMR, SPR) complemented 
by docking studies are straightforward methods to elucidate the binding mode of a 
ligand. However, they cannot be used in every case, as ligands with known binding 
sites and a crystal structure of the protein are required, but not always available. 
Nevertheless, given that these requirements are fulfilled, the presented methods can 
pave the way for a structure-based design process, especially if co-crystallization 
efforts fail. 
 
4.3 Intracellular activity
Sustainable permeation into the cell interior is a prerequisite for intracellular activity 
of anti-infectives. A study of O’Shea and Moser shows, that Gram negative bacteria 
are much more difficult to access than Gram positive cells, due to their orthogonal 
double membrane system and the equipment with broad spectrum efflux pumps 
[O’Shea and Moser 2008]. 
The results of this work clearly confirm these findings. The synthesized RNAP 
inhibitors (Publication A and B) exhibit potent antibacterial effects against the Gram 
positive pathogen S. aureus and B. subtilis (MIC values as low as 2 µg/mL). In 
contrast, the Gram negative wildype strains E. coli K12 and P. aeruginosa were 
insusceptible regarding the applied inhibitors. Taking into consideration the low 
micromolar MIC values determined with E.coli TolC, efflux pumps might be a 
bottleneck for antibacterial activity of the novel compounds. Results from a 
continuative study corroborate this hypothesis as a combined application of the 
ureidothiophenes with the efflux pump inhibitor PAN improved their antibacterial 
effects [Elgaher et al. 2013]. Besides potential efflux, the synthesized inhibitors do 
not meet the required physicochemical criteria. The majority of drugs entering Gram 
negative cells bear clogD7.4 values below 0. None of the compounds A/1−A/40 
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reaches down to this region. Hence, if a Gram negative activity is desired, further 
structural variations leading to optimized physicochemical properties need to be 
accomplished. The latter is challenging taking into account the predominant lipophilic 
character of the RNAP “switch region”, limiting the introduction of hydrophilic 
moieties. Thus, even though the “switch region” is highly conserved among a wide 
range of bacteria, it might not be suitable for efficient antibiotics against Gram 
negative strains. 
The PqsD inhibitors described in Publication D and E address a target in 
P. aeruginosa and can therefore only perform their task by reaching the cell interior. 
As these compounds are based on the RNAP inhibitors described above, structural 
changes accompanied by improved physicochemical properties are required to 
accomplish this goal. The replacement of N-ethyl-benzylamine by -amino acids 
contributed to both, decreasing the clogD7.4 to an acceptable range between −1.6 
and 0.6 (D/4−D/6). However, a reduction of HHQ levels in a whole cell assay could 
not be achieved. Even the introduction of moieties that are known to increase the 
permeation into Gram negative cells (for example a N-acetylcysteamine (NAC) 
thioester (E/24) or a cell penetrating peptide (E/25)), was not successful. These 
results lead to the hypothesis that the ureidothiophene core structure is responsible 
for the recognition and subsequent elimination by efflux pumps, a problem which can 
only be overcome by even more drastical structure variations or for example a 
combined application with efflux pump inhibitors. 
4.4 Overcoming existing resistances
Rising emergence of bacterial resistances towards established antibiotics creates a 
continuous need for novel anti-infectives. Publication A addresses this task by the 
development of small molecule RNAP inhibitors that target the “switch region”, a so 
far underexploited binding site of this macromolecule. The “switch region” was 
unambiguously proven as a binding site of the obtained ureidothiophenes by 
competition STD and INPHARMA NMR experiments (publication B). The new 
inhibitors, display a >1500 fold lower resistance frequency (exemplarily shown for 
compound A/15) as the clinically used rifampicin and the natural product myx A. This 
phenomenon can be explained by the fact that A/15 occupies only a part of the 
binding pocket area that is covered by myx. Especially mutations in the narrow side 
pocket, contact site of the myx eastern chain and thus leading to myx resistance 
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[Mukhopadhyay et al. 2008, Srivastava et al. 2012], should not affect the antibacterial 
activity of our compounds. Another mechanism that can contribute to the low 
resistance frequency might be the effect on another target site. Results from an 
intrinsic fluorescence quenching assay corroborate this hypothesis showing a 
concentration dependent curve with a biphasic character (compare Figure S2b in 
supporting information of publication B) indicating a second binding site on RNAP.  
In summary it can be stated that lower sensitivity of the new RNAP inhibitors to 
resistance development might be a significant advantage in daily clinical 
administration. Furthermore their potent antibacterial activity, especially against 
MRSA isolates and rifampicin resistant E. coli TolC strains, underscores their high 
potential for drug development. 
4.5 Total/semi-synthesis vs. mutasynthesis 
Publication C deals with the production of “unnatural, natural” -pyrone antibiotics 
using mutasynthesis. As stated in the introduction (paragraph 1.4), mutasynthesis 
can be a powerful alternative to total synthesis. However, its practicability as well as 
its efficiency should in each case be critically compared with approaches involving 
total- or semi-synthesis [Kirschning et al. 2007]. The first bottleneck, while aiming for 
the production of comprehensive libraries, might be a narrow substrate specificity of 
the involved biosynthetic enzymes. In the case of myx-derivatives this especially 
includes the ketosynthase MxnB, catalyzing the Claisen-condensation between the 
two independently assembled chains, yielding the characteristic -pyrone core. 
Several artificial -keto thioester precursors with variations compared to the native 
substrate were accepted by MxnB, confirming that a wide range of structurally 
diverse myx analogs can be covered by mutasynthesis. Apparently only the -methyl 
group and the -double bond are essential for incorporation. Initial trials to isolate 
mutasynthesis products failed due to low yields. This hurdle has to be cleared to 
make mutasynthesis an efficient method that can compete with total synthesis of 
myx derivatives. E.g. expression of the biosynthesis pathway in a heterologous 
system, producing higher amounts of the desired derivatives, could be a solution. An 
alternative option is provided by an enzymatic in vitro synthesis of -pyrone-analogs, 
currently explored in our group [Sucipto and Sahner et al., manuscript in preparation]. 
Herein, two artificial chains (western and eastern) are connected by purified MxnB, 
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supplemented with the appropriate carrier proteins (CP). Making use of this method, 
a reduction of losses associated with the complicated isolation and purification 
processes one is facing during mutasynthesis can be achieved. Furthermore, given 
that the required enzymes can be obtained in good yields, the culture size is no 
longer a determinant for the outcome of the production. 
 
4.6 Ureidothiophene-2-carboxylic acids
This thesis reports on ureidothiophene-2-carboxylic acids as inhibitors of the bacterial 
enzymes RNAP and PqsD. They excel by an established synthesis, allowing 
relatively easy modifications and thus, being interesting for medicinal chemistry 
approaches. As the name suggests, the compounds include a thiophene core, 
decorated with a carboxylic acid group in 2 and a ureido moiety in 3 position. Several 
reports in literature describe a very similar motif (substituted 2-aminothiophene-3-
carbonyl) as a cause for promiscuous activity precluding selectivity [Baell and 
Holloway 2010, Soelaiman et al. 2003, Broom et al. 2006, Huth et al. 2005]. Both 
structural features only differ by the position of the sulfur inside the ring (Fig. 15). The 
close structural analogy suggests a similar behavior and thus promiscuity of the 
inhibitors developed in this work.  
 
Figure 15. Comparison of a 3-amino-2-carbonyl thiophene with 2-amino-3-carbonyl thiophene 
illustrating their close structural relation. 
The results in this thesis prove that it is absolutely possible to obtain selective 
inhibitors that feature a 3-amino-2-carbonyl-thiophene motif. It was clearly shown that 
RNAP inhibition can only be achieved if a 5’aryl substituent at the thiophene core is 
decorated with lipophilic EWGs. In contrast the PqsD inhibitor D/1 is equipped with 
an electron donating methoxy functionality and consequently displays almost no 
RNAP inhibition (selectivity factor: 40). Furthermore, a very sharp SAR can be 
observed for the PqsD inhibitors themselves. Slight structural changes at the amino 
acid residue, not involving the thiophene core, cause a drastical reduction of the 
inhibitory potency.  
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Taken together, chemical entities comprising a thiophene core equipped with amino 
and carbonyl function might be at higher risk of being promiscuous binders. 
Nevertheless, selective inhibitors can be obtained by introduction of the appropriate 
substituents, ideally guided by structure-based design. 
 
4.7 Summary and outlook
4.7.1 Small molecule RNAP inhibitors (Publication A and B) 
Based on a virtual screening hit, ureidothiophenes-2-carboxylic acids have been 
discovered as potent “switch region” inhibitors of the bacterial RNAP. They excel at 
good bactericidal effects against Gram positive strains and the Gram negative efflux 
mutant E. coli TolC. Furthermore the novel inhibitors exhibit an outstandingly low 
resistance frequency compared to established antibiotics. Especially the most potent 
compound A/40 is very lipophilic (logP > 6) and thus lacks drug-likeness and 
acceptable water solubility. The introduction of hydrophilic substituents is challenging 
due to the overall high lipophilicity of the “switch region”. However, some polar amino 
acids as well as accessible backbone atoms might be addressable, enabling the 
formation of additional interactions and improvement of the physicochemical 
properties.  
An alternative strategy to achieve drug-likeness might be a prodrug-approach. The 
advantage of such an approach would be that it is independent from the active form 
of the inhibitor. Hence, a cleavable polar appendage could be attached to the most 
potent RNAP inhibitor A/40 for example via an ester bond. Upon entrance into the 
cell it could be cleaved by a non-specific bacterial esterase to set the active form 
free. 
4.7.2 “Unnatural natural” myx derivatives (Publication C) 
Recently, the biosynthetic pathway of the natural -pyrone antibiotic myx has been 
elucidated [Sucipto et al. 2013]. The thereby obtained knowledge was used in this 
thesis to produce new myx analogs using a mutasynthesis approach (Publication C). 
Firstly, the substrate specificity of the involved biosynthetic enzymes was 
investigated and the essential structural features for successful precursor 
incorporation were determined. Taking these findings into consideration we 
proceeded with the investigation of structurally more diverse substrates. A crystal 
structure of Th. thermophilus RNAP in complex with myx (PDB-ID: 3DXJ) guided a 
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structure based introduction of further functional groups in order to form additional 
interactions. Moreover, chemical moieties were attached enabling synthetic 
modification of the novel myx analogs (Fig. 16). 15 out of a total of 18 examined 
precursors were incorporated, rendering mutasynthesis a serious alternative to total 
synthesis. Future studies might include even more chemically diverse precursors to 
expand the chemical space of the -pyrone antibiotics. 
 
 
Figure 16. Proposal for synthetic modifications of the myx analogs C/W10 and C/W11. 
 
Initial trials to isolate the generated myx analogs produced by mutasynthesis, failed 
due to low production yields. This problem needs to be solved to enable isolation of 
sufficient amounts to determine biological activity and to derive further SAR. In terms 
of increasing the myx (derivative) production, heterologous expression of the 
biosynthetic gene cluster in a different strain and subsequent mutasynthesis, might 
be a promising approach. Another strategy could be a scale-up of the in vitro 
condensation experiment presented above (section 4.5). Being successful in 
expressing and purifying the required enzymes in large amounts, the enzymatic in 
vitro condensation represents an attractive alternative to mutasynthesis, as it is a 
rather clean process, decreasing yield losses associated with complex purification 
protocols.   
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4.7.3 PqsD inhibitors (Publication D and E) 
In Publication D, compound D/1 was identified as an inhibitor of the P. aeruginosa 
quorum sensing enzyme PqsD with moderate activity (IC50: 6 µM). Its stoichiometric 
binding to PqsD was confirmed using ITC. SPR competition experiments 
complemented by computational docking studies were used to determine the binding 
mode of D/1. The validated binding mode enabled a structure based optimization 
process yielding the potent PqsD inhibitor D/6 with an IC50 value of 0.5 µM. The 
accuracy of the determined binding mode was underlined by the targeted 
development of a covalent inhibitor (D/12) binding to the protein as predicted, proven 
by MALDI-ToF and HPLC-MS methods. In Publication E, the at that time most potent 
compound D/6 (= E/B) was further investigated. The systematic design of novel 
inhibitors revealed the contribution and importance of nearly all of its functional 
groups. Furthermore, results from SPR competition experiments in combination with 
docking studies guided a successful merging of two inhibitor classes (Fig. 17). The 
resulting inhibitors (E/21 and E/22) display higher activity (IC50: 0.14 and 0.35 µM) by 
profiting from the combined interactions with the protein. Even though being highly 
active in the cell free enzyme assay, none of the investigated PqsD inhibitors 
possessed intracellular potency. Several moieties were introduced into the molecule 
that should facilitate their permeation into P. aeruginosa cells but remained 
unsuccessful. Possible bottlenecks include the transmembrane permeation of the 
compounds themselves or efflux systems. Continuative studies should focus on 
solving this problem for example by applying the inhibitors in combination with efflux 
pump inhibitors. 
 
Figure 17: Illustration of the merging of two PqsD inhibitor classes. The resulting compound E/21 
contains features of both classes and displays increased inhibitory potency. 
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6 Supporting Information 
This section contains the relevant supporting information of the studies presented 
in section 3. It includes additional details on experimental procedures, as well as 
further figures and results.  
6.1 Supporting Information for Publication A
Full supporting information is available online:  
http://www.sciencedirect.com/science/article/pii/S0223523413002924 
6.1.1  Hansch Analysis of Ring A (compounds 3, 8–22) 
 
For the investigation of the quantitative relationship between the biological activity 
and the subsituents on the phenyl ring A, π (lipophilicity constant) [1] and σ 
(Hammet substituent constant) [1]  were used in a multiple regression correlation 
methodology. 
Table S1. Set of compounds and substituent parameters used for the multiple 
regression analysis. 
Cpd R
1
 IC50 E. coli RNAP pIC50
a
 σ π 
3 4-Cl 75 µM 4.12 0.23 0.71 
8 H 292 µM 3.52 0 0 
9 4-OCH3 240 µM 3.62 –0.27 –0.02 
10 4-CH3 137 µM 3.86 –0.17 0.56 
11 4-CF3 51 µM 4.29 0.54 0.88 
12 4-NO2 73 µM 4.14 0.78 –0.28 
13 4-CN 133 µM 3.88 0.66 –0.57 
14 4-OCF3 45 µM 4.35 0.30 1.30 
15 3-Cl 72 µM 4.14 0.37 0.71 
16 3-CF3 53 µM 4.28 0.43 0.88 
17 3-NO2 80 µM 4.10 0.71 –0.28 
18 3,4-di-Cl 22 µM 4.66 0.60 1.42 
19 2,4-di-Cl 32 µM 4.49 0.46 1.42 
20 2,5-di-Cl 35 µM 4.46 0.60 1.42 
21 3,5-di-Cl 25 µM 4.60 0.74 1.42 
22 3-CF3-, 4-Cl 21 µM 4.68 0.66 1.59 
a 
pIC50 = –log(IC50); 
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6.1.2 Biology 
 
Figure S1. Effect of 18 on RNA synthesis in E. coli TolC. 
 
Table S2. RNA inhibition and antibacterial activity of 4 and the references 5, 6 
and 7. 
Cpd structure Inhibition of RNAP
a 
MIC (µg/mL)
b,c 
4 
 
    2% @ 25 µM >25 
5 
 
    3% @ 25 µM >25 
6     2% @ 50 µM >25 
7     4% @ 100 µM 33 
a 
Inhibition of E. coli RNA polymerase; 
b 
Minimal inhibitory concentration in E. coli TolC; 
c
               
>: MIC-determination was limited due to insufficient solubility of the tested compounds. 
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6.1.3 Docking pose and interaction map of compound 23 
 
Figure S2: Docking simulation of compound 23 and two dimensional illustration of the 
interaction between 23 and RNAP. The main interacting amino acids and the key interactions 
are highlighted. Polar amino acids are illustrated in purple and hydrophobic amino acids in 
green circles 
6.1.4 Chemistry 
Scheme S1: Synthesis of 5-aryl-3-ureidothiophene-2-carboxylic acids. 
 
 
Method A, general procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic 
acid methylester (II) [2]: POCl3 (26.1 g, 0.17 mol) was added dropwise to DMF 
(24.9 g, 0.34 mol) maintaining the temperature beyond 25 °C (cooling in ice bath) 
and stirred for additional 15 min. The acteophenon I (85.0 mmol) was added 
slowly and the temperature was kept between 40 and 60 °C. After complete 
addition, the mixture was stirred for 30 minutes at room temperature. 
Hydroxylamine hydrochloride (23.6 g, 0.34 mol) was carefully added portionwise 
(exothermic reaction!) and the reaction was stirred for additional 30 min without 
heating. After cooling to room temperature, the mixture was poured into ice water 
(300 mL). The precipitated β-chloro-cinnamonitrile was collected by filtration, 
washed with H2O (2 x 50 mL) and dried under reduced pressure over CaCl2. In 
the next step sodium (1.93 g, 84.0 mmol.) was dissolved in MeOH (85 mL) and 
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methylthioglycolate (6.97 g, 65.6 mmol) was added to the stirred solution. The β-
chloro-cinnamonitrile (61.1 mmol) was added and the mixture was heated to 
reflux for 30 min. After cooling to room temperature, the mixture was poured in 
ice water (300 mL). The precipitated solid was collected by filtration, washed with 
H2O (2 x 50 mL) and dried under reduced pressure over CaCl2. If necessary, 
recrystallisation was performed from EtOH. 
 
Method B, general procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic 
acid (III): The 5-Aryl-3-amino-2-carboxylic acid methyl ester (16.6 mmol) was 
added to a solution of KOH (60 mL, 0.6M in H2O) and MeOH (60 mL). The 
mixture was heated to reflux for 3 h, concentrated, and washed with EtOAc (2 x 
50 mL). The aqueous layer was cooled with ice and acidified with a saturated 
aqueous solution of KHSO4. The precipitated solid was collected by filtration, 
washed with H2O (2 x 30 mL) and dried under reduced pressure over CaCl2. 
 
Method C, general procedure for the synthesis of 5-Aryl-2-thiaisatoic-anhydrid 
(IV) [3,4]: To a solution of the 5-Aryl-3-amino-2-carboxylic acid (III) (5.28 mmol) in 
THF (50 mL) a solution of phosgene (6.10 mL, 20 wt% in toluene, 11.6 mmol) 
was added dropwise over a period of 30 min. The reaction mixture was stirred for 
2 h at room temperature, followed by the addition of saturated aqueous solution 
of NaHCO3 (30 mL) and H2O (50 mL). The resulting mixture was extracted with 
EtOAc/THF (1:1, 3 x 100 mL). The organic layer was washed with saturated 
aqueous NaCl (100 mL), dried (MgSO4) and concentrated. The crude material 
was suspended in a mixture of n-hexane/EtOAc (2:1, 50 mL) heated to 50 °C and 
after cooling to room temperature separated via filtration. 
 
Method D, general procedure for the synthesis of of 5-Aryl-3-ureidothiophene-2-
carboxylic acid (V) [5]: The 5-Aryl-2-thiaisatoic-anhydrid (IV) (0.46 mmol) was 
suspended in water (7.5 mL) and the appropriate amine (4.60 mmol) was added. 
The reaction mixture was stirred, heated to 100 °C and then cooled to room 
temperature. The reaction mixture was poured into a mixture of concentrated HCl 
and ice (1:1) and extracted with EtOAc/THF (1:1, 60 mL). The organic layer was 
washed with aqueous HCl (2M), followed by saturated aqueous NaCl (2 x 50 
mL), dried (MgSO4) and concentrated. The crude material was suspended in a 
mixture of n-hexane/EtOAc (2:1, 20 mL) heated to 50 °C and after cooling to 
room temperature separated via filtration. 
 
5-(4’-Chlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (3). The title compound was prepared from 4’-
chloroacetophenone according to methods A–D. Yellow powder, m.p. 173–
174 °C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.39 (q, J = 
7.1 Hz, 2 H), 4.58 (s, 2 H), 7.24–7.38 (m, 5 H), 7.50 (d, J = 8.5 Hz,  2 H), 7.71 (d, 
J = 8.5 Hz, 2 H), 8.29 (s, 1 H), 10.06 (s, 1 H), 13.40 (br. s, 1 H, COOH) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 107.2, 117.8, 127.1, 127.1, 
127.4, 128.5, 129.3, 131.5, 133.8, 138.1, 146.1, 146.7, 153.0, 165.6 ppm. 
 
Methyl-5-(4’-chlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-
thiophen-2-carboxylate (4). A mixture of 3 (150 mg, 0.36 mmol), K2CO3 (58 mg, 
0.42 mmol) and iodomethane (55.4 mg, 0.39 mmol) was stirred in DMF (15 mL) 
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at room temperature for 72 h. The reaction was stopped by addition of H2O (50 
mL). The mixture was extracted with CH2Cl2 (3 x 30 mL). The combined organic 
layers were washed with a saturated solution of K2CO3 (3 x 50 mL) and with 
saturated NaCl (50 mL), dried (MgSO4) and evaporated in vacuo  to yield the 
desired product as a light yellow powder. 1H NMR (300 MHz, DMSO-d6) δ = 1.17 
(t, J = 7.1 Hz, 3 H), 3.39 (d, J = 7.1 Hz, 2 H), 3.81 (s, 3 H, OCH3), 4.59 (s, 2 H), 
7.23–7.40 (m, 5 H ), 7.52 (d, J = 8.6 Hz, 2 H), 7.73 (d, J = 8.6 Hz, 2 H), 8.31 (s, 1 
H), 9.78 (br. s, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.7, 49.3, 
52.1, 105.9, 117.9, 127.2, 127.2, 127.5, 128.5, 129.3, 131.3, 134.0, 138.0, 146.9, 
147.0, 152.9, 164.2 ppm.   
 
4,5,6,7,8,9-Hexahydro-2-(3-phenylureido)cycloocta[b]thiophene-3-
carboxlyic acid (5). The title compound was prepared from 7 according to the 
procedure reported by Arhin et al. [9] 1H NMR (300 MHz, DMSO-d6) δ = 1.15–
1.30 (m, 2 H), 1.35–1.47 (m, 2 H), 1.50–1.66 (m, 4 H), 2.67 (t, J = 5.4 Hz, 2 H), 
2.86 (t, J = 5.9 Hz, 2 H), 7.00 (t, J = 7.3 Hz, 1 H), 7.29 (dd, J = 7.8, 7.3 Hz, 2 H), 
7.49 (d, J = 7.8 Hz, 2 H), 10.13 (s, 1 H), 10.72 (s, 1 H), 12.71 (br. s., 1 H, COOH) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 24.6, 25.2, 25.9, 29.7, 32.0, 110.0, 
118.5, 122.4, 127.1, 128.8, 133.0, 139.2, 148.5, 151.1, 166.9 ppm.  
 
Ethyl 4,5,6,7,8,9-hexahydro-2-(3-phenylureido)cycloocta[b]thiophene-3-
carboxylate (6). The title compound was prepared according to the procedure 
reported by Arhin et al. [9] 1H NMR (300 MHz, DMSO-d6): δ = 1.15–1.30 (m, 2 H), 
1.32 (t, J = 7.1 Hz, 3 H) 1.35–1.49 (m, 2 H), 1.50–1.65 (m, 4 H), 2.63–2.74 (m, 2 
H), 2.85 (t, J = 6.0 Hz, 2 H), 4.31 (q, J = 7.1 Hz, 2 H), 7.01 (t, J = 7.3 Hz,1 H), 
7.30 (dd, J = 7.6, 7.3 Hz, 2 H), 7.49 (d, J = 7.6 Hz, 2 H), 10.17 (br. s, 1 H), 10.66 
(br. s, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 14.0, 24.9, 25.2, 26.0, 29.5, 
32.0, 60.0, 60.0, 109.2, 118.4, 122.4, 127.5, 128.8, 132.3, 139.1, 148.9, 151.1, 
165.4 ppm. 
 
tert-Butyl 4,5,6,7,8,9-hexahydro-2-(3-phenylureido)cycloocta[b]thiophene-3-
carboxylate (7). The title compound was prepared according to the procedure 
reported by Arhin et al. [9] 1H NMR (300 MHz, CDCl3) δ = 1.26–1.31 (m, 2 H), 
1.41–1.52 (m, 2 H), 1.57 (s, 9 H), 1.59–1.67 (m, 4 H), 2.67–2.77 (m, 2 H), 2.80–
2.94 (m, 2 H), 6.83 (s, 1 H), 7.08–7.16 (tt, J = 7.4, 1.1 Hz,1 H), 7.30–7.38 (m, 2 
H), 7.46 (m, 2 H), 11.06 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3) δ = 25.4, 25.6, 
26.4, 26.7, 28.3, 30.1, 32.3, 81.6, 111.3, 120.3, 124.1, 128.3, 129.1, 133.1, 
137.7, 149.3, 151.2, 166.6 ppm. 
 
5-(Phenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-carboxylic 
acid (8). The title compound was prepared from acetophenone according to 
methods A–D. Yellow powder, m.p. 169–171 °C. 1H NMR (300 MHz, DMSO-d6): 
δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 Hz, 2 H), 4.59 (s, 2 H), 7.24–7.50 (m, 
8 H), 7.70 (m, 2 H), 8.29 (s, 1 H), 10.08 (s, 1 H), 13.33 (br. s, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 106.8, 117.3, 125.7, 127.1, 
127.1, 128.5, 129.3, 129.4, 132.7, 138.1, 146.8, 147.7, 153.1, 165.7 ppm. 
 
5-(4’-Methoxyphenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (9). The title compound was prepared from 4’-
methoxyacetophenone according to methods A–D. Beige powder, m.p. 169–170 
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°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1, 3 H), 3.39 (q, J = 7.0 Hz, 2 
H, OCH3), 3.80 (s, 3 H), 7.02 (d, J = 8.9 Hz, 2 H), 7.29–7.38 (m, 5 H), 7.63 (d, J = 
8.9 Hz, 2 H), 8.17 (s, 1 H), 10.10 (s, 1 H), 13.21 (br.s, 1 H, COOH) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 55.3, 105.6, 114.7, 116.1, 125.3, 
127.1, 127.1, 127.2, 128.5, 138.1, 147.0, 147.9, 153.1, 160.2, 165.8 ppm. 
 
5-(4’-Methylphenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (10). The title compound was prepared from 4’-
methylacetophenone according to methods A–D. Orange powder, m.p. 174–178 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.0 Hz, 3 H), 2.33 (s, 3 H, 
CH3), 3.39 (q, J = 7.0 Hz, 2 H), 4.58 (s, 2 H), 7.24–7.38 (m, 7 H), 7.58 (d, J = 8.2 
Hz, 2 H), 8.24 (s, 1 H), 10.09 (s, 1 H), 13.31 (br. s, 1 H, COOH) ppm. 13C NMR 
(75 MHz, DMSO-d6): δ = 13.6, 21.3, 42.3, 49.8, 106.7, 117.2, 126.1, 127.6, 
127.6, 129.0, 130.4, 138.6, 139.5, 147.3, 148.4, 153.5, 166.3 ppm. 
 
5-(4’-Trifluoromethylphenyl)-3-[(N-ethylbenzylamino)carbonylamino]-
thiophen-2-carboxylic acid (11). The title compound was prepared from 4’-
trifluoromethylacetophenone according to methods A–D. Grey powder, m.p. 193–
194 °C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 
7.1 Hz, 2 H), 4.59 (s, 2 H), 7.24–7.38 (m, 5 H), 7.79 (d, J = 8.4 Hz, 2 H), 7.91 (d, 
J = 8.4 Hz, 2 H), 8.41 (s, 1 H), 10.05 (s, 1 H), 13.47 (br. s, 1 H, COOH) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 108.2, 124.0 (q, JCF = 272.0 Hz), 
126.2 (q, JCF = 3.7 Hz), 126.4, 127.2, 128.4, 128.5, 129.3 (q, JCF = 32.0 Hz) 
136.5, 138.1, 145.3, 146.7, 153.0, 165.6 ppm. 
 
5-(4’-Nitrophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (12). The title compound was prepared from 4’-
nitroacetophenone according to methods A–D. Yellow powder, m.p. 201–202 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 Hz, 2 
H), 4.59 (s, 2 H), 7.25–7.38 (m, 5 H), 7.96 (d, J = 8.9 Hz, 2 H), 8.25 (d, J = 8.9 
Hz, 2 H), 8.45 (s, 1 H), 10.02 (s, 1 H), 13.53 (br. s, 1 H, COOH) ppm. 13C NMR 
(75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 109.2, 119.7, 124.5, 126.7, 127.2, 
128.5, 138.0, 138.7, 144.3, 146.6, 147.2, 153.0, 165.5 ppm. 
 
5-(4’-Cyanophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (13).  
 
Scheme 2. Synthesis of compound 13:  
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5-(4’-Bromophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (13a) was prepared from 4’-bromo-acetophenone according to 
methods A–D. 1H NMR (300 MHz, DMSO-d6): δ ppm 1.16 (t, J = 7.0 Hz, 3 H), 
3.39 (q, J = 7.0 Hz, 2 H), 4.58 (s, 2 H), 7.24–7.38 (m, 5 H), 7.65 (m, 4 H), 8.30 (s, 
1 H), 10.06 (s, 1 H), 13.42 (br. s, 1 H, COOH) ppm.  
 
The title compound 13 was prepared from 13a according to the following 
procedure:[6] A stirred solution of 13a (410 mg, 0.85 mmol), K4[Fe(CN)6]∙3H2O 
(71.8 mg, 0.17 mmol) and Na2CO3 (94.5 mg, 0.85 mmol) in NMP (6 mL) was 
degassed and kept under a nitrogen atmosphere. Pd(PPh3)4 (30.0 mg, 3 Mol%) 
was added and the resulting mixture was heated for 16 h at 140 °C. The reaction 
mixture was allowed to cool to room temperature. An additional amount of 
Pd(PPh3)4 (10.0 mg, 1 Mol%) was added and the mixture was heated for 2 h at 
140 °C. After cooling to room temperature the reaction mixture was poured into a 
mixture concentrated HCl and ice (1:1, 50 mL) followed by extraction with 
EtOAc/THF (1:1, 60 mL). The organic layer was washed with aqueous HCl (2M), 
followed by saturated aqueous NaCl (2 x 50 mL), dried (MgSO4) and 
concentrated. The crude material was suspended in a mixture of n-hexane/EtOAc 
(2:1, 20 mL) heated to 50 °C and after cooling to room temperature separated via 
filtration. Yellow powder, m.p. 183–185 °C. 1H NMR (300 MHz, DMSO-d6): δ = 
1.16 (t, J = 6.7 Hz, 3 H), 3.40 (q, J = 6.7 Hz, 2 H), 4.59 (s, 2 H), 7.24–7.38 (m, 5 
H), 7.86–7.93 (m, 4 H), 8.41 (s, 1 H), 10.06 (s, 1 H), 13.58 (br. s, 1 H, COOH) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41,8, 49.3, 108.9, 111.3, 118.5, 
119.3, 126.4, 127.2, 128.5, 133.2, 136.9, 138.1, 144.9, 146.6, 153.0, 165.5 ppm. 
 
5-(4’-Trifluoromethoxyphenyl)-3-[(N-ethylbenzylamino)carbonylamino]-
thiophen-2-carboxylic acid (14). The title compound was prepared from 4’-
trifluoromethoxyacetophenone according to methods A–D. White powder, m.p. 
187–190 °C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 6.7 Hz, 3 H), 3.39 (q, 
J = 6.7 Hz, 2 H), 4.59 (s, 2 H), 7.24–7.38 (m, 5 H), 7.45 (d, J = 8.1 Hz, 2 H), 7.83 
(d, J = 8.1 Hz, 2 H), 8.31 (s, 1 H), 10.07 (s, 1 H), 13.44 (br. s, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6) δ = 13.1, 41.8, 49.3, 107.5, 118.1, 120.0 ((q, JCF = 
257.0 Hz), 121.8, 127.1, 127.8, 128.5, 132.0, 138.1, 145.7, 146.7, 148.7, 153.0, 
165.6 ppm. 
 
5-(3’-Chlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (15). The title compound was prepared from 3’-
chloroacetophenone according to methods A–D. Beige powder, m.p. 199–201 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 
Hz, 2 H), 4.58 (s, 2 H), 7.24–7.37 (m, 5 H), 7.45–7.50 (m, 2 H), 7.62–7.66 (m, 1 
H), 7.70–7.73 (m, 1 H) 8.31 (s, 1 H), 10.05 (s, 1 H), 13.44 (br. s, 1 H, COOH) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 107.6, 118.3, 124.5, 
125.2, 127.1, 127.2, 128.5, 128.9, 131.2, 134.1, 134.7, 138.1, 145.6, 146.6, 
153.0, 165.6 ppm. 
 
5-(3’-Trifluoromethylphenyl)-3-[(N-ethylbenzylamino)carbonylamino]-
thiophen-2-carboxylic acid (16). The title compound was prepared from 3’-
trifluoroacetophenone according to methods A–D. White powder, m.p. 207–209 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 
Hz, 3 H), 4.59 (s, 2 H), 7.24–7.38 (m, 5 H), 7.70 (dd, J = 7.8, 7.7 Hz, 1 H), 7.78 
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(d, J = 7.8 Hz, 1 H ), 7.94–7.97 (m, 1 H), 8.01 (d, J = 7.7 Hz, 1 H),  8.39 (s, 1 H), 
10.06 (s, 1 H), 13.50 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 
13.1, 41.8, 49.3, 108.9, 118.6, 121.9 (q, JCF = 3.7 Hz), 123.8 (q, JCF = 272.7 Hz), 
125.65 (q, JCF = 3.7 Hz), 127.1, 128.5, 129.8, 130.1 (q, JCF = 32.8  Hz), 130.6, 
133.7, 138.1, 14.4, 146.6, 153.0, 165.6 ppm. 
 
5-(3’-Nitrophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (17). The title compound was prepared from 3’-
nitroacetophenone according to methods A–D. Beige powder, m.p. 184–185 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.17 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 Hz, 2 
H), 4.59 (s, 2 H),  7.24–7.38 (m, 5 H), 7.74 (dd, J = 8.1, 8.0 Hz, 1 H), 8.14 (dd, J 
= 8.1, 1.7 Hz, 1 H), 8.23 (dd, J = 8.1, 1.7 Hz, 1 H), 8.38 (dd, J = 1.7 Hz, 1 H), 8.41 
(s, 1 H), 10.04 (s, 1 H), 13.53 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 13.1, 41.8, 49.3, 108.2, 119.0, 119.1, 119.9, 123.6, 127.2, 128.5, 
131.0, 132.0, 134.1, 138.0, 144.5, 146.6, 148.4, 153.0, 165.5 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (18). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Beige powder, m.p. 198–200 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.15 (t, J = 7.1 Hz, 3 H), 3.39 (q, J = 7.1 
Hz, 2 H), 4.58 (s, 2 H), 7.23–7.38 (m, 5 H), 7.63 (dd, J = 8.5, 1.7 Hz, 1 H), 7.66 
(d, J = 8.5 Hz, 1 H), 7.89 (d, J = 1.7 Hz, 2 H), 8.30 (s, 1 H), 10.03 (s, 1 H), 13.46 
(br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 42.8, 49.3, 
107.9, 118.7, 125.8, 127.1, 127.1, 127.2, 128.5, 131.3, 131.6, 132.1, 133.2, 
138.1, 144.3, 146.6, 153.0, 165.6 ppm. 
 
5-(2’,4’-dichlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (19). The title compound was prepared from 2’,4’-
dichloroacetophenone according to methods A–D. Off-white powder, m.p. 
212−214 °C.  1H NMR (300 MHz, DMSO-d6): δ = 1.15 (t, J = 7.1 Hz, 3 H), 3.39 
(q, J = 7.1 Hz, 2 H), 4.58 (s, 2 H), 7.23–7.37 (m, 5 H), 7.53 (dd, J = 8.5, 2.1 Hz, 1 
H), 7.68 (d, J = 8.5 Hz, 1 H), 7.79 (d, J = 2.1 Hz, 1 H), 8.27 (s, 1 H), 10.04 (s, 1 
H), 13.51 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 
49.3, 108.8, 122.1, 127.1, 128.1, 128.5, 130.1, 130.5, 132.1, 132.4, 134.3, 138.0, 
142.3, 145.6, 153.0, 165.6 ppm. 
 
5-(2’,5’-dichlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (20). The title compound was prepared from 2’,5’-
dichloroacetophenone according to methods A–D. Brown powder, m.p. 172–174 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.16 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 
Hz, 2 H), 4.58 (s, 2 H),  7.24–7.37 (m, 5 H), 7.53 (dd, J = 8.6, 2.5 Hz, 1 H), 7.65 
(d, J = 8.6 Hz, 1 H), 7.70 (d, J = 2.5 Hz, 1 H), 8.26 (s, 1 H), 10.04 (s, 1 H), 13.53 
(br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 
109.1, 122.5, 127.1, 128.5, 130.0, 130.2, 130.5, 132.2, 132.3, 133.2, 138.0, 
138.0, 141.8, 145.5, 153.0, 165.5 ppm. 
 
5-(3’,5’-dichlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (21). The title compound was prepared from 2’,4’-
dichloroacetophenone according to methods A–D. Grey powder. 1H NMR (300 
MHz, DMSO-d6): δ = 1.16 (t, J = 6.9 Hz, 3 H), 3.39 (q, J = 6.9 Hz, 2 H), 4.58 (s, 1 
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H), 7.22–7.41 (m, 5 H), 7.64 (dd, J = 1.7 Hz, 1 H), 7.71 (dd, J = 1.7 Hz, 2 H), 8.34 
(s, 1 H), 10.11 (s, 1 H) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.1, 41.8, 49.3, 
109.1, 119.4, 123.4, 124.3, 127.1, 127.2, 128.3, 128.5, 134.8, 135.0, 136.1, 
138.1, 143.5, 146.2, 153.0, 165.6 ppm. 
 
5-(3’-Trifluoromethyl,4’-Chlorophenyl)-3-[(N-
ethylbenzylamino)carbonylamino]-thiophen-2-carboxylic acid (22). The title 
compound was prepared from 3’-trifluoromethyl,4’-chloroacetophenone according 
to methods A–D. White powder, m.p. 202–203 °C. 1H NMR (300 MHz, DMSO-
d6): δ = 0.86 (t, J = 7.1 Hz, 3 H), 3.40 (q, J = 7.1 Hz, 2 H), 4.59 (s, 2 H), 7.24–
7.38 (m, 5 H), 7.78 (d, J = 8.9 Hz, 1 H), 7.96–8.02 (m, J = 6.3, 2.2 Hz, 2 H), 8.37 
(s, 1 H), 10.05 (s, 1 H), 13.54 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 13.1, 41.8, 49.3, 108.3, 119.1, 122.5 (q, JCF = 272.7 Hz), 124.6 (q, 
JCF = 5.2 Hz), 127.1, 127.4 (q, JCF = 30.6 Hz), 128.5, 131.0 (q, JCF = 1.5 Hz), 
131.1, 132.3, 132.6, 138.0, 144.1, 146.6, 153.0, 165.5 ppm. 
 
5-(4’-Chloro-3’-(4’’-((methoxycarbonyl)amino)butyl)-phenyl)-3-[(N-
ethylbenzylamino) carbonylamino]-thiophen-2-carboxylic acid (23). 
 
Scheme S3: Synthesis of compound 23: 
 
 
 
 
3’-Bromo-4’-chloro-acetophenone (23a) was prepared from 4’-chloro-
acetophenone [7]: AlCl3 (38.9 g, 0.29 mol) was slowly added to a solution of 4’-
chloro-acetophenone (15.0 g, 97.7 mmol) in CHCl2CH3 (250 mL) at 0 °C. 
Bromine (5.55 g, 0.11 mol) was added dropwise over 30 min. The resulting 
mixture was stirred for 72 h at room temperature. The reaction mixture was 
diluted with CH2Cl2 (100 mL) and cautiously washed with aqueous NaOH (2M, 2 
x 100 mL) and saturated aqueous NaCl (100 mL). The organic layer was dried 
(MgSO4) and the solvents were removed in vacuo. The crude product was 
crystallized from n-heptane affording 14.0 g of a crystalline solid. Orange crystals. 
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1H NMR (DMSO-d6, 300 MHz): δ = 2.59 (s, 3 H), 7.78 (d, J = 8.4 Hz, 1 H), 7.93 
(dd, J = 8.4, 2.0 Hz, 1 H), 8.24 (d, J = 2.0 Hz, 1 H) ppm. 
 
5-(3’-Bromo-4’-chlorophenyl)-3-[(N-ethylbenzylamino)carbonylamino]-
thiophen-2- carboxylic acid (23b) was prepared from 3’-bromo,4’-
chloroacetophenone according to methods A–D. Yellow powder, m.p. 173–174 
°C. 1H NMR (DMSO-d6, 300 MHz): δ = 1.16 (t, J = 7.0 Hz, 3 H), 3.40 (q, J  = 6.9 
Hz, 2 H), 4.58 (s, 2 H), 7.07–7.45 (m, 5 H), 7.54–7.81 (m, 2 H), 8.04 (d, J = 1.8 
Hz, 1 H), 8.31 (s, 1 H), 10.04 (s, 1 H), 13.49 (br. s, 1 H) ppm. 13C NMR (DMSO-
d6, 75 MHz): δ = 13.1, 41.8, 49.3, 107.9, 118.7, 122.5, 126.5, 127.1, 128.5, 130.4, 
131.2, 133.3, 133.7, 138.0, 144.2, 146.6, 153.0, 165.6 ppm. 
  
N-(Methoxycarbonyl)-3-butenylamine (23c) was prepared from 4-pentenoic 
acid [8]: 4-Pentenoic acid (5.00 g, 50.0 mmol) and triethylamine (5.40 g, 53.0 
mmol) were dissolved in toluene (75 mL). Diphenylphosphoryl azide (13.8 g, 50.2 
mmol) was added via a syringe over 5 min and the resulting solution was heated 
for 2 h at 80 °C. The reaction was allowed to cool to 50 °C, MeOH (22 mL, 0.54 
mol) was added and the resulting mixture was stirred at 50 °C for 14 h. The 
reaction mixture was cooled to room temperature and the solvents were removed 
under reduced pressure. The resulting yellow oil was diluted with Et2O (100 mL), 
water (50 mL) and a saturated aqueous solution of Na2CO3 (10 mL). The 
aqueous layer was separated and extracted with Et2O (5 x 50 mL). The combined 
organic layers were washed with saturated NaCl (2 x 100 mL), dried (MgSO4) 
and concentrated to afford 5.00 g of a light brown oil. NMR purity ca. 90%. The 
compound was used in the next step without further purification. 1H NMR (300 
MHz, CDCl3): δ = 2.25 (m, 2 H), 3.25 (m, 2 H), 3.66 (s, 3 H, OCH3), 4.74 (br. s, 1 
H, NH), 4.97–5.23 (m, 2 H), 5.75 (ddt, J = 17.1, 10.3, 6.8 Hz, 1 H) ppm.  
 
The title compound 23 was prepared according to the following procedure: 
To a solution of 23c (142 mg, 1.10 mmol) in anhydrous THF (1 mL) at 0 °C under 
nitrogen was added a solution of 9-BBN (0.5M in THF, 1.98 mL, 0.99 mmol). The 
mixture was allowed to warm to room temperature and stirred for 16 h. A solution 
of 23a (300 mg, 0.61 mmol) in THF (3 mL), PdCl2(dppf) (17.4 mg, 3 Mol%) and 
aqueous NaOH (3M, 0.73 mL) were added and the reaction mixture was heated 
to reflux for 16 h. After cooling to room temperature the solvent was removed in 
vacuo. The crude material was purified via preparative HPLC (RP18, 
acetonitrile/H2O 50% → 95%). White powder, m.p. 62–65°C. 
1H NMR (300 MHz, 
acetone-d6): δ = 1.22 ppm (t, J = 7.1 Hz, 3 H), 1.55–1.82 (m, 4 H), 2.80–2.96 (m, 
2 H),  3.11–3.27 (m, 2 H), 3.47 (q, J = 7.1 Hz, 2 H), 3.55 (s, 3 H, OCH3), 4.67 (s, 
2 H), 6.20 (br. s, 1 H), 7.21–7.31 (m, 1 H), 7.31–7.43 (m, 4 H), 7.48 (d, J = 8.3 
Hz, 1 H), 7.59 (dd, J = 8.3, 2.1 Hz, 1 H), 7.75 (d, J = 2.1 Hz, 1 H), 8.42 (s, 1 H), 
10.17 (s, 1 H). 13C NMR (75 MHz, acetone-d6): δ = 13.6, 27.9, 33.8, 41.2, 41.3, 
42.7, 50.5, 51.8, 107.4, 119.0, 126.0, 128.1, 128.5, 129.0, 129.5, 131.1, 133.4, 
135.2, 139.5, 142.1, 148.4, 149.0, 154.3, 154.4, 157.8, 166.4 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-ureido-thiophen-2-carboxylic acid (24). The title 
compound was prepared from 3’,4’-dichloroacetophenone according to methods 
A–D. Yellow powder, m.p. 217–218 °C. 1H NMR (300 MHz, DMSO-d6): δ = 6.76 
(br. s, 2 H, NH2), 7.64 (dd, J = 8.4, 2.1 Hz, 2 H), 7.7 (d, J = 8.4 Hz, 1 H), 7.85 (s, J 
= 2.1 Hz, 1 H), 8.31 (s, 1 H), 9.29 (s, 1 H), 13.20 (br. s, 1 H, COOH) ppm. 13C 
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NMR (75 MHz, DMSO-d6): δ = 107.8, 119.4, 125.9, 127.2, 131.4, 131.5, 132.1, 
133.4, 143.6, 146.2, 154.6, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-i-propylamino)carbonylamino]-thiophen-2-
carboxylic acid (25). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 212–214 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.11 (d, J = 6.5 Hz, 6 H), 3.77 (q, J = 6.5 
Hz, 1 H), 7.58–7.65 (m, 2 H), 7.69 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 1.8 Hz, 1 H), 
8.33 (s, 1 H), 9.24 (s, 1 H), 13.24 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ = 22.7, 41.3, 107.3, 119.4, 125.8, 127.2, 131.4, 131.5, 132.1, 133.5, 
143.6, 146.3, 153.0, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-butylamino)carbonylamino]-thiophen-2-
carboxylic acid (26). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 216–217 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 0.89 (t, J = 7.3 Hz, 3 H), 1.26–1.48 (m, 4 
H), 3.06–3.12 (m, 2 H), 7.64 (dd, J = 8.4, 2.1 Hz, 2 H), 7.70 (d, J = 8.4 Hz, 1 H), 
7.89 (d, J = 2.1 Hz, 1 H), 8.32 (s, 1 H), 9.29 (s, 1 H), 13.18 (br. s, 1 H, COOH) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.6, 19.5, 25.1, 31.5, 107.3, 119.4, 
125.8, 127.2, 131.4, 131.5, 132.1, 133.4, 143.6, 146.3, 153.7, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-pentylamino)carbonylamino]-thiophen-2-
carboxylic acid (27). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 213–215 
°C.  
1H NMR (300 MHz, DMSO-d6): δ = 0.87 (t, J = 6.8 Hz, 3 H), 1.26–1.31 (m, 4 H), 
.40–1.49 (m, 2 H), 3.05–3.11 (m, 2 H), 7.64 (dd, J = 8.4, 2.0 Hz, 1 H), 7.66 (br. s, 
1 H), .69 (d, J = 2.0 Hz, 1 H), 7.89 (d, J = 8.4 Hz, 1 H), 8.32 (s, 1 H), 9.29 (s, 1 
H), 13.19 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.9, 21.8, 
28.6, 29.1, 39.3, 107.3, 119.4, 125.8, 127.2, 131.4, 131.5, 132.1, 133.4, 143.6, 
146.3, 153.7, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-hexylamino)carbonylamino]-thiophen-2-
carboxylic acid (28). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Beige powder, m.p. 198–
200 °C. 1H NMR (300 MHz, DMSO-d6): δ = 0.86 (t, J = 6.9 Hz, 3 H), 1.27–1.45 
(m, 8 H), 3.08 (m, 2 H), 7.64 (dd, J = 8.4, 2.1 Hz, 3 H), 7.68 (d, J = 8.4 Hz, 1 H), 
7.89 (d, J = 2.1 Hz, 1 H), 8.32 (s, 1 H), 9.29 (s, 1 H), 13.18 (br. s, 1 H, COOH) 
ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.9, 22.1, 26.1, 29.4, 31.0, 39.3, 107.3, 
119.4, 125.8, 127.2, 131.3, 131.4, 132.1, 133.4, 143.6, 146,3, 153.7, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-phenylamino)carbonylamino]-thiophen-2-
carboxylic acid (29). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 219–220 
°C.  
1H NMR (300 MHz, DMSO-d6): δ = 7.01 (t, J = 7.4 Hz, 1 H), 7.30 (dd, J = 8.0, 7.4 
Hz, 2 H), 7.53 (d, J = 8.0 Hz, 2 H), 7.64–7.68 (dd, J = 8.5, 1.5 Hz, 1 H), 7.72 (d, J 
= 8.5 Hz, 1 H), 7.95 (d, J = 1.5 Hz, 1 H), 8.37 (s, 1 H), 9.64 (s, 1 H), 10.02 (s, 1 
H), 13.37 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 108.8, 
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118.6, 119.5, 122.3, 125.9, 127.3, 128.8, 131.4, 131.6, 132.1, 133.3, 139.4, 
143.9, 145.2, 151.3, 164.5 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-benzylamino)carbonylamino]-thiophen-2-
carboxylic acid (30). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 214–216 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 4.32 (d, J = 5.7 Hz, 2 H), 7.23–7.37 (m, 
5 H), 7.65 (dd, J = 8.4, 2.1 Hz, 1 H), 7.70 (d, J = 8.4 Hz, 1 H), 7.91 (d, J = 2.1 Hz, 
1 H), 8.22 (t, J = 5.7 Hz, 1 H), 8.34 (s, 1 H), 9.43 (s, 1 H), 13.24 (br. s, 1 H, 
COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 43.0, 107.7, 119.4, 125.9, 126.8, 
127.2, 127.3, 128.3, 131.4, 131.5, 132.1, 133.4, 139.8, 143.7, 146.0, 153.8, 
164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-phenethylamino)carbonylamino]-thiophen-2-
carboxylic acid (31). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 205–207 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 2.77 (t, J = 7.5 Hz, 2 H), 3.30–3.38 (m, 2 
H), 7.17–7.34 (m, 5 H), 7.65 (dd, J = 8.5, 2.1 Hz, 1 H), 7.70 (d, J = 8.5 Hz, 1 H), 
7.79 (t, J = 4.7 Hz, 1 H), 7.90 (d, J = 2.1 Hz, 1 H), 8.34 (s, 1 H), 9.32 (s, 1 H), 
13.21 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 35.5, 40.9, 
107.5, 119.4, 125.9, 126.1, 127.2, 128.3, 128.6, 131.4, 131.5, 132.1, 133.4, 
139.5, 143.7, 146.1, 153.8, 164.6 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-methylphenylamino)carbonylamino]-thiophen-
2-carboxylic acid (32). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 215–216 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 3.27 (s, 3 H, CH3), 7.38–7.54 (m, 5 H), 
7.65 (d, J = 8.5 Hz, 1 H), 7.70 (d, J = 8.5 Hz, 1 H), 7.91 (s, 1 H), 8.34 (s, 1 H), 
9.60 (s, 1 H), 13.25 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 
37.0, 107.9, 118.3, 125.9, 127.3, 127.5, 127.9, 130.1, 131.4, 131.6, 132.1, 133.3, 
141.9, 144.2, 146.0, 152.5, 165.0 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-methylbenzylamino)carbonylamino]-thiophen-
2-carboxylic acid (33). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 212–
214°C. 1H NMR (300 MHz, DMSO-d6): δ = 3.02 (s, 3 H, CH3), 4.59 (s, 2 H), 7.25–
7.39 (m, 5 H), 7.67 (dd, J =  8.5, 1.5 Hz, 1 H), 7.70 (d, J = 8.5 Hz, 1 H), 7.94 (d, J 
= 1.5 Hz, 1 H), 8.33 (s, 1 H), 10.03 (s, 1 H), 13.50 (br. s, 1 H, COOH) ppm. 13C 
NMR (75 MHz, DMSO-d6): δ = 34.2, 51.3, 108.1, 118.7, 125.9, 127.2, 127.3, 
128.6, 131.4, 131.6, 132.1, 133.3, 137.7, 144.3, 146.5, 153.4, 165.5 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-ethylphenylamino)carbonylamino]-thiophen-2-
carboxylic acid (34). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Green powder, m.p. 210–212 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 1.10 (t, J = 7.1 Hz, 3 H), 3.72 (q, J = 7.1 
Hz, 2 H), 7.38–7.55 (m, 5 H), 7.65 (dd, J = 8.5, 2.1 Hz, 1 H), 7.70 (d, J = 8.5 Hz, 
1 H), 7.92 (d, J = 2.1 Hz, 1 H), 8.35 (s, 1 H), 9.47 (s, 1 H), 13.21 (br. s, 1 H, 
COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.4, 43.7, 107.8, 118.4, 125.9, 
127.3, 128.3, 128.7, 130.2, 131.4, 131.6, 132.1, 133.3, 139.9, 144.2, 146.0, 
152.1, 165.0 ppm. 
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5-(3’,4’-dichlorophenyl)-3-[(N-n-propylbenzylamino)carbonylamino]-
thiophen-2-carboxylic acid (35). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 195–197 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 0.88 (t, J = 7.5 Hz, 3 H), 1.55–1.67 (m, 2 
H), 3.29 (t, J = 7.5 Hz, 2 H), 4.59 (s, 2 H), 7.24–7.37 (m, 5 H), 7.65–7.71 (m, 2 H), 
7.93–7.95 (m, 1 H), 8.33 (s, 1 H), 10.07 (s, 1 H), 13.53 (br. s, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6) δ = 11.0, 21.0, 48.9, 49.8, 107.9, 118.7, 125.9, 
127.1, 127.3, 128.5, 131.4, 131.6, 132.1, 133.3, 138.1, 144.4, 146.6, 153.1, 
165.7 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-propylphenethylamino)carbonylamino]-
thiophen-2-carboxylic acid (36). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. White powder, m.p. 178–
179 °C. 1H NMR (300 MHz, DMSO-d6): δ = 0.88 (t, J = 7.4 Hz, 3 H), 1.60 (m, 2 
H), 2.89 (t, J = 7.4 Hz, 2 H), 3.25 (t, J = 7.4 Hz, 2 H), 3.50, J = 7.4 Hz, 2 H), 7.19–
7.32 (m, 5 H), 7.65–7.71 (m, 2 H), 7.93 (m, 1 H), 8.33 (s, 1 H), 10.03 (s, 1 H), 
13.56 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 11.0, 21.2, 
34.1, 49.0, 49.1, 197.7, 118.7, 125.9, 126.2, 127.3, 128.4, 128.8, 131.4, 131.6, 
132.1, 133.3, 138.7, 144.4, 146.7, 152.6, 165.8 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-butylphenylamino)carbonylamino]-
thiophen-2-carboxylic acid (37). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Green powder, m.p. 187–188 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 0.87 (t, J = 7.1 Hz, 3 H), 1.17–1.51 (m, 4 
H), 3.69 (t, J = 7.3 Hz, 2 H), 7.37–7.70 (m, 7 H), 7.87–7.95 (m, 1 H), 8.35 (s, 1 H), 
9.48 (s, 1 H), 13.21 (br. s, 1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 
13.7, 19.3, 29.8, 48.4, 107.7, 118.4, 125.9, 127.3, 128.2, 128.6, 130.2, 131.4, 
131.6, 132.1, 133.3, 140.2, 144.2, 146.1, 152.4, 165.0 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-butylbenzylamino)carbonylamino]-thiophen-
2-carboxylic acid (38). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. Yellow powder, m.p. 193–194 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 0.88 (t, J = 7.4 Hz, 3 H), 1.24–1.36 (m, 2 
H), 1.50–1.65 (m, 2 H), 3.26–3.38 (m, 2 H), 4.59 (s, 2 H), 7.26–7.35 (m, 5 H), 
7.60-7.70 (m, 2 H), 7.90-7.96 (m, 1 H),  8.33 (s, 1 H), 10.06 (s, 1 H), 13.52 (br. s, 
1 H, COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 13.6, 19.5, 29.8, 47.0, 49.8, 
107.9, 118.7, 125.9, 127.1, 127.3, 128.5, 131.4, 131.6, 132.1, 133.3, 138.1, 
144.4, 146.6, 153.1, 165.7 ppm. 
 
5-(3’,4’-dichlorophenyl)-3-[(N-n-butylphenethylamino)carbonylamino]-
thiophen-2-carboxylic acid (39). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. White powder, m.p. 178–179 
°C. 1H NMR (300 MHz, DMSO-d6): δ = 0.88 (t, J = 7.3 Hz, 3 H), 1.24–1.37 (m, 2 
H), 1.50–1.60 (m, 2 H), 2.89 (t, J = 7.8 Hz, 2 H), 3.28 (t, J = 7.3 Hz, 2 H), 3.50 (t, 
J = 7.8 Hz, 2 H), 7.19–7.32 (m, 5 H), 7.65–7.72 (m, 2 H), 7.94 (d, J =  1.5 Hz, 1 
H), 8.33 (s, 1 H), 10.03 (s, 1 H), 13.54 (br. s, 1 H, COOH) ppm. 13C NMR (75 
MHz, DMSO-d6): δ = 13.7, 19.6, 30.1, 34.1, 47.1, 49.1, 107.7, 118.7, 125.9, 
126.2, 127.3, 128.4, 128.8, 131.4, 131.6, 132.1, 133.3, 138.7, 144.3, 146.7, 
152.6, 165.8 ppm. 
6  SUPPORTING INFORMATION                                                                                               161 
 
5-(3’,4’-dichlorophenyl)-3-[(N-dibenzylamino)carbonylamino]-thiophen-2-
carboxylic acid (40). The title compound was prepared from 3’,4’-
dichloroacetophenone according to methods A–D. White powder, m.p. 190–191 
°C. 
1H NMR (300 MHz, DMSO-d6): δ = 4.64 (s, 4 H), 7.26–7.38 (m, 10 H), 7.65–7.71 
(m, 2 H), 7.92–7.94 (m, 1 H), 8.35 (s, 1 H), 10.08 (s, 1 H), 12.66 (br. s, 1 H, 
COOH) ppm. 13C NMR (75 MHz, DMSO-d6): δ = 49.9, 50.1, 118.8, 125.9, 127.1, 
127.3, 127.3, 128.6, 128.6, 128.9, 130.0, 131.4, 131.6, 131.8, 132.1, 133.3, 
137.2, 137.2, 144.2, 146.2, 153.5, 165.4 ppm.  
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6.1.5 HPLC purity 
Table S3. Purity and retention times of compounds 3−40. 
Compound Purity [%] Retention time [min]
a 
3 100 14.52 
4 99 18.61 
5 95 14.80 
6 100 16.33 
7 96 18.84 
8 99 13.38 
9 98 13.51 
10 96 14.09 
11 98 14.59 
12 98 13.47 
13 97 12.61 
14 99 14.69 
15 99 14.57 
16 97 14.44 
17 98 13.40 
18 100 15.45 
19 99 15.14 
20 99 14.80 
21 95 15.64 
22 97 15.29 
23 95 14.49 
24 100 11.24 
25 98 13.45 
26 99 14.09 
27 100 15.05 
28 100 15.63 
29 98 15.00 
30 96 14.25 
31 97 14.64 
32 98 14.56 
33 96 14.85 
34 99 15.36 
35 98 15.91 
36 99 16.58 
37 95 16.30 
38 99 16.44 
39 98 16.93 
40 96 16.36 
a
 In a gradient run the percentage of acetonitrile (containing 0.1% trifluoroacetic acid) was 
increased from a initial concentration of 0% at 0 min to 100% at 15 min and kept at 100% for 
5 min. 
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6.2 Supporting Information for Publication B 
 
Full supporting information is available online:  
http://pubs.acs.org/doi/suppl/10.1021/cb5005433/suppl_file/cb5005433_si_001.pdf 
6.2.1 Supplemental experimental procedures 
Intrinsic fluorescence quenching assay. Intrinsic fluorescence quenching 
assay was performed as described by Mukhopadhyay et al. (1) with slight 
modifications. Fluorescence emission intensities of RNAP core enzyme in TB 
[100 µl; 50 mM Tris-HCl (pH 8.0), 100 mM KCl, 10 mM MgCl2, 1 mM dithiotreitol, 
0.01 % Tween 20, 5% glycerol] were measured before and 10 min after addition 
of the inhibitors [10 µl; TB, 50% DMSO]. Employing a Polarstar Omega (BMG 
Labtech, Ortenberg, Germany) 280 nm and 350 nm were chosen as excitation 
and emission wavelengths, respectively. The observed reductions of intrinsic 
fluorescence at each inhibitor concentration were corrected for dimethyl 
sulfoxide/ buffer dilution and the inner-filter effect using N-acetyltryptophanamide. 
Data were plotted as percent quenching of the intrinsic fluorescence in 
dependence of inhibitor concentration. The highest observed quenching was set 
at 100%. Data are means of three independent determinations. For non-linear 
regression analysis GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) 
was used. Experimental data of rifampicin was fitted to a one-site binding model, 
whereas data of compound 6, which showed a biphasic quenching, was fitted to 
a two-affinity model (2) as demonstrated by Döppenschmitt et al. (3) earlier. 
 
3-(3-(4-Methoxybenzyl)ureido)-5-(3-nitrophenyl)thiophene-2-carboxylic 
acid 
 
The title compound was prepared from 3’-nitroacetophenone according to the 
general procedures A-D. 1H NMR (DMSO-d6, 300 MHz): δ = 13.22 (br. s, 1H), 
9.41 (s, 1H), 8.44 (s, 1H), 8.37 (t, J = 1.7 Hz, 1H), 8.23 (dd, J = 1.7, 8.1 Hz, 1H), 
8.09–8.20 (m 2H), 7.75 (t, J = 8.1 Hz, 1H), 7.24 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 
8.6 Hz, 2H), 4.24 (d, J = 5.6 Hz, 2H), 3.73 (s, 3H) ppm. 13C NMR (DMSO-d6, 75 
MHz): δ = 164.5, 158.3, 153.8, 148.4, 146.1, 143.8, 134.2, 131.9, 131.6, 131.0, 
128.7, 123.5, 119.8, 119.6, 113.7, 107.9, 55.0, 42.5 ppm. HPLC-Purity: 96.3 % 
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6.2.2 Supplemental figures 
 
Figure S1. Myx binding pocket including mutated amino acids. Myxopyronin A is colored in 
green. β subunit amino acids are colored in turquois, β' subunit amino acids are colored in 
yellow. 
 
     
Figure S2. Effect of increasing inhibitor concentrations on the intrinsic fluorescence of 
RNAP. (A) rifampicin (B) 6 
 
For rifampicin, as expected and as already shown for myxopyronin (1), a 
monophasic curve progression was obtained, meaning that the compound is 
binding to a single binding site. 
In contrast, 6 exhibits a biphasic character of the curve indicating that the 
compounds bind to more than one single binding site 
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Figure S3. Numbering of atoms of compound 13. 
6.2.3 Supplemental tables 
Table S1. Antibiogram of the MRSA strains 
Antibiotic                /            
MRSA 
COL USA300 
Lac 
5191 R44 
ampicillin R R R R 
oxacillin R R R R 
gentamicin S S S S 
ciprofloxacin S R R S 
moxifloxacin S I R S 
erythromycin S R R R 
clindamycin S S R R 
linezolid S S S S 
daptomycin S S S S 
vancomycin S S S S 
tetracyclin R S S R 
tigecycline S S S S 
fosfomycin S S R S 
fusidinsäure S S S S 
rifampicin S S S S 
trimethoprim/sulfamethoxazol S S S R 
R, resistant; I, intermediary resistant; S, susceptible 
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Table S2. MIC value determination in Ec TolC “switch region” mutants 
Compd 
Ec TolC 
wild type 
MIC [µg/ml] 
 
Ec TolC 
βˈ K334G 
MIC [µg/ml] 
 
 
Ec TolC 
βˈ K334E 
MIC [µg/ml] 
 
Ec TolC 
βˈ K345T 
MIC [µg/ml] 
 
Ec TolC 
βˈ K345N 
MIC [µg/ml] 
 
Ec TolC 
β V1275M 
MIC [µg/ml] 
 
Ec TolC 
β E1279K 
MIC [µg/ml] 
 
 
Ec TolC 
β L1291F 
MIC [µg/ml] 
A1 
12.5–25 25 
> 25 >25 25 25 25 25 
A2 
25 12.5 
> 25 12.5–25 25 25 25 12.5–25 
A4 
25 50 
> 50 25–50 50 25 25 25 
A5 
12.5 25 
> 25 12.5–25 12.5 25 12.5 12.5 
A7 
25 25 
> 50 25–50 25 25 25 25 
Myx 
1.25 10 
> 10 > 25 > 25 > 25 > 25 2.5 
Rif 
6.25 6.25 
6.25 12.5 12.5 12.5 6.25–12.5 6.25–12.5 
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Table S3. In vitro transcription assay with wild type/ mutant RNAPs 
Compd 
RNAP 
wild type 
IC50 [µM] 
RNAP 
β S1322E 
IC50 [µM] 
 
RNAP 
βˈ Δ334–5 
IC50 [µM] 
 
RNAP 
βˈ K334A 
IC50 [µM] 
 
RNAP 
βˈ K334E 
IC50 [µM] 
 
RNAP 
βˈ K345A 
IC50[µM] 
A1 21.3 ± 0.1 18.7 ±  0.9 22.1 ± 1.8 23 ±  0.1 21.6 ±  1.3 16.6 ±  2 
A5 18.8 ± 1.9 17.9 ± 1.3 21.7 ± 3.9 20.5 ± 2.9 nd
a 12.2 ± 0.5 
A7 35.4 ± 0.8 34.8 ± 2.5 35.3 ± 2.3 32.8 ± 5.2 33.6 ± 0.3 27.5 ± 4.9 
A8 11.6 ± 0.7 9.4 ± 1.9 10.3 ± 0.5 9.9 ± 0.5 7.7 ± 0.1 7.3 ± 1.2 
A10 22.6 ± 0.1 20.7 ± 0.8 22.1 ± 0.8 21.5 ± 1.8 24 ± 4.7 19.6 ± 1.6 
A11 16.5 ± 2.9 12.5 ± 0.1 15.7 ± 0.6 15.6 ± 0.8 nd
a 12.8 ± 0.3 
B2 16.5 ± 1.3 13.9 ± 0.7 15.5 ± 1.5 14.8 ± 2.4 13.3 ± 1.5 12.6 ± 0.5 
Myx 0.28 ± 0.02 5.4 ± 0.1 0.63 ± 0.09  0.13 ± 0.02 0.49 ± 0.10 > 4 
Rif 33.6 ± 2.3 b > 500 b 12.5 ± 1.6
 b 21 ± 0.6 b nda 19 ± 1 b 
a nd: not determined, b: IC50 [nM] 
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Table S4. Plasmid details. Plasmid pVS10, the pIA-derivatives and MF10 encode 
the E. coli rpoA-rpoB -rpoC [His6] and rpoZ ORFs under control of a T7 promoter 
(4). Plasmid pRL663 encodes C-terminally hexahistidine-tagged E. coli RNAP β’ 
subunit under control of a β tac promoter (5). Plasmid pRL706 encodes C-
terminally hexahistidine-tagged E. coli RNAP β subunit under control of a trc 
promoter (6). 
Plasmid Amino Acid Substitution RNAP subunit 
pVS10 - - 
pIA878 S1322E β 
pIA879 K334A β' 
pIA882 K345A β' 
pIA883 Δ334-5 β' 
MF10 K334E β' 
pRL663 derivative K345N β' 
pRL663 derivative K345T β' 
pRL706 derivative V1275M β 
pRL706 derivative L1291F β 
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6.3 Supporting Information for Publication C 
Full supporting information is available online:  
http://onlinelibrary.wiley.com/store/10.1002/cbic.201402666/asset/supinfo/cbic_2014
02666_sm_miscellaneous_information.pdf?v=1&s=74c688f0c2861498377e6c59b49
52a528743ef18  
6.3.1 Experimental procedures 
6.3.1.1 Chemistry 
Materials and methods 
Starting materials were purchased from commercial suppliers and used without 
further purification. Column flash chromatography was performed on silica gel 
(40–63 µM), and reaction progress was monitored by TLC on TLC Silica Gel 60 
F254 (Merck). All moisture-sensitive reactions were performed under nitrogen 
atmosphere using oven-dried glassware and anhydrous solvents. 1H and 13C 
NMR spectra were recorded on Bruker Fourier spectrometers (500/300 or 126/75 
MHz) at ambient temperature with the chemical shifts recorded as δ values in 
ppm units by reference to the hydrogenated residues of deuteriated solvent as 
internal standard. Coupling constants (J) are given in Hz and signal patterns are 
indicated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, 
quartet; quin, quintet; sxt, sextet; m, multiplet, br., broad signal. 
Synthesis and spectroscopic data of compounds 1–18 
 
Scheme 1: General Synthesis of unsaturated β-keto-N-acetylcysteamine (SNAC)-esters 
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Scheme 2: General synthesis of β-keto-N-acetylcysteamine (SNAC)-esters. 
  
Scheme 3: Synthesis of N-acetylcysteamine (SNAC)-esters 
 
Precursor compounds could be synthesized by the following methods: 
General Procedure A for synthesis of acylmeldrums acids from acyl chlorides:[1] 
To a solution of meldrums acid (10.8 g, 75.0 mmol) and pyridine (12.0 g, 0.15 
mol) in anhydrous CH2Cl2 (50 mL) at 0 ºC was added dropwise a solution of the 
appropriate acyl chloride (80.0 mmol) in anhydrous CH2Cl2 (20 mL). The resulting 
orange mixture was stirred for 1 h at 0 ºC and then for 1 h at room temperature. 
The reaction mixture was diluted with CH2Cl2 (50 mL) and washed with aqueous 
2M HCl (3 x 50 mL), brine (2 x 50 mL), dried (MgSO4) and concentrated under 
reduced pressure. The crude material was filtered over a short pad of SiO2 
eluting with n-hexane/ EtOAc 2:1. 
General Procedure B for synthesis of oxinones from acylmeldrums acids:[2] The 
appropriate acylmeldrums acid (20.0 mmol) was dissolved in toluene (25 mL) and 
acetone (2.0 mL). The solution was heated under reflux for 2 h. The solvents 
were removed under reduced pressure and the crude material was purified by 
flash chromatography (SiO2, n-hexane/EtOAc) or vacuum distillation. 
General Procedure C for synthesis of dioxinon phosphonates:[3] To a solution of 
diisopropylamine (7.18 mL, 51.1 mmol) in THF (30 mL) was added dropwise a 
solution of n-BuLi (2.5M in n-hexane, 20.5 mL, 51.1 mmol) at 0 °C. After stirring 
for 30 minutes, the reaction mixture was cooled to ‒78 °C and the appropriate 
2,2-dimethyl-4H-1,3-dioxin-4-one (36.5 mmol) was added over 5 min. After 40 
min chlorodiethylphosphite (7.62 mL, 53.0 mmol) was added and the cooling bath 
was removed. When the mixture reached room temperature, it was diluted with 
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Et2O (200 mL), washed with half-saturated brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. The resulting yellow oil was dissolved in CH2Cl2 (60 mL) 
and aqueous H2O2 (30%, 13 mL) was carefully added at 0 °C. The solution was 
stirred for 1 h and diluted with EtOAc (200 mL). After separation, the organic 
layer was washed with brine (2 x 100 mL), dried (MgSO4) and concentrated in 
vacuo. The crude material was purified by flash chromatography (SiO2, EtOAc). 
General Procedure D for the Horner-Wadsworth-Emmons olefination for the 
preparation of unsaturated dioxinones:[4] To a solution of diisopropylamine (1.04 
mL, 7.13 mmol) in THF (20 mL) was added a solution of n-BuLi (2.5M in n-
hexane, 2.85 mL, 7.13 mmol) at 0 °C. After stirring for 30 min, the reaction 
mixture was cooled to –78 ºC. A solution of the appropriate phosphonate (6.84 
mmol) in THF (10 mL) was added to the reaction mixture, and the resulting 
mixture was warmed to 0 ºC and stirred for 15 min. After cooling to –78 ºC, 
HMPA (2.10 mL, 12.1 mmol) was added and stirring was continued for 30 min. A 
solution of the appropriate aldehyde (6.84 mmol) in THF (10 mL) was added 
slowly. The reaction mixture was allowed to warm slowly to 0 ºC and stirred for 
1 h. After diluting with EtOAc (80 mL), the mixture was washed with saturated 
aqueous NH4Cl (3 x 40 mL) and brine (50 mL). The organic layer was dried 
(MgSO4) and concentrated. The crude material was purified by flash 
chromatography (SiO2, n-hexane/EtOAc).  
General procedure E for synthesis of β-keto-N-acetylcysteamine (SNAC)-esters 
from dioxinones:[5] A degassed solution of the appropriate dioxinone (0.95 mmol), 
N-acetylcysteamine (SNAC-H, 0.15 g, 1.25 mmol) in toluene (6 mL) was refluxed 
for 16 h under a nitrogen atmosphere. After cooling to room temperature the 
solvent was evaporated under reduced pressure and the crude product was 
purified by flash column chromatography (SiO2, n-hexane/EtOAc = 1:1 → EtOAc) 
to afford the desired SNAC ester. 
General procedure F for synthesis of acylmeldrums acids from carboxylic acids 
via DCC coupling:[6] A solution of the appropriate acid (10.6 mmol) and DCC 
(2.19 g, 10.6 mmol) in anhydrous CH2Cl2 (20 mL) was stirred for 30 min at 0°C. A 
white solid precipitated. DMAP (1.94 g, 15.9 mmol) and meldrums acid (1.52 g, 
10.6 mmol) were subsequently added. The cooling bath was removed and the 
reaction mixture was stirred for 2 h at room temperature. The insoluble urea was 
filtered off and the filter-cake was washed with ice-cold CH2Cl2 (10 mL). The 
combined filtrates were washed with 1M HCl (2 x 50 mL), H2O (2 x 50 mL) and 
brine (75 mL), dried (MgSO4) and concentrated. To remove last residues of urea, 
the crude material was filtered over cotton.  
General procedure G for synthesis of β-keto-N-acetylcysteamine (SNAC)-esters 
from acylmeldrums acids:[5] A degassed solution of the appropriate acylmeldrums 
acid (0.80 mmol), N-acetylcysteamine (SNAC-H, 0.12 g, 1.00 mmol) in toluene (6 
mL) was refluxed for 16 h under a nitrogen atmosphere. After cooling to room 
temperature the solvent was evaporated under reduced pressure and the crude 
product was purified by flash column chromatography (SiO2, n-hexane/EtOAc = 
1:1 → EtOAc) to afford the desired β-keto-SNAC ester. 
General procedure H for synthesis of N-acetylcysteamine (SNAC)-esters from 
carboxylic acids via DCC coupling: A solution of the appropriate acid (1.06 mmol) 
6  SUPPORTING INFORMATION                                                                                               173 
 
and DCC (0.41 g, 1.06 mmol) in anhydrous CH2Cl2 (5 mL) was stirred for 30 min 
at 0°C. A white solid precipitated. DMAP (0.37 g, 1.59 mmol) and SNAC-H (0.24 
g, 1.06 mmol) were subsequently added. The cooling bath was removed and the 
reaction mixture was stirred for 2 h at room temperature. The insoluble urea was 
filtered off and the filter-cake was washed with ice-cold CH2Cl2 (10 mL). The 
combined filtrates were evaporated in vacuo and the crude product was purified 
by flash column chromatography (SiO2, n-hexane/EtOAc = 1:1 → EtOAc) to 
afford the desired SNAC ester. 
 
Synthesis and spectroscopic data of intermediates. 
(E)-3-(3-Hydroxyphenyl)acrylaldehyde (IM-1). The title compound was 
prepared from 3-hydroxybenzaldehyde according to the following procedure: A 
mixture of 3-hydroxybenzaldehyde (5.00 g, 41.0 mmol) and vinyl acetate (4.15 
mL, 45.1 mmol) in acetonitrile (15 mL) was added at room temperature to a 
suspension of potassium carbonate (6.80 g, 49.2 mmol) in acetonitrile (50 mL) 
and water (0.2 mL). The reaction mixture was refluxed for 40 h and cooled to 
room temperature. The reaction mixture was diluted with water (50 mL) and 
EtOAc (50 mL). The aqueous layer was separated and extracted with EtOAc (2 x 
50 mL). The combined organic layers were dried (MgSO4) and concentrated in 
vacuo. The residue was purified by flash column chromatography (SiO2, n-
hexane/EtOAc = 8:1 → 2:1) to afford the title compound. Yield: 25%, orange 
solid. 1H NMR (DMSO-d6): δ =  9.68 (br. s, 1H), 9.65 (d, J = 7.7 Hz, 1H), 7.65 (d, 
J = 15.8 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.08 (t, J = 2.4 
Hz, 1H), 6.89 (ddd, J = 8.0, 2.4, 1.0 Hz, 1H), 6.73 (dd, J = 15.8, 7.7 Hz, 1H) ppm. 
13C NMR (DMSO-d6): δ = 194.4, 157.8, 153.5, 135.3, 130.1, 128.3, 119.6, 118.4, 
115.0 ppm. 
(E)-3-(3-((tert-Butyldimethylsilyl)oxy)phenyl)acrylaldehyde (IM-2). The title 
compound was prepared from IM-1 according to the following procedure: 
Imidazole (0.86 g, 12.7 mmol) was added to a solution of IM-1 (0.76 g, 5.13 
mmol) and tert-butyldimethylchlorosilane (0.92 g, 6.10 mmol) in anhydrous N,N-
dimethylformamide (10 mL). The mixture was stirred for 3 h, diluted with 5% 
aqueous NaHCO3 (50 mL), and extracted with EtOAc (4 x 50 mL). The combined 
organic layers were washed with brine (100 mL), dried (MgSO4), and evaporated 
in vacuo to yield the title compound. Yield: 82%, yellow oil. 1H NMR (DMSO-d6): δ 
= 9.66 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 15.9 Hz, 1H), 7.34−7.38 (m, 2H), 
7.19−7.22 (m, 1H), 6.94−6.99 (m, 1H), 6.84 (dd, J = 15.9, 7.7 Hz, 1H), 0.96 (s, 
9H), 0.21 (s, 6H) ppm. 13C NMR (DMSO-d6): δ = 194.3, 155.5, 152.9, 135.6, 
130.2, 128.7, 122.7, 121.9, 119.8, 25.5, 17.9, −4.6 ppm. 
(E)-3-(3-Bromophenyl)acrylaldehyde (IM-3). The title compound was prepared 
from 3-bromobenzaldehyde according to the following procedure: A solution of 3-
bromobenzaldehyde (5.00 g, 27.0 mmol) in H2O (6 mL) was filled into a 100 mL 
three-necked round bottom flask equipped with an thermometer. NaOH (54.0 mg, 
1.35 mmol) was added and dissolved. A solution of vinylacetate (0.41 g, 10.4 
mmol) in H2O (1 mL) was added dropwise. The temperature was kept at 25 °C 
and NaOH (270 mg, 0.68 mmol) in H2O (1 mL) was added via a syringe. 
Afterwards another portion of vinylacetate (0.41 g, 10.4 mmol) in H2O (1 mL) was 
added and the reaction mixture was stirred over night at room temperature. The 
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reaction was neutralized with acetic acid, diluted with 50 mL H2O and extracted 
with Et2O (2 x 100 mL). The organic layers were combined, washed with brine 
(100 mL), dried (MgSO4), and evaporated in vacuo. The residue was purified by 
flash chromatography (SiO2, n-hexane/EtOAc = 20:1 → 15:1). Yield: 12%, yellow 
oil. 1H NMR (CDCl3): δ = 9.72 (d, J = 7.5 Hz, 1H), 7.71 (s, 1H), 7.57 (d, J = 7.7 
Hz, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.40 (d, J = 15.9 Hz, 1H), 7.32 (t, J = 7.7 Hz, 
1H), 6.70 (dd, J = 15.9, 7.5 Hz, 1H) ppm. 13C NMR (CDCl3): δ = 193.2, 150.6, 
136.1, 134.0, 131.2, 130.6, 129.7, 126.9, 123.2 ppm. 
Pent-4-yn-1-ol (IM-4). The title compound was prepared according to the 
following procedure: 4-Pentynoyc acid (3.00 g, 30.6 mmol) was dissolved in 
anhydrous THF (90 mL) and cooled to 0 °C. Triethylamine (4.69 mL, 33.6 mL) 
and methylchloroformate (2.60 mL, 33.6 mmol) were subsequently added and the 
reaction was stirred at 0 °C for 20 min. The occurring white precipitate was 
filtered off, afterwards under a nitrogen atmosphere and the filtrate was added to 
a solution of NaBH4 (1.85 g, 49.9 mmol) in water (60 mL) at 0 °C. The resulting 
mixture was stirred for 1 h at 0 °C and for additional  2 h at room temperature. 
The reaction was carefully quenched with 1M HCl (20 mL) until bubbling ceased. 
The mixture was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with a saturated solution of NaHCO3 (100 mL) and brine 
(100 mL), dried (MgSO4) and concentrated in vacuo to yield the title compound. 
Yield: 39%, colorless liquid. 1H NMR (CDCl3): δ = 3.75 (t, J = 6.4 Hz, 2H), 2.31 
(dt, J = 7.0, 2.7 Hz, 2H), 1.97 (t, J = 2.7 Hz, 1H), 1.85 (s, 1H), 1.77 (quin, J = 6.4 
Hz, 2H) ppm.13C NMR (CDCl3): δ = 83.8, 68.7, 61.4, 31.0, 14.9 ppm. 
Pent-4-ynal (IM-5). The title compound was prepared from IM-4 according to the 
general procedure shown for IM-7 and used in the next step without further 
purification.  
4-(tert-Butyldimethylsilyloxy)butan-1-ol (IM-6). The title compound was 
prepared according to the following procedure: To a suspension of potassium 
hydride (1.32 g, 33.0 mmol) in THF (40 mL) 1,4-butanediol (3.00 g, 33.3 mmol) 
was added at room temperature and stirred for 45 min. A voluminous white 
precipitate formed. To the reaction mixture was added tert-butyldimethylsilyl 
chloride (4.97 g, 33.0 mmol) and stirring was continued for 45 min. The mixture 
was diluted with Et2O (200 mL), washed with aqueous K2CO3 (10%, 50 mL) and 
brine (2 x 100 mL), dried (MgSO4) and concentrated in vacuo. Yield: 99%, 
colorless oil. 1H NMR (CDCl3): δ = 3.63−3.69 (m, 4H), 2.51 (t, J = 5.6 Hz, 1H), 
1.62−1.69 (m, 4H), 0.91 (s, 9H), 0.08 (s, 6H) ppm.13C NMR (CDCl3): δ = 63.3, 
62.7, 30.2, 29.8, 25.9, 18.3, −5.4 ppm. 
4-(tert-Butyldimethylsilyloxy)butanal (IM-7). The title compound was prepared 
from IM-6 according to the following procedure: To a stirred suspension of PCC 
(10.6 g, 49.2 mmol) and NaOAc (0.49 g, 9.84 mmol) in CH2Cl2 (100 mL) a 
solution of the alcohol IM-6 (6.70 g, 32.8 mmol) in CH2Cl2 (100 mL) was added. 
After 7 h the reaction mixture was diluted with Et2O (100 mL) and the mixture was 
filtered over short pad of celite. The solvents were evaporated in vacuo and the 
residue was purified by flash chromatography (SiO2, n-hexane/EtOAc = 20:1 → 
10:1). Yield: 30%, colorless oil. 1H NMR (CDCl3): δ = 9.79 (t, J = 1.7 Hz, 1H), 
3.65 (t, J = 6.0 Hz, 2H), 2.51 (dt, J = 7.1, 1.7 Hz, 2H), 1.86 (quin, J = 6.5 Hz, 2H), 
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0.89 (s, 9H), 0.05 (s, 6H) ppm. 13C NMR (CDCl3): δ = 202.6, 62.1, 40.8, 25.9, 
25.5, 18.3, −5.4 ppm. 
(E)-6-(tert-Butyldimethylsilyloxy)hex-2-enal (IM-8). The title compound was 
prepared from IM-7 according to the following procedure: To a solution 
formylmethylenetriphenylphosphorane (3.01 g, 9.90 mmol) in benzene (80 mL), a 
solution of the aldehyde IM-7 (2.00 g, 9.90 mmol) in benzene (15 mL) was added 
and the mixture was heated under reflux for 24 h. After removal of the solvent, 
the crude material was purified by flash chromatography (SiO2, n-hexane/EtOAc 
= 12:1 → 10:1). Yield: 58%, light yellow oil. 1H NMR (CDCl3): δ = 9.46 (d, J = 7.9 
Hz, 1H), 6.84 (dd, J = 15.7, 6.8 Hz, 1H), 6.08 (ddt, J = 15.7, 7.9, 1.5 Hz, 1H), 3.61 
(t, J = 6.1 Hz, 2H), 2.34−2.41 (m, 2H), 1.63−1.72 (m, 2H), 0.84 (s, 9H), 0.00 (s, 
6H) ppm. 13C NMR (CDCl3): δ = 194.0, 158.6, 133.0, 62.0, 30.9, 29.3, 25.9, 18.3, 
15.4 ppm. 
3-((tert-Butyldimethylsilyl)oxy)benzoic acid (IM-9). The title compound was 
prepared from 3-hydroxybenzoic acid according to the following procedure: 
Imidazole (1.36 g, 20.0 mmol) was added to a solution of 3-hydroxybenzoic acid 
(1.00 g, 7.24 mmol) and tert-butyldimethylchlorosilane (1.31 g, 8.69 mmol) in 
anhydrous N,N-dimethylformamide (15 mL). The mixture was stirred for 3 h at 
room temperature and then diluted with acetone (50 mL). The solvents were 
evaporated in vacuo and the residue was dissolved in EtOAc (50 mL). The 
organic layer was washed with H2O (2 x 40 mL) and brine (30 mL), dried 
(MgSO4), and evaporated in vacuo to yield the title compound. Yield: 38%, 
colorless crystals. 1H NMR (CDCl3) δ = 7.73 (td, J = 8.0, 1.1 Hz, 1H), 7.58 (t, J = 
2.5 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.10 (ddd, J = 8.0, 2.5, 1.1 Hz, 1H), 1.01 (s, 
9H), 0.24 (s, 6H) ppm. 13C NMR (CDCl3) δ = 171.7, 155.8, 130.7, 129.5, 125.7, 
123.2, 121.5, 25.6, 18.2, −4.5 ppm. 
(S)-(2-Acetamidoethyl) 3-((tert-butyldimethylsilyl)oxy)benzothioate (IM-10). 
The title compound was prepared from IM-9 according to the general procedure 
H: Yield 51%, white solid. 1H NMR (CDCl3) δ = 7.57 (d, J = 7.7 Hz, 1H), 
7.39−7.44 (m, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.03−7.12 (m, 1H), 5.92 (br. s., 1H), 
3.50−3.60 (m, 1H), 3.23 (t, J = 6.4 Hz, 1H), 1.98 (s, 3H), 1.01 (s, 9H), 0.23 (s, 6H) 
ppm. 13C NMR (CDCl3) δ = 191.6, 169.9, 155.6, 137.6, 129.3, 125.1, 119.9, 
118.1, 76.8, 76.6, 76.2, 39.3, 28.2, 25.2, 22.8, −4.9 ppm 
5-(1-Hydroxyethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (IM-11). The title 
compound was prepared from acetyl chloride according to the general procedure 
A: Yield: 83%, yellow solid. 1H NMR (CDCl3): δ = 15.12 (s, 1H), 2.68 (s, 3H), 1.74 
(s, 6H) ppm. 13C NMR (CDCl3): δ = 194.6, 170.2, 160.4, 104.9, 91.8, 26.8, 23.5 
ppm. 
6-Methyl-2,2-dimethyl-4H-1,3-dioxin-4-one (IM-12). The title compound was 
prepared from IM-11 according to the general procedure B: Yield: 85%, yellow 
oil. 1H NMR (CDCl3): δ = 5.19 (s, 1H), 1.94 (s, 3H), 1.64 (s, 6H) ppm. 
13C NMR 
(CDCl3): δ = 168.6, 161.1, 106.2, 93.7, 24.9, 19.8 ppm. 
Diethyl 1-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methylphosphonate (IM-13). 
The title compound was prepared from IM-12 according to the general procedure 
C: Yield: 62%, yellow resin. 1H NMR (CDCl3) δ = 5.39 (d, J = 3.6 Hz, 1H), 
4.08−4.24 (m, 4H), 2.80 (d, J = 22.1 Hz, 2H), 1.71 (s, 6H), 1.35 (t, J = 7.1 Hz, 6H) 
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ppm.13C NMR (75 MHz, CDCl3): δ = 163.0 (d, J = 9.7 Hz), 160.5, 107.1, 96.2 (d, 
J = 8.2 Hz), 62.6 (d, J = 6.7 Hz), 32.4 (d, J = 137.1 Hz), 24.9, 16.3(d, J = 6.0 Hz) 
ppm. 
6-((1E,3E)-Hepta-1,3-dien-1-yl)-2,2-dimethyl-4H-1,3-dioxin-4-one (IM-14). The 
title compound was prepared from IM-13 according to the general procedure D 
using trans-2-hexen-1-al as aldehyde: Yield: 42%. 1H NMR (CDCl3): δ = 6.92 (dd, 
J = 15.2, 9.9 Hz, 1H), 5.98−6.14 (m, 2H), 5.90 (d, J = 15.2 Hz, 1H), 5.21 (s, 1H), 
2.16 (q, J = 7.2 Hz, 2H), 1.72 (s, 6H), 1.46 (sxt, J = 7.4 Hz, 2H), 0.95 (t, J = 7.4 
Hz, 3H) ppm.13C NMR (CDCl3): δ = 163.5, 161.7, 143.4, 138.5, 128.9, 120.6, 
105.9, 93.6, 34.8, 24.8, 21.8, 13.4 ppm. 
5-(1-Hydroxypropylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (IM-15). The 
title compound was prepared from propionyl chloride according to the general 
procedure A: Yield: 93%, orange crystals. 1H NMR (CDCl3): δ = 15.35 (br. s, 1H), 
3.10 (q, J = 7.4 Hz, 2H), 1.72 (s, 6H), 1.25 (t, J = 7.4 Hz, 3H) ppm.13C NMR 
(CDCl3): δ = 198.9, 170.2, 160.2, 104.8, 90.9, 29.4, 26.7, 9.6 ppm. 
6-Ethyl-2,2-dimethyl-4H-1,3-dioxin-4-one (IM-16). The title compound was 
prepared from IM-15 according to the general procedure B: Yield: 80%, yellow 
oil. 1H NMR (CDCl3): δ = 5.22 (t, J = 1.0 Hz, 1H), 2.24 (dq, J = 7.6, 1.0 Hz, 2H), 
1.67 (s, 6H), 1.12 (t, J = 7.6 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 173.1, 161.5, 
106.2, 92.2, 26.7, 24.9, 9.9 ppm. 
Diethyl 1-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)ethylphosphonate (IM-17). 
The title compound was prepared from IM-16 according to the general procedure 
C: Yield: 75%. Light yellow oil. 1H NMR (CDCl3): δ = 5.37 (d, J = 3.5 Hz, 1H), 
4.08−4.18 (m, 4H), 2.77 (dq, J = 23.9, 7.3 Hz, 1H), 1.69 (s, 6H), 1.30−1.45 (m, 
9H) ppm.13C NMR (CDCl3): δ = 168.1 (d, J = 8.2 Hz), 160.8 (d, J = 2.2 Hz), 
106.8, 94.9 (d, J = 6.7 Hz), 62.1 (dd, J = 6.7, 4.5 Hz), 36.9 (d, J = 137.1 Hz), 24.8 
(d, J = 70.8 Hz), 16.4 (d, J = 6.0 Hz), 12.1 (d, J = 6.0 Hz) ppm. 
5-((2E,4E)-1-Hydroxy-2,5-dimethylocta-2,4-dien-1-ylidene)-2,2-dimethyl-1,3-
dioxane-4,6-dione (IM-18). The title compound was prepared from IM-17 
according to the general procedure D using IM-41 as aldehyde: Yield: 60 %, 
yellow oil. 1H NMR (CDCl3) δ = 7.09 (d, J = 11.8 Hz, 1H), 6.14 (dd, J = 11.8, 1.2 
Hz, 1H), 5.41 (s, 1H), 2.12 (t, J = 7.5 Hz, 2H), 1.85 (s, 3H), 1.83 (s, 3H), 1.68 (s, 
6H), 1.47 (sxt, J = 7.4 Hz, 2H), 0.87 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (CDCl3) δ = 
166.0, 162.3, 148.5, 130.0, 124.0, 120.6, 105.7, 91.2, 42.7, 24.8, 20.9, 17.0, 
13.6, 11.9 ppm. 
2,2-Dimethyl-6-((2E,4E)-octa-2,4-dien-2-yl)-4H-1,3-dioxin-4-one (IM-19). The 
title compound was prepared from IM-17 according to the general procedure D 
using trans-2-hexen-1-al as aldehyde: Yield: 42%. 1H NMR (CDCl3): δ = 6.85 (d, 
J = 11.3 Hz, 1H), 6.36 (dd, J = 14.8, 11.3 Hz, 1H), 6.07 (dt, J = 14.8, 7.5 Hz, 1H), 
5.42 (s, 1H), 2.15−2.20 (m, 2H), 1.86 (s, 3H) 1.68 (s, 6H) 1.39−1.48 (m, 2H), 0.90 
(t, J = 7.4 Hz, 1H) ppm. 13C NMR (CDCl3): δ = 165.7, 162.2, 143.3, 134.3, 125.9, 
124.4, 105.8, 91.6, 35.3, 24.9, 22.1, 13.6, 12.1 ppm. 
(E)-2,2-Dimethyl-6-(oct-2-en-2-yl)-4H-1,3-dioxin-4-one (IM-20). The title 
compound was prepared from IM-17 according to the general procedure D using 
hexanal as aldehyde: Yield: 37%, colorless oil. 1H NMR (CDCl3): δ = 6.41 (t, J = 
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7.4 Hz, 1H), 5.40 (s, 1H), 2.20 (q, J = 7.4 Hz, 2H), 1.79 (s, 3H), 1.70 (s, 6H), 
1.40−1.49 (m, 2H), 1.27−1.36 (m, 4H), 0.90 (t, J = 6.9 Hz. 3H) ppm. 13C NMR 
(CDCl3): δ = 165.8, 162.5, 138.1, 126.9, 105.9, 91.2, 31.6, 28.7, 28.5, 24.9, 22.4, 
13.9, 12.1 ppm. 
2,2-Dimethyl-6-((2E,4E)-5-phenylpenta-2,4-dien-2-yl)-4H-1,3-dioxin-4-one 
(IM-21). The title compound was prepared from IM-17 according to the general 
procedure D using trans-cinnamaldehyde: Yield: 50%, yellow oil. 1H NMR 
(CDCl3): δ = 7.48−7.51 (m, 2H), 7.30−7.40 (m, 4H), 7.14 (dd, J = 14.1, 11.3 Hz, 
1H), 7.06 (d, J = 11.3 Hz, 1H), 6.90 (d, J = 14.1 Hz, 1H), 5.54 (s, 1H) 2.02 (s, 
3H), 1.75 (s, 6H) ppm.13C NMR (CDCl3): δ = 165.3, 162.2, 139.2, 136.6, 134.0, 
128.8, 127.0, 127.0, 123.7, 106.0, 92.3, 25.0, 12.5 ppm. 
(E)-2,2-Dimethyl-6-(5-phenylpent-2-en-2-yl)-4H-1,3-dioxin-4-one (IM-22). The 
title compound was prepared from IM-17 according to the general procedure D 
using hydrocinnamaldehyde as aldehyde: Yield: 13%, colorless resin. E-isomer 
only. 1H NMR (CDCl3): δ = 7.12−7.32 (m, 5H), 6.44 (t, J = 7.5 Hz, 1H), 5.40 (s, 
1H), 2.76 (t, J = 7.6 Hz, 2H), 2.48−2.56 (m, 2H), 1.73 (s, 3H), 1.70 (s, 6H) ppm. 
13C NMR (CDCl3): δ = 165.6, 162.4, 141.0, 136.5, 128.4, 128.3, 127.8, 126.2, 
106.0, 91.5, 35.0, 30.6, 24.9, 12.1 ppm. 
6-((2E,4E)-5-(3-((tert-Butyldimethylsilyl)oxy)phenyl)penta-2,4-dien-2-yl)-2,2-
dimethyl-4H-1,3-dioxin-4-one (IM-23). The title compound was prepared from 
IM-17 according to the general procedure D using IM-2 as aldehyde: Yield: 16%, 
yellow oil. 1H NMR (CDCl3): δ = 7.22 (dd, J = 7.8, 7.8 Hz, 1H), 7.02−7.12 (m, 3H), 
6.93 (dd, J = 1.9, 1.8 Hz, 1H), 6.75−6.88 (m, 2H), 5.53 (s, 1H), 2.02 (s, 3H), 1.75 
(s, 6H), 1.01 (s, 9H), 0.23 (s, 6H) ppm.13C NMR (CDCl3): δ = 165.3, 162.3, 156.1, 
139.2, 138.1, 134.0, 129.7, 127.0, 123.9, 120.6, 120.2, 118.6, 106.0, 92.3, 25.7, 
25.1, 18.2, 12.6, 4.4 ppm. 
6-((2E,4E)-5-(3-Bromophenyl)penta-2,4-dien-2-yl)-2,2-dimethyl-4H-1,3-
dioxin-4-one (IM-24) The title compound was prepared from IM-17 according to 
the general procedure D using IM-3 as aldehyde: Yield: 50%, yellow solid. 1H 
NMR (CDCl3) δ = 7.61 (t, J = 1.6 Hz, 1H), 7.34−7.44 (m, 2H), 7.22 (t, J = 7.8 Hz, 
1H), 7.10 (dd, J = 14.3, 11.4 Hz, 1H), 7.02 (d, J = 11.4 Hz, 1H), 6.78 (d, J = 14.3 
Hz, 1H), 5.54 (s, 1H), 2.02 (s, 3H), 1.74 (s, 6H) ppm.13C NMR (CDCl3): δ = 165.0, 
162.0, 138.7, 137.2, 133.3, 131.4, 130.2, 129.5, 128.0, 125.7, 125.0, 122.9, 
106.0, 92.6, 25.0, 12.5 ppm. 
(4E,6E)-(S)-2-Acetamidoethyl-7-(3-((tert-butyldimethylsilyl)oxy)phenyl)-4-
methyl-3-oxohepta-4,6-dienethioate (IM-25). The title compound was prepared 
from IM-23 according to the general procedure E: Yield: 53%, yellow oil. 1H NMR 
(CDCl3): δ = 7.11−7.30 (m, 2H), 6.96−7.11 (m, 2H), 6.70−6.96 (m, 3H), 6.11 (br. 
s, 1H), 4.01 (s, 2H), 3.35−3.51 (m, 2H), 3.08 (q, J = 6.1 Hz, 2H), 1.97 (s, 3H), 
1.93 (s, 3H), 0.96 (s, 9H), 0.18 (s, 6H) ppm. 13C NMR (CDCl3): δ = 193.1, 193.0, 
170.3, 156.0, 141.3, 137.5, 135.5, 129.8, 128.1, 124.0, 121.1, 120.5, 118.8, 52.8, 
39.2, 29.2, 25.6, 23.1, 18.2, 11.8, −4.4 ppm.  
(E)-5-(1-Hydroxy-2-methylhept-2-en-6-yn-1-ylidene)-2,2-dimethyl-1,3-
dioxane-4,6-dione (IM-26). The title compound was prepared from IM-17 
according to the general procedure D using IM-5 as aldehyde: Yield: 53 %, 
colorless oil.  1H NMR (CDCl3) δ = 6.40 (dt, J = 7.2, 1.1 Hz, 1H), 5.43 (s, 1H), 
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2.39−2.50 (m, 2H), 2.29−2.37 (m, 2H), 1.95−2.00 (m, 1H), 1.81 (s, 3H), 1.70 (s, 
6H) ppm. 13C NMR (CDCl3) δ = 165.3, 162.2, 134.9, 128.5, 106.0, 91.8, 83.0, 
69.1, 27.6, 24.9, 17.9, 12.3 ppm. 
6-((2E,4E)-8-((tert-Butyldimethylsilyl)oxy)octa-2,4-dien-2-yl)-2,2-dimethyl-4H-
1,3-dioxin-4-one (IM-27). The title compound was prepared from IM-17 
according to the general procedure D using IM-8 as aldehyde: Yield: 29%, yellow 
oil. 1H NMR (CDCl3): δ = 6.83 (d, J = 11.2 Hz, 1H), 6.39 (ddd, J = 14.9, 11.2, 1.0 
Hz, 1H), 6.09 (td, J = 14.9, 7.2 Hz, 1H), 5.44 (s, 1H), 3.61 (t, J = 6.2 Hz, 2H), 2.26 
(q, J = 7.2 Hz, 2H), 1.87 (s, 3H), 1.71 (s, 6H), 1.58−1.67 (m, 2H), 0.89 (s, 9H), 
0.04 (s, 6H) ppm. 13C NMR (CDCl3): δ = 165.4, 162.3, 143.0, 137.8, 134.2, 126.1, 
124.7, 105.9, 91.8, 62.4, 32.0, 29.3, 25.9, 25.0, 18.3, 12.2, −5.3 ppm. 
5-(1-Hydroxybutylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (IM-28). The title 
compound was prepared from butyryl chloride according to the general procedure 
A:  
Yield: 92%, yellow oil. 1H NMR (CDCl3): δ = 15.30 (s, 1H), 3.05 (t, J = 7.5 Hz, 
2H), 1.73 (s, 6H), 1.72 (sxt, J = 7.5 Hz, 2H), 1.03 (t, J = 7.5 Hz, 3H) ppm. 13C 
NMR (CDCl3): δ = 198.0, 170.5, 160.2, 104.7, 91.3, 37.4, 26.8, 19.6, 13.8 ppm.  
6-Propyl-2,2-dimethyl-4H-1,3-dioxin-4-one (IM-29). The title compound was 
prepared from IM-28 according to the general procedure B: Yield: 82%, yellow 
oil. 1H NMR (CDCl3): δ = 5.22 (s, 1H), 2.18 (t, J = 7.5 Hz, 2H), 1.66 (s, 6H), 1.57 
(sxt, J = 7.5 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 171.9, 
161.4, 106.2, 93.1, 35.4, 24.9, 19.1, 13.4 ppm. 
Diethyl 1-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)propylphosphonate (IM-30). 
The title compound was prepared from IM-29 according to the general procedure 
C: Yield: 45%, light yellow oil. 1H NMR (acetone-d6): δ = 5.46 (d, J = 3.4 Hz, 1H), 
4.08−4.23 (m, 4H), 2.83 (ddd, J = 22.9, 10.8, 4.3 Hz, 1H), 1.77−2.01 (m, 2H), 
1.69 (s, 6H), 1.26−1.34 (m, 6H), 1.00 (t, J = 7.4 Hz, 3H) ppm.13C NMR (acetone-
d6): δ = 167.5 (d, J = 8.2 Hz), 160.6 (d, J = 2.2 Hz), 107.6, 97.1 (d, J = 8.2 Hz), 
63.7 (d, J = 6.7 Hz), 45.7 (d, J = 136.4 Hz), 25.3 (d, J = 7.5 Hz), 21.0 (d, J = 3.7 
Hz), 16.8 (d, J = 6.0 Hz), 12.7 (d, J = 15.7 Hz) ppm. 
2,2-Dimethyl-6-((3E,5E)-6-phenylhexa-3,5-dien-3-yl)-4H-1,3-dioxin-4-one (IM-
31). The title compound was prepared from IM-30 according to the general 
procedure D using trans-cinnamaldehyde: Yield: 25%, yellow solid. 1H NMR 
(CDCl3) 3E,5E-isomer only: δ = 7.41 (m, 2H), 7.19−7.32 (m, 3H), 7.03 (dd, J = 
14.8, 11.3 Hz, 1H), 6.92 (d, J = 11.3 Hz, 1H), 6.82 (d, J = 14.8 Hz, 1H), 5.50 (s, 
1H), 2.41 (q, J = 7.6 Hz, 2H), 1.67 (s, 6H), 1.06 (t, J = 7.6 Hz, 3H) ppm. 13C NMR 
(CDCl3): δ =164.6, 162.4, 139.5, 136.6, 133.7, 133.5, 128.8, 127.0, 123.4, 106.0, 
92.0, 25.0, 20.1, 14.4 ppm. 
Ethyl 2-methyloctanoate (IM-32). The title compound was prepared from IM-35 
according to the following procedure: The unsaturated ester IM-35 (1.20 g, 6.60 
mmol) was dissolved in EtOH (50 mL). After addition of Pd/C (5%, 6 mg) the 
mixture was hydrogenated in a Parr apparatus at 3 bar H2 for 24 h. The catalyst 
was filtered off and the filter cake was washed with EtOAc (30 mL). The 
combined filtrates were concentrated in vacuo. The residue was dissolved in 
CH2Cl2 (50 mL) and filtered over a short pad of SiO2 eluting with CH2Cl2. The 
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solvent was removed in vacuo. Yield: 73%, colorless liquid. 1H NMR (CDCl3): δ = 
4.13 (q, J = 7.1 Hz, 2H), 2.42 (tq, J = 6.9, 6.5 Hz, 1H), 1.59−1.71 (m, 1H), 
1.33−1.46 (m, 1H), 1.22−1.33 (m, 8H), 1.26 (t, J = 7.1 Hz, 3H), 1.14 (d, J = 6.9 
Hz, 3H), 0.88 (t, J = 6.7 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 177.0, 60.0, 39.6, 
33.8, 31.7, 29.2, 27.2, 22.6, 17.1, 14.3, 14.0 ppm. 
2-Methyloctanoic acid (IM-33). The title compound was prepared from IM-32 
according to the following procedure: To a solution of the ester IM-32 (0.90 g, 
4.80 mmol) in MeOH (25 mL) was added a solution of NaOH (0.97 g, 24.2 mmol) 
in H2O (8 mL). The resulting mixture was heated under reflux for 16 h. After 
cooling to room temperature the MeOH was evaporated in vacuo. The aqueous 
layer was cooled to 0 °C and acidified to pH 2 by addition of HCl (2M). The 
mixture was extracted with EtOAc (3 x 40 mL). The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure. Yield: 92%, white 
solid. 1H NMR (CDCl3): δ = 10.97 (br. s, 1H), 2.45 (tq, J = 7.1, 6.9 Hz, 1H), 
1.64−1.75 (m, 1H), 1.69 (quin, J = 7.1, 1H), 1.25−1.37 (m, 8H), 1.18 (d, J = 6.9 
Hz, 3H), 0.89 (t, J = 6.7 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 183.5, 39.4, 33.5, 
31.7, 29.2, 27.1, 22.6, 16.8, 14.0 ppm. 
5-(1-Hydroxy-2-methyloctylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (IM-
34). The title compound was prepared from IM-33 according to the general 
procedure F:  
Yield: 64 %, orange oil. Keto/enol = 1:3. 1H NMR (CDCl3): δ = 15.46 (br. s, 1H), 
4.03 (sxt, J = 6.8 Hz, 1H), 1.72 (s, 6H), 1.17−1.50 (m, 10H), 1.20 (d, J = 6.8 Hz, 
3H), 0.85 (t, J = 6.8 Hz, 3H) ppm.13C NMR (CDCl3): δ = 202.1, 170.8, 160.1, 
104.6, 91.0, 37.9, 34.0, 31.6, 29.2, 27.2, 26.8, 22.5, 17.4, 14.0 ppm. 
(2E,4E)-Ethyl 2-methylocta-2,4-dienoate (IM-35). The title compound was 
prepared according to the following procedure: (1-
Ethoxycarbonylmethyl)triphenylphosphonium bromide (8.86 g, 20.0 mmol) and 
K2CO3 (4.00 g, 28.9 mmoL) were dissolved in a mixture of CH2Cl2 (60 mL) and 
H2O (50 mL). After the dropwise addition of trans-2-hexen-1-al (1.50 g, 15.0 
mmol) the reaction mixture was heated under reflux overnight. The organic layer 
was washed with H2O (2 x 50 mL), dried (MgSO4) and concentrated in vacuo. 
The residue was purified by flash chromatography (SiO2, n-hexane/EtOAc = 
10:1). Yield: 87%, light yellow oil. 2E,4E/2Z,4E = 20:1. 1H NMR (CDCl3) 2E,4E-
isomer only: δ = 7.17 (d, J = 11.2 Hz, 1H), 6.35 (tq, J = 15.0, 11.2, 1.4 Hz, 1H), 
6.07 (dt, J = 15.0, 7.5 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 2.17 (q, J = 7.3 Hz, 2H), 
1.93 (s, 3H), 1.47 (sxt, J = 7.3 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H), 0.93 (t, J = 7.3 
Hz, 3H) ppm. 13C NMR (CDCl3): δ = 168.7, 142.9, 138.6, 126.1, 125.1, 60.4, 
35.3, 22.2, 14.3, 13.7, 12.5 ppm. 
(2E,4E)-2-Methylocta-2,4-dienoic acid (IM-36). The title compound was 
prepared from IM-35 according to the following procedure: To a solution of the 
ester IM-35 (1.30 g, 7.10 mmol) in MeOH (30 mL) was added a solution of NaOH 
(1.32 g, 33.1 mmol) in H2O (10 mL). The resulting mixture was heated under 
reflux for 16 h. After cooling to room temperature the MeOH was evaporated in 
vacuo. The aqueous layer was cooled to 0 °C and acidified to pH 2 by addition of 
HCl (2M). The mixture was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. 
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Yield. 91%; yellow solid. 2E,4E/2Z,4E = 20:1. 1H NMR (CDCl3) 2E,4E-isomer 
only: δ = 11.36 (br. s, 1H), 7.30 (d, J = 11.3 Hz, 1H), 6.38 (dd, J = 15.1, 11.3 Hz, 
1H), 6.15 (dt, J = 15.1, 7.5 Hz, 1H), 2.12−2.28 (m, 2H), 1.94 (s, 3H), 1.41−1.52 
(m, 2H), 0.94 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 174.3, 144.5, 141.1, 
126.1, 124.1, 35.4, 22.1, 13.7, 12.1 ppm. 
(2E,4E)-Ethyl 2-methyl-5-phenylpenta-2,4-dienoate (IM-37). The title 
compound was prepared according to the following procedure: (1-
Ethoxycarbonylmethyl)triphenylphosphonium bromide (8.86 g, 20.0 mmol) and 
K2CO3 (4.00 g, 28.9 mmoL) were dissolved in a mixture of CH2Cl2 (60 mL) and 
H2O (50 mL). After the dropwise addition of E-cinnamaldehyde (1.98 g, 15.0 
mmol) the reaction mixture was heated under reflux overnight. The organic layer 
was washed with H2O (2 x 50 mL), dried (MgSO4) and concentrated in vacuo. 
The residue was purified by flash chromatography (SiO2, n-hexane/EtOAc = 
10:1). Yield: 93%, light yellow oil. 2E,4E/2Z,4E = 11:1. 1H NMR (CDCl3) 2E,4E-
isomer only: δ = 7.41 (m, 2H), 7.20−7.32 (m, 3H), 7.20 (d, J = 11.3 Hz, 1H), 6.99 
(dd, J = 15.5, 11.3 Hz, 1H), 6.80 (d, J = 15.5 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 
1.98 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (CDCl3): δ = 168.4, 138.9, 
138.1, 136.6, 128.7, 128.6, 127.5, 127.0, 124.0, 60.6, 14.3, 12.9 ppm. 
(2E,4E)-2-Methyl-5-phenylpenta-2,4-dienoic acid (IM-38). The title compound 
was prepared from IM-37 according to the following procedure: To a solution of 
the ester IM-37 (3.00 g, 14.8 mmol) in MeOH (80 mL) was added a solution of 
NaOH (2.77 g, 69.3 mmol) in H2O (20 mL). The resulting mixture was heated 
under reflux for 16 h. After cooling to room temperature the MeOH was 
evaporated in vacuo. The aqueous layer was cooled to 0 °C and acidified to pH 2 
by addition of HCl (2M). The mixture was extracted with EtOAc (3 x 100 mL). The 
combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. Yield: 97%, white solid. 2E,4E/2Z,4E = 11:1. 1H NMR (CDCl3) 2E,4E-
isomer only: δ = 11.27 (br. s, 1H), 7.40−7.44 (m, 3H), 7.23−7.32 (m, 2H), 7.22 (d, 
J = 11.2 Hz, 1H), 7.00 (dd, J = 15.4, 11.2 Hz, 1H), 6.85 (d, J = 15.4 Hz, 1H), 1.99 
(s, 3H) ppm. 13C NMR (CDCl3): δ = 173.9, 140.6, 140.2, 136.4, 128.9, 128.8, 
127.2, 126.4, 123.7, 12.5 ppm. 
Ethyl (E)-3-methylhex-2-enoate (IM-39). The title compound was prepared 
according to the following procedure: To a solution of NaH (1.46 g, 60.9 mmol) in 
THF (250 mL) was added dropwise a solution of triethyl phosphonoacetate (13.0 
g, 58.1 mmol) in THF (50 mL) at 0 °C. The resulting mixture was allowed to warm 
to room temperature and stirred for 30 minutes. A solution of 2-pentanone (5.00 
g, 58.1 mmol) in THF (50 mL) was slowly added and the reaction was heated to 
80 °C overnight. The reaction was quenched by addition of a saturated NH4Cl 
solution (200 mL). The resulting mixture was extracted with Et2O (3 x 100 mL). 
The combined organic layers were washed with H2O (100 mL) and brine (100 
mL) and dried over MgSO4. The solvents were evaporated in vacuo to afford a 
yellow liquid. The crude material was purified by flash column chromatography 
(SiO2, n-hexane/EtOAc = 20:1) to afford the title compound as a colorless liquid. 
Yield: 88%, colorless liquid. E/Z = 3.2:1, 1H NMR (CDCl3) E-isomer only: δ = 5.66 
(q, J = 1.2 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.15 (d, J = 1.3 Hz, 3H), 2.08−2.14 
(m, 2H), 1.51 (sxt, J = 7.4, 2H), 1.28 (t, J = 7.1 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H) 
ppm. 13C NMR (CDCl3): δ = 166.9, 159.9, 115.6, 59.4, 42.9, 20.5, 18.6, 14.3, 13.6 
ppm. 
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(E)-3-Methylhex-2-en-1-ol (IM-40). The title compound was prepared from IM-39 
according to the following procedure: A suspension of LiAlH4 in anhydrous Et2O 
(60 mL) was cooled to 0 °C. AlCl3 was added and the resulting mixture was 
stirred for 15 minutes. A solution of IM-43 (5.00 g, 32.0 mmol) in Et2O (15 mL) 
was added and stirring was continued for 1.5 h at 0 °C. Addition of an aqueous 
solution of NaOH (5% m/m, 20 mL) lead to precipitation of aluminium hydroxides. 
The reaction mixture was filtered over a short bed of MgSO4 which was rinsed 
with Et2O (50 mL). Removal of the solvent in vacuo afforded the title compound 
as a colorless liquid. Yield: 44%, colorless oil. E/Z = 4:1, 1H NMR (CDCl3) E-
isomer only: δ = 5.41 (tq, J = 6.9, 1.3 Hz, 1H), 4.07−4.20 (m, 2H), 2.00 (t, J = 7.5 
Hz, 2H), 1.66 (d, J = 1.3 Hz, 3H), 1.39−1.51 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H) ppm. 
13C NMR (CDCl3): δ = 139.9, 123.3, 59.4, 41.6, 20.7, 16.1, 13.7 ppm. 
(E)-3-Methylhex-2-enal (IM-41). The title compound was prepared from IM-40 
according to the following procedure: To a stirred suspension of PCC (4.28 g, 
19.9 mmol) and NaOAc (200 mg, 3.98 mmol) in CH2Cl2 (100 mL) a solution of the 
alcohol IM-40 (1.60 g, 14.0 mmol) in CH2Cl2 (100 mL) was added. After 7 h the 
reaction mixture was diluted with Et2O (100 mL) and the mixture was filtered over 
short pad of celite. The solvents were evaporated in vacuo and the residue was 
purified by flash chromatography (SiO2, n-hexane/EtOAc = 20:1 → 10:1). Yield: 
46%, colorless oil. E/Z = 2:1, 1H NMR (CDCl3) E-isomer only: δ = 9.99 (d, J = 8.0 
Hz, 1H), 5.87 (dq, J = 8.0, 1.2 Hz, 1H), 2.19 (t, J = 7.4 Hz, 2H), 2.15 (d, J = 1.2 
Hz, 3H), 1.54 (q, J = 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (CDCl3): 
δ = 191.3, 164.1, 127.4, 42.6, 20.3, 17.4, 13.6 ppm. 
Ethyl (2E,4E)-2,5-dimethylocta-2,4-dienoate (IM-42). The title compound was 
prepared from IM-41 according to the following procedure: To a suspension of 
NaH (0.16 g, 6.55 mmol) in THF (30 mL) was added dropwise a solution of 
triethyl phosphonoacetate (1.49 g, 6.24 mmol) in THF (5 mL) at 0 °C. The 
resulting mixture was allowed to warm to room temperature and stirred for 30 
minutes. IM-41 (0.70 g, 6.24 mmol), dissolved in THF (5 mL) was slowly added 
and the reaction was stirred at room temperature over night. The reaction was 
quenched by addition of a saturated NH4Cl solution (50 mL). The resulting 
mixture was extracted with Et2O (3 x 30 mL). The combined organic layers were 
washed with H2O (30 mL) and brine (30 mL) and dried over MgSO4. The solvents 
were evaporated in vacuo to afford a yellow liquid. The residue was purified by 
flash column chromatography (SiO2, n-hexane/EtOAc = 20:1) to afford the title 
compound as a colorless oil. Yield: 57%, colorless oil. Mixture of regioisomers, 
approx: 2E,4E = 53%, 2E,4Z = 26%, 2Z,4E = 13%, 2Z,4Z = 7%; 1H NMR 
(CDCl3): 2E,4E and 2E,4Z isomers only: δ = 7.58−7.67 (m, 1H), 6.17−6.21 (m, 
0.35H), 6.16 (dq, J = 11.8, 1.3 Hz, 0.65H), 4.22 (q, J = 7.1 Hz, 2H), 2.28 (t, J = 
7.5 Hz, 0.70H), 2.14 (t, J = 7.5 Hz, 1.30H), 1.85−1.95 (m, 6H), 1.43−1.57 (m, 2H), 
1.31 (t, J = 7.1 Hz, 3H), 0.86−0.98 (m, 3H) ppm. 13C NMR (CDCl3) mixture of 
regioisomers: δ = 169.1, 169.0, 148.5, 148.3, 148.1, 134.4, 134.1, 124.6, 124.4, 
121.5, 120.7, 60.4, 42.8, 39.6, 34.6, 33.1, 31.9, 30.3, 29.7, 24.7, 21.5, 21.0, 20.8, 
20.6, 20.5, 17.1, 14.3, 14.2, 14.1, 14.1, 13.9, 13.7, 12.4, 12.3 ppm. 
(2E,4E)-2,5-Dimethylocta-2,4-dienoic acid (IM-43). The title compound was 
prepared from IM-42 according to the following procedure: To a solution of the 
ester IM-42 (0.70 g, 3.57 mmol) in MeOH (15 mL) was added a solution of NaOH 
(0.70 g, 17.5 mmol) in H2O (5 mL). The resulting mixture was heated under reflux 
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for 2 h. After cooling to room temperature the MeOH was evaporated in vacuo. 
The aqueous layer was cooled to 0 °C and acidified to pH 2 by addition of HCl 
(2M). The mixture was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. Yield: 83 
%, yellow oil. Mixture of regioisomers, approx: 2E,4E = 53%, 2E,4Z = 26%, 2Z,4E 
= 13%, 2Z,4Z = 7%; 1H NMR (CDCl3) 2E,4E and 2E,4Z isomers only: δ = 
7.44−7.51 (m, 1H), 6.12−6.18 (m, 0.35H), 6.12 (dq, J = 11.9, 1.2 Hz, 0.65H), 4.22 
(q, J = 7.1 Hz, 2H), 2.30 (t, J = 7.5 Hz, 0.70H), 2.17 (t, J = 7.5 Hz, 1.30H), 
1.85−1.95 (m, 6H), 1.44−1.59 (m, 2H), 0.86−1.03 (m, 3H) ppm. 13C NMR (CDCl3) 
mixture of regioisomers: δ = 174.6, 174.5, 173.8, 152.3, 150.2, 149.9, 136.8, 
136.5, 124.7, 123.5, 123.4, 121.6, 120.8, 42.8, 39.6, 34.7, 33.2, 24.8, 21.6, 21.0, 
20.6, 20.5, 20.5, 17.2, 13.9, 13.7, 12.0, 11.9 ppm. 
(4E,6E)-(S)-2-Acetamidoethyl-10-((tert-butyldimethylsilyl)oxy)-4-methyl-3-
oxodeca-4,6-dienethioate (IM-44). The title compound was prepared from IM-27 
according to the general procedure E: Yield 99 %. Keto/enol = 3:1 1H NMR 
(acetone-d6): δ = 12.86 (s, 0.25H, enol C=COH), 7.40−7.60 (m, 1H, NH), 7.22 (d, 
J = 10.7 Hz, 0.75H, keto CH=CMe), 7.11 (d, J = 11.3 Hz, 0.25H, enol CH=CMe), 
6.84 (m, 0.25H), 6.48−6.61 (m, 0.75H, CH=CH), 6.32 (dt, J = 15.0, 7.3 Hz, 0.75H, 
keto CHCH2), 6.13 (dt, J = 14.8, 7.2 Hz, 0.25H, enol CHCH2), 5.81 (s, 0.25H, 
enol CO=CH), 4.09 (s, 1.50H, keto COCH2), 3.66−3.71 (m,  2H, CH2O), 
3.32−3.43 (m, 2H, CH2N), 3.00−3.12 (m, 2H, CH2S), 1.91−1.60 (m, 8H), 0.90 (s, 
9H), 0.06 (s, 6H) ppm. 13C NMR (acetone-d6): δ = 194.2, 193.6, 171.3, 171.0, 
146.0, 142.5, 134.4, 127.7, 62.9, 60.6, 53.4, 39.7, 32.9, 32.8, 32.4, 26.4, 22.8, 
20.9, 18.9, 14.6, 11.6, −5.1 ppm. 
Synthesis and spectroscopic data of precursor compounds 
(S)-2-Acetamidoethyl-(4E,6E)-4,7-dimethyl-3-oxodeca-4,6-dienethioate (1). 
The title compound was from IM-18 prepared according to the general procedure 
E: Yield 65 %. Keto/enol = 4:1, 4E,6E/4Z,6E = 2:1. 1H NMR (acetone-d6) 4E,6E-
isomer keto only: δ = 7.49 (dd, J = 11.5, 1.2 Hz, 1H), 7.29 (br. s, 1H), 6.27−6.37 
(m, 1H), 4.12 (s, 2H), 3.32 (q, J = 6.8 Hz, 2H), 3.02 (t, J = 6.8 Hz, 2H), 2.15−2.25 
(m, 2H), 1.95 (s, 3H), 1.85 (s, 3H), 1.84 (s, 3H), 1.53 (sxt, J = 7.4 Hz, 2H), 0.91 (t, 
J = 7.4 Hz, 3H) ppm. 13C NMR (acetone-d6) 4E,6E-isomer keto only: δ = 194.0, 
193.5, 170.2, 151.7, 138.2, 133.9, 122.1, 53.9, 43.5, 39.6, 29.8, 22.9, 21.7, 17.5, 
14.1, 11.4 ppm. MS (ESI) m/z: 312.0 [M+H]+ 
(4E,6E)-(S)-2-Acetamidoethyl-4-methyl-3-oxodeca-4,6-dienethioate (2). The 
title compound was from IM-19 prepared according to the general procedure E: 
Yield 25 %. Keto/enol = 4:1 4E,6E/4Z,6E = 8:1. 1H NMR (DMSO-d6) 4E,6E-
isomer keto only: δ = 8.03 (br. s, 1H), 7.21 (d, J = 11.0 Hz, 1H), 6.48−6.54 (m, 
1H), 6.30 (dt, J = 15.1, 7.5 Hz, 1H), 4.15 (s, 2H), 3.17 (m, 2H), 2.92 (t, J = 6.9 Hz, 
2H), 2.14−2.22 (m, 2H), 1.77−1.79 (m, 6H), 1.40−1.48 (m, 2H), 0.90 (t, J = 7.5 
Hz, 3H) ppm. 13C NMR (DMSO-d6) 4E,6E-isomer keto only: δ = 193.8, 193.0, 
169.4, 145.6, 141.9, 132.9, 126.8, 52.4, 38.1, 34.8, 28.5, 22.5, 21.6, 13.6, 11.3 
ppm. MS (ESI) m/z: 298.1 [M+H]+  
(4E,6E)-(S)-2-Acetamidoethyl-3-oxodeca-4,6-dienethioate (3). The title 
compound was prepared from IM-14 according to the general procedure E: Yield 
50 %. Orange powder. Keto/enol = 1:2 1H NMR (acetone-d6) 4E,6E-isomer enol 
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only: δ = 12.46 (s, 1H), 7.36 (br. s, 1H), 7.13 (dd, J = 15.2, 10.7, 1H), 6.27−6.35 
(m, 1H), 6.11−6.20 (m, 1H), 5.94 (d, J = 15.2 Hz, 1H), 5.65 (s, 1H), 3.37 (q, J = 
6.6 Hz, 2H), 3.08 (t, J = 6.6 Hz, 2H), 2.12−2.22 (m, 2H), 1.87 (s, 3H), 1.41−1.51 
(m, 2H), 0.92 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (acetone-d6) 4E,6E-isomer enol 
only: δ = 195.1, 192.3, 168.5, 143.8, 140.5, 130.5, 123.6, 101.3, 39.9, 35.8, 28.8, 
22.9, 22.8, 14.0 ppm. MS (ESI) m/z: 284.1 [M+H]+ 
(E)-(S)-2-Acetamidoethyl-4-methyl-3-oxodec-4-enethioate (4). The title 
compound was prepared from IM-20 according to the general procedure E: Yield 
66%, yellow oil. Keto/enol = 3:1 1H NMR (acetone-d6) 4E,6E-isomer keto only: δ 
= 7.35 (br. s, 1H, NH), 6.81 (t, J = 7.3 Hz, 1H), 4.06 (s, 2H), 3.33 (q, J = 6.7 Hz, 
2H), 3.01 (t, J = 6.7 Hz, 2H), 2.53−2.65 (m, 2H), 2.21−2.34 (m, 2H), 1.87 (s, 3H), 
1.75 (s, 3H), 1.42−1.55 (m, 2H), 1.30−1.37 (m, 4H), 0.89 (t, J = 7.0 Hz. 3H) ppm. 
1H NMR (acetone-d6) 4E,6E-isomer keto only: δ = 194.1, 193.4, 170.6, 146.9, 
137.5, 53.5, 39.6, 32.3, 29.8, 29.6, 28.9, 23.2, 22.9, 14.3, 11.4 ppm. MS (ESI) 
m/z: 300.2 [M+H]+ 
(S)-2-Acetamidoethyl-4-methyl-3-oxodecanethioate (5). The title compound 
was prepared from IM-34 according to the general procedure G: Yield 75%, 
yellow resin. Keto/enol = 3:1 1H NMR (acetone-d6) keto only: δ = 7.74 (br. s, 1H), 
3.86 (s, 2H), 3.38 (quin, J = 6.8 Hz, 2H), 3.04 (q, J = 6.8 Hz, 2H), 2.69 (quin, J = 
6.8 Hz, 1H), 1.95 (s, 3H), 1.25−1.39 (m, 10H), 1.07 (d, J = 6.8 Hz, 3H), 0.87 (t, J 
= 6.8 Hz, 3H) ppm. 13C NMR (acetone-d6) keto only: δ = 206.0 (HMBC), 193.0, 
172.3, 56.2, 47.3, 39.8, 33.2, 32.4, 30.0, 29.3, 27.7, 23.3, 22.8, 16.1, 14.4 ppm. 
MS (ESI) m/z: 302.8 [M+H]+ 
(4E,6E)-(S)-2-Acetamidoethyl-4-methyl-3-oxo-7-phenylhepta-4,6-
dienethioate (6). The title compound was prepared from IM-21 according to the 
general procedure E: Yield 60 %, yellow solid. Keto/enol = 2:1, 1H NMR (acetone-
d6): δ = 12.82 (s, 0.35H, enol C=COH), 7.99 (br. s, 1H, NH), 7.60−7.66 (m, 2H), 
7.26−7.52 (m, 5H), 7.13 (d, J = 14.7 Hz, 0.65H, keto CMe=CH), 6.99 (d, J = 13.9 
Hz, 0.35H, enol CMe=CH), 5.88 (s, 0.35H, enol CO=CH), 4.19 (s, 1.30H, keto 
COCH2), 3.37−3.47 (m, 2H, CH2N), 3.13 (t, J = 6.8 Hz, 0.70H, keto CH2S), 3.06 
(t, J = 6.7 Hz, 1.30H, enol CH2S), 1.98−1.99 (m, 6H, COCH3, C=CCH3) ppm.
13C 
NMR (acetone-d6): δ = 194.4, 194.2, 173.3, 173.2, 142.6, 142.1, 139.8, 137.9, 
137.5, 136.3, 135.8, 130.0, 129.8, 129.7, 129.5, 128.4, 128.1, 125.3, 125.3, 98.4, 
53.3, 40.4, 39.9, 29.3, 28.3, 22.7, 20.9, 12.6, 11.9 ppm. MS (ESI) m/z: 332.1 
[M+H]+ 
(4E,6E)-(S)-2-Acetamidoethyl-4-ethyl-3-oxo-7-phenylhepta-4,6-dienethioate 
(7). The title compound was prepared from IM-31 according to the general 
procedure E: Yield 88 %, yellow resin. Keto/enol = 2:1, 4E,6E/4Z,6E = 10:1. 1H 
NMR (acetone-d6) 4E,6E-isomer only: δ = 12.99 (br. s, 0.35H, enol C=COH), 
7.58−7.69 (m, 2H), 7.24−7.57 (m , 6H), 7.08−7.18 (m, 0.65H). 7.00 (d, J = 14.5 
Hz, 0.35H), 5.95 (s, 0.35H, enol CO=CH), 4.19 (s, 1.30H, keto COCH2), 
3.33−3.45 (m, 2H, CH2N), 3.12 (t, J = 6.8 Hz, 0.70H, enol CH2S), 3.05 (t, J = 6.7 
Hz, 1.30H, keto CH2S), 2.56 (q, J = 7.5 Hz, 0.70H, enol CH2CH3), 2.55 (q, J = 7.5 
Hz, 1.30H, keto CH2CH3), 1.92 (s, 1.05H, enol COCH3), 1.90 (s, 1.95H, keto 
COCH3), 1.11 (s, 1.05H, enol CH2CH3), 1.00 (s, 1.95H, keto CH2CH3) ppm.
13C 
NMR (acetone-d6): δ = 193.6, 193.5, 171.0, 142.7, 142.1, 142.0, 140.1, 137.9, 
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135.4, 130.0, 129.8, 129.7, 129.6, 128.4, 128.1, 125.0, 124.9, 98.2, 53.6, 40.0, 
39.7, 29.6, 28.8, 22.9, 20.3, 19.8, 15.2, 14.7 ppm. MS (ESI) m/z: 346.0 [M+H]+ 
(E)-(S)-2-Acetamidoethyl-4-methyl-3-oxo-7-phenylhept-4-enethioate (8). The 
title compound was prepared from IM-22 according to the general procedure E: 
Yield 62 %. Keto/enol = 3:1, 1H NMR (acetone-d6): δ = 12.83 (s, 0.25H, enol 
C=COH), 7.47 (br. s, 1H, NH), 7.21−7.32 (m, 4H, Ar-H), 7.16−7.21 (m, 1H, Ar-H), 
6.85 (t, J = 7.2 Hz, 0.75H, keto CMe=CH), 6.67 (t, J = 7.4 Hz, 0.25H, enol 
CMe=CH), 5.73 (s, 0.25H, CO=CH), 4.04 (s, 1.50H, keto COCH2), 3.31−3.42 (m, 
2H, CH2N), 3.08 (t, J = 6.8 Hz, 0.50H, keto CH2S), 3.02 (t, J = 6.9 Hz, 1.50H, enol 
CH2S), 2.75−2.84 (m, 2 H, CH2Ph), 2.53−2.65 (m, 2H, CH2CH=C), 1.90 (s, 
0.75H, enol COCH3), 1.90 (s, 2.25H, keto COCH3), 1.73 (s, 0.75H, enol 
C=CCH3), 1.67 (s, 2.25H, keto C=CCH3) ppm. 
13C NMR (acetone-d6): keto only: 
δ = 194.1, 193.4, 171.2, 145.7, 145.6, 142.2, 138.0, 129.4, 129.3, 127.0, 53.4, 
39.7, 35.1, 32.0, 22.9, 11.3 ppm. MS (ESI) m/z: 334.1 [M+H]+ 
(4E,6E)-(S)-2-Acetamidoethyl-7-(3-hydroxyphenyl)-4-methyl-3-oxohepta-4,6-
dienethioate (9). The title compound was prepared from IM-25 according to the 
following procedure: To a solution of IM-25 (0.08 g, 0.17 mmol) in THF (1.50 mL) 
was added a solution of nBu4NF (1.0 M THF solution, 0.21 mL, 0.21 mmol) at 
0 °C. After stirring for 6 h at room temperature, the reaction was stopped by 
adding saturated aqueous NH4Cl (10 mL). The crude products were extracted 
with EtOAc (3 x 10 mL), and the combined organic layers were washed with 
brine, dried (MgSO4), and concentrated in vacuo. The residue was purified by 
flash column chromatography (SiO2, n-hexane/EtOAc = 1:1 → EtOAc) to afford 
the title compound. Yield 92%, yellow solid. Keto/enol = 5:1, 4E,6E/4Z,6E = 3:1. 
1H NMR (DMSO-d6) keto only: δ = 9.51 (s, 1H), 8.03 (t, J = 5.30 Hz, 1H), 
7.13−7.44 (m, 3H), 6.86−7.13 (m, 3H), 6.68−6.80 (m, 1H), 4.20 (s, 2H), 3.18 (q, J 
= 6.7 Hz, 2H), 2.94 (t, J = 6.7 Hz, 2H), 1.92 (s, 3H), 1.79 (s, 3H) ppm.13C NMR 
(DMSO-d6): δ = 193.5, 192.9, 169.3, 157.7, 141.6, 141.2, 137.4, 134.8, 129.8, 
124.4, 118.5, 116.4, 113.9, 52.5, 38.1, 28.5, 22.5, 11.5 ppm. MS (ESI) m/z: 347.9 
[M+H]+ 
(S)-2-Acetamidoethyl-(4E,6E)-7-(3-bromophenyl)-4-methyl-3-oxohepta-4,6-
dienethioate (10). The title compound was prepared from IM-24 according to the 
general procedure E: Yield 40 %, yellow solid. Keto/enol = 1:1, 1H NMR (CDCl3) 
keto only: δ = 7.65 (t, J = 1.9 Hz, 1H), 7.39−7.42 (m, 1H), 7.36−7.38 (m, 1H), 
7.23 (t, J = 7.9 Hz, 1H), 7.16 (dd, J = 11.0, 1.3 Hz, 1H), 7.12 (dd, J = 14.8, 11.0 
Hz, 1H), 6.88 (d, J = 14.8 Hz, 1H), 6.07 (br. s, 1H), 4.05 (s, 2H), 3.48 (m, 2H), 
3.11 (t, J = 6.6 Hz, 2H), 2.02 (d, J = 1.3 Hz, 3H), 1.97 (s, 3H) ppm.13C NMR 
(CDCl3): δ = 193.1, 193.0, 170.4, 140.5, 139.4, 138.9, 136.4, 130.2, 129.9, 126.0, 
125.7, 125.2, 123.0, 52.9, 39.2, 29.2, 23.1, 11.9 ppm. MS (ESI) m/z: 411.7 
[M+H]+ 
(S)-2-Acetamidoethyl-(E)-4-methyl-3-oxonon-4-en-8-ynethioate (11). The title 
compound was prepared from IM-26 according to the general procedure G: Yield 
50 %. Keto/enol = 3:1. 1H NMR (CDCl3) keto only: δ = 6.62−6.72 (m, 1H), 6.08 
(br. s, 1H), 3.98 (s, 2H), 3.47 (m, 2H), 3.10 (t, J = 6.2 Hz, 2H), 2.28−2.57 (m, 4H), 
2.01 (t, J = 2.6 Hz, 1H), 1.97 (s, 3H), 1.82 (s, 3H) ppm. 13C NMR (CDCl3): δ = 
193.3, 193.1, 170.5, 143.0, 138.1, 82.6, 69.5, 52.6, 39.2, 29.2, 28.1, 23.2, 17.6, 
11.5 ppm. MS (ESI) m/z: 281.9 [M+H]+ 
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(4E,6E)-(S)-2-Acetamidoethyl-10-hydroxy-4-methyl-3-oxodeca-4,6-
dienethioate (12). The title compound was prepared from IM-44 according to the 
following procedure: To a solution of IM-44 (0.17 g, 0.40 mmol) in THF (4.0 mL) 
was added a solution of nBu4NF (1.0 M in THF, 1.0 mL, 1.00 mmol) at 0 °C. After 
stirring for 6 h at room temperature, the reaction was stopped by adding 
saturated aqueous NH4Cl (30 mL). The mixture was extracted with EtOAc (3 x 30 
mL), and the combined organic layers were washed with brine, dried (MgSO4), 
and concentrated in vacuo. The residue was purified by flash column 
chromatography (SiO2, n-hexane/EtOAc = 1:1 → EtOAc) to afford the title 
compound. Yield 96 %, yellow oil. Keto/enol = 3:1.1H NMR (acetone-d6): δ = 
12.78 (s, 0.25H, enol C=COH), 7.95−8.04 (m, 1H, NH), 7.25 (d, J = 10.7 Hz, 
0.75H, keto CH=CMe), 7.08 (d, J = 11.3 Hz, 0.25H, enol CH=CMe), 6.49−6.63 
(m, 1H, CH=CH), 6.35 (dt, J = 15.0, 7.3 Hz, 0.75H, keto CHCH2), 6.16 (dt, J = 
14.8, 7.2 Hz, 0.25H, enol CHCH2), 5.80 (s, 0.25H, enol CO=CH), 4.12 (s, 1.50H, 
keto COCH2), 3.60 (t, J = 6.5 Hz, 2H, CH2OH), 3.33−3.45 (m, 2H, CH2N), 3.11 (t, 
J = 6.8 Hz, 0.50H, enol CH2S), 3.04 (t, J = 6.7 Hz, 1.50H, ketoCH2S), 2.24−2.34 
(m, 2H, C=CCH2), 1.98 (s, 0.75H, enol COCH3), 1.97 (s, 2.25H, keto COCH3), 
1.87 (s, 0.75H, enol C=CCH3), 1.82 (s, 2.25H, keto C=CCH3), 1.63−1.71 (m, 2H, 
CH2CH2OH) ppm. 
13C NMR (acetone-d6) keto only: δ = 194.7, 194.4, 173.5, 
146.6, 143.1, 134.2, 127.5, 62.1, 53.1, 39.9, 32.5, 30.7, 29.2 (HSQC), 22.7, 11.6 
ppm. MS (ESI) m/z: 314.2 [M+H]+ 
(S)-2-Acetamidoethyl butanethioate (13). The title compound was prepared 
from butyryl chloride according to the general procedure H: Yield 81%, yellow oil. 
1H NMR (acetone-d6) δ = 7.36 (br. s, 1H), 3.28−3.34 (m, 2H), 2.98 (t, J = 6.9 Hz, 
2H), 2.55 (t, J = 7.4 Hz, 2H), 1.87 (s, 3H), 1.65 (app. sxt., J = 7.4 Hz, 2 H), 0.92 
(t, J = 7.4 Hz, 3H) ppm. 13C NMR (acetone-d6) δ = 199.1, 170.6, 46.4, 39.8, 29.0, 
22.9, 19.8, 13.7 ppm. MS (ESI) m/z: 190.1 [M+H]+ 
(S)-2-Acetamidoethyl benzothioate (14). The title compound was prepared 
from benzoic acid according to the general procedure H: Yield 75%, white resin. 
1H NMR (acetone-d6): δ = 7.92−8.00 (m, 2H), 7.67 (tt, J = 7.4, 1.3 Hz, 1H), 7.54 
(tt, J = 7.4, 1.3, 2H), 7.38 (br. s, 1H), 3.36−3.50 (m, 2H), 3.20 (t, J = 6.9 Hz, 2H), 
1.88 (s, 3H) ppm. 13C NMR (acetone-d6): δ = 191.8, 170.3, 138.0, 134.6, 129.8, 
127.9, 39.7, 22.9 ppm. MS (ESI) m/z: 224.0 [M+H]+ 
(S)-2-Acetamidoethyl-3-hydroxybenzothioate (15). The title compound was 
prepared from 3-hydroxybezoic acid according to the general procedure H: Yield 
62%, white solid. 1H NMR (acetone-d6): δ = 9.15 (br. s, 1H), 7.54 (br. s, 1H), 
7.40−7.46 (m, 2H), 7.35 (t, J = 8.1 Hz, 1H), 7.10−7.15 (m, 1H), 3.40−3.49 (m, 
2H), 3.19 (t, J = 6.7 Hz, 2H), 1.92 (s, 3H) ppm. 13C NMR (acetone-d6) δ = 191.6, 
171.0, 158.9, 139.3, 130.9, 121.7, 119.1, 114.4, 39.8, 29.3, 22.9 ppm. MS (ESI) 
m/z: 239.9 [M+H]+ 
(S)-2-Acetamidoethyl-(2E,4E)-2,5-dimethylocta-2,4-dienethioate (16). The title 
compound was prepared from IM-43 according to the general procedure H: Yield 
43%, yellow oil. Mixture of regioisomers, approx: 2E,4E = 53%, 2E,4Z = 26%, 
2Z,4E = 13%, 2Z,4Z = 7%; 1H NMR (acetone-d6) 2E,4E isomer only: δ = 
7.58−7.67 (m, 2H), 6.23 (dq, J = 11.5, 1.3 Hz, 1H), 3.30−3.36 (m, 2H), 3.03 (t, J = 
6.6 Hz, 2H), 2.18 (t, J = 7.4 Hz, 2H), 1.93 (s, 3H), 1.88 (s, 3H), 1.87 (s, 3H), 1.51 
(app. sxt., J = 7.4 Hz, 2H,), 0.89 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (acetone-d6) 
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2E,4E isomer only: δ = 192.9, 170.4, 150.9, 134.0, 133.2, 121.3, 43.3, 39.9, 29.1, 
22.9, 21.7, 17.4, 14.1, 12.6 ppm. MS (ESI) m/z: 270.1 [M+H]+ 
(2E,4E)-(S)-2-Acetamidoethyl-2-methylocta-2,4-dienethioate (17). The title 
compound was prepared from IM-36 according to the general procedure H: Yield 
30%, yellow oil. 1H NMR (acetone-d6): δ = 7.69 (br. t, 1H), 7.16 (d, J = 10.9 Hz, 
1H), 6.46 (d, J = 15.1, 10.9 Hz, 1H), 6.24 (d, J = 15.1, 7.3 Hz, 1H), 3.31−3.39 (m, 
2H), 3.05 (t, J = 6.8 Hz, 2H), 2.18−2.24 (m, 2H), 1.94 (s, 3H), 1.93 (s, 3H), 
1.44−1.52 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H) ppm.13C NMR (acetone-d6): δ = 193.0, 
171.3, 145.6, 138.4, 133.5, 126.7, 40.0, 36.0, 28.9, 22.9, 22.8, 14.0, 12.7 ppm. 
MS (ESI) m/z: 256.1 [M+H]+ 
(2E,4E)-(S)-2-Acetamidoethyl-2-methyl-5-phenylpenta-2,4-dienethioate (18). 
The title compound was prepared from IM-38 according to the general procedure 
H: Yield 43%, yellow oil. 2E,4E/2Z,4E = 14:1, 1H NMR (acetone-d6) 4E,6E-isomer 
only: δ = 7.74 (t, J = 5.2 Hz, 1H), 7.59−7.63 (m, 2H), 7.28−7.40 (m, 4H), 7.28 (dd, 
J = 14.6, 11.0 Hz, 1H), 7.05 (d, J = 14.6 Hz, 1H), 3.35−3.44 (m, 2H), 3.11 (t, J = 
6.7 Hz, 2H), 2.08 (s, 3H), 2.02 (s, 3H) ppm.13C NMR (acetone-d6): δ =192.9, 
170.9, 141.5, 138.2, 137.6, 135.7, 129.9, 129.7, 128.3, 124.6, 39.9, 29.2 (HSQC), 
22.9, 13.0 ppm. MS (ESI) m/z: 290.1 [M+H]+ 
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6.3.1.2 Construction of in-frame deletion mutant and point mutation 
mutants in Myxococcus fulvus Mx f50 
Table S1. List of Strains and Plasmids used in this study 
Strain/Plasmid Description Reference 
E.coli strains 
HS996 Host for general cloning experiments Invitrogen 
SCS110 Host for cloning experiments to prepare 
plasmid DNA free of Dam or Dcm methylation 
Stratagene 
Myxococcus fulvus strains 
Mx f50 Myxopyronin producing wild-type strain Irschik et al.
[7]
 
Mx f50pHSU-mxn18 
(mxnK) 
mxnK in-frame deletion mutant;  
no myxopyronin production 
this study 
Mx f50pHSU-mxn48 
(CP-1
W
, point mutation at 
CP-1
W
, S1686A) 
CP-1
W
 point mutation;  
myxopyronin production (trace amount) 
this study 
Mx f50pHSU-mxn49 
(CP-4
W
, point mutation at 
CP-4
W
, S5168A) 
CP-3
W
 point mutation;  
myxopyronin production (trace amount) 
this study 
Plasmids   
pSWU41 
 
Vector contains a neomycin 
phosphotransferase (nptII) gene for selection 
and a levansucrose (sacB) gene for counter 
selection 
Wu et al.
[8]
 
pHSU-mxn18 mxnK gene deletion construct, in which a 
5624 bp fragment of mxnC-mxnH was 
deleted in-frame 
 
pHSU-mxn48 CP-1
W
 point mutation construct in which the 
active site serine residue is exchanged with 
alanine residue (S1668A) 
this study 
pHSU-mxn49 CP-3
W
 point mutation construct in which the 
active site serine residue is exchanged with 
alanine residue (S5168A) 
this study 
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Table S2. List of primers used in this study 
Primer 
name 
Sequence (5’3’) 
Restriction   
sites  
(in bold) 
mxn54 GCGTTGATGGATCCACAGCA BamHI 
mxn55 TGTATCGCGGCCGCTCAGTGCCGCTGAACCCGAAC NotI 
mxn56 GATACAGCGGCCGCCTTTCCGAGTCCAGCAGC NotI 
mxn57 GTATCGAGCTCATCTGCTGTCCTCTGCCT SacI 
mxn70  CTTGCGCCCTGAGTGCTT  
mxn71  AACACCTCACGGTCCGAC  
mxn72 CCCATCGTCCACAGCTTC  
mxn73 GCACTACAAGCGGCTCTG  
mxn169 GATACACGATCGCACGAGTTCCGAGTCCTC PvuI 
mxn170 CTGCAGGATGAGGGCGTC  
mxn171 TCGACGCCCTCATCCTGCAGGAGTTGATGGCGGAG
CTG 
 
mxn172 TCTATGGCGGCCGCGAGCGCGACCTTGATGAC NotI 
mxn174 GATACACGATCGGACACACACCGGAAGCTG PvuI 
mxn175 ATTCACCAGCGCGTCGAC  
mxn176 CGGCGTCGACGCGCTGGTGAATCTGAGAATCGTCC  
mxn177 TCTATGGAGCTCTTGAGCTGCAGGATGACC NotI 
mxn185 TCGCTCATCCTGCAGGA  
mxn187 CGAGTCGAGTCCCATGG  
mxn189 CAACAGCTTCCTCGACG  
mxn191 TCCCTGGTGAATCTGAGA  
mxn193 GGAGTCGACGCCGAAC  
mxn195 TCGGACTGATGAAGGGGT  
mxn205 CCTTCGGGGAGATGTTGA  
mxn206 GAAGGCCTCCACGTTCTC  
pJET1.2For CGACTCACTATAGGGAGAGCGGC  
pJET1.2Rev AAGAACATCGATTTTCCATGGCAG  
pSWU41-F GTGCAAAAAAGCGGTTAG  
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Figure S1. Schematic representation of in-frame deletion of 5.6 kb mxnK by construct pHSU-
mxn18, (a), confirmation by Southern blot (b) and the expected fragment size after hydrolysis 
of wild type and mutant genomic DNA with a set of three restriction enzymes and a DIG-
labelled 602 bp probe amplified from Mx f50 genomic DNA using the primers mxn79 and 
mxn80. M: Marker III (Roche), 1: hydrolysis with AfeI, 2: hydrolysis with BspHI, 3: hydrolysis 
with BglII.  
a 
b c 
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Figure S2. Schematic illustration of mutasynthesis using M. fulvus Mx X50 mutants with 
partially functional western chain assembly line. a) A culture of a CP-1
W
 mutant was 
supplemented with the appropriate precursor which is incorporated in the subsequent 
biosynthesis pathway. b) A culture of a CP-4
W
 mutant was supplemented with the 
appropriate precursor which is incorporated in the subsequent biosynthesis pathway. 
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6.3.2 Characterization of the myxopyronin derivatives W1-W18 
Calculated and expected masses 
Table S3. Characterization of novel myxopyronin A analogues with representative fragmentation patterns observed  
 
Chemical 
formula 
Calculated 
mass 
m/z [M+H]+ 
Observed 
m/z [M+H]+ 
Fragmentation due to losses of 
H2O 
(m/z = 
18) 
CH3OH 
(m/z = 
32) 
H2N-CO2CH3 
(m/z = 75) 
H2N-CO2CH3, 
CO2 (m/z = 
119) 
Myx A C23H32NO6 418.22241 418.22217 400.2112
9 
386.1957
6 
343.18988 299.20017 
W1 C23H32NO6 418.22241 418.22227 400.2111
2 
386.1956
7 
343.18981 299.20007 
W2 C22H30NO6 404.20676 404.20666 386.1958
8 
372.1802
0 
329.17446 285.18464 
W4 C22H32NO6 406.22241 406.22250 388.2107
8 
374.1955
9 
331.18951 287.19987 
W6 C25H28NO6 438.19111 438.19103 420.1793
0 
406.1639
2 
363.15828 319.16866 
W7 C26H30NO6 452.20676 452.20686 434.1954
4 
420.1814
6 
377.17400 333.18430 
W8 C25H30NO6 440.20676 440.20659 422.1952
9 
408.1795
4 
365.17410 321.18438 
W9 C25H28NO7 454.18602 454.18643 436.1746
8 
n.o 379.15314 335.16345 
W10 C25H26NO6
Br 
516.10163 516.10175 498.0907
3 
484.0753
0 
441.06942 397.07952 
W11 C21H26NO6 388.17546 388.17557 n.o n.o 313.14233 269.15311 
W12 C22H30NO7 420.20167 420.20148 402.1905
9 
n.o 345.16920 301.17982 
W13 C23H32NO6 418.22241 418.22232 400.2116
3 
386.1959
0 
343.18984 299.19999 
W14 C26H30NO6 452.20676 452.20670 434.1973
6 
420.1802
7 
377.17516 333.18508 
W16 C23H32NO6 418.22241 418.22235 400.2113
7 
386.1959
8 
343.18972 299.20000 
W17 C22H30NO6 404.20676 404.20675 386.1963
5 
372.1820
4 
329.17496 285.18512 
W18 C25H28NO6 438.19111 438.19118 420.1804
1 
406.1649
1 
363.15886 319.16910 
   n.o. = not observed 
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6.4 Supporting Information for Publication D 
Full supporting information is available online:  
http://pubs.acs.org/doi/suppl/10.1021/jm401102e/suppl_file/jm401102e_si_001.pdf 
6.4.1  Experimental procedures 
6.4.1.1 Chemistry 
6.4.1.1.1 Synthesis and spectroscopic data of compounds 1–12 
 
Methyl 3-amino-5-(4’-methoxyphenyl)thiophene-2-carboxylate (IIa). The title 
compound was prepared from 4’-methoxyacetophenone according to general 
procedure A and used directly in the next step without further purification. 1H 
NMR (DMSO-d6, 500 MHz): δ = 7.56 (d, J = 8.8 Hz, 2 H), 7.00 (d, J = 8.8 Hz, 2 
H), 6.86 (s, 1 H), 6.56 (br. s, 2 H), 3.79 (s, 3 H, OCH3), 3.72 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-d6, 126 MHz): δ = 163.9, 160.0, 155.7, 147.7, 127.0, 125.3, 
114.9, 114.6, 95.7, 55.3, 50.8 ppm. 
 
Methyl 3-amino-5-(4’-phenoxyphenyl)thiophene-2-carboxylate (IIb). The title 
compound was prepared from 4’-phenoxyacetophenone according to general 
procedure A and used directly in the next step without further purification. 1H 
NMR (DMSO-d6, 500 MHz): δ = 7.64 (d, J = 8.8 Hz, 2 H), 7.46−7.40 (m, 2 H), 
7.22−7.17 (m, 1 H), 7.11−7.06 (m, 2 H), 7.04 (d, J = 8.8 Hz, 2 H), 6.91 (s, 1 H), 
6.59 (br. s, 2 H), 3.72 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-d6, 126 MHz): δ = 
163.9, 157.7, 155.9, 147.0, 130.2, 127.8, 127.4, 124.1, 119.3, 118.7, 115.7, 96.2, 
50.9 ppm. 
 
Methyl 3-amino-5-(4’-bromophenyl)thiophene-2-carboxylate (IIc). The title 
compound was prepared from 4’-bromoacetophenone according to general 
procedure A. 1H NMR (CDCl3, 300 MHz): δ = 7.51 (d, J = 8.0 Hz, 2 H), 7.43 (d, J 
= 8.0 Hz, 2 H), 6.75 (s, 1 H), 5.49 (br. s., 2 H), 3.85 (s, 3 H, OCH3) ppm. 
13C NMR 
(CDCl3, 75 MHz): δ = 164.8, 154.2, 147.6, 132.3, 132.1, 127.3, 123.0, 115.8, 
100.7, 51.3 ppm. 
 
3-Amino-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (IIIa). The title 
compound was prepared from IIa according to general procedure B. 1H NMR 
(DMSO-d6, 300 MHz): δ = 7.55 (d, J = 8.8 Hz, 2 H), 6.99 (d, J = 8.8 Hz, 2 H), 6.84 
(s, 1 H), 3.79 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 165.3, 
159.9, 155.3, 147.0, 127.0, 125.6, 115.0, 114.6, 97.1, 55.3 ppm. 
 
3-Amino-5-(4’-phenoxyphenyl)thiophene-2-carboxylate (IIIb). The title 
compound was prepared from IIb according to general procedure B. 1H NMR 
(DMSO-d6, 500 MHz): δ = 7.63 (d, J = 8.8 Hz, 2 H), 7.47−7.38 (m, 2 H), 
7.23−7.16 (m, 1 H), 7.08 (d, J = 8.8 Hz, 2 H), 7.06−6.99 (m, 2 H), 6.90 (s, 1 H) 
ppm. 13C NMR (DMSO-d6, 126 MHz): δ = 165.2, 157.5, 155.9, 146.3, 130.2, 
128.1, 127.3, 124.0, 119.2, 118.7, 115.8, 97.7 ppm. 
 
3-Amino-5-(4’-bromophenyl)thiophene-2-carboxylic acid (IIIc). The title 
compound was prepared from IIc according to general procedure B. 1H NMR 
(DMSO-d6, 500 MHz): δ = 7.63 (d, J = 8.8 Hz, 2 H), 7.57 (d, J = 8.8 Hz, 2 H), 6.98 
(s, 1 H) ppm. 13C NMR (DMSO-d6, 126 MHz): δ = 165.2, 155.1, 145.3, 132.2, 
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132.1, 127.5, 122.0, 116.8, 98.5 ppm. 
 
6-(4’-Methoxyphenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione 
(IVa). The title compound was prepared from IIIa according to general procedure 
C. 1H NMR (DMSO-d6, 300 MHz): δ = 12.28 (s, 1 H), 7.74 (d, J = 8.9 Hz, 2 H), 
7.12 (s, 1 H), 7.04 (d, J = 8.9 Hz, 2 H), 3.82 (s, 3 H, OCH3) ppm. 
13C NMR 
(DMSO-d6, 75 MHz): δ = 161.1, 155.5, 155.0, 149.6, 148.6, 127.9, 124.1, 114.8, 
111.2, 103.1, 55.4 ppm. 
 
6-(4’-Phenoxyphenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione 
(IVb). The title compound was prepared from IIIb according to general procedure 
C. 1H NMR (DMSO-d6, 500 MHz): δ = 12.33 (br. s., 1 H), 7.83 (d, J = 8.8 Hz, 2 
H), 7.48−7.43 (m, 2 H), 7.23 (t, J = 7.4 Hz, 1 H), 7.18 (s, 1 H), 7.13−7.10 (m, 2 
H), 7.08 (d, J = 8.8 Hz, 2 H) ppm. 13C NMR (DMSO-d6, 126 MHz): δ = 158.9, 
155.4, 155.0, 154.8, 149.6, 148.5, 130.3, 128.4, 126.4, 124.4, 119.6, 118.6, 
112.1, 103.8 ppm. 
 
6-(4’-Bromophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVc). 
The title compound was prepared from IIIc according to general procedure C. 
1H NMR (DMSO-d6, 500 MHz): δ = 12.39 (br. s., 1 H), 7.77 (d, J = 8.8 Hz, 2 H), 
7.70 (d, J = 8.8 Hz, 2 H), 7.29 (s, 1 H) ppm. 13C NMR (DMSO-d6, 126 MHz): δ = 
155.1, 153.5, 149.7, 148.6, 132.4, 130.8, 128.3, 123.8, 113.4, 104.7 ppm. 
 
3-(3’’-Benzyl-3’’-ethylureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic 
acid (1). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 13.21 (br. s, 1 H, COOH ), 10.10 
(s, 1 H), 8.17 (s, 1 H), 7.63 (d, J = 8.9 Hz, 2 H), 7.38–7.29 (m, 5 H), 7.02 (d, J = 
8.9 Hz, 2 H), 3.80 (s, 3 H, OCH3), 3.39 (q, J = 7.1 Hz, 2 H), 1.16 (t, J = 7.1, 3 H) 
ppm. 13C NMR (DMSO-d6, 75 MHz,): δ = 165.8, 160.2, 153.1, 147.9, 147.0, 
138.1, 128.5, 127.2, 127.1, 127.1, 125.3, 116.1, 114.7, 105.6, 55.3, 49.3, 41.8, 
13.1 ppm. 
 
5-(4’-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid (2). The title 
compound was prepared from IVa according to general procedure D. 1H NMR 
(DMSO-d6, 300 MHz): δ = 12.92 (br. s., 1 H, COOH), 9.30 (s, 1 H), 8.15 (s, 1 H), 
7.60 (d, J = 8.8 Hz, 2 H), 7.01 (d, J = 8.8 Hz, 2 H), 6.81 (br. s, 2 H), 3.76 (s, 3 H, 
OCH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 164.8, 160.0, 154.7, 147.1, 146.6, 
127.1, 125.4, 116.7, 114.7, 105.4, 55.3 ppm. 
 
5-(4’-Phenoxyphenyl)-3-ureidothiophene-2-carboxylic acid (3). The title 
compound was prepared from IVb according to general procedure D. 1H NMR 
(DMSO-d6, 300 MHz): δ = 12.99 (br. s., 1 H, COOH), 9.30 (s, 1 H), 8.21 (s, 1 H), 
7.68 (d, J = 8.8 Hz, 2 H), 7.49−7.38 (m, 2 H), 7.25−7.14 (m, 1 H), 7.13−7.02 (m, 4 
H), 6.90−6.60 (m, 2 H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 164.7, 157.7, 
155.9, 154.6, 146.5, 146.4, 130.2, 127.9, 127.5, 124.1, 119.3, 118.8, 117.5, 
106.1 ppm. 
 
3-(3’’-(Carboxymethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic 
acid (4). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.79 (br. s., 2 H, COOH), 9.47 
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(s, 1 H), 8.13 (s, 1 H), 8.08 (t, J = 5.6 Hz, 1 H), 7.61 (d, J = 8.8 Hz, 2 H), 7.01 (d, 
J = 8.8 Hz, 2 H), 3.83−3.77 (m, 2 H) 3.80 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-
d6, 75 MHz): δ = 171.9, 164.7, 160.1, 154.1, 147.2, 146.1, 127.1, 125.4, 116.7, 
114.7, 105.7, 55.3, 41.3 ppm. 
 
3-(3’’-(2-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic 
acid (5). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.58 (br. s., 2 H, COOH), 9.34 
(s, 1 H), 8.16 (s, 1 H), 7.90− 7.72 (m, 1 H), 7.60 (d, J = 8.4 Hz, 2 H), 7.01 (d, J = 
8.4 Hz, 2 H), 3.80 (s, 3 H, OCH3), 3.33−3.24 (m, 2 H), 2.44 (t, J = 6.2 Hz, 2 H) 
ppm. 13C NMR (DMSO-d6, 75 MHz) δ = 173.0, 164.7, 160.1, 153.8, 147.1, 146.3, 
127.1, 125.4, 116.7, 114.7, 105.4, 55.3, 35.6, 34.3 ppm. 
 
(S)-3-(3’’-(1-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-
carboxylic acid (6). The title compound was prepared from IVa according to 
general procedure D 1H NMR (DMSO-d6, 300 MHz): δ = 12.76 (br. s., 2 H, 
COOH), 9.43 (s, 1 H), 8.14 (s, 1 H), 8.09 (d, J = 7.1 Hz, 1 H), 7.61 (d, J = 8.8 Hz, 
2 H), 7.03 (d, J = 8.8 Hz, 2 H), 4.22−4.08 (m, 1 H), 3.81 (s, 3 H, OCH3), 1.32 (d, J 
= 7.30 Hz, 3 H, CH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 174.7, 164.7, 
160.1, 153.5, 147.2, 146.1, 127.1, 125.4, 116.6, 114.7, 105.6, 55.3, 48.3, 17.4 
ppm. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-methoxyphenyl)thiophene-
2-carboxylic acid (7). The title compound was prepared from IVa according to 
general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.84 (br. s., 2 H, 
COOH), 9.42 (s, 1 H), 8.15 (d, J = 7.9 Hz, 1 H), 8.09 (s, 1 H), 7.69−7.51 (m, J = 
8.8 Hz, 2 H), 7.37−7.25 (m, 4 H), 7.25−7.17 (m, 1 H), 7.03−6.97 (m, J = 8.8 Hz, 2 
H), 4.56−4.28 (m, 1 H), 3.79 (s, 3 H, OCH3), 3.11 (dd, J = 13.9, 4.6 Hz, 1 H), 2.88 
(dd, J = 13.9, 9.8 Hz, 1 H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.6, 
160.1, 153.7, 147.1, 145.9, 137.7, 129.0, 128.2, 127.1, 126.4, 125.4, 116.7, 
114.7, 105.8, 55.3, 54.4, 36.9 ppm. 
 
5-(4’-Methoxyphenyl)-3-(3’’-phenethylureido)thiophene-2-carboxylic acid 
(8). The title compound was prepared from IVa according to general procedure D. 
1H NMR (DMSO-d6, 300 MHz): δ = 12.96 (br. s., 1 H, CCOH), 9.33 (s, 1 H), 8.18 
(s, 1 H), 7.84−7.70 (m, 1 H), 7.61 (d, J = 8.3 Hz, 2 H), 7.39−7.13 (m, 5 H), 7.02 
(d, J = 8.3 Hz, 2 H), 3.80 (s, 3 H, OCH3), 3.42−3.26 (m, 2 H), 2.90−2.67 (m, 2 H) 
ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 164.8, 160.0, 153.8, 147.2, 146.5, 139.5, 
128.6, 128.3, 127.1, 126.1, 125.4, 116.7, 114.7, 105.2, 55.3, 41.0, 35.5 ppm. 
 
(R)-3-(3’’-(1-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-
carboxylic acid (9). The title compound was prepared from IVa according to 
general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.76 (br. s., 2 H, CCO), 
9.43 (s, 1 H), 8.14 (s, 1 H), 8.09 (d, J = 7.1 Hz, 1 H), 7.61 (d, J = 8.9 Hz, 2 H), 
7.01 (d, J = 8.9 Hz, 2 H), 4.22−4.08 (m, 1 H), 3.80 (s, 3 H, OCH3), 1.31 (d, J = 7.4 
Hz, 3 H, CH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 174.7, 164.7, 160.1, 
153.5, 147.2, 146.1, 127.1, 125.4, 116.6, 114.7, 105.6, 55.3, 48.3, 17.4 ppm. 
 
(R)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-methoxyphenyl)thiophene-
2-carboxylic acid (10). The title compound was prepared from IVa according to 
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general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.84 (br. s., 2 H, 
CCOH), 9.42 (s, 1 H), 8.15 (d, J = 7.9 Hz, 1 H), 8.09 (s, 1 H), 7.59 (d, J = 8.8 Hz, 
2 H), 7.37−7.25 (m, 4 H), 7.25−7.17 (m, 1 H), 7.00 (d, J = 8.8 Hz, 2 H), 4.56−4.28 
(m, 1 H), 3.79 (s, 3 H, OCH3), 3.11 (dd, J = 13.9, 4.6 Hz, 1H), 2.88 (dd, J = 13.9, 
9.8 Hz, 1 H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.6, 160.1, 153.7, 
147.1, 145.9, 137.7, 129.0, 128.2, 127.1, 126.4, 125.4, 116.7, 114.7, 105.8, 55.3, 
54.4, 36.9 ppm. 
 
3-(3’’-(2-Carboxypropan-2-yl)ureido)-5-(4’-methoxyphenyl)thiophene-2-
carboxylic acid (11). The title compound was prepared from IVa according to 
general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.59 (br. s., 2 H, 
CCOH), 9.37 (s, 1 H), 8.13 (s, 1 H), 8.01 (s, 1 H), 7.61 (d, J = 8.8 Hz, 2 H), 7.00 
(d, J = 8.8 Hz, 2 H), 3.80 (s, 3 H, OCH3), 1.40 (s, 6 H, (CH3)2) ppm. 
13C NMR 
(DMSO-d6, 75 MHz): δ = 176.0, 164.7, 160.0, 153.0, 147.2, 146.1, 127.1, 125.4, 
116.5, 114.7, 105.4, 55.3, 54.9, 25.3 ppm. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-(2-chloroacetamido)phenyl) 
thiophene-2-carboxylic acid (12).  
 
Scheme S2: Synthesis of compound 12. 
 
 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-bromophenyl)thiophene-2-
carboxylic acid (12a) was prepared from IVc according to general procedure D. 
1H NMR (DMSO-d6, 300 MHz): δ = 12.93 (br. s., 2 H, CCOH), 9.42 (s, 1 H), 8.23 
(s, 1 H), 8.17 (d, J = 7.9 Hz, 1 H), 7.70−7.54 (m, 4 H), 7.38− 7.14 (m, 5 H), 
4.47−4.30 (m, 1 H), 3.11 (dd, J = 13.9, 4.8 Hz, 1 H), 2.88 (dd, J = 13.9, 9.7 Hz, 1 
H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.5, 164.5, 153.7, 145.7, 145.4, 
137.7, 132.2, 132.0, 129.0, 128.2, 127.6, 126.4, 122.3, 118.5, 107.3, 54.4, 37.0 
ppm. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-aminophenyl)thiophene-2-
carboxylic acid (12b) was prepared from 12a according to the following 
procedure: CuI (10 mg, 5.30 µmol), 12a (127 mg, 0.26 mmol), Na3PO4∙12 H2O 
(100 mg, 0.26 mmol), 25−28% aqueous ammonia (0.5 mL) and PEG-400 (1 mL) 
were added to a sealed tube. The reaction was stirred at 100 °C for 24 h, cooled 
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to 0 °C and cautiously acidified with 1 M HCl to pH 4−5. The resulting mixture 
was extracted with EtOAc (3 x 50 mL). The combined organic layers were 
washed with water (50 mL) and brine (50 mL), dried over MgSO4 and 
concentrated to afford the title compound. The crude product was used in the 
next step without further purification. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-(2-chloroacetamido)phenyl) 
thiophene -2-carboxylic acid (12) was prepared from 12b according to the 
following procedure: A solution of 12b (142 mg, 1.10 mmol) and triethylamine 
(142 mg, 1.10 mmol) in CH2Cl2 (6 mL) was stirred at −78 °C under stream of 
nitrogen. 2-Chloroacetyl chloride in CH2Cl2 (4 mL) was added slowly and stirring 
was continued for 1 h at −78 °C, 1 h at 0 °C and 1 h at room temperature. The 
solution was diluted with ice water (30 mL) and acidified with a saturated solution 
of KHSO4. The resulting mixture was extracted with EtOAc (3 x 50 mL). The 
combined organic layers were then washed with water (50 mL) and brine (50 
mL), dried over MgSO4 and concentrated in vacuo. The crude material was 
purified via preparative HPLC (RP18, acetonitrile/H2O 50% → 95%) to yield the 
title compound as a light green solid. (Purity: 90%) 1H NMR (DMSO-d6, 300 
MHz): δ = 12.89 (br. s., 2 H, CCOH), 10.48 (s, 1 H), 9.41 (s, 1 H), 8.16 (d, J = 7.8 
Hz, 1 H), 8.15 (s, 1 H), 7.73−7.62 (m, 4 H), 7.33−7.20 (m, 5 H), 4.43−4.34 (m, 1 
H), 4.27 (s, 2 H, CH2Cl), 3.14−3.07 (m, 1 H), 2.92−2.84 (m, 1 H) ppm. 
13C NMR 
(DMSO-d6, 176 MHz): δ = 173.7, 164.9, 164.7, 153.8, 146.8, 145.9, 139.4, 137.8, 
129.1, 128.3, 128.2, 126.5, 126.4, 119.8, 117.3, 106.3, 54.5, 43.6, 36.9 ppm. 
6.4.1.2 Biology and biophysics 
6.4.1.2.1 SPR - mutagenesis studies  
Preparation of PqsD mutant 
R223A PqsD mutant was generated using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s 
instructions using the pET28b(+)/pqsD plasmid as a template. Briefly, pqsD gene 
was amplified through 16 cycles of PCR. After treatment with DpnI, the PCR 
product was transformed into E. coli strain XL1-Blue. Plasmid DNA was purified 
using the GenEluteTM HP Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO) 
and sequenced to confirm the site-directed mutations. The primer sequence of 
the mutations: 
Primer-design: 
Arg223Ala-Mutante: 
Wild:5‘ GCGAGTTCCTCATGCGCGGCCGGCCGATGTTCGAGC 3´ 
Mut: 5‘ GCGAGTTCCTCATGCGCGGCGCGCCGATGTTCGAGC 3´ 
Sequence of the Primer: 
R223A_PqsD_Forward:       
5' GCGAGTTCCTCATGCGCGGCGCGCCGATGTTCGAGC 3' 
R223A_PqsD_Reverse:  
5' GCTCGAACATCGGCGCGCCGCGCATGAGGAACTCGC 3'  
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6.4.2 Selectivity data for hit compounds: PqsD vs. RNAP inhibition 
Table S1. Inhibitory activities of several virtual hit compounds against PqsD and 
RNAP and the derived selectivity factors. 
 
R IC50 PqsD [µM] IC50 RNAP [µM] Selectivity factor
[a]
 
4-OCH3 6 241 40 
3,4-di-Cl 4 22 5.5 
3-CF3, 4-Cl 3 21 7.0 
2,5-di-Cl 9 35 4.0 
4-NO2 10 73 7.3 
4-CF3 8 51 6.4 
4-OCF3 9 45 5.0 
H 50 292 6.0 
[a]
 Selectivity factor was calculated as IC50(RNAP) IC50(PqsD)
−1 
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6.4.3  Results from SPR experiments 
6.4.3.1 Competition experiments for identification of the binding mode 
 
Figure S1. SPR-competition experiments with model compounds 1–3 competitor compounds 
A (black) and B (red) from the 2-nitrophenyl methanol class. Reference without competition 
is shown in blue. A reduced response in competition with A can be observed exclusively for 
compound 3. The reference signal is shown in grey. 
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Figure S2. Visualization of the SPR-competition results shown in Figure S1. Competitor A 
(yellow), competitor B (magenta) a) A does not affect the binding of 1 (green). b) B leads to 
sterical clash with methoxy group of 1 (green). c) A does not affect the binding of 2 (blue). d) 
B leads to sterical clash with methoxy group of 2 (blue). e) A leads to sterical clash with 
phenoxy group of 3 (turquoise). f) B leads to sterical clash with phenoxy group of 3 
(turquoise). 
6.4.3.2 Experiment with R223A mutant and compound 2 
 
Figure S3. SPR-experiment with compound 2 revealed different responses with PqsD 
wildtype (blue) and the R223A mutant (green) 
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6.4.4. STD-NMR spectrum of 7 
 
Figure S4. Reference (black) and STD NMR difference (red) spectra of compound 7 in complex with PqsD. Samples comprising 100:1 7/PqsD 
were prepared in 20 mM Na3PO4, 50 mM NaCl, and 5 mM MgCl2, pH 7.0, and spectra were recorded at 298 K. Overlaid spectra were normalized 
to the signals for 2H-21, which gave the strongest enhancement  
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6.4.5.  MALDI-ToF-MS spectra  
6.4.5.1 PqsD 
 
Figure S5. MALDI-ToF-MS analysis of tryptic digested PqsD. For the sake of clarity, only signals >15% intensity are labeled.  
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6.4.5.2 PqsD + 12 
 
Figure S6. MALDI-ToF-MS analysis of tryptic digested PqsD after preincubation with 12. For the sake of clarity, only signals >15% intensity are 
labeled. 
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6.4.6 LC-ESI-MS data 
 
Figure S7. LC-ESI-MS data. Top panel (red): Reference sample containing only PqsD. 
Bottom panel (blue): PqsD after 30 minutes preincubation with compound 12. Mass shift of 
465 Da indicates covalent binding of 12. 
 
6.4.7 HPLC purities 
Table S2. Purities and retention times of compounds 1−12. 
Compound Purity [%] Retention time [min]
a 
1 98 13.51 
2 97 9.74 
3 95 12.32 
4 97 9.65 
5 95 9.82 
6 95 10.06 
7 100 10.86 
8 96 13.60 
9 98 10.01 
10 97 11.97 
11 99 10.44 
12 90 10.76 
a
 In a gradient run the percentage of acetonitrile (containing 0.1% trifluoroacetic acid) was 
increased from a initial concentration of 0% at 0 min to 100% at 15 min and kept at 100% for 
5 min. 
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6.5 Supporting Information for Publication E 
6.5.1 Synthesis and spectroscopic data of compounds 1–24 
 
Scheme S1: General synthesis of 5-aryl-3-ureidothiophene-2-carboxylic acids. 
Method A, general procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic acid 
methylester (II) [1]: POCl3 (26.1 g, 0.17 mol) was added dropwise to DMF (24.9 g, 
0.34 mol) maintaining the temperature beyond 25 °C (cooling in ice bath) and stirred 
for additional 15 min. The acteophenon I (85.0 mmol) was added slowly and the 
temperature was kept between 40 and 60 °C. After complete addition, the mixture 
was stirred for 30 minutes at room temperature. Hydroxylamine hydrochloride (23.6 
g, 0.34 mol) was carefully added portionwise (exothermic reaction!) and the reaction 
was stirred for additional 30 min without heating. After cooling to room temperature, 
the mixture was poured into ice water (300 mL). The precipitated β-chloro-
cinnamonitrile was collected by filtration, washed with H2O (2 x 50 mL) and dried 
under reduced pressure over CaCl2. In the next step sodium (1.93 g, 84.0 mmol.) 
was dissolved in MeOH (85 mL) and methylthioglycolate (6.97 g, 65.6 mmol) was 
added to the stirred solution. The β-chloro-cinnamonitrile (61.1 mmol) was added and 
the mixture was heated to reflux for 30 min. After cooling to room temperature, the 
mixture was poured in ice water (300 mL). The precipitated solid was collected by 
filtration, washed with H2O (2 x 50 mL) and dried under reduced pressure over CaCl2. 
If necessary, recrystallisation was performed from EtOH. 
Method B, general procedure for the synthesis of 5-Aryl-3-amino-2-carboxylic acid 
(III): The 5-Aryl-3-amino-2-carboxylic acid methyl ester (16.6 mmol) was added to a 
solution of KOH (60 mL, 0.6M in H2O) and MeOH (60 mL). The mixture was heated 
to reflux for 3 h, concentrated, and washed with EtOAc (2 x 50 mL). The aqueous 
layer was cooled with ice and acidified with a saturated aqueous solution of KHSO4. 
The precipitated solid was collected by filtration, washed with H2O (2 x 30 mL) and 
dried under reduced pressure over CaCl2. 
Method C, general procedure for the synthesis of 5-Aryl-2-thiaisatoic-anhydrid (IV) 
[2,3]: To a solution of the 5-Aryl-3-amino-2-carboxylic acid (III) (5.28 mmol) in THF 
(50 mL) a solution of phosgene (6.10 mL, 20 wt% in toluene, 11.6 mmol) was added 
dropwise over a period of 30 min. The reaction mixture was stirred for 2 h at room 
temperature, followed by the addition of saturated aqueous solution of NaHCO3 (30 
mL) and H2O (50 mL). The resulting mixture was extracted with EtOAc/THF (1:1, 3 x 
100 mL). The organic layer was washed with saturated aqueous NaCl (100 mL), 
dried (MgSO4) and concentrated. The crude material was suspended in a mixture of 
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n-hexane/EtOAc (2:1, 50 mL) heated to 50 °C and after cooling to room temperature 
separated via filtration. 
Method D, general procedure for the synthesis of 5-Aryl-3-ureidothiophene-2-
carboxylic acid (V) [4]: The 5-Aryl-2-thiaisatoic-anhydrid (IV) (0.46 mmol) was 
suspended in water (7.5 mL) and the appropriate amine (0.92 mmol) was added. 
After addition of triethylamine (1.84 mmol), the reaction mixture was stirred, heated to 
100 °C and then cooled to room temperature. The reaction mixture was poured into a 
mixture of concentrated HCl and ice (1:1) and extracted with EtOAc/THF (1:1, 60 
mL). The organic layer was washed with aqueous HCl (2M), followed by saturated 
aqueous NaCl (2 x 50 mL), dried (MgSO4) and concentrated. The crude material was 
suspended in a mixture of n-hexane/EtOAc (2:1, 20 mL) heated to 50 °C and after 
cooling to room temperature separated via filtration. 
 
 
Scheme S2: General procedure for Suzuki coupling. 
Method E, general procedure for the synthesis of (VI):[5] A mixture of the bromo-aryl 
compound (1 eq, 0.20 mmol), the boronic acid (2 eq, 0.40 mmol), Pd(PPh3)4 (0.1 eq, 
0.02 mmol) and Na2CO3 (6 eq, 1.20 mmol) in H2O (2 mL), THF (6mL) and Toluol (6 
mL) were heated at 80°C under N2 flow overnight. The reaction mixture was poured 
into a mixture of concentrated HCl and ice (1:1, 50 mL) and extracted with EtOAc (2 x 
50 mL). The organic layer was washed with H2O, dried (MgSO4) and evaporated. 
The crude product was purified using preparative HPLC. 
Methyl 3-amino-5-(4’-methoxyphenyl)thiophene-2-carboxylate (IIa). The title 
compound was prepared from 4’-methoxyacetophenone according to general 
procedure A and used directly in the next step without further purification. 1H NMR 
(DMSO-d6, 500 MHz): δ = 7.56 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 6.86 (s, 
1H), 6.56 (br. s, 2H), 3.79 (s, 3H, OCH3), 3.72 (s, 3H, OCH3) ppm. 
13C NMR (DMSO-
d6, 125 MHz): δ = 163.9, 160.0, 155.7, 147.7, 127.0, 125.3, 114.9, 114.6, 95.7, 55.3, 
50.8 ppm. 
Methyl 3-amino-5-phenylthiophene-2-carboxylate (IIb) The title compound was 
prepared from acetophenone according to general procedure A and used directly in 
the next step without further purification. 1H NMR (DMSO-d6, 500 MHz): δ = 7.61–
7.64 (m, 2H), 7.43–7.47 (m, 2H), 7.38–7.42 (m, 1H), 6.98 (s, 1H), 6.59 (br. s, 2H), 
3.73 (s, 3H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 163.9, 155.5, 147.5, 132.7, 
129.2, 129.1, 125.5, 116.2, 96.6, 50.9 ppm. 
Methyl 3-amino-7-methoxy-4,5-dihydronaphtho[1,2-b]thiophene-2-carboxylate 
(IIc). The title compound was prepared from 6-methoxy tetralone according to the 
following procedure:[6] The conversion to the -chloro-cinnamonitrile was performed 
like described in the general procedure A. For the next, sodium sulphite nonahydrate 
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(10.9 g, 45.5 mmol) was suspended in DMF (50 mL) and heated to 40 °C for 30 min. 
A solution of the -chloro-cinnamonitrile (5.00 g, 22.8 mmol) in DMF (20 mL) was 
added dropwise and the resulting mixture was stirred at 50 °C for 2 h. Methyl 
bromoacetate (6.96 g, 45.5 mmol) was dissolved in DMF (20 mL), slowly added and 
stirring was continued overnight. A solution Na (1.05 g, 45.5) in dry ethanol (100 mL) 
was freshly prepared and added to the reaction mixture. After 1.5 h, the reaction was 
cooled to room temperature and diluted with cold H2O (200 mL). The product 
appeared as a yellow solid and was filtered off. The product turned grey after 
washing with 100 mL cold H2O and drying under vacuum. 
1H NMR (DMSO-d6, 300 
MHz): δ = 7.28 (d, J = 8.4 Hz, 1H), 6.89 (s, 1H), 6.82 (dd, J = 2.4, 8.4 Hz, 1H), 6.50 
(br. s, 2H), 3.78 (s, 3H), 3.73 (s, 3H), 2.90 (tt, J = 7.5, 8.1 Hz, 2H), 2.61 (tt, J = 7.5, 
8.1 Hz, 2H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 164.2, 159.7, 153.3, 140.2, 
137.6, 125.7, 124.6, 122.9, 113.9, 112.4, 94.7, 55.2, 50.8, 28.0, 20.3 ppm. 
Methyl 3-amino-5-(3-bromophenyl)thiophene-2-carboxylate (IId). The title 
compound was prepared from 3’-bromoacetophenone according to general 
procedure A and used directly in the next step without further purification. 1H NMR 
(DMSO-d6, 500 MHz): δ = 7.80 (t, J = 1.9 Hz, 1H), 7.63 (ddd, J = 0.9, 1.9, 7.9 Hz, 
1H), 7.59 (ddd, J = 0.9, 1.9, 7.9 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.04 (s, 1H), 6.60 
(br. s, 2H), 3.74 (s, 3H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 163.8, 155.3, 
145.4, 135.0, 131.8, 131.3, 127.9, 124.7, 122.5, 117.3, 97.3, 51.0 ppm. 
Methyl 3-amino-5-(4’-bromophenyl)thiophene-2-carboxylate (IIe). The title 
compound was prepared from 4’-bromoacetophenone according to general 
procedure A and used directly in the next step without further purification. 1H NMR 
(CDCl3, 300 MHz): δ = 7.51 (d, J = 8.0 Hz, 2 H), 7.43 (d, J = 8.0 Hz, 2 H), 6.75 (s, 1 
H), 5.49 (br. s., 2 H), 3.85 (s, 3 H, OCH3) ppm. 
13C NMR (CDCl3, 75 MHz): δ = 164.8, 
154.2, 147.6, 132.3, 132.1, 127.3, 123.0, 115.8, 100.7, 51.3 ppm. 
3-Amino-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (IIIa). The title 
compound was prepared from IIa according to general procedure B and used directly 
in the next step without further purification. 1H NMR (DMSO-d6, 300 MHz): δ = 7.55 
(d, J = 8.8 Hz, 2 H), 6.99 (d, J = 8.8 Hz, 2 H), 6.84 (s, 1 H), 3.79 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 165.3, 159.9, 155.3, 147.0, 127.0, 125.6, 115.0, 
114.6, 97.1, 55.3 ppm. 
3-Amino-5-phenylthiophene-2-carboxylic acid (IIIb). The title compound was 
prepared from IIb according to general procedure B and used directly in the next step 
without further purification. 1H NMR (DMSO-d6, 500 MHz): δ = 7.56–7.69 (m, 2H), 
7.33–7.50 (m, 3H), 6.96 (s, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 165.2, 
155.1, 146.8, 133.0, 129.2, 129.0, 125.5, 116.3, 98.1 ppm. 
3-Amino-7-methoxy-4,5-dihydronaphtho[1,2-b]thiophene-2-carboxylic acid 
(IIIc). The title compound was prepared from IIc according to general procedure B 
and used directly in the next step without further purification. 1H NMR (DMSO-d6, 300 
MHz): δ = 7.27 (d, J = 8.2 Hz, 1H), 6.89 (br. s., 1H), 6.81 (d, J = 8.2 Hz, 1H), 3.77 (s, 
3H), 2.89 (t, J = 7.0 Hz, 2H), 2.55–2.68 (m, 2H) ppm. 13C NMR (DMSO-d6, 75 MHz): 
δ = 165.6, 159.5, 152.7, 139.3, 137.5, 125.9, 124.4, 123.1, 113.9, 112.4, 96.5, 55.2, 
28.1, 20.4 ppm. 
3-Amino-5-(3-bromophenyl)thiophene-2-carboxylic acid (IIId). The title compound 
was prepared from IId according to general procedure B and used directly in the next 
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step without further purification. 1H NMR (DMSO-d6, 500 MHz): δ = 7.79 (t, J = 1.9 
Hz, 1H), 7.62 (ddd, J = 0.9, 1.9, 7.9 Hz, 1H), 7.58 (ddd, J = 0.9, 1.9, 7.9 Hz, 1H), 7.39 
(t, J = 7.9 Hz, 1H), 7.03 (s, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 165.2, 
155.0, 144.7, 135.3, 131.6, 131.3, 127.8, 124.6, 122.4, 117.4, 98.8 ppm. 
3-Amino-5-(4’-bromophenyl)thiophene-2-carboxylic acid (IIIe). The title 
compound was prepared from IIe according to general procedure B and used directly 
in the next step without further purification. 1H NMR (DMSO-d6, 500 MHz): δ = 7.63 
(d, J = 8.8 Hz, 2 H), 7.57 (d, J = 8.8 Hz, 2 H), 6.98 (s, 1 H) ppm. 13C NMR (DMSO-d6, 
125 MHz): δ = 165.2, 155.1, 145.3, 132.2, 132.1, 127.5, 122.0, 116.8, 98.5 ppm. 
3-Aminothiophene-2-carboxylic acid (IIIf). The title compound was prepared from 
Methyl 3-amino-2-thiophenecarboxylate according to general procedure B and used 
directly in the next step without further purification. 1H NMR (DMSO-d6, 300 MHz): δ 
= 7.47 (d, J = 5.4 Hz, 1 H), 6.59 (d, J = 5.4 Hz, 1 H) ppm. 
6-(4’-Methoxyphenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVa). 
The title compound was prepared from IIIa according to general procedure D and 
used directly in the next step without further purification. 1H NMR (DMSO-d6, 
300 MHz): δ = 12.28 (s, 1 H), 7.74 (d, J = 8.9 Hz, 2 H), 7.12 (s, 1 H), 7.04 (d, J = 8.9 
Hz, 2 H), 3.82 (s, 3 H, OCH3) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 161.1, 155.5, 
155.0, 149.6, 148.6, 127.9, 124.1, 114.8, 111.2, 103.1, 55.4 ppm. 
6-Phenyl-2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione (IVb). The title compound 
was prepared from IIIb according to general procedure D and used directly in the 
next step without further purification. 1H NMR (DMSO-d6, 500 MHz): δ = 7.76–7.83 
(m, 2H), 7.47–7.54 (m, 3H), 7.26 (s, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 
155.2, 155.1, 149.8, 148.6, 131.5, 130.5, 129.5, 126.3, 112.8, 104.4 ppm. 
3-Methoxy-5,6-dihydro-8H-naphtho[2',1':4,5]thieno[3,2-d][1,3]oxazine-8,10(7H)-
dione (IVc). The title compound was prepared from IIIc according to general 
procedure D and used directly in the next step without further purification. 1H NMR 
(DMSO-d6, 300 MHz): δ = 12.19 (br. s., 1H), 7.46 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 2.3 
Hz, 1H), 6.87 (dd, J = 2.3, 8.5 Hz, 1H), 3.80 (s, 3H), 2.94 (tt, J = 7.1, 7.8 Hz, 2H), 
2.80 (tt, J = 7.1, 7.8 Hz, 2H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 160.8, 155.1, 
149.0, 147.7, 147.4, 138.3, 125.6, 123.6, 121.8, 114.0, 112.9, 101.8, 55.4, 27.6, 
20.1ppm. 
6-(3-bromophenyl)-2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione (IVd). The title 
compound was prepared from IIId according to general procedure D and used 
directly in the next step without further purification. 1H NMR (DMSO-d6, 500 MHz): δ 
= 12.41 (br. s., 1H), 8.05 (t, J = 1.7 Hz, 1H), 7.80 (ddd, J = 1.0, 1.9, 7.9 Hz, 1H), 7.69 
(ddd, J = 1.0, 1.9, 7.9 Hz, 1H), 7.46 (t, J = 8.04 Hz, 1H), 7.36 (s, 1H) ppm. 13C NMR 
(DMSO-d6, 125 MHz): δ = 155.1, 152.9, 149.3, 148.5, 133.8, 133.1, 131.5, 128.7, 
125.5, 122.7, 113.9, 105.2 ppm. 
6-(4’-Bromophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVe). 
The title compound was prepared from IIIe according to general procedure D and 
used directly in the next step without further purification. 1H NMR (DMSO-d6, 
500 MHz): δ = 12.39 (br. s., 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 
7.29 (s, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 155.1, 153.5, 149.7, 148.6, 
132.4, 130.8, 128.3, 123.8, 113.4, 104.7 ppm. 
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2H-Thieno[3,2-d][1,3]oxazine-2,4(1H)-dione (IVf). The title compound was 
prepared from IIIf according to general procedure D and used directly in the next step 
without further purification. 1H NMR (DMSO-d6, 300 MHz): δ = 12.21 (br. s., 1H), 8.24 
(d, J = 5.2 Hz, 1H), 6.94 (d, J = 5.2 Hz, 1H) ppm. 
6-(4-Methoxy-2-methylphenyl)-2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione (IVg). 
The title compound was prepared from IIIg according to general procedure D and 
used directly in the next step without further purification. 1H NMR (DMSO-d6, 
300 MHz): δ = 12.23 (br. s., 1H), 7.43 (d, J = 8.57 Hz, 1H), 6.84–7.01 (m, 3H), 3.80 
(s, 3H), 2.41 (s, 3H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 160.3, 155.0, 154.9, 
148.8, 148.5, 137.5, 131.2, 123.9, 116.6, 115.5, 112.1, 104.4, 55.3, 20.9 ppm. 
(S)-5-(3-Bromophenyl)-3-(3-(1-carboxy-2-phenylethyl)ureido)thiophene-2-
carboxylic acid (Va). The title compound was prepared from IVd according to 
general procedure E and used directly in the next step without further purification. 1H 
NMR (DMSO-d6, 500 MHz): δ = 12.88 (br. s., 2H), 9.42 (s, 1H), 8.23 (s, 1H), 8.18 (d, 
J = 7.9 Hz, 1H), 7.81 (t, J = 1.7 Hz, 1H), 7.64–7.69 (ddd, J = 1.0, 1.9, 7.9 Hz, 1H, 
1H), 7.57–7.62 (ddd, J = 1.0, 1.9, 7.9 Hz, 1H, 1H), 7.25–7.33 (m, 4H), 7.17–7.25 (m, 
1H), 4.39 (ddd, J = 4.6, 8.0, 9.5 Hz, 1H), 3.11 (dd, J = 4.8, 13.9 Hz, 1H), 2.88 (dd, J = 
9.8, 13.9 Hz, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 173.6, 164.5, 153.7, 
145.5, 144.7, 137.7, 135.0, 131.8, 131.4, 129.1, 128.2, 128.0, 126.4, 124.8, 122.5, 
119.0, 107.8, 54.4, 37.0 ppm. 
(S)-5-(4-Bromophenyl)-3-(3-(1-carboxy-2-phenylethyl)ureido)thiophene-2-
carboxylic acid (Vb). The title compound was prepared from IVe according to 
general procedure E and used directly in the next step without further purification. 
1H NMR (DMSO-d6, 300 MHz): δ = 12.93 (br. s., 2H), 9.42 (s, 1H), 8.23 (s, 1H), 8.17 
(d, J = 7.9 Hz, 1H), 7.54–7.70 (m, 4H), 7.14–7.38 (m, 5H), 4.30–4.47 (m, 1H), 3.04–
3.17 (m, 1H), 2.80–2.95 (m, 1H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.5, 
164.5, 153.7, 145.7, 145.4, 137.7, 132.2, 132.0, 129.0, 128.2, 127.6, 126.4, 122.3, 
118.5, 107.3, 54.4, 37.0 ppm. 
5-(4-Methoxyphenyl)-3-(3-(phosphonomethyl)ureido)thiophene-2-carboxylic (1). 
The title compound was prepared from IVa according to general procedure D. 
1H NMR (DMSO-d6, 300 MHz): δ = 9.43 (s, 1H), 8.15 (s, 1H), 7.89–8.09 (m, 1H), 7.60 
(d, J = 8.6 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 3.80 (s, 3H), 3.25–3.50 (m, 2H) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 164.5, 160.0, 153.9, 147.0, 146.1, 127.0, 125.4, 
116.9, 114.7, 105.7, 55.3, 36.2-37.8 (d, HSQC, N-C-P) ppm. MS (ESI) m/z: 386.8 
[M+H]+ 
(S)-3-(3-(1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido)-5-(4-methoxyphenyl) thio 
phene-2-carboxylic (2). The title compound was prepared from IVa according to 
general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.81 (br. s., 2H), 9.41 (s, 
1H), 9.20 (br. s., 1H), 8.07–8.12 (m, 1H), 8.09 (s, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.06 
(d, J = 8.3 Hz, 2H), 7.00 (d, J = 8.7 Hz, 1H), 6.68 (d, J = 8.3 Hz, 2H), 4.20–4.38 (m, 
1H), 3.79 (s, 3H), 2.97 (dd, J = 4.4, 13.7 Hz, 1H), 2.76 (dd, J = 9.7, 13.7 Hz, 1H) 
ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.8, 164.6, 160.1, 155.9, 153.7, 147.1, 
145.9, 130.0, 127.7, 127.1, 125.4, 116.8, 115.0, 114.7, 105.7, 55.3, 54.8, 36.2 ppm. 
MS (ESI) m/z: 456.9 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-(4-methoxyphenyl)ethyl)ureido)-5-(4-methoxyphenyl)thio-
phene-2-carboxylic (3). The title compound was prepared from IVa according to 
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general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.83 (br. s., 2H), 9.41 (s, 
1H), 8.12 (d, J = 8.01 Hz, 1H), 8.09 (s, 1H), 7.59 (d, J = 8.75 Hz, 2H), 7.19 (d, J = 
8.50 Hz, 2H), 7.00 (d, J = 8.80 Hz, 2H), 6.86 (d, J = 8.57 Hz, 2H), 4.25–4.42 (m, 1H), 
3.79 (s, 3H), 3.71 (s, 3H), 2.96–3.11 (m, 1H), 2.71–2.87 (m, 1H) ppm. 13C NMR 
(DMSO-d6, 75 MHz): δ = 173.7, 164.6, 160.1, 157.9, 153.7, 147.1, 145.9, 130.1, 
129.5, 127.1, 125.4, 116.7, 114.7, 113.7, 105.7, 55.3, 54.9, 54.7, 36.1 ppm. MS (ESI) 
m/z: 471.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-(4-chlorophenyl)ethyl)ureido)-5-(4-methoxyphenyl)thio-
phene-2-carboxylic acid (4). The title compound was prepared from IVa according 
to general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.88 (br. s., 2H), 9.42 (s, 
1H), 8.14 (d, J = 8.0 Hz, 1H), 8.08 (s, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.5 
Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 4.29–4.47 (m, 1H), 3.79 (s, 
3H), 3.03–3.15 (m, 1H), 2.80–2.97 (m, 1H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 
173.4, 164.6, 160.1, 153.7, 147.2, 145.8, 136.7, 131.2, 131.0, 128.2, 127.1, 125.4, 
116.7, 114.7, 105.8, 55.3, 54.2, 36.3 ppm. MS (ESI) m/z: 475.1 [M+H]+ 
(S)-3-(3-(Carboxy(phenyl)methyl)ureido)-5-(4-methoxyphenyl)thiophene-2-
carboxylic acid (5). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.90 (br. s., 2H), 9.55 (s, 1H), 8.60 
(d, J = 7.0 Hz, 1H), 8.15 (s, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.25–7.53 (m, 5H), 7.01 (d, 
J = 8.1 Hz, 2H), 5.28 (d, J = 7.0 Hz, 1H), 3.80 (s, 3H) ppm. 13C NMR (DMSO-d6, 75 
MHz): δ = 172.4, 164.5, 160.1, 153.5, 147.1, 145.8, 137.4, 128.6, 128.0, 127.6, 
127.1, 125.4, 116.9, 114.7, 106.1, 57.2, 55.3 ppm. MS (ESI) m/z: 427.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-3-phenylpropyl)ureido)-5-(4-methoxyphenyl)thiophene-2-
carboxylic acid (6). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.82 (br. s., 2H), 9.51 (s, 1H), 
7.97–8.34 (m, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.12–7.39 (m, 5H), 7.01 (d, J = 8.5 Hz, 
2H), 4.06–4.18 (m, 1H), 3.80 (s, 3H), 2.69 (t, J = 7.1 Hz, 2H), 1.76–2.16 (m, 2H) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 174.2, 164.8, 160.1, 153.8, 147.3, 146.1, 141.0, 
128.4, 128.3, 127.1, 126.0, 125.4, 116.7, 114.7, 105.6, 55.3, 52.3, 33.0, 31.5 ppm. 
MS (ESI) m/z: 455.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-methylpropyl)ureido)-5-(4-methoxyphenyl)thiophene-2-
carboxylic acid (7). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.72 (br. s., 2H), 9.49 (s, 1H), 8.16 
(s, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 
4.07–4.15 (m, 1H), 3.80 (s, 3H), 2.04–2.17 (m, 1H), 0.85 - 1.01 (m, 6H) ppm. 13C 
NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.5, 160.0, 154.1, 147.0, 146.0, 127.1, 
125.4, 117.0, 114.7, 105.8, 58.1, 55.3, 29.8, 19.2, 17.9 ppm. MS (ESI) m/z: 392.9 
[M+H]+ 
(S)-3-(3-(1-Carboxy-2-hydroxyethyl)ureido)-5-(4-methoxyphenyl)thiophene-2-
carboxylic acid (8). The title compound was prepared from IVa according to general 
procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.77 (br. s., 2H), 9.50 (s, 1H), 
8.01–8.23 (m, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 5.00 (br. s., 1H), 
4.17–4.29 (m, 1H), 3.80 (s, 3H), 3.62–3.77 (m, 2H) ppm. 13C NMR (DMSO-d6, 75 
MHz): δ = 172.5, 164.5, 160.0, 153.9, 147.0, 145.9, 127.0, 125.4, 116.9, 114.7, 
105.9, 61.5, 55.5, 55.3 ppm. MS (ESI) m/z: 380.8 [M+H]+ 
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(S)-3-(3-(3-Amino-1-carboxy-3-oxopropyl)ureido)-5-(4-methoxyphenyl)thio-
phene-2-carboxylic (9). The title compound was prepared from IVa according to 
general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.76 (br. s., 2H), 9.44 (s, 
1H), 8.13 (s, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.61 (d, J = 8.8 Hz, 2H), 7.38 (br. s., 1H), 
7.02 (d, J = 8.8 Hz, 2H), 6.92 (br. s., 1H), 4.40–4.56 (m, 1H), 3.80 (s, 3H), 2.55–2.64 
(m, 1H), 2.45–2.55 (m, 1H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.4, 171.0, 
164.6, 160.1, 153.6, 147.1, 146.0, 127.1, 125.4, 116.8, 114.7, 105.8, 55.3, 49.6, 37.0 
ppm. MS (ESI) m/z: 407.9 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-(1H-indol-3-yl)ethyl)ureido)-5-(4-methoxyphenyl)thio-
phene-2-carboxylic acid (10). The title compound was prepared from IVa according 
to general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.80 (br. s., 2H), 10.85 
(br. s., 1H), 9.43 (s, 1H), 8.15 (d, J=7.7 Hz, 1H), 8.10 (s, 1H), 7.53–7.65 (m, 3H), 7.34 
(d, J=7.9 Hz, 1H), 7.17 (d, J=2.0 Hz, 1H), 6.95–7.12 (m, 4H), 4.40–4.51 (m, 1H), 3.79 
(s, 3H), 3.21 (dd, J=14.7, 4.7 Hz, 1H), 3.03 (dd, J=14.7, 9.0 Hz, 1H) ppm. 13C NMR 
(DMSO-d6, 75 MHz): δ = 174.0, 164.6, 160.0, 153.7, 147.1, 145.9, 136.1, 127.1, 
127.1, 125.4, 123.6, 120.9, 118.4, 118.1, 116.8, 114.7, 111.4, 109.9, 105.7, 55.3, 
53.7, 27.3 ppm. MS (ESI) m/z: 480.0 [M+H]+ 
((2-Carboxy-5-(4-methoxyphenyl)thiophen-3-yl)carbamoyl)-L-glutamic acid (11). 
The title compound was prepared from IVa according to general procedure D. 
1H NMR (DMSO-d6, 300 MHz): δ = 12.59 (br. s., 3H), 9.48 (s, 1H), 8.14 (s, 1H), 8.06 
(d, J = 7.64 Hz, 1H), 7.61 (d, J = 8.80 Hz, 2H), 7.01 (d, J = 8.85 Hz, 2H), 4.10–4.23 
(m, 1H), 3.80 (s, 3H), 2.23–2.44 (m, 2H), 1.93–2.07 (m, 1H), 1.72–1.89 (m, 1H) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 173.9, 173.7, 164.8, 160.1, 153.8, 147.2, 146.0, 
127.1, 125.4, 116.6, 114.7, 105.8, 55.4, 52.0, 30.1, 26.6 ppm. MS (ESI) m/z: 423.0 
[M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-5-(4-hydroxyphenyl)thiophene-2-
carboxylic acid (12). The title compound was prepared from B according to the 
following procedure: B (1 eq, 0.25 mmol) was filled in a crimp vial which was sealed 
afterwards. The vessel was evacuated and subsequently flushed with N2. This cycle 
was repeated three times. Dry DCM (5 mL) were added and the resulting solution 
was cooled to -78°C. BBr3 (12 eq, 3.00 mmol) were added and the reaction was 
stirred for 48 h and allowed to warm to room temperature. Afterwards the reaction 
was cooled to -78°C again and quenched by the addition of MeOH (5 mL). After 
warming up to room temperature, 2M HCl (5 mL) were added and the resulting 
mixture was extracted with EtOAc (3 x 20 mL). The organic layer was washed with 
brine (50 mL), dried (MgSO4) and evaporated. The crude product was purified using 
preparative HPLC. 1H NMR (DMSO-d6, 300 MHz): δ = 12.82 (br. s., 2H), 9.87 (br. s., 
1H), 9.41 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 8.03 (s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 
7.14–7.35 (m, 5H), 6.82 (d, J = 8.5 Hz, 2H), 4.35–4.41 (m, 1H), 3.10 (dd, J = 4.7, 
13.9 Hz, 1H), 2.87 (dd, J = 9.7, 13.9 Hz, 1H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 
173.6, 164.6, 158.6, 153.7, 147.8, 145.9, 137.7, 129.0, 128.2, 127.1, 126.4, 123.8, 
116.1, 116.0, 105.2, 54.4, 36.9 ppm. MS (ESI) m/z: 426.8 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-5-phenylthiophene-2-carboxylic acid 
(13). The title compound was prepared from IVb according to general procedure D. 
1H NMR (DMSO-d6, 300 MHz): δ = 12.89 (br. s., 2H), 9.42 (s, 1H), 8.21 (s, 1H), 8.17 
(d, J = 7.9 Hz, 1H), 7.65 (d, J = 6.9 Hz, 2H), 7.36–7.54 (m, 3H), 7.16–7.35 (m, 5H), 
4.33–4.47 (m, 1H), 3.10 (dd, J = 4.8, 13.9 Hz, 1H), 2.88 (dd, J = 9.7, 13.9 Hz, 1H) 
ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.6, 153.7, 146.9, 145.7, 137.7, 
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132.7, 129.3, 129.2, 129.1, 128.2, 126.4, 125.6, 117.9, 106.9, 54.4, 37.0 ppm. MS 
(ESI) m/z: 411.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)thiophene-2-carboxylic acid (14). The 
title compound was prepared from IVf according to general procedure D. 1H NMR 
(DMSO-d6, 300 MHz): δ = 12.84 (br. s., 2H), 9.38 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 
7.83 (d, J = 5.5 Hz, 1H), 7.69 (d, J = 5.5 Hz, 1H), 7.14–7.37 (m, 5H), 4.37 (dt, J = 3.4, 
4.8 Hz, 1H), 3.09 (dd, J = 4.7, 13.9 Hz, 1H), 2.86 (dd, J = 9.7, 13.2 Hz, 1H) ppm. 13C 
NMR (DMSO-d6, 75 MHz): δ = 173.6, 164.7, 153.7, 145.4, 137.7, 131.5, 129.0, 
128.2, 126.4, 121.8, 107.8, 54.3, 37.0 ppm. MS (ESI) m/z: 335.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-5-(4-methoxy-2-methylphenyl)thio-
phene-2-carboxylic acid (15). The title compound was prepared from IVg according 
to general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.86 (br. s., 2H), 9.41 (s, 
1H), 8.14 (d, J = 8.0 Hz, 1H), 7.86 (s, 1H), 7.33 (d, J = 8.6 Hz, 1H), 7.18–7.33 (m, 
5H), 6.91 (d, J = 2.5 Hz, 1H), 6.84 (dd, J = 8.6, 2.6 Hz, 1H), 3.08 (dd, J = 14.1, 4.8 
Hz, 1H), 2.86 (dd, J = 14.1, 9.7 Hz, 1H), 2.36 (s, 3 H) ppm. 13C NMR (DMSO-d6, 
75 MHz): δ = 173.6, 164.6, 159.5, 153.7, 146.7, 145.0, 137.7, 137.0, 130.8, 129.0, 
128.2, 126.4, 125.1, 120.9, 116.4, 111.9, 106.7, 55.2, 54.4, 36.9, 20.9 ppm. MS (ESI) 
m/z: 454.7 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-7-methoxy-4,5-dihydronaphtho[1,2-
b]thiophene-2-carboxylic acid (16). The title compound was prepared from IVc 
according to general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 12.83 (br. s., 
2H), 8.70 (s, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.19–7.32 (m, 
4H), 6.89 (d, J = 2.3 Hz, 1H), 6.83 (dd, J = 2.4, 8.3 Hz, 1H), 4.35–4.49 (m, 1H), 3.78 
(s, 3H), 3.10 (dd, J = 4.7, 13.7 Hz, 1H), 2.88 (dd, J = 8.7, 13.7 Hz, 1H), 2.76 (app t, J 
= 7.6 Hz, 2H), 2.25–2.45 (m, 2H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.4, 
164.0, 159.7, 154.0, 143.0, 139.3, 137.9, 137.4, 132.8, 129.3, 128.2, 126.4, 124.4, 
123.1, 113.8, 112.5, 111.8, 55.2, 54.1, 37.6, 28.5, 23.3 ppm. MS (ESI) m/z: 466.8 
[M+H]+ 
 
 
Scheme S3: Synthesis of compound 17.  
 
5-(4-Methoxyphenyl)thiophen-3-amine (17a) was prepared from IIIa according to 
the following procedure: To a solution of IIIa (4.4 mmol) in DCM, was added HCl (2 M 
aq, 10 mL). The resulting mixture was heated to 80 °C for 18 h. The reaction was 
cooled to room temperature and alkalized with 2M KOH. The aqueous layer was 
extracted with DCM (3 x 50 mL). The organic phase was washed with brine (1 x 100 
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mL), dried (MgSO4) and evaporated to yield the title compound which was used in 
the next step without further purification. 
 
Phenyl (5-(4-methoxyphenyl)thiophen-3-yl)carbamate (17b) was prepared from 
17a according to the following procedure: To a solution of 17a (3.4 mmol) in dry DCM 
(30 mL), pyridine (3.4 mmol) was added and the resulting mixture was cooled to 
0 °C. Phenyl chloroformate (3.4 mmol) was added dropwise at 0 °C. The reaction 
was allowed to warm to room temperature and stirred until the reaction was 
completed (checked by TLC). The solvent was evaporated and the residue was 
suspended in ice water. After acidification with a saturated KHSO4 solution, the 
aqueous layer was extracted with DCM (3 x 50 mL). The organic phase was washed 
with an ice cold half saturated KHSO4 solution (2 x 50 mL) and brine (1 x 50 mL), 
dried (MgSO4) and evaporated to yield the title compound which was sufficiently pure 
to be used in the next step without further purification. 
 
((5-(4-Methoxyphenyl)thiophen-3-yl)carbamoyl)-L-phenylalanine (17): The title 
compound was prepared from 17b according to the following procedure: 17b (1eq), 
triethylamine and L-phenylalanine were dissolved in dry DMSO (7 mL) and stirred at 
50°C for 50 h until the reaction was completed. The reaction mixture was poured into 
a mixture of concentrated HCl and ice (1:1) and extracted with EtOAc/THF (1:1, 60 
mL). The organic layer was washed with aqueous HCl (2M), followed by saturated 
aqueous NaCl (2 x 50 mL), dried (MgSO4) and concentrated. The crude material was 
suspended in a mixture of n-hexane/EtOAc (2:1, 20 mL) heated to 50 °C and after 
cooling to room temperature separated via filtration. 1H NMR (DMSO-d6, 300 MHz): δ 
= 12.78 (br. s., 1H), 8.90 (s, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.18–7.35 (m, 5H), 7.14 (d, 
J = 1.3 Hz, 1H), 7.03 (d, J = 1.3 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 6.35 (d, J = 8.0 Hz, 
1H), 4.45 (dt, J = 5.2, 7.7 Hz, 1H), 3.78 (s, 3H), 3.03–3.16 (m, 1H), 2.87–3.03 (m, 1H) 
ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 173.5, 158.9, 154.5, 141.1, 138.2, 137.3, 
129.2, 128.2, 126.5, 126.4, 126.3, 116.1, 114.5, 103.4, 55.2, 53.7, 37.3 ppm. MS 
(ESI) m/z: 397.0 [M+H]+ 
(S)-5-([1,1'-Biphenyl]-3-yl)-3-(3-(1-carboxy-2-phenylethyl)ureido)thiophene-2-
carboxylic acid (18). The title compound was prepared from Va according to general 
procedure E. 1H NMR (DMSO-d6, 500 MHz): δ = 12.90 (br. s., 2H), 9.44 (s, 1H), 8.28 
(s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.84 (t, J = 1.7 Hz, 1H), 7.71 - 7.75 (m, 2H), 7.69 (td, 
J = 1.7, 7.8 Hz, 1H), 7.65 (td, J = 1.7, 7.8 Hz, 1H), 7.53–7.57 (m, 1H), 7.47–7.52 (m, 
2H), 7.39–7.43 (m, 1H), 7.26–7.33 (m, 4H), 7.20–7.24 (m, 1H), 4.40 (ddd, J = 4.7, 
7.9, 9.7 Hz, 1H), 3.11 (dd, J = 4.7, 14.0 Hz, 1H), 2.88 (dd, J = 9.7, 14.0 Hz, 1H) ppm. 
13C NMR (DMSO-d6, 125 MHz): δ = 173.6, 164.6, 153.7, 146.7, 145.7, 141.3, 139.4, 
137.7, 133.4, 130.0, 129.1, 129.0, 128.2, 127.9, 127.6, 126.9, 126.4, 124.8, 123.7, 
118.3, 107.1, 54.4, 37.0 ppm. MS (ESI) m/z: 487.0 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-5-(4'-(hydroxymethyl)-[1,1'-biphenyl]-
3-yl)thiophene-2-carboxylic acid (19). The title compound was prepared from Va 
according to general procedure E. 1H NMR (DMSO-d6, 500 MHz): δ = 12.99 (br. s., 
2H), 9.44 (s, 1H), 8.28 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.84 (t, J = 1.7 Hz, 1H), 7.67–
7.71 (m, 3H), 7.62–7.65 (m, 1H), 7.51–7.56 (m, 1H), 7.43 (d, J = 8.5 Hz, 2H), 7.26–
7.33 (m, 4H), 7.19–7.24 (m, 1H), 4.56 (s, 2H), 4.40 (ddd, J = 4.7, 8.1, 9.8 Hz, 1H), 
3.11 (dd, J = 4.7, 13.9 Hz, 1H), 2.88 (dd, J = 9.8, 13.9 Hz, 1H) ppm. 13C NMR 
(DMSO-d6, 125 MHz): δ = 173.6, 164.6, 153.7, 146.8, 145.7, 142.3, 141.2, 137.7, 
137.7, 133.4, 130.0, 129.1, 128.2, 127.5, 127.1, 126.6, 126.4, 124.6, 123.6, 118.3, 
107.1, 62.6, 54.4, 37.0 ppm. MS (ESI) m/z: 517.0 [M+H]+ 
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(S)-5-([1,1'-Biphenyl]-4-yl)-3-(3-(1-carboxy-2-phenylethyl)ureido)thiophene-2-
carboxylic acid (20). The title compound was prepared from Vb according to 
general procedure E. 1H NMR (DMSO-d6, 500 MHz): δ = 12.90 (br. s, 2H), 9.45 (s, 
1H), 8.26 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 7.73–7.78 (m, 4H), 7.69–7.73 (m, 2H), 
7.46–7.51 (m, 2H), 7.37–7.41 (m, 1H), 7.27–7.33 (m, 4H), 7.19–7.24 (m, 1H), 4.41 
(ddd, J = 4.8, 8.0, 9.7 Hz, 1H), 3.11 (dd, J = 4.8, 13.9 Hz, 1H), 2.89 (dd, J = 9.7, 13.9 
Hz, 1H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 173.6, 164.6, 153.7, 146.4, 145.8, 
140.7, 139.1, 137.7, 131.8, 129.0, 129.0, 128.2, 127.8, 127.4, 126.5, 126.4, 126.1, 
117.9, 107.0, 54.4, 36.9 ppm. MS (ESI) m/z: 486.4 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-phenylethyl)ureido)-5-(4'-(hydroxymethyl)-[1,1'-biphenyl]-
4-yl)thiophene-2-carboxylic acid (21). The title compound was prepared from Vb 
according to general procedure E. 1H NMR (DMSO-d6, 500 MHz): δ = 12.97 (br. s, 
2H), 9.44 (s, 1H), 8.25 (s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 8.7 Hz, 2H), 7.73 
(d, J = 8.7 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.26–7.33 (m, 
4H), 7.19–7.24 (m, 1H), 4.55 (s, 2H), 4.35–4.45 (m, 1H), 3.11 (dd, J = 4.7, 14.0 Hz, 
1H), 2.88 (dd, J = 9.8, 14.0 Hz, 3H) ppm. 13C NMR (DMSO-d6, 125 MHz): δ = 173.6, 
164.6, 153.7, 146.5, 145.8, 142.3, 140.6, 137.7, 137.4, 131.6, 129.1, 128.2, 127.3, 
127.1, 126.4, 126.2, 126.1, 117.8, 106.8, 62.6, 54.4, 37.0 ppm. MS (ESI) m/z: 516.9 
[M+H]+ 
 
 
Scheme S3: Synthesis of compound 22. 
 
(4-Bromophenyl)(2-nitrophenyl)methanol (22a) was prepared according to the 
following procedure: A solution of 2-iodo-nitrobenzene (1.0 eq) in THF (10mL/g 
reagent) was cooled to – 40 °C and a solution of phenylmagnesium chloride (2M in 
THF, 1.1 eq) was added dropwise. The solution was stirred for 30 min at –40 °C, 3-
bromobenzaldehyde was added and the reaction was completed at –40 °C (checked 
by TLC). The mixture was quenched with a saturated solution of NH4Cl (5 mL) and 
diluted with water (5 mL). The aqueous phase was extracted with ethyl acetate (three 
times) and the combined organic layers were washed with brine, dried, and 
concentrated under reduced pressure. The residue was purified by column 
chromatography over silica gel to yield the desired product. 1H NMR (CDCl3, 
300 MHz): δ = 7.81 (dd, J = 1.3, 7.8 Hz, 1H), 7.57 (dd, J = 1.3, 7.8 Hz, 1H), 7.52 (td, 
J = 1.3, 7.8 Hz, 1H), 7.32 (d, J = 8.6 Hz, 2H), 7.37 (td, J = 1.3, 7.8 Hz, 1H), 7.07 (d, J 
= 8.6 Hz, 2H), 6.23 (d, J = 4.4 Hz, 1H), 3.14 (d, J = 4.4 Hz, 1H) ppm. 13C NMR 
(CDCl3, 75 MHz): δ = 148.0, 140.4, 137.9, 133.5, 131.5, 129.2, 128.7, 128.6, 124.7, 
121.9, 70.7 ppm. 
6  SUPPORTING INFORMATION                                                                                                       215 
 
(2-Nitrophenyl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol 
(22b) was prepared from 22a according to the following procedure: 22a (1 eq), 
bis(pinakolato)diboron (1.2 eq) and potassium acetate (3 eq) were dissolved in dry 
1,4-Dioxane (20 mL). The system was evacuated and subsequently flushed with 
nitrogen three times. [1,1′-Bis(diphenylphosphino)ferrocene]dichloro palladium (0.05 
eq) was added and the resulting mixture was heated to 85 °C for 24 h. The reaction 
was cooled to room temperature and the solvent was evaporated. The residue was 
dissolved in EtOAc (150 mL), the organic layer was washed with H2O (1 x 100 mL) 
and brine (1 x 100 mL) and dried (MgSO4). The solvent was evaporated and the 
crude product was purified by flash column chromatography (EtOAc/ hexane 1:6) to 
yield the title compound. 1H NMR (CDCl3, 300 MHz): δ = 7.90 (dd, J = 1.3, 8.2 Hz, 
1H), 7.77 (d, J = 8.0 Hz, 2H), 7.68 (dd, J = 1.3, 7.6 Hz, 1H), 7.59 (dt, J = 1.3, 7.6 Hz, 
1H), 7.42 (ddd, J = 1.3, 7.6, 8.2 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 6.41 (d, J = 4.4 Hz, 
1H), 3.26 (d, J = 4.4 Hz, 1H), 1.33 (s, 12H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 
148.3, 144.5, 138.3, 134.9, 133.3, 129.5, 128.4, 126.1, 124.6, 83.8, 71.2, 24.8 ppm. 
3-(3-((S)-1-Carboxy-2-phenylethyl)ureido)-5-(4'-(hydroxy(2-nitrophenyl)methyl)-
[1,1'-biphenyl]-4-yl)thiophene-2-carboxylic acid (22) The title compound was 
prepared from Va and 22b according to general procedure E. 1H NMR (300 MHz, 
acetone-d6): δ = 9.53 (s, 1H), 8.40 (s, 1H), 7.98 (dd, J = 1.2, 7.9 Hz, 1H), 7.93 (dd, J 
= 1.2, 8.2 Hz, 1H), 7.74–7.84 (m, 5H), 7.70 (d, J = 8.2 Hz, 2H), 7.53–7.60 (m, 1H), 
7.47 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 7.9 Hz, 1H), 7.26–7.37 (m, 4H), 7.18–7.25 (m, 
1H), 6.51 (s, 1H), 4.69–4.80 (m, 1H), 3.29 (dd, J = 5.0, 14.0 Hz, 1H), 3.07 (dd, J = 
8.85, 14.0 Hz, 1H) ppm. 13C NMR (75 MHz, acetone-d6): δ = 173.8, 165.6, 154.7, 
149.5, 148.8, 148.1, 143.9, 142.1, 140.1, 140.0, 138.6, 134.1, 133.4, 130.3, 130.0, 
129.3, 129.3, 128.7, 128.5, 127.6, 127.5, 127.3, 125.0, 118.9, 107.1, 70.8, 55.5, 38.6 
ppm. MS (ESI) m/z: 637.9 [M+H]+ 
(S)-3-(3-(1-Carboxy-2-(1H-imidazol-4-yl)ethyl)ureido)-5-(4-methoxyphenyl) 
thiophene-2-carboxylic acid (23). The title compound was prepared from IVa 
according to general procedure D. 1H NMR (DMSO-d6, 300 MHz): δ = 9.59 (br. s., 
1H), 8.10 (d, J = 7.73 Hz, 1H), 8.00 (s, 1H), 7.82 (d, J = 0.7 Hz, 1H), 7.50 (d, J = 8.9 
Hz, 2H), 6.88–6.95 (m, 3H), 4.27–4.41 (m, 1H), 3.71 (s, 3H), 2.98 (dd, J = 4.7, 15.0 
Hz, 1H), 2.83 (dd, J = 9.3, 15.0 Hz, 1H) ppm. 13C NMR (DMSO-d6, 75 MHz): δ = 
173.5, 165.5, 159.9, 153.8, 146.0, 144.9, 134.3, 132.6, 126.9, 125.7, 116.9, 116.7, 
114.7, 108.2, 55.3, 53.2, 28.5 ppm. MS (ESI) m/z: 430.9 [M+H]+ 
 
 
Scheme S4: Synthesis of compound 24. 
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S-(2-Acetamidoethyl)(S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropane 
thioate (24a) was prepared according to the following procedure:[7] A solution of 
boc-L-phenylalanine (400 mg, 1.50 mmol), N-acetylcysteamine (215 mg, 1.80 mmol) 
and DMAP (18.3 mg, 0.15 mmol) in dry DCM (10 mL) was cooled to 0°C. DCC (371 
mg, 1.80 mmol), dissolved in DCM (10 mL) was added dropwise and the ice bath 
was removed afterwards. Stirring was continued for 48 h until the reaction was 
completed. The solids were filtered off and rinsed with cold DCM (10 mL). The filtrate 
was washed with 1M HCl (30 mL), a saturated NaHCO3 solution (30 mL), H2O (30 
mL) and brine (30 mL). After drying (MgSO4), the solvent was evaporated and the 
residue was purified via column flash chromatography (100% EtOAc) to yield the 
desired product. 1H NMR (Acetone-d6, 300 MHz): δ = 7.18–7.35 (m, 5H), 6.63 (d, J = 
8.5 Hz, 1H), 4.46 (ddd, J = 4.5, 8.5, 10.2 Hz, 1H), 3.33 (q, J = 6.9 Hz, 2H), 3.21 (dd, J 
= 4.5, 14.1 Hz, 1H), 2.98 (t, J = 6.9 Hz, 2H), 2.87–2.95 (m, 1H), 1.88 (s, 3H), 1.34 (s, 
9H) ppm. 
(S)-1-((2-Acetamidoethyl)thio)-1-oxo-3-phenylpropan-2-aminium chloride (24b) 
was prepared from 24a according to the following procedure:[8] A solution of 24a 
(475 mg, 1.30 mmol) in dry DCM (5 mL) was cooled to 0 °C. TFA (1.30 mL) was 
added very slowly and the resulting mixture was stirred at 0 °C for 2 h. The mixture 
was concentrated to about 2 mL, then diluted with 2 mL DCM and again 
concentrated. This cycle was repeated three times and afterwards, the entire solvent 
was evaporated. The residue was dissolved in EtOAc (30 mL) and the resulting 
organic layer was washed with 1M NaOH (10 mL). The solvent was evaporated 
again and the residue was treated with H2O (2 mL) and 2M HCl (2 mL). After washing 
the aqueous phase with EtOAc (2 x 2 mL), it was lypophylized to yield the title 
compound. 1H NMR (DMSO-d6, 300 MHz): δ = 7.23–7.37 (m, 5H), 7.13 (br. s., 3H), 
4.34–4.49 (m, 1H), 3.04–3.28 (m, 4H), 2.90–3.00 (m, 2H), 1.79 (s, 3H) ppm. 
13C NMR (DMSO-d6, 75 MHz): δ = 196.0, 169.4, 134.4, 129.6, 128.6, 127.3, 59.5, 
37.7, 36.8, 28.3, 22.5 ppm. 
(S)-3-(3-(1-((2-Acetamidoethyl)thio)-1-oxo-3-phenylpropan-2-yl)ureido)-5-(4-
methoxyphenyl)thiophene-2-carboxylic acid (24) The title compound was 
prepared from 24b according to the following procedure: 24b (52.0 mg, 0.19 mmol) 
and VIa (63.0 mg, 0.21 mmol) were mixed in a reaction vial and capped. The system 
was evacuated and subsequently flushed with N2. This cycle was repeated five times. 
Dry DMSO (2 mL) was added and the reactants were dissolved under stirring. Dry 
triethylamine (42.5 mg, 0.42 mmol) was added dropwise with a Hamilton syringe and 
the resulting mixture was stirred at room temperature for 2 h. The reaction mixture 
was poured into a mixture of concentrated HCl and ice (1:1, 50 mL) and extracted 
with EtOAc/THF (1:1, 3 x 60 mL). The organic layer was washed with 2M HCl (2 x 50 
mL), followed by brine (1 x 50 mL), dried (MgSO4) and concentrated. The crude 
material was purified using preparative HPLC. 1H NMR (500 MHz, DMSO-d6): δ = 
13.09 (br. s., 1H), 9.51 (s, 1H), 8.54 (d, J = 7.6 Hz, 1H), 8.07 (s, 1H), 8.03 (t, J = 5.5 
Hz, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.26–7.33 (m, 4H), 7.18–7.25 (m, 1H), 7.00 (d, J = 
8.8 Hz, 2H), 4.53 (ddd, J = 4.6, 7.7, 10.4 Hz, 1H), 3.79 (s, 3H), 3.07–3.21 (m, 3H), 
2.80–2.95 (m, 3H), 1.78 (s, 3H) ppm. 13C NMR (125 MHz, DMSO-d6): δ = 201.4, 
169.2, 164.7, 160.1, 153.4, 147.4, 145.6, 137.2, 129.0, 128.3, 127.1, 126.6, 125.2, 
116.5, 114.7, 106.0, 61.4, 55.3, 38.1, 37.0, 27.9, 22.ppm. MS (ESI) m/z: 541.8 
[M+H]+ 
  
6  SUPPORTING INFORMATION                                                                                                       217 
 
6.5.2 Surface plasmon resonance (SPR) 
 
 
Figure S1: SPR sensorgrams of B (Figure S1a), 21 (Figure S1b) and 22 (Figure S1c) at 
increasing concentrations (blue  red  green). Left panel: Before treatment with ACoA; Right 
panel: After treatment with ACoA.  
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